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CHAPTER 1
GENERAL INTRODUCTION AND 
OUTLINE OF THE THESIS
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GENERAL INTRODUCTION
After an outbreak of a flu-like illness among Australian abattoir workers in 1935, Edward 
Holbrook Derrick, who investigated the outbreak, was the first who described Q fever in 
1937 [1]. As the causative pathogen of this flu-like illness was unknown at that time, the 
disease was called “Query (Q) fever”. In subsequent years, the causative agent of Q fever 
was identified, and was named Coxiella burnetii, derived from a combination of Frank 
Macfarlane Burnet (Australia) and Herald Rea Cox (USA), because of their effort in the 
discovery of the bacterium [2, 3]. This discovery did not result in adaptation of the name of 
the disease, which is understandable as still several queries around this disease exist.
Edward Holbrook Derrick [Queensland, Australia] (left), and his first notes on C. burnetii (right) [4]. 
© Copyright 2008 The Medical Journal of Australia. Reproduced with permission
The causative agent of Q fever
C. burnetii, the aetiological pathogen, is a small Gram-negative intracellular coccobacillus. 
Even though historically classified in the Rickettsiaceae family, phylogenetic investigations, 
mainly based on 16s rRNA sequence analysis [5] and genome sequencing [6], led to 
the reclassification into the Coxiellaceae family in the order Legionellales of the gamma 
subdivision of Proteobacteria. C. burnetii exhibits a developmental cycle that contains two 
morphologically distinct forms, a small cell variant (SCV) and a large cell variant (LCV) [7, 8]. 
The SCV, a metabolically inactive, small, dense, highly resistant spore-like form, is resistant 
to adverse conditions that may be encountered by the pathogen while in the extracellular 
environment [8, 9]. Following passive entry into the host-cell, the SCV becomes located in 
an acidic cytoplasmic vacuole, and eventually prevents fusion with lysosomes enhancing 
the pathogen’s survival [9, 10]. This process triggers the transformation to the LCV, which 
is in contrast to SCV a metabolically active, relatively fragile cell type [11]. To complete the 
life cycle, the bacterial population eventually transforms into SCVs, which are released upon 
lysis of the host cell [9]. Another essential characteristic is that C. burnetii displays two 
antigenic forms, namely phase I and phase II. Phase variation is related mainly to variation in 
the lipopolysaccharide (LPS) on the outer side of the membrane of the bacterium [12]. The 
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highly infectious phase I refers to C. burnetii with full-length LPS molecules with O-chains, 
as found in naturally infected animals, arthropods, and humans. In contrast, phase II is 
considered avirulent and possesses LPS with truncated O-side chains and is only obtained in 
the laboratory following serial passage in cell cultures or embryonated egg cultures [9, 13]. 
In daily clinical practice, this phase variation and the subsequent antibody response is used 
to differentiate between a past infection, acute Q fever, and chronic Q fever. 
Q fever is a zoonosis, i.e. transmission to humans occurs through an animal reservoir, and a 
wide variety of animal species are reservoirs of C. burnetii in nature. Even though domestic 
ruminants (cattle, sheep, and goats) are considered as the main reservoir for the pathogen 
[5, 14], the bacterium has been found in a variety of other animal species [15-17]. Animals 
shed C. burnetii in milk, faeces, urine, and in birth by-products [18-21]. Especially during 
parturition, high amounts of bacteria enter the environment, resulting in a wind-borne 
spread of C. burnetii over a large area [22-24]. The bacterium is highly infective, as low doses 
already induce asymptomatic seroconversion [25]. Inhalation of contaminated aerosols 
are the main route of human infection [5]; however, the ingestion of contaminated dairy 
products has also been associated with seroconversion in humans [26]. Even though human-
to-human transmission has been described [27-31], this is rarely seen and not considered to 
be an important route of transmission.
C. burnetii (left), the causative agent of Q fever, and the morphologically distinct forms: 
SCV (middle) and LCV (right). Courtesy:  National Institute of Allergy and Infectious Diseases
The occurrence of Q fever in the Netherlands
After its first documentation in 1937, Q fever appeared to be common all over the world 
[32], except for New-Zealand [33]. For a long time, Q fever was considered an occupational 
disease, mainly among farmers, veterinarians, and laboratory workers. However, numerous 
human Q fever outbreaks have been reported in many countries [34-47], of which many 
were associated with livestock farming. In the Netherlands, the first three human cases of Q 
fever were identified in 1956 [48, 49], and it became a notifiable disease for humans in 1975 
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[50]. Until 2007, an annual number of human cases up to 32 per year were notified nationally 
[39], with an estimated seroprevalence, i.e. an indication of past infections, of 2.4% [51, 52]. 
From 2007 until 2010, the Netherlands experienced an exceptionally large Q fever outbreak 
among humans. During this period, over 4000 patients with symptomatic acute Q fever 
were notified, and it was estimated that at least 32,200 individuals experienced a latent 
infection [53, 54]. Subsequently, the seroprevalence of Q fever increased to approximately 
12.2%-20.4% in 2009 [55, 56]. Preceding this major outbreak, an increased abortion rate 
among goats was observed in several provinces, particularly in the southern part of the 
Netherlands. As most patients lived in densely-populated urban areas with intensive goat 
farming, and abortions are accompanied by the spreading of high loads of C. burnetii-
contaminated aerosols in the air [5, 16, 57], dairy goats were identified to be the source 
of the epidemic [45, 58]. Compared to 2007, outbreaks of similar size had been reported 
in other countries; however, the number of notifications kept increasing to 1000 and 2354 
cases in 2008 and 2009, respectively [59]. To prevent further spread, drastic measures were 
taken, including the culling of pregnant goats and sheep at infected farms and a vaccination 
programme [39]. Eventually, this resulted in a massive reduction in the number of new 
patients from 2010 onwards. At present, a similar number of notified cases is seen as before 
2007 [59].
Clinical manifestations
Acute Q fever
The incubation period ranges from four days up to six weeks [60, 61], with most cases occurring 
2-3 weeks after exposure [16, 62, 63]. Infection with C. burnetii causes symptomatic disease 
in approximately 40% of all patients [5]. The presentation varies from a mild self-limiting flu-
like illness to pneumonia or a hepatitis-like syndrome [57, 64, 65]. Signs and symptoms are 
usually non-specific and compatible with many infectious diseases, and can differ per region 
[5, 16, 17, 57, 61, 62]. Therefore, the diagnosis is often missed and the incidence of Q fever 
among humans is probably underestimated [66]. Rarely, more severe manifestations are 
described [62], and the case fatality rate of acute Q fever is approximately 1%-2% [16, 57, 
67]. A hospitalisation rate of 2%-5% has been reported throughout literature [16, 34, 57]. 
In the Netherlands, however, a hospitalisation rate of 50% was registered in 2007, which 
stabilized around 20% in the years after [68]. Diagnosis is mainly based on (recognizing) the 
clinical presentation in combination with laboratory test results. In case of suspicion of acute 
Q fever, it is recommended to perform polymerase chain reaction (PCR) and serological 
evaluation [69]. C. burnetii DNA can be detected in serum in the early acute phase of disease 
using PCR [70]. However, the sensitivity of PCR in detecting DNA decreases when antibodies 
against C. burnetii develop, if no development to chronic Q fever occurs. Antibodies appear 
in the first two weeks after the initial symptoms [61, 62]. Several serological techniques 
exist to diagnose acute Q fever of which immunofluorescence assay (IFA) is the reference 
method, but other suitable techniques are available, such as complement fixation test 
(CFT) and enzyme-linked immunosorbent assay (ELISA) [62, 71]. In the classical serological 
response of acute Q fever, antibodies directed against phase II antigens are first detectable, 
shortly thereafter followed by antibodies against phase I. In general, antibodies to phase 
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II predominate in the acute stage of disease and after convalescence from acute Q fever 
without signs of chronic infection, whereas high levels of IgG antibodies to phase I more 
than 3 months after the primary infection are found in chronic Q fever [62, 72]. Besides a 
positive PCR in the early stage of disease, the diagnosis of acute Q fever can made using two 
serum samples with an interval of at least two weeks, showing seroconversion or a fourfold 
rise in antibodies. Although IgG antibodies tend to be more persistent than IgM antibodies, 
all frequently persist for months to even years after the initial infection [73, 74]. 
Reproduction of the antibody responses (IFA), culture, and PCR in acute Q fever (left) and chronic Q 
fever (right)
Treatment should be started as soon as Q fever is suspected. Although C. burnetii is known 
for its self-limiting character, treatment of the acute infection decreases the duration of 
fever [75], reduces the risk of hospitalisation [76], and shortens the recovery period from 
pneumonia [77]. The treatment of choice in the acute setting is doxycycline 200 mg/day 
for 2-3 weeks [76], whereas moxifloxacin 400mg/day for 2-3 weeks is advised in case of 
doxycycline intolerance [78]. Most patients with symptomatic acute Q fever recover 
completely with only a serological scar left, but infection with C. burnetii is notorious for 
causing long-term sequelae, i.e. chronic Q fever and Q fever fatigue syndrome (QFS). In 
case of clear risk factors for development of chronic Q fever, prophylactic treatment might 
prevent persistent infection [79-81].
Chronic Q fever
Following initial infection, chronic Q fever develops in 1%–5% of C. burnetii-infected patients 
[5, 82], and is characterised by the persistence of viable C. burnetii. Most patients do not 
recall an acute Q fever episode, indicating that asymptomatic primary infections can also 
result in development of chronic Q fever [83]. It mostly manifests within the first year 
following infection, but the disease can also present itself several years later [79, 82, 84]. 
Chronic Q fever usually develops insidiously and most patients are asymptomatic or report 
only non-specific symptoms such as low-grade fever, night sweats, and weight loss [5, 84, 
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85]. Frequently, this causes a delay in diagnosis with subsequently a more severe clinical 
presentation at diagnosis [65, 86]. Chronic Q fever presents mainly as vascular infection 
[83], including mycotic aneurysms and infections of vascular prosthesis, and endocarditis 
[17], followed by less frequently reported manifestations such as osteomyelitis, pericarditis, 
and hepatitis [85]. Clear risk factors for the development of chronic Q fever are heart valve 
pathology, including valve prostheses and pre-existent valvulopathy, vascular prostheses, 
and aneurysms [65, 79, 87, 88]. Other factors that might be associated with an increased 
risk are immunosuppresion, older age, pregnancy, and (mild) renal insufficiency [46, 57, 87]. 
Diagnosing chronic Q fever has proven to be challenging. Routine blood cultures remain 
negative. In addition, culturing C. burnetii is difficult and time-consuming, requires a level 
3 biosafety laboratory, and lacks sensitivity [89]. Both serology and DNA detection in blood 
or tissue using PCR aid the laboratory diagnosis of chronic Q fever [82]. A positive PCR or 
culture of C. burnetii in blood or tissue, in the absence of a serologic profile for acute Q fever, 
is considered diagnostic for chronic Q fever, although sensitivity of these techniques is low 
[83, 90]. Serological analysis is therefore essential. Because chronic Q fever is characterized 
by persistent high titres of IgG antibodies against C. burnetii phase I antigens [57, 91], the 
IgG phase I titre is used as standard for the serological diagnosis of chronic Q fever. The 
cut-off titre depends on the used method, and varies between in-house-developed IFA and 
commercially available IFA [72, 82, 92]. However, in case of absence of PCR positivity, serology 
alone is insufficient for diagnosing chronic Q fever, and clinical data should be included [93]. 
Furthermore, localisation of infectious foci is important, because, in addition to prolonged 
antimicrobial therapy, adjuvant therapeutic measures such as surgical drainage or graft 
replacement are often necessary [85, 94, 95]. In conclusion, the diagnosis currently relies on 
a combination of symptoms, risk factors, microbiological findings, and imaging techniques. 
Long-term antibiotic treatment, preferably doxycycline combined with hydroxychloroquine, 
for at least 18-24 months, sometimes in combination with surgery, is necessary to reduce 
morbidity and mortality, which is up to 60% of patients if left untreated [88, 96]. However, 
even in case of adequate antibiotic treatment, chronic Q fever still has a high case fatality 
rate [83]. In addition, the antibiotic treatment itself sometimes causes mortality [83], and 
at least frequently causes important side effects, including gastrointestinal complaints and 
severe photosensitivity.
QFS
This thesis especially focuses on QFS, occurring in approximately 20% of cases following a 
symptomatic acute Q fever infection. In contrast to chronic Q fever, which also occurs after 
asymptomatic C. burnetii infection, no viable C. burnetii is present. Already in 1960, fatigue 
was notified as complaint following acute Q fever [97]. However, it was until 1992 before 
the first reference to QFS, referred to as “post Q fever fatigue syndrome”, appeared in the 
scientific literature [98]. Ever since, QFS has been recognised and described all over the 
world [99-103]. Following the major Q fever outbreak in the Netherlands, several reports 
were published showing a high rate of severe fatigue and decreased health status in the 
years after infection [104-107]. Although the existence of QFS is debated by some [108], 
and fatigue following infection with C. burnetii might not be specific compared to fatigue 
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following other infectious diseases, it occurs frequently and has important clinical and 
economical consequences. Therefore, this sequel should be taken seriously, as it has major 
implications for both patients and treating physicians [109, 110], especially in the case of 
an outbreak. Subsequently, QFS appeared to be the major cause of the Q fever-related 
economical burden of the Dutch outbreak [111]. At present, Q fever is endemic almost all 
over the world, and it can be anticipated that new outbreaks will occur in the future, leading 
to a growing number of patients with long-term sequelae. Like in chronic fatigue syndrome 
(CFS) and patients with fatigue following Lyme disease, a vast medical consumption can be 
anticipated in the absence of an accessible and effective intervention and clear guidelines. 
With an increasing number of QFS patients in the aftermath of the outbreak, and the societal 
need for uniform criteria for the syndrome, a national guideline on QFS was formulated 
and published in 2012 [112]. However, several knowledge gaps existed and still exist with 
regard to QFS. Despite the lack of a formal comparison, this consensus guideline was 
therefore partly based on the diagnosis and treatment of CFS, as QFS and CFS at least partly 
overlap in symptoms. Furthermore, as for other forms of chronic fatigue [113], patients 
frequently report accompanying symptoms [98, 114, 115]. According to the Dutch guideline, 
the diagnosis of QFS can be made after a uniform diagnostic work-up, and the definition 
comprises a severe fatigue related to an acute Q fever infection, which lasts for at least six 
months and causes significant disabilities in daily functioning. The fatigue should be of new 
onset or should increase significantly due to the acute Q fever infection. Finally, chronic 
Q fever and other causes of fatigue, somatic or psychiatric, need to be excluded [112]. 
However, international consensus has not been reached yet. Although QFS increasingly 
received attention in previous years, the underlying pathophysiological mechanism remains 
to be elucidated, hampering treatment based on aetiological insight. Several hypotheses 
regarding the aetiology of QFS exist [74, 103, 116-118], all requiring further confirmation as 
contradictory results have been published. Also evidence-based information concerning the 
treatment of QFS patients is lacking, as no randomised controlled trials have been done. The 
published reports concerning treatment of QFS included mostly patients without clear QFS 
definition, and are mostly case-reports or suffer from other major limitations [102, 103, 119-
121], limiting the extrapolation of findings. Finally, information on prevention and prognosis 
is underrepresented in the international literature. The Q fever outbreak in the Netherlands 
provided a unique opportunity to investigate QFS more thoroughly. The studies described in 
this thesis contribute to the knowledge on QFS and challenges in both acute and chronic Q 
fever, and will hopefully lead to improvement of clinical care for Q fever patients, especially 
for those with QFS. 
OUTLINE OF THE THESIS
The primary aim of this thesis was to increase the recognition of QFS, to reveal new insights 
in the pathophysiology of QFS, and to evaluate the efficacy of treatment with cognitive 
behavioural therapy and long-term doxycycline (part I). A secondary aim of this thesis was 
to investigate diagnostic and treatment challenges in both acute and chronic Q fever (part 
II).
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In order to perform research into aetiology and treatment, awareness and recognition of 
QFS is mandatory. Part I of this thesis starts with chapter 2, which contains a systematic 
review of the available literature regarding fatigue following acute Q fever. In chapter 3, a 
comparison is made between QFS patients and CFS patients, with a focus on inflammatory 
markers and possible fatigue perpetuating cognitions and behaviour. In chapter 4 the 
question was addressed whether there is an aberrant antigen-specific IFNу-production and 
IFNу/IL-2 ratio in QFS patients. This might provide insight in the potential pathophysiological 
mechanisms underlying this debilitating long-term complication, which remain unclear at 
present. Furthermore, it is still unclear whether effective treatment for QFS is possible. 
Chapter 5 contains the study protocol to assess the efficacy of both cognitive behavioural 
therapy and long-term doxycycline in QFS patients. The results of this randomised placebo-
controlled trial (the Qure study) are presented in chapter 6. 
Part II of this thesis starts with the challenge of differentiating acute Q fever from other 
pathogens in patients presenting to hospitals, described in chapter 7. Furthermore, outcome 
of patients hospitalised with acute Q fever was evaluated, and the effect of prophylactic 
treatment for those patients with an indication to prevent development of chronic Q fe ver 
was analysed. Another challenging query is to localise the infection in case of chronic Q 
fever. In chapter 8, the value of 18F-fluorodeoxyglucose positron emission tomography (FDG-
PET/CT) and echocardiography in detecting the localization of infection in chronic Q fever 
patients was evaluated. Once chronic Q fever has been diagnosed, it often requires intensive 
and prolonged antibiotic treatment, which frequently causes serious side effects. In chapter 
9, a series of patients is described with treatment-induced cutaneous hyperpigmentation, 
a relatively rare phenomenon. But even in case of adequate treatment, chronic Q fever 
remains an unpredictable disease with a high mortality rate. In chapter 10, the severity of 
this disease and the diversity of signs and symptoms that may occur is underlined, in which a 
fatal case of an immunocompromised patient with an unusual disseminated chronic Q fever 
infection is described.
In chapter 11, a general discussion and future perspectives are provided, followed by the 
summary and conclusions in chapter 12 (English) and chapter 13 (Dutch).
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ABSTRACT
Background: Long-term fatigue with detrimental effects on daily functioning often occurs 
following acute Q-fever. Following the 2007-2010 Q-fever outbreak in the Netherlands with 
over 4000 notified cases, the emphasis on long-term consequences of Q-fever increased. 
The aim of this study was to provide an overview of all relevant available literature, and 
to identify knowledge gaps regarding the definition, diagnosis, background, description, 
aetiology, prevention, therapy, and prognosis, of fatigue following acute Q-fever.
Design: A systematic review was conducted through searching Pubmed, Embase, and 
PsycInfo for relevant literature up to 26th May 2015. References of included articles were 
hand searched for additional documents, and included articles were quality assessed.
Results: Fifty-seven articles were included and four documents classified as grey literature. 
The quality of most studies was low. The studies suggest that although most patients recover 
from fatigue within 6-12 months after acute Q-fever, approximately 20% remain chronically 
fatigued. Several names are used indicating fatigue following acute Q-fever, of which Q-fever 
fatigue syndrome (QFS) is most customary. Although QFS is described to occur frequently in 
many countries, a uniform definition is lacking. The studies report major health and work-
related consequences, and is frequently accompanied by nonspecific complaints. There is 
no consensus with regard to aetiology, prevention, treatment, and prognosis.
Conclusions: Long-term fatigue following acute Q-fever, generally referred to as QFS, 
has major health-related consequences. However, information on aetiology, prevention, 
treatment, and prognosis of QFS is underrepresented in the international literature. In order 
to facilitate comparison of findings, and as platform for future studies, a uniform definition 
and diagnostic work-up and uniform measurement tools for QFS are proposed.
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INTRODUCTION
Q-fever, caused by the Gram-negative intracellular coccobacillus Coxiella burnetii, is a 
zoonosis that occurs worldwide [1]. Between 2007 and 2010 the largest Q-fever outbreak 
ever described in the literature occurred in the Netherlands, resulting in 4107 notifications 
[2].
Fatigue following acute Q-fever, also referred to as Q-fever fatigue syndrome (QFS), has 
been described worldwide in up to 20%-30% of patients [3-8] and may last up to ten years 
or longer [7, 9]. Although some debated the term QFS [10], it has been frequently used 
throughout literature. QFS patients experience an impaired health status, pulmonary 
disorders, and impairment of general and social functioning [3, 7-9, 11, 12], and QFS 
accounted for major Q-fever-related economic cost during the Dutch outbreak [13]. 
Therefore, although not always recognised as a (diagnostic) problem, this sequel has major 
implications. The word “syndrome” refers to other frequently accompanying nonspecific 
symptoms [3, 8, 9, 14] resembling chronic fatigue syndrome (CFS) [15, 16]. However, in CFS 
the cause is usually unknown, while in QFS a C. burnetii infection can be identified as the 
trigger. Furthermore, QFS has a sudden onset of fatigue, while in CFS this is often not the 
case. Several queries regarding QFS without clear answers exist. A uniform international 
definition is not available, and tools to assess this syndrome and its consequences vary [5, 
6, 17]. Hypotheses on aetiology appear contradictory [18], and vary from altered cytokine 
production [6, 19], development of symptoms determined by host and genetic factors 
[19-21], to the perpetuation of symptoms due to psychogenic factors and behaviour [8]. 
Furthermore, opinions on possible treatment of QFS differ [5, 6, 17], and questions exist 
regarding prevention and prognosis.
The aim of this first systematic review regarding fatigue after acute Q-fever in humans is 
to provide an overview of all relevant available literature, and to identify knowledge gaps 
regarding the definition, diagnosis, background, description, aetiology, prevention, therapy, 
and prognosis. This provides an evidence map both for physicians and patients.
METHOD
Search strategy and selection criteria
Relevant articles were identified through a systematic literature search in the scientific 
databases Medline, Embase and PsycInfo up to the 26th of May 2015 (Table 1). As Pubmed 
was used to search in Medline, only Pubmed is mentioned in this article. There were no 
restrictions on year of publication, language, and article or study type. Abstracts without full-
text were excluded, as well as non-human studies. During the first selection step, potentially 
relevant references were selected based on screening of titles and or abstracts by two 
investigators independently (GM and SPK, both content area experts). Potentially relevant 
articles were included for full-text assessment. Articles on fatigue following acute Q-fever 
that could provide information on the following domains: diagnosis (i.e. definition and/or 
diagnosis), background/descriptive (i.e. incidence, prevalence, the course of fatigue and the 
role of co-morbidity, and other complaints besides fatigue), aetiology (i.e. pathophysiology, 
predictors), prevention/therapy, and prognosis, were selected.
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During the full-text assessment, articles without original or relevant data were excluded, 
upon an independent decision of each investigator, followed by consensus if needed. In case 
of any disagreement, the verdict of a third independent investigator was conclusive. If GM 
or SPK was a (co-)author of a potentially relevant article, a third independent investigator 
assessed and decided (both selection steps) on inclusion. GM and SPK translated non-English 
articles, if needed, native speakers where sought. If native speakers were unavailable, the 
corresponding author was contacted. If this yielded no response, the article was excluded.
Reference lists of included full-text articles were hand searched for additional relevant 
publications. If the title (or keyword in the title) suggested potential information on the topic, 
retrieval and full-text assessment followed. Finally, the World Health Organization, Centres 
for Disease Control and Prevention (CDC), Queensland Health, and gov.uk websites were 
searched for guidelines. Documents with relevant information that were identified during 
the search, but not classified as peer-reviewed articles, were included as grey literature.
Table 1. Search strategy used in Pubmed, Embase, and PsycInfo.
2QFS, A SYSTEMATIC REVIEW  | 33
Quality assessment
The methodological quality of case-control and cohort studies was assessed with the 
Newcastle-Ottawa Scale (NOS) [22], that evaluates selection (maximum of 4 stars), 
comparability (maximum of 2 stars), and outcome (maximum of 3 stars). For economic 
evaluations, the ‘Evers checklist’ was used [23]. Case-series were assessed with a quality 
appraisal tool with 18 criteria. A score of ≥14 criteria (≥70%) was considered acceptable 
[24]. No specific instruments exist to assess the quality of case-reports, which in general 
is considered to have a low level of evidence. Therefore, the quality was assessed with 
a method based on the Coordination of Cancer Clinical Practice Guidelines in Europe 
(CoCanCPG), addressing eight criteria: an appropriate and clearly focused question, 
representative population, description of the survey method or data collection, outcome 
measures defined and described, response rate reported, and results valid and applicable to 
the targeted patient group. Articles could score: -/-, -, +/-, +, or ++ on these items. Although 
personal opinions were included to obtain a complete overview of all literature, these were 
not quality assessed as in general the quality is considered low.
Data extraction and presentation
Study populations and definitions per included article were summarised in a separate table 
(S1 Table). Included articles were summarised in main domain tables: diagnosis, background/
descriptive, aetiology, prevention/therapy, and prognosis (S2-S5 Tables). If articles contained 
additional information on other domains, this was noted in the main table. The following 
information was provided per article, if applicable: year of publication in chronological order 
starting with the oldest articles; first author; country; year of the study; study period and 
duration; study type; number of patients and controls; patient characteristics; co-morbidity; 
outcome measurement tools; intervention(s); outcome; conclusion(s)/recommendation(s); 
and the quality of the article. In case an article could not be assessed with any of the 
mentioned tools, this was stated in the table in column quality assessment (QA) as not 
applicable (NA). Grey literature was similarly ordered in a separate table (S6 Table).
RESULTS
Inclusion of articles
The search yielded 1044 references (Fig 1); Pubmed n=537, Embase n=489, PsycInfo 
n=18, of which 223 were duplicates. During the first selection phase, 680 references were 
excluded as not relevant, 141 identified as potentially relevant, and the full-text articles 
were searched. One full-text article (Spanish) could not be obtained from three different 
libraries and as the author could not be reached, the article was excluded. Three conference 
abstracts without full-text article were excluded. Of the remaining 137 full-text articles, 51 
articles were deemed not relevant, 29 had no original data, and for three no translation 
was available (two Russian, one Japanese). The remaining 54 articles were included and 
hand searching their reference lists yielded 22 potentially relevant articles, of which three 
were included after full-text assessment. From the reference lists of included articles, we 
identified one guideline, one dissertation, two book chapters, and one economic report. 
After confirmation of relevance, these were included as grey literature except for one book 
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Figure 1. Flow diagram of identified literature.
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chapter as retrieval was not possible. In total, we included 57 articles and four grey literature 
documents.
Classification in domains
The 57 included articles were classified into one of the main domains: diagnosis (n=4, S2 
Table), background/descriptive (n=29, S3 Table), aetiology (n=18, S4 Table), and prevention/
therapy (n=6, S5 Table). As none of the included articles described the course of fatigue in 
QFS, no articles were classified into the domain prognosis. Grey literature (n=4) is presented 
in S6 Table.
Quality of included literature
From the four articles in the table diagnosis, one article was assessed with the NOS and 
scored 4/9 possible stars [25]. The remaining items (five stars) could not be assessed, as 
these items were not applicable for this study. The other three articles were personal 
opinions [10, 26, 27].
The quality of 21/29 articles in the domain background/descriptive was assessed with the 
NOS. Most articles had a moderate quality; however, none scored on all specific applicable 
criteria, mostly because of inadequate controls in the design or analysis. For four articles, 
not all items could be assessed, as these were not applicable for these studies. The quality 
of three case-reports (n=1) was low [28-30]. The quality of one study regarding burden of 
disease was not assessed [31], as no standard quality assessment checklist was available for 
this study category. One economic evaluation scored well (16/19) [32]. Two articles were 
personal opinions [33, 34], and one was a personal observation [35].
The quality of 15/18 articles on aetiology was assessed with the NOS. Although none scored 
on all specific applicable criteria, the quality of the articles was considered moderate. Seven 
articles did not score on comparability although applicable, as they lacked a correction for 
other factors that might explain the outcome. For four articles, not all possible stars could be 
retrieved, as these items were not applicable for these studies. Two laboratory case studies 
were not quality assessed [36, 37], and one article was a personal opinion [38].
The quality of 2/6 prevention/therapy articles was assessed with the NOS. One study scored 
4/9 stars, but none on comparability [39], while the other scored on 4/5 applicable items 
[6]. The quality of two case-reports (n=1) [40, 41] was below average, as was that of the 
case-series (n=3) [5], that scored on only 9/18 criteria. One article, a study protocol, was not 
quality assessed [42]. The Dutch QFS guideline was developed based on the AGREE criteria 
[43], and therefore considered to be of good quality [17]. The quality of the other grey 
literature was not assessed.
Definition and diagnosis
Nineteen articles contained information on diagnosis of which four were classified in the 
main table diagnosis (S2 Table) [10, 25-27].
Terminology
The name QFS was introduced in 1992 [44]. Ever since, it has been debated whether fatigue 
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following acute Q-fever is a separate entity compared to other forms of post-infective fatigue 
or CFS [27]. Some argue that chronic fatigue is a non-specific subjective state or symptom 
after Q-fever rather than a diagnosis [27]. Other consider QFS as a description of CFS 
implicating a specific micro-organism, and that this terminology might result in increased 
health-care costs [10]. Others stated that due to convincing evidence of a causal factor, 
QFS is a causally-defined subset of CFS, and that this factor should take precedence in the 
diagnostic statement [26]. Names used to indicate fatigue following acute Q-fever, include: 
residual asthenia following Q fever [38], postinfective fatigue or postinfective fatigue 
syndrome [10, 12, 18, 31, 45-47], postinfectious chronic fatigue [11], post-Q-fever debility 
syndrome [35], post-Q-fever chronic fatigue syndrome [35], qCFS [36], Q fever induced 
chronic fatigue syndrome [48], post-Q-fever fatigue or post-Q-fever fatigue syndrome [36, 
49], post-(acute) Q-fever (fatigue) syndrome [5, 14, 26, 28, 33, 50], and most frequently 
Q-fever fatigue syndrome (QFS or QFFS) [6, 8, 10, 19-21, 26, 30, 33, 36, 39, 42, 50-52].
In conclusion, the term QFS has been used for years and seems generally accepted.
Definition of QFS
An overview of the study populations and definitions used is provided for articles (S1 Table) 
and grey literature (S6 Table). Seven articles lacked a definition of the study population or 
of QFS [10, 26, 27, 33-35, 38]. In 32 articles the study population was defined but QFS was 
not [3, 7, 9, 11, 12, 14, 18, 25, 31, 32, 36, 37, 45-47, 49, 52-67]. In five articles individual 
patients were considered to have QFS, without providing a definition [5, 28-30, 40]. Six 
articles provided a definition of QFS [6, 8, 19, 39, 42, 48], which has been used in articles in 
subsequent years [20, 21, 50, 51]. A detailed description of QFS is published in a thesis [44], 
but is based on a retrospective comparative-cohort study and is not available online. In the 
Dutch QFS guideline [17], QFS is defined as: a severe fatigue causing significant disabilities in 
daily life present for at least 6 months, with a temporal relationship with acute Q-fever, and 
not caused by co-morbidity. Fatigue should be absent before acute Q-fever or should have 
significantly increased since the infection.
In conclusion, there is no international uniform definition for QFS.
Diagnosis
No articles provided complete information on the diagnostic work-up. The Dutch guideline 
on QFS bases diagnosis on a combination of history, physical examination and laboratory 
examination excluding other causes of fatigue, and should at least include erythrocyte 
sedimentation rate, C-reactive protein (CRP), creatine kinase, thyroid stimulating hormone, 
leukocytes with differentiation, creatinine, alkaline phosphatase, alanin aminotransferase, 
calcium, glucose, ferritin, and a urinary sediment. Through the use of validated questionnaires 
fatigue severity should be objectified. Morbid obesity (BMI>40) and substance abuse 
should lead to refraining from diagnosing QFS. It is not possible to diagnose QFS in case 
of: depression (if this preceded current symptoms), schizophrenia, psychosis, dementia or 
eating disorders (unless already resolved for a minimum of 5 years) [17].
In conclusion, the Dutch guideline on QFS provides a clear diagnostic work-up.
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Background/descriptive
Of the 40 articles containing background/descriptive information, 29 were classified in the 
main table background/descriptive (S3 Table) [3, 7-9, 11, 12, 14, 28-35, 52, 53, 56-59, 61, 
62, 64-69].
Incidence and prevalence of fatigue following C. burnetii infection
Fatigue following acute Q-fever was first described in 1960 [68]. Without indicating a 
time-relation with acute Q-fever, it was noted in 1990 that 4% of acute Q-fever cases had 
prolonged fatigue [53]. In 1992, it was stated that approximately 23% of study subjects 
developed QFS within 12 months following acute Q-fever [44]. Ever since, several studies 
on fatigue following acute Q-fever reported different prevalences. It was stated that 5-10% 
of patients experience residual asthenia six months after acute Q-fever and only few after 
one year [38]. In a reaction, it was underlined that a substantial proportion of acute Q-fever 
patients have symptoms similar to QFS for 6-9 months after the acute infection and then 
recover, but 8-10% of patients exhibit symptoms for at least a year [33]. This is similar to 
other reports, showing persistent symptoms for longer than two years [3], up to six years 
after the infection with 66% of patients reporting fatigue [14]. In Australia, QFS is the 
most common sequel of acute Q-fever reported to affect 10-15% of patients [70]. Higher 
percentages were described, with up to 28% of patients meeting the Centres for Disease 
Control and Prevention criteria for CFS 5 to 14 years after acute Q-fever, compared to none 
in the control group [8, 15]. The highest percentage of reported fatigue was 69% five years 
after acute Q-fever [9]. CFS criteria were met by 42% of C. burnetii-infected patients and 
26% of controls [9, 15]. Ten years after acute Q-fever, 68% of patients reported fatigue of 
any duration [54], of whom 20% met the CFS criteria [15]. Excluding co-morbidity, 8% of 
patients met the CFS criteria compared to none of the controls [54]. C. burnetii-exposed 
compared to non-exposed subjects reported ten years later a fatigue prevalence of 65% vs. 
35%, respectively, and 19% vs. 4% met the CFS criteria [7, 15]. In accordance, later results 
demonstrated fatigue to be more common after Q-fever compared to controls [58], up to 
two [61] and six years later [49, 69].
Post-infective fatigue following Epstein-Barr virus, Ross River virus or C. burnetii infection, 
was reported in 35% of cases after six weeks, 27% after three months, 12% after six 
months, and 9% after 12 months, regardless of the infective agent [12]. And, although not 
significantly different, 12 months after acute Q-fever, patients were more fatigued than after 
Legionnaires’ disease, while being younger and having less pre-existing health problems 
[11]. In patients with a lower respiratory tract infection who were C. burnetii seropositive 
10-19 months after the acute illness, 40% reported clinically relevant fatigue, compared 
to 64% of seronegatives, concluding that patients have long-term health problems after a 
lower respiratory tract infection in general [64].
In conclusion, fatigue following acute Q-fever might not be specific but occurs frequently 
and may persist for years. A large variance in prevalence of fatigue after Q-fever is reported 
between countries, due to differences in definitions, study designs and populations, and 
measurement tools, which impairs direct comparisons.
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Health status, burden of disease and economic impact
A sustained decrease in health status or health-related quality of life was reported [3, 58, 
61]. Twelve months after acute Q-fever, 50% of patients had a reduced general quality of 
life [11]. Other studies show a significant linear improvement in health status after acute 
Q-fever, but it was still reduced after 24 months in more than one third of all patients [67]. 
Twenty-seven months after acute Q-fever, 52% of patients reported persistent symptoms 
and lower scores on 5/8 Short Form 36 (SF-36) scales [71] compared to uninfected controls 
[3]. Four years after acute Q-fever, patients also had a significantly reduced health status 
compared to healthy controls [65]. To obtain a detailed overview of the patients’ health, 
a combination of the complete Nijmegen Clinical Screening Instrument (NCSI) [72] with 
subdomains (Role Physical, Bodily Pain, Social Functioning, and Role Emotional) of the 
SF-36 was advised [25]. Two studies focus on the burden of disease of fatigue following 
acute Q-fever [31, 32], one also assessed the economic impact of the outbreak in the 
Netherlands [13]. In 1992, for Australian C. burnetii-infected abattoir workers the costs per 
year for medical care and loss of wages for endocarditis and for QFS were calculated [44]. 
QFS represented the largest burden of disease [32, 44]. Furthermore, others found that, 
although the number of disability adjusted life years was higher for influenza, on a per case 
basis, Q-fever was more severe, and overall the burden of disease was more than eight 
times higher than for influenza, due to long-term sequelae [31]. The estimated income loss 
was largest due to the accumulation over time as a consequence of the projected duration 
of sick leave, and QFS was estimated to be one of the major Q-fever-related economic cost 
during the Dutch outbreak [13].
In conclusion, there are clear indications that fatigue following acute Q-fever results in a 
high burden of disease, a major negative impact on the health status of patients, and has 
significant economic implications.
Work-related consequences
In 1960, it was noticed that the majority of acute Q-fever patients recovered within weeks 
and returned to work [68]. However, this convalescence period was prolonged in 25% of 
cases who were absent from work for more than 6 weeks, 20% longer than 8 weeks, up 
to 23 weeks [68]. The mean period of sick-leave increased with age [68]. Later studies 
revealed that following acute Q-fever, 40% of patients were absent from work for more 
than one month [62]. After 12-26 months 9% was unable to function at premorbid levels 
due to fatigue and diminished concentration while more than 30% had not fully resumed 
daily activities, in 81% due to fatigue [62]. Besides work-related consequences, patients 
were more likely to report functional impairment in performing daily activities than healthy 
controls [46]. Q-fever patients showed a reduced work participation, from 45% after three 
months to 19% after 12 months, versus 15% of patients with Legionnaires’ disease after 12 
months [66]. Factors associated with reduced work participation were: having symptoms; a 
higher level of sorrow; being a former smoker (compared to never smoking); not consuming 
alcohol; and receiving treatment for health-related effects of Q-fever [66].
In conclusion, the majority of patients return to work within the first 12 months after acute 
Q-fever, although up to 20% reported reduced work participation.
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Course of fatigue following acute Q-fever and the role of co-morbidity
Following acute Q-fever, 69% of patients self-reported fatigue, which dropped to 52% at six 
months to 26% at 12 months [57]. Studies using the NCSI found that severe fatigue following 
acute Q-fever improved from 73% at three months, to 60% at 12 months [11, 67]. Twelve 
to 26 months after acute Q-fever up to 59% of patients reported fatigue of which 44% had 
severe fatigue [59], whilst after 24 months 37% of patients compared to 3% of healthy 
controls, reported severe fatigue [67]. Higher rates of 51% were described four years after 
infection [65]. Most articles describe a continuous fatigue syndrome, up to 74 months after 
the initial infection [19], while relapsing or remittent fatigue patterns also seemed to occur 
[3], up to 57 months [19] after acute Q-fever. One article reported a fatigue free period of 
2-4 months after acute Q-fever, eventually followed by QFS [5]. A disease period up to 20 
years has also been reported [44]. Pre-existing health problems were associated with a long-
term reduced health status including fatigue [59, 62, 67].
In conclusion, the percentage of patients who experience severe fatigue following acute 
Q-fever slowly decreases over time, mainly in the first 6-12 months. Fatigue remains a 
persistent complaint in approximately 20% of patients, with varying percentages and 
variability in the reported course of fatigue following acute Q-fever, and may persist for up 
to 20 years.
Complaints besides fatigue
QFS is frequently compared to CFS, and patients who fulfil the international CFS criteria by 
definition have multiple symptoms [15, 16]. The mean number of symptoms was higher 
in Q-fever exposed subjects 10 years after exposure compared to controls [7]. Patients 
with post-infective fatigue, including Q-fever-related post-infective fatigue, reported more 
symptoms in general and fatigue-related symptoms in particular [46]. Twelve to 26 months 
after acute Q-fever 40% of patients reported additional complaints [62]. An overview of 
frequently reported complaints besides fatigue after acute Q-fever is given below.
Musculoskeletal complaints. Myalgia and arthralgia were frequent complaints of patients 
considered to have QFS [5, 6, 17, 28, 39, 40, 44, 70]. Musculoskeletal pain accompanied 
fatigue 12 months after several infections [12], and was associated with a higher age [18]. 
Myalgia was significantly more often present 5-14 years after acute Q-fever compared to 
controls [8]. Twelve to 26 months after acute Q-fever, 4% of patients reported myalgia [62]. 
Myalgia was a major complaint in 23% of working patients 12 months after acute Q-fever 
[66]. Arthralgia was reported by 69% of patients up to six years after acute Q-fever [14], and 
was more severe compared to controls [9]. Both myalgia and arthralgia were also described 
in up to 70% of patients after a laboratory documented C. burnetii infection [52]. Compared 
to controls, presumed QFS patients had a higher pain score [48].
Neurocognitive problems. Although some authors found no association between C. burnetii 
seropositivity and concentration difficulties [56], neurocognitive difficulties were described 
in patients with post-infective fatigue, including QFS patients, 12 months after primary 
infection [12]. In addition, older subjects reported more neurocognitive symptoms [18]. 
Twelve to 26 months after acute Q-fever, 4% of patients had difficulties concentrating [62]. 
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Concentration and memory problems were also shown to be a major complaint in 24% of 
working Q-fever patients 12 months after the infection [66]. Although no difference was 
found in the frequency of memory problems between cases and controls, the severity was 
significantly higher after Q-fever [9]. A lack of concentration and short memory impairment 
within a year following acute Q-fever was also reported [17, 44], while another study found 
decreased concentration and mental acuity that could last up to 5-10 years [70].
Sleeping problems. Six years after acute Q-fever, 65% of patients reported a disturbed sleep 
pattern, which was significantly more frequent than in controls [14]. This was also reported 
by others [17, 29, 44, 70], including unrefreshing sleep [5].
Headache. Headache was frequently reported [5, 6, 17, 28, 30, 39, 52, 68, 70]. Twelve 
months after acute Q-fever, 24% of working patients reported frequent headaches [66]. 
Another study reported headache in 47% of patients six years after acute Q-fever [14]. 
Although the frequency of headache was similar to controls, the same authors found that 
the severity of headache was more profound in those after Q-fever [9].
Blurred vision. Blurred vision six years after acute Q-fever was similar to controls [14], but 
was more prevalent and more severe five years after acute Q-fever compared to controls in 
another study (34% vs. 18%) [9]. Blurred vision was also reported by others [17, 44]. Visual 
complaints were noted by 2% of patients 12 to 26 months after acute Q-fever [62].
Increased (night) sweating. Night sweats starting 6-12 months after acute Q-fever were 
described [70]. Twelve to 26 months after acute Q-fever, 3% of patients reported night 
sweats [62]. In comparison to controls, night sweats were more common after acute Q-fever 
[17, 44, 70]. Most QFS patients had this symptom for 5-10 years [70], up to 14 years [8, 28]. 
A combination of night sweating and increased sweating was also reported [30]. Increased 
sweating occurred with 53% more frequent after acute Q-fever compared to controls [14]. 
Others reported 53% of cases with increased sweating [5, 9]. Some authors considered 
abnormal sweating at least ten times a year as major QFS symptom [44].
Respiratory tract problems. Following acute Q-fever, 9% of patients complained of persistent 
chest symptoms [53]. Others reported that 47% of presumed QFS patients complained of 
cough and a sore throat with a mean symptom duration of four years [52]. Others reported 
these complaints also [17, 28-30, 39]. Five years after acute Q-fever, 51% of cases complained 
of breathlessness on exertion [9], compared to 32% of controls. Six years after acute Q-fever, 
59% of patients complained of cough, 49% of breathlessness, and 51% of chest pain, all 
significantly more frequently than controls [14]. Furthermore, an association between QFS 
and bronchial asthma has been suggested [30].
Mood disorders. Patients with fatigue after acute Q-fever have been reported to experience 
increased irritability [14], mood disturbances [12, 17], and anger [70]. Mental problems, 
e.g. depression and unstable moods, can occur within a year following acute Q-fever [44], 
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whereas, with regard to depression, most subjects were healthy before the infection [44]. 
Two years after acute Q-fever more psychosocial complaints were observed compared to 
controls [61]. Common symptoms of psychological distress were reported significantly more 
in patients with post-infective fatigue, including QFS patients, compared to healthy controls 
[46]. Others hypothesise that Q-fever-related fatigue might be explained by psychological 
distress, caused by uncertainty about their illness and repeated medical contacts that 
reinforce perceptions of ill health [7]. Some contradict this hypothesis [67]. Infection with 
C. burnetii was followed by depression in 10% of cases [53]. Three case-reports (all n=1) 
[28-30] reported a C. burnetii-triggered depression, leading to thoughts of death [28], a 
near suicide attempt [30], and suicide [29]. The suggestion was that cytokine network 
abnormalities after a C. burnetii infection might underlie the onset of depression [28, 29, 
73]. Although a possible relationship between high IgG phase II C. burnetii-antibodies and 
depression was suggested [69], others found no association between seropositivity, and 
depression, depressive ideas or overall psychiatric morbidity [56].
Other complaints. Other reported symptoms accompanying prolonged fatigue after Q-fever 
are severe malaise [40, 41], setback upon exertion and the need for prolonged rest after 
simple tasks [5, 8, 68], poor appetite [30, 68], gastrointestinal symptoms [6, 17, 29, 30, 44, 
70], muscle fasciculation or spasms [8, 17, 41, 44, 70], dizziness [14, 17, 30], light intolerance 
[8, 19], tinnitus [28], taste disturbance [28, 29], loss of libido [17, 19], nasal and bronchial 
congestion [8, 17], and enlarged or painful lymph nodes [17, 70]. Bradycardia was postulated 
as a sign of QFS [35], and palpitations were described [30]. Even though reported in several 
studies [8, 17, 19, 44], alcohol intolerance was not statistically more frequent in the Q-fever 
group six years after acute Q-fever when compared to controls [14]. A slightly elevated body 
temperature (below 38 degrees Celsius) was described in QFS patients [5, 6, 28, 30, 39-41, 
44, 70]. Up to 53% of assumed QFS patients felt feverish for four years [52].
In conclusion, besides fatigue as the main complaint, several nonspecific symptoms 
accompanying fatigue following C. burnetii infection were described. Commonly reported 
symptoms include musculoskeletal complaints, neurocognitive symptoms, sleeping 
problems, headaches, blurred vision, increased (night) sweating, respiratory complaints, 
and mood disorders.
Aetiology
Of the 28 articles that contained information on aetiology, 18 were classified in the main 
table aetiology (S4 Table) [18-21, 36-38, 45-51, 54, 55, 60, 63].
Pathophysiology
Genetic variance and relationship with fatigue. No relation [3] or correlation [47] between 
genetic factors and QFS was found. A lack of a coherent set of gene expression correlating 
across cohorts argued against the genetic signature for post-infective fatigue or CFS [47]. 
In contrast, another study found similar gene expression patterns for QFS and CFS patients 
[48]. The frequency of human leukocyte antigen – group DR (HLA-DR)-11 was significantly 
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increased in QFS patients compared to controls. Also, more polymorphic variants within the 
NRAMP1 gene differing from the wild type were found, as well as significant differences 
in allelic variant frequencies within interferon-y (IFNy) genes, but effects were thought to 
be multigenic and cumulative. It was hypothesised that QFS might result from individual 
variations in immune response to C. burnetii [50]. QFS patients differed in the frequency of 
HLA-DRB1*11 carriage and the 2/2 genotype of the IFNy intron 1 microsatellite compared 
to control groups [51]. Carriage was associated with reduced IFNy and interleukin(IL)-2 
responses from stimulated peripheral blood mononuclear cells (PBMC) [51].
In conclusion, results regarding genetic variations in host immune responses in QFS were 
contradictory.
Immunological aspects. An immunological basis for QFS or other post-infective fatigue 
syndromes was debated in several articles. A reduction in reported fatigue correlated with 
improvement in the delayed-type hypersensitivity skin response and general health scores 
[45]. Resolving fatigue after acute infection seemed associated with improved cell-mediated 
immunity, supporting an immunological basis for post-infective fatigue [45]. Upregulation 
of 2’,5’-oligoadenylate synthetase (2-5AS) activity in PBMC of CFS patients was present, 
but a relation between C. burnetii antibody titres and 2-5AS activities lacked [55]. It was 
however suggested that C. burnetii infection is associated with 2-5AS activities in some CFS 
patients, as 2-5AS activities changed from positive to negative in one CFS patient when C. 
burnetii antibodies disappeared [55]. In acute Q-fever IL-6 and CRP seemed predictive of 
more severe disease, but no support was found that these were associated with prolonged 
fatigue [63]. Markers of inflammation and pro-inflammatory cytokine concentrations did 
not remain altered in patients with post-infective fatigue [12, 18].
In conclusion, no clear evidence exists with regard to an immunological basis involving 
2-5AS, IL-6, and CRP for the development of QFS.
Immunomodulatory complex and cell-mediated immunity. Persistence of C. burnetii or its 
antigens resulting in chronic immune stimulation with subsequent fatigue [8, 19-21, 36, 
37, 49], or causing dysregulation of the macrophage/T-lymphocyte axis with subsequently 
aberrant monokine and lymphokine production mediating symptoms [8], was hypothesised. 
Cytokine release patterns of PBMC of QFS patients were aberrant with an accentuated 
IL-6 release, a decreased number of IL-2 responders, and an increased number of IFNy 
responders [19]. In vitro, using human samples, an increased cellular immune response and 
cytokine dysregulation was found with increased levels of IL-6 and IL-10, and decreased level 
of IL-2 [70]. A significant correlation between IL-6 and scores for key and total symptoms 
was found [19]. The detection of low levels of C. burnetii DNA in bone marrow aspirates, 
thin needle liver biopsies, and blood mononuclear cells, supports cytokine dysregulation 
and immunomodulation caused by C. burnetii persistence [20]. Others showed a more 
complex interaction between host-regulated disease and persistent C. burnetii DNA carriage 
- either live, dormant, or dead but with undegraded DNA - in bone marrow, irrespective 
of clinical state [21]. An additional but variable factor of host regulation of cell-mediated 
immunity was postulated, determining the level of persistence and symptomatic outcomes. 
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It was hypothesised that in Q-fever without sequelae, the process of multiplication of live 
Coxiella was largely confined to bone marrow, in contrast to QFS, in which a modulated 
immune response caused increased levels of C. burnetii genome in bone marrow with 
increased shedding into peripheral blood [21]. Subsequently, one of the core hypotheses 
postulated included the presence of an immunomodulatory complex, consisting of non-
viable undegraded C. burnetii DNA or its antigens, causing an abnormal cell-mediated 
immune response via damaged macrophages [37]. This stops the patient from clearing 
the microbe completely, leading to ongoing production of pro-inflammatory cytokines 
and subsequently fatigue. In contrast to QFS patients, those who fully recovered from 
acute Q-fever had no immunomodulatory complex [37]. The bacteraemia is restricted by 
humoral and cell-mediated immunity, by clearing of C. burnetii DNA containing components 
with an immunomodulatory effect of cell-mediated immunity and dendritic cells causing 
dysregulation, cytokines and other immune mediators, giving rise to symptoms [70]. The 
complexes appeared more likely to be a residue of the original heavy seeding during the 
bacteraemia of the acute infection, rather than the product of an ongoing multiplication, 
destruction and renewal of infection [21]. QFS follows clinical overt infection, rarely 
subclinical infection, and the systemic symptoms of QFS may reflect a wide distribution of 
parasitized mononuclear phagocytes [36, 37]. In other patient cohorts, neither viable C. 
burnetii nor DNA in PBMC was detected [49].
In conclusion, several studies point towards cytokine dysregulation mediating symptoms 
in QFS. This may originate from an immunomodulatory complex consisting of non-viable 
undegraded C. burnetii DNA or its antigens. However, results regarding remnant C. burnetii 
DNA were contradictory.
Cardiac involvement in QFS. No ECG abnormalities excess in the Coxiella-exposed cohort 
with fatigue was found in comparison to controls [54]. Post-infective fatigue was associated 
with higher heartbeat discrimination accuracy, increased resting heart rate with decreased 
heart rate variability, and a lower pressure pain threshold [46]. The altered cardiac response 
was believed to be a stress response portraying an over-responsive system lacking dynamic 
flexibility [46]. Heightened interoceptive sensitivity with strong symptom correlation was 
also found. This suggests physiological hyper-vigilance and response inflexibility in post-
infective fatigue [46].
In conclusion, there is no evidence for direct cardiac involvements in QFS, but there is some 
evidence for physiological hyper-vigilance and response inflexibility in patients with post-
infective fatigue.
(Bio)psychological origin of QFS. It is unknown whether chronic fatigue following Q-fever 
is directly caused by the bacterium or if it is (bio)psychological in origin [38]. As subjective 
symptoms are difficult to quantify, it was stated that they might reflect an observational 
bias, C. burnetii strain or cultural differences, or genetic susceptibility [38]. In addition to the 
immune stimulation hypothesis, interpretations range from compensation-driven through 
psychogenic perpetuation of original symptoms or depression [8]. Q-fever patients with 
fatigue symptoms had higher somatisation scores, a higher tendency for hypochondriac 
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worries and beliefs, a higher level of psychosocial complaints, and reduced quality of life 
[61]. The non-proven presumption was that Q-fever triggered fatigue development and 
that the risk of developing symptoms might be increased by hypochondriac features and a 
tendency to somatisation, supporting a biopsychological aetiology [61].
In conclusion, some studies supported the view of a biopsychological aetiology of QFS.
Predictors of post-infective fatigue syndrome, including QFS
Psychological factors and demographics. Post-infective fatigue appeared to be stereotyped 
across different infective triggers, and it was suggested that the host response rather than 
psychological or microbial factors determined ongoing symptoms [18]. No source of exposure 
was associated with developing persistent symptoms [3]. Premorbid and intercurrent 
psychiatric disorders were not predictive for post-infective fatigue [12]. In contrast to the 
biopsychological aetiology [61], it was recently suggested that psychological distress was not 
an important factor in explaining increased fatigue levels after acute Q-fever [67]. Although 
some found that gender was not a predictor [12], others found an overrepresentation of 
women in high severity groups for fatigue, mood disturbance and neurocognitive difficulties 
[60]. Being female or a young adult, and smoking were characteristics significantly associated 
with long-term reduced health status including fatigue [62, 67]. In contrast, another study 
found no association between fatigue and age [59].
In conclusion, neither psychological nor microbial factors seem to predict post-infective 
fatigue, including QFS.
Severity of the acute illness. It was stated that one of the key risk factors for the development 
of post-infective fatigue, including QFS patients, is the severity of the acute illness [12]. 
Patients with post-infective fatigue had a longer mean duration of the acute illness, and 
more days in bed and days out of role during the acute phase compared to controls [18].The 
clinical expression of acute Q-fever seemed an essential factor in the subsequent sustained 
decrease in health status [58], which is supported by the finding that QFS usually follows 
acute Q-fever and rarely if ever asymptomatic infection [70]. Pre-existing health problems 
[62, 67], and hospitalisation, as an indicator of the severity of the initial infection, were 
also fatigue predictors [59, 62]. No symptoms during the acute Q-fever infection were 
predictors for persisting symptoms [3], nor did these determine the long-term health status 
[65]. Neither IL-6 and CRP levels nor antibiotic treatment during the acute infection were 
predictors for the development of prolonged fatigue [3, 63]. No relationship was found 
between fatigue and antibody titres six years after the Q-fever infection [49].
In conclusion, the severity of the acute Q-fever infection seems a key factor for worse long-
term health status, including fatigue and QFS.
Genetic factors in predicting fatigue. A single nucleotide polymorphism (SNP) of the T allele 
IFNy+874T/A appeared to be the best predictor of increased fatigue after the acute phase of 
several infections, including C. burnetii [60]. While the C allele of IL-10-592C/A SNP exerted 
a protective effect on neurocognitive difficulties, the A allele IL-10-592 SNP and G allele IL-
6-174G/C SNP were associated with increased mood disturbance [60].
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In conclusion, as evidence is scarce, more research is needed regarding genetic factors 
predicting fatigue in QFS.
Prevention/therapy
Eleven articles contained information on prevention/therapy of which six are classified in 
the main table prevention/therapy (S5 Table) [5, 6, 39-42].
Prevention
No articles on the prevention of QFS were found. The Dutch guideline on QFS proposes to 
advice patients within the first six months after acute Q-fever or after established QFS to: 
i) stay mentally and physically as active as possible, adjust pace if necessary; ii) alternate 
activities, also within activities; iii) keep fulfilling the role in daily life; iv) maintain a regular 
sleep-wake pattern; v) avoid focusing on fatigue; and vi) focus on feasible activities and 
appreciate accomplishments [17]. It is also proposed to explain that most patients recover 
within the first 6-12 months following acute Q-fever.
Antibiotic treatment
Four articles reported on the effect of long-term antibiotic treatment in assumed QFS patients 
[5, 6, 39, 40]. No randomised controlled trial (RCT) was found. Treatment with either 3 
months of minocycline 200mg/day (n=18), levofloxacine 200mg/day (n=1), or erythromycin 
400mg/day (n=1), improved performance status and reduced fatigue [6], concluding that 
minocycline was useful in treating QFS [6]. In a pilot-study, treatment with three months 
of minocycline 100mg/day (n=29), doxycycline 100mg/day (n=26), or levofloxacin 200mg/
day (n=3), showed improvement in performance status, headache, and mean weekly 
temperature [39]. A case-series (n=3) [5] and case-report (n=1) [40] showed inconsistent 
results of treatment with long-term antibiotics. According to others, the positive effect of 
antibiotic treatment for QFS is not confirmed nor advised [17]. The efficacy of long-term 
antibiotic treatment is now tested in a RCT but results are not yet available [42].
In conclusion, available data on long-term antibiotic treatment for QFS are scarce and 
inconsistent.
Cognitive behavioural therapy (CBT) and graded exercise therapy (GET)
CBT proved effective in reducing symptoms and improving functioning in CFS patients [74, 
75], and in chronic fatigue in chronic illnesses [76-78]. It was suggested as treatment option 
for QFS patients who experience psychological distress [61]. Based on CFS literature and 
similarities between CFS and QFS, CBT is advised in the Dutch QFS guideline, although 
suspected not to be beneficial for all patients [17]. The effectiveness of CBT treatment for 
QFS is currently under investigation [42]. Also GET is recommended for QFS patients, as 
proven effective in reducing fatigue in CFS [17].
In conclusion, although evidence is lacking, CBT and GET might be effective in reducing 
fatigue in QFS patients.
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Treatment of QFS-related symptoms
Three articles (all n=1) reported treatment of QFS-related symptoms [28-30]. The authors 
concluded that education and counselling about QFS and QFS-related symptoms should be 
provided to QFS patients [28]. Attention to the patient’s mental state is necessary in order to 
recognise accompanying symptoms, e.g. depressive thoughts, that should be treated [30], 
and involving a psychiatrist early ought to be considered [29]. This has been recognised 
before, where tricyclic antidepressants were beneficial treatment of mental problems after 
acute Q-fever [44].
In conclusion, education and counselling of patients about QFS and QFS-related symptoms 
seems important, as well as considering a patient’s mental state.
Alternative treatment
Alternative therapies for QFS patients were described (both n=1), including Kampo formula 
Tsumura Hochu-ekki-To granules, which appeared not to be effective [40], and Kampo 
formula Shakuyaku-Kanzo-To granules, which resulted in alleviation of stiffness in hand and 
arm [41].
At present, evidence for the use of alternative treatment lacks.
DISCUSSION
This first systematic review on fatigue following acute Q-fever, includes 57 articles and four 
grey documents up to the 26th of May 2015. The main limitation is the lack of a uniform 
definition of fatigue after Q-fever and the absence of a standardized diagnostic tool. In 
addition, the terminology both for fatigue and C. burnetii-related fatigue differed between 
publications and in time. Consequently, comparison of outcomes is difficult or impossible. 
Although not all articles could be quality assessed, these were nevertheless included as 
their information was considered valuable.
An international uniform definition of QFS, discriminating fatigue caused by C. burnetii from 
other post-infective fatigue syndromes and CFS is unavailable [19, 26, 36]. As the Dutch 
QFS guideline provides the most detailed description of QFS [17], we propose to use its 
definition and diagnostic work-up internationally. An international uniform definition 
provides the opportunity to achieve uniformity in diagnosis, treatment, and comparison 
of research results. It also provides recognition for physicians and acknowledgement for 
patients, reducing fear concerning uncertainty about their disease, providing an opportunity 
to continue their path to recovery [79, 80].
Whether fatigue following acute Q-fever is a separate entity compared to other forms of 
post-infective fatigue is debatable [10, 12, 18, 27, 44, 47, 81], but should not hamper the 
use of the term QFS.
Although differences in incidence and prevalence were reported, approximately 20% of 
patients remain chronically fatigued following an acute Q-fever infection. These differences 
can be explained by lack of recognition, uniform definition and diagnostic work-up, follow-up, 
and assessment tools. Using similar validated screening instruments is essential to compare 
studies [34]. Therefore, we advocate using validated screening instruments for measuring 
fatigue severity and disabilities, preferably with international available instruments [82], 
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such as the Checklist Individual Strength or Chalder Fatigue Scale for fatigue [83, 84], and 
the NCSI, SF-36, or Sickness Impact Profile for disabilities [71, 72, 85]. This also helps to 
map the impact of QFS. The cut-off period of 6 months to diagnose QFS has been proposed 
as most patients recover spontaneously within this period, which corresponds with the 
internationally accepted definition for CFS [15, 16]. In QFS, fatigue frequently lasts beyond 
a year and mostly more than 5 to 10 years [8, 14]. Many nonspecific symptoms described 
accompanying fatigue in QFS were not systematically monitored as prospective data were 
unavailable. Most studies did not report the time-relation between these symptoms, fatigue, 
and the Q-fever infection, nor the frequency of occurrence. Therefore, it was not possible 
to list all symptoms possibly related to fatigue following C. burnetii infection nor provide 
a temporal or causal relationship. However, guidelines with regard to the examination 
of chronic fatigue should be followed to rule out other diseases which can cause chronic 
fatigue.
Several hypotheses regarding the underlying pathophysiological mechanism of QFS were 
proposed, but no conclusive answers have been identified yet. Research on the relationship 
between genetic factors and QFS is contradictory and scarce. Several studies point towards 
cytokine dysregulation mediating symptoms in QFS, including an immunomodulatory 
complex consisting of non-viable undegraded C. burnetii DNA and or its antigens. However, 
these results need further confirmation, as most studies regarding this topic have been done 
by the same study group and contradictory results exist with regard to the presence of C. 
burnetii DNA in QFS. Several queries exist regarding predictors of QFS. Neither psychological 
nor microbiological factors seemed to predict post-infective fatigue. Only the severity of the 
acute Q-fever infection appears a predictor of long-term reduced health status.
No uniformity exists regarding optimal treatment for QFS. Results from RCTs using long-
term antibiotics are not available, and the available studies all suffer from several important 
limitations, such as the lack of a clear QFS description, the inclusion of patients with a 
symptom duration of 1-4 months, and the inclusion of patients with positive C. burnetii 
PCR at baseline, possibly indicating chronic Q-fever, and can therefore not be generalized. 
As the evidence of beneficial antibiotic treatment in QFS patients lacks, it should not be 
prescribed for QFS patients. The recommended treatment after diagnosis of QFS in the 
Dutch QFS guideline is based on CFS literature, and consists of CBT and, if available GET. The 
effectiveness of these treatments in QFS has not been proven yet. A randomised placebo-
controlled trial in order to evaluate the efficacy of both long-term doxycycline and CBT in 
QFS patients is currently performed [42]. Treatment should at least focus on the provision of 
medical care, physical rehabilitation and additional psychological support [81]. Furthermore, 
physicians should be aware of accompanying complaints, especially depressive thoughts, 
which require treatment at an early stage [29]. Alternative treatments were only effective in 
one case-report and are therefore not recommended. Finally, the prognosis of QFS patients 
is unclear regardless if treated or not.
In conclusion, the occurrence and long-term persistence of fatigue following acute 
Q-fever, generally referred to as QFS, has major health-related consequences. Information 
on aetiology, prevention, treatment, and prognosis of QFS is underrepresented in the 
international literature. In order to facilitate comparison of findings, and as a platform 
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for future preferably prospective studies, we propose a uniform definition of QFS and the 
use of uniform measurement tools. In addition, in order to facilitate comparison of long-
term sequelae following several infectious agents, and as a platform for further preferably 
prospective studies, an international collaboration and a research agenda are desirable with 
regard to micro-organisms known for causing post-infective fatigue, in which C. burnetii 
should undoubtedly be included.
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10
 t
o 
≤4
0,
 w
it
h 
Q
F 
no
t 
be
in
g 
co
ns
id
er
ed
 t
o 
be
 c
au
sa
lly
 r
el
at
ed
 t
o 
th
e 
pr
es
en
ti
ng
 c
om
pl
ai
nt
. 
N
o 
de
fin
iti
on
 fo
r 
fa
ti
gu
e 
19
95
, P
. H
ar
ve
y-
Su
tt
on
 [3
]
N
o 
st
ud
y 
po
pu
la
ti
on
 o
r 
Q
FS
 d
efi
ni
ti
on
 
19
96
, B
. M
ar
m
io
n 
[4
]
5-
14
 y
rs
 p
os
t 
la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
(A
Q
F 
de
fin
ed
 a
s 
a 
CF
T 
ti
tr
e 
of
 ≥
1:
25
6 
or
 a
 4
-f
ol
d 
ri
se
 in
 p
ha
se
 II
 a
nti
bo
di
es
),
 Q
FS
 d
efi
ne
d 
as
: 1
) i
nc
ap
ac
it
ati
ng
 fa
ti
gu
e 
re
qu
ir
in
g 
pr
ol
on
ge
d 
re
st
 a
ft
er
 s
im
pl
e 
ta
sk
s;
 2
) n
au
se
a,
 p
er
si
st
en
t 
he
ad
ac
he
; 3
) f
ee
lin
g 
fe
ve
ri
sh
 w
it
h 
pr
of
us
e,
 o
do
ri
fe
ro
us
 s
w
ea
ts
 a
t 
ni
gh
t,
 u
su
al
ly
 a
fe
br
ile
; 4
) m
ya
lg
ia
 in
 a
ny
 m
us
cl
e 
gr
ou
p;
 5
) i
nt
er
m
itt
en
t 
fa
sc
ic
ul
ati
on
 o
f m
us
cl
e 
fib
re
s 
an
d 
m
us
cl
e 
te
nd
er
ne
ss
 o
n 
pa
lp
ati
on
; 6
) a
rt
hr
al
gi
a 
w
it
ho
ut
 s
w
el
lin
g,
 in
 a
ny
 jo
in
t 
in
cl
ud
in
g 
co
st
oc
ho
nd
ra
ls
; 7
) e
th
an
ol
 
in
to
le
ra
nc
e 
co
m
pa
re
d 
w
it
h 
ca
pa
ci
ty
 b
ef
or
e 
A
Q
F;
 a
nd
 8
) i
nt
er
ru
pt
ed
 s
le
ep
 p
att
er
ns
, e
xc
es
si
ve
 a
nd
 u
nr
ea
so
na
bl
e 
ir
ri
ta
bi
lit
y,
 
un
re
lia
bl
e 
sh
or
t-
te
rm
 m
em
or
y,
 a
nd
 p
oo
r 
co
nc
en
tr
ati
on
. L
es
s 
fr
eq
ue
nt
 c
om
pl
ai
nt
s:
 b
lo
ati
ng
, i
rr
it
ab
le
 b
ow
el
 s
yn
dr
om
e,
 n
as
al
 a
nd
 
br
on
ch
ia
l c
on
ge
sti
on
, b
lu
rr
ed
 v
is
io
n,
 b
ri
gh
t 
lig
ht
 in
to
le
ra
nc
e,
 a
nd
 e
nl
ar
ge
m
en
t 
an
d 
pa
in
 in
 ly
m
ph
 n
od
es
. D
efi
ni
ti
on
 C
FS
: a
cc
or
di
ng
 
to
 t
he
 1
99
4 
in
te
rn
ati
on
al
 C
FS
 c
ri
te
ri
a 
[5
]
19
96
, J
. A
yr
es
 [6
]
6 
yr
s 
po
st
 A
Q
F 
[7
, 8
] (
A
Q
F 
de
fin
ed
 a
s 
a 
CF
T 
ti
tr
e 
of
 ≥
1:
25
6 
or
 a
 4
-f
ol
d 
ri
se
 in
 p
ha
se
 II
 a
nti
bo
di
es
),
 n
o 
Q
FS
 d
efi
ni
ti
on
, b
ut
 r
at
he
r 
de
sc
ri
pti
on
 o
f c
om
pl
ai
nt
s 
be
in
g 
si
gn
ifi
ca
nt
ly
 m
or
e 
pr
ev
al
en
t 
in
 p
as
t 
Q
F 
ca
se
s 
i.c
.w
. c
on
tr
ol
s:
 jo
in
t 
pa
in
s,
 s
le
ep
 d
is
tu
rb
an
ce
, c
ou
gh
, 
sw
ea
ti
ng
, i
rr
it
ab
ili
ty
, c
he
st
 p
ai
n,
 b
re
at
hl
es
sn
es
s,
 a
nd
 d
iz
zi
ne
ss
19
98
, J
. A
yr
es
 [9
]
5 
yr
s 
po
st
 A
Q
F 
[7
, 8
] (
A
Q
F 
de
fin
ed
 a
s 
a 
CF
T 
ti
tr
e 
of
 ≥
1:
25
6 
or
 a
 4
-f
ol
d 
ri
se
 in
 p
ha
se
 II
 a
nti
bo
di
es
),
 n
o 
Q
FS
 d
efi
ni
ti
on
, b
ut
 r
at
he
r 
de
sc
ri
pti
on
 o
f c
om
pl
ai
nt
s 
be
in
g 
si
gn
ifi
ca
nt
ly
 m
or
e 
pr
ev
al
en
t 
in
 p
as
t 
Q
F 
ca
se
s 
i.c
.w
. c
on
tr
ol
s:
 fa
ti
gu
e,
 s
w
ea
ti
ng
, b
re
at
hl
es
sn
es
s 
on
 e
xe
rti
on
, b
lu
rr
ed
 v
is
io
n,
 w
it
h 
sy
m
pt
om
 s
ev
er
it
y 
in
 Q
F 
ca
se
s 
be
in
g 
hi
gh
er
 fo
r 
fa
ti
gu
e,
 b
lu
rr
ed
 v
is
io
n,
 s
w
ea
ti
ng
, m
em
or
y 
de
te
ri
or
ati
on
, j
oi
nt
 p
ai
ns
 a
nd
 h
ea
da
ch
es
19
98
, B
. B
en
ne
t 
[1
0]
PI
FS
 p
ati
en
ts
 fr
om
 D
IO
S 
or
 fr
om
 t
he
 U
ni
ve
rs
it
y 
H
ea
lt
h 
Se
rv
ic
e 
at
 t
he
 U
ni
ve
rs
it
y 
of
 N
ew
 S
ou
th
 W
al
es
 w
ho
se
 s
ym
pt
om
s 
ha
ve
 b
ee
n 
pr
es
en
t 
≤4
 w
ks
19
98
, K
. K
at
o 
[1
1]
Pa
ti
en
ts
 w
it
h 
ch
ro
ni
c 
no
ns
pe
ci
fic
 s
ym
pt
om
s,
 s
uc
h 
as
 fa
ti
gu
e,
 jo
in
t 
ac
he
s,
 s
le
ep
 d
is
tu
rb
an
ce
, n
ig
ht
 s
w
ea
ts
, m
ya
lg
ia
 a
ff
ec
ti
ng
 
va
ri
ou
s 
m
us
cl
e 
gr
ou
ps
, n
au
se
a,
 p
er
si
st
en
t 
he
ad
ac
he
, a
nd
 s
o 
on
, w
it
ho
ut
 d
ia
gn
os
is
 o
r 
tr
ea
tm
en
t 
hi
st
or
y 
of
 Q
F 
an
d 
liv
in
g 
in
 c
lo
se
 
co
nt
ac
t 
w
it
h 
an
im
al
s,
 p
re
se
nt
ed
 b
et
w
ee
n 
M
ar
ch
 1
99
6 
an
d 
A
pr
il 
19
97
 t
o 
th
e 
D
ep
ar
tm
en
t 
of
 In
te
rn
al
 M
ed
ic
in
e 
an
d 
Ps
yc
ho
so
m
ati
c 
M
ed
ic
in
e,
 N
ih
on
 U
ni
ve
rs
it
y 
H
ea
lt
h 
Sc
ie
nc
e 
Ce
nt
re
. H
ea
lt
hy
 c
on
tr
ol
s:
 w
it
ho
ut
/f
ew
 c
om
pl
ai
nt
s,
 w
ho
 r
ec
ei
ve
d 
an
nu
al
 e
xa
m
in
ati
on
s 
at
 t
he
 s
am
e 
ho
sp
it
al
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 d
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S1
 T
ab
le
 c
on
ti
nu
ed
. O
ve
rv
ie
w
 o
f s
tu
dy
 p
op
ul
ati
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
In
cl
ud
ed
 a
rti
cl
es
St
ud
y 
po
pu
la
ti
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
19
98
, I
. P
en
tti
la
 [1
2]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
ts
: 1
) s
ev
er
e 
in
ca
pa
ci
ta
ti
ng
 fa
ti
gu
e 
≥6
 m
o 
po
st
 A
Q
F,
 w
it
h 
sy
m
pt
om
 s
co
re
 >
10
0;
 2
) p
re
se
nc
e 
of
 m
ya
lg
ia
 a
nd
 
ar
th
ra
lg
ia
; a
nd
 3
) a
bn
or
m
al
 s
w
ea
ts
, p
ar
ti
cu
la
rl
y 
at
 n
ig
ht
. I
n 
ad
di
ti
on
, m
os
t 
pa
ti
en
ts
 h
ad
 o
th
er
 s
ym
pt
om
s 
su
ch
 a
s 
in
ap
pr
op
ri
at
e 
ex
ha
us
ti
on
 o
n 
m
in
or
 e
xe
rti
on
, m
us
cl
e 
fa
sc
ic
ul
ati
on
, h
ea
da
ch
es
, b
ri
gh
t 
lig
ht
 in
to
le
ra
nc
e,
 e
th
an
ol
 in
to
le
ra
nc
e,
 in
te
rr
up
te
d 
an
d 
un
re
fr
es
hi
ng
 s
le
ep
 p
att
er
ns
, i
rr
ati
on
al
 ir
ri
ta
bi
lit
y,
 lo
ss
 o
f l
ib
id
o,
 d
ep
re
ss
io
n,
 im
pa
ir
m
en
t 
m
en
ta
l c
on
ce
nt
ra
ti
on
 a
nd
 s
ho
rt
-t
er
m
 
m
em
or
y.
 R
es
ol
vi
ng
 Q
FS
: r
ec
ru
it
ed
 in
 s
im
ila
r 
w
ay
 a
ft
er
 s
ev
er
al
 y
rs
 o
bs
er
va
ti
on
, b
ut
 s
ym
pt
om
 s
co
re
 d
ro
pp
ed
 fr
om
 v
al
ue
s 
>1
00
 t
o 
≤9
5.
 Q
F 
w
it
ho
ut
 Q
FS
: 6
 m
o 
po
st
 A
Q
F 
w
it
ho
ut
 c
om
pl
ex
 o
f s
ym
pt
om
s 
an
d 
lo
w
 s
ym
pt
om
 s
co
re
 (1
-3
5)
19
99
, J
. S
ca
dd
in
g 
[1
3]
N
o 
st
ud
y 
po
pu
la
ti
on
 o
r 
Q
FS
 d
efi
ni
ti
on
20
00
, R
. H
ar
ri
s 
[1
4]
D
efi
ni
ti
on
 o
f Q
FS
 p
ati
en
ts
: c
on
fo
rm
 [1
2]
. C
on
tr
ol
s:
 c
on
fo
rm
 [1
2]
20
02
, J
. A
yr
es
 [1
5]
10
 y
rs
 p
os
t 
la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
[7
, 8
] (
A
Q
F 
de
fin
ed
 a
s 
a 
CF
T 
ti
tr
e 
of
 ≥
1:
25
6 
or
 a
 4
-f
ol
d 
ri
se
 in
 p
ha
se
 II
 a
nti
bo
di
es
).
 C
on
tr
ol
s:
 n
o 
se
ro
lo
gi
ca
l e
vi
de
nc
e 
of
 p
as
t 
ex
po
su
re
 t
o 
C.
b.
 D
efi
ni
ti
on
 fa
ti
gu
e:
 a
cc
or
di
ng
 t
o 
th
e 
19
94
 in
te
rn
ati
on
al
 C
FS
 c
ri
te
ri
a 
[5
, 1
6]
20
02
, M
. W
ild
m
an
 [1
7]
10
 y
rs
 p
os
t 
la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
[7
, 8
] (
A
Q
F 
de
fin
ed
 a
s 
a 
CF
T 
ti
tr
e 
of
 ≥
1:
25
6 
or
 a
 4
-f
ol
d 
ri
se
 in
 p
ha
se
 II
 a
nti
bo
di
es
).
 D
efi
ni
ti
on
 
fa
ti
gu
e:
 s
co
re
 ≥
4 
us
in
g 
th
e 
tr
ad
iti
on
al
 s
co
ri
ng
 s
ys
te
m
 fo
r 
th
e 
fa
ti
gu
e 
qu
es
ti
on
na
ir
e 
[1
8]
. D
efi
ni
ti
on
 IC
F:
 fa
ti
gu
ed
 a
nd
 d
es
cr
ib
in
g 
fa
ti
gu
e 
>5
0%
 o
f t
he
 ti
m
e 
fo
r 
6 
m
o.
 D
efi
ni
ti
on
 C
FS
: I
CF
 a
nd
 fu
nc
ti
on
al
 im
pa
ir
m
en
t 
an
d 
≥4
 a
dd
iti
on
al
 s
ym
pt
om
s 
ac
co
rd
in
g 
to
 t
he
 
19
94
 in
te
rn
ati
on
al
 d
ia
gn
os
ti
c 
cr
it
er
ia
 [5
].
 C
on
tr
ol
s:
 n
o 
se
ro
lo
gi
ca
l e
vi
de
nc
e 
of
 p
as
t 
ex
po
su
re
 t
o 
C.
b.
20
02
, D
. R
ao
ul
t 
[1
9]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
t:
 r
es
id
ua
l a
st
he
ni
a 
fo
llo
w
in
g 
Q
F 
at
 6
 m
o 
po
st
 A
Q
F
20
02
, B
. M
ar
m
io
n 
[2
0]
N
o 
st
ud
y 
po
pu
la
ti
on
 o
r 
Q
FS
 d
efi
ni
ti
on
20
02
, M
. W
ild
m
an
 [2
1]
N
o 
st
ud
y 
po
pu
la
ti
on
 o
r 
Q
FS
 d
efi
ni
ti
on
. D
efi
ni
ti
on
 fa
ti
gu
e:
 a
cc
or
di
ng
 t
o 
th
e 
19
94
 in
te
rn
ati
on
al
 C
FS
 c
ri
te
ri
a 
[5
, 1
6]
20
03
, T
. H
at
ch
ett
e 
[2
2]
3 
an
d 
27
 m
o 
po
st
 A
Q
F 
[2
3]
, n
o 
Q
FS
 d
efi
ni
ti
on
. C
on
tr
ol
s:
 w
it
ho
ut
 A
Q
F 
du
ri
ng
 s
am
e 
ou
tb
re
ak
 c
oh
or
t
20
03
, K
. H
el
bi
g 
[2
4]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
ts
: c
on
fo
rm
 [1
2]
. R
ec
ov
er
ed
 Q
FS
: c
on
fo
rm
 [1
2]
20
03
 K
. I
ku
ta
 [2
5]
CF
S 
ba
se
d 
on
 t
he
 1
98
8 
CD
C 
w
or
ki
ng
 c
as
e 
de
fin
iti
on
 [2
6]
 a
nd
 t
he
 M
in
is
tr
y 
of
 H
ea
lt
h 
an
d 
W
el
fa
re
 o
f J
ap
an
, f
ro
m
 T
ott
or
i U
ni
ve
rs
it
y 
H
os
pi
ta
l, 
Yo
na
go
, a
nd
 fr
om
 O
sa
ka
 U
ni
ve
rs
it
y 
H
os
pi
ta
l, 
O
sa
ka
, J
ap
an
. H
ea
lt
hy
 c
on
tr
ol
s:
 fr
om
 T
ott
or
i U
ni
ve
rs
it
y 
H
os
pi
ta
l Y
on
ag
o
20
04
, Y
. A
ra
sh
im
a 
[2
7]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
ts
: p
ro
lo
ng
ed
 n
on
sp
ec
ifi
c 
co
m
pl
ai
nt
s,
 w
it
h 
ge
ne
ra
l f
ati
gu
e 
of
 u
nk
no
w
n 
or
ig
in
, o
r 
he
ad
ac
he
, s
lig
ht
ly
 e
le
va
te
d 
bo
dy
 t
em
pe
ra
tu
re
 (3
7-
37
,5
˚C
),
 a
rt
hr
al
gi
a,
 o
r 
m
ya
lg
ia
, w
it
h 
C.
b.
 s
er
op
os
iti
ve
 d
efi
ne
d 
by
 Ig
M
II 
≥1
:3
2 
or
 Ig
G
II 
≥1
:1
28
 (o
r 
≥1
:6
4 
if 
an
ti
bo
dy
 fo
r 
B.
 h
en
se
la
e 
w
as
 n
eg
ati
ve
) a
nd
/o
r 
de
te
ct
ab
le
 C
.b
. D
N
A
, f
or
 3
 m
o 
ti
ll 
4 
yr
s,
 b
et
w
ee
n 
Ju
ly
 a
nd
 N
ov
em
be
r 
20
01
 fr
om
 t
he
 
D
ep
ar
tm
en
t 
of
 In
te
rn
al
 M
ed
ic
in
e 
of
 t
he
 N
ih
on
 U
ni
ve
rs
it
y 
Sc
ho
ol
 o
f M
ed
ic
in
e,
 T
ok
yo
20
04
, H
. T
ho
m
as
 [2
8]
8 
yr
s 
po
st
 r
ec
ru
it
m
en
t 
in
 1
99
1 
fr
om
 a
 r
an
do
m
 s
am
pl
e 
of
 fa
rm
er
s 
dr
aw
n 
fr
om
 t
he
 M
in
is
tr
y 
of
 A
gr
ic
ul
tu
re
, F
is
he
ri
es
 a
nd
 F
oo
d 
Ju
ne
 
A
gr
ic
ul
tu
ra
l C
en
su
s 
lis
ts
 o
f a
gr
ic
ul
tu
ra
l h
ol
di
ng
s,
 w
it
h 
C.
b.
 s
er
op
os
iti
vi
ty
 d
efi
ne
d 
by
 Ig
G
II 
≥1
:3
2.
 N
o 
Q
FS
 d
efi
ni
ti
on
20
05
, B
. M
ar
m
io
n 
[2
9]
D
efi
ni
ti
on
 U
K 
ca
se
s:
 1
2 
yr
s 
po
st
 la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
[7
, 8
] (
A
Q
F 
de
fin
ed
 a
s 
a 
CF
T 
ti
tr
e 
of
 ≥
1:
25
6 
or
 a
 4
-f
ol
d 
ri
se
 in
 p
ha
se
 II
 
an
ti
bo
di
es
).
 D
efi
ni
ti
on
 fa
ti
gu
e:
 c
on
fo
rm
 [1
7]
. D
efi
ni
ti
on
 A
us
tr
al
ia
n 
Q
FS
 c
as
es
: c
on
fo
rm
 [1
2,
 1
4]
, 9
 m
o-
5 
yr
s 
po
st
 A
Q
F.
 D
efi
ni
ti
on
 
fa
ti
gu
e:
 a
cc
or
di
ng
 t
o 
th
e 
19
94
 in
te
rn
ati
on
al
 C
FS
 c
ri
te
ri
a 
[5
]
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 T
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le
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on
ti
nu
ed
. O
ve
rv
ie
w
 o
f s
tu
dy
 p
op
ul
ati
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
In
cl
ud
ed
 a
rti
cl
es
St
ud
y 
po
pu
la
ti
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
20
05
, K
. H
el
bi
g 
[3
0]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
ts
: a
s 
in
 [1
2,
 2
9]
. D
efi
ni
ti
on
 A
Q
F 
w
it
h 
as
ym
pt
om
ati
c 
re
co
ve
ry
: 1
2 
yr
s 
po
st
 la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
[7
, 8
] (
A
Q
F 
de
fin
ed
 a
s 
a 
CF
T 
ti
tr
e 
of
 ≥
1:
25
6 
or
 a
 4
-f
ol
d 
ri
se
 in
 p
ha
se
 II
 a
nti
bo
di
es
),
 w
it
h 
co
m
pl
et
e 
re
co
ve
ry
 w
it
ho
ut
 Q
FS
 o
r 
ot
he
r 
ch
ro
ni
c 
se
qu
el
. D
efi
ni
ti
on
 Q
IE
: c
lin
ic
al
 e
vi
de
nc
e 
of
 e
nd
oc
ar
di
ti
s 
by
 o
bs
er
va
ti
on
 o
f v
eg
et
ati
on
s 
on
 u
lt
ra
sc
an
 o
r 
on
 h
is
to
pa
th
ol
og
ic
al
 
ex
am
in
ati
on
 o
f t
he
 d
is
ea
se
d 
va
lv
e,
 a
nd
 a
 c
om
pa
ti
bl
e 
se
ro
lo
gi
ca
l p
ro
fil
e 
de
fin
ed
 b
y 
Ig
G
I a
nd
 II
 >
32
0,
 lo
w
 o
r 
no
 Ig
M
 a
nd
 Ig
A
I ≥
16
0,
 
an
d 
PC
R 
po
si
ti
ve
 e
xa
m
in
ati
on
 o
f v
al
ve
 v
eg
et
ati
on
 s
pe
ci
m
en
s 
an
d 
in
 s
om
e 
in
st
an
ce
s 
by
 is
ol
ati
on
 o
f C
.b
. i
n 
ce
ll 
cu
lt
ur
e 
or
 la
bo
ra
to
ry
 
an
im
al
s,
 C
au
ca
si
an
s 
m
ai
nl
y 
fr
om
 N
ew
 S
ou
th
 W
al
es
 a
nd
 Q
ue
en
sl
an
d
20
05
, E
. I
w
ak
am
i [
31
]
D
efi
ni
ti
on
 C
FS
 p
ati
en
ts
: a
cc
or
di
ng
 t
o 
th
e 
19
94
 in
te
rn
ati
on
al
 C
FS
 c
ri
te
ri
a 
[5
, 3
2]
, i
n 
co
m
bi
na
ti
on
 w
it
h 
pr
ov
en
 C
.b
. i
nf
ec
ti
on
 d
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se
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. D
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, f
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. D
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 t
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l m
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, b
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 c
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 c
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 b
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se
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. D
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 b
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 m
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 m
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 d
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 b
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. C
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 C
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 c
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 p
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: b
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 D
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 d
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, m
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 T
ab
le
 c
on
ti
nu
ed
. O
ve
rv
ie
w
 o
f s
tu
dy
 p
op
ul
ati
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
In
cl
ud
ed
 a
rti
cl
es
St
ud
y 
po
pu
la
ti
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
20
12
, J
. O
os
te
rh
ee
rt
 [5
9]
N
o 
st
ud
y 
po
pu
la
ti
on
 o
r 
Q
FS
 d
efi
ni
ti
on
20
12
, S
. Y
ak
ub
o 
[6
0]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
ts
: g
en
er
al
 fa
ti
gu
e,
 n
au
se
a,
 s
to
m
ac
h 
pa
in
, a
bn
or
m
al
 s
en
sa
ti
on
 in
 t
he
 m
ou
th
, s
or
e 
th
ro
at
, a
nd
 t
ro
ub
le
 
sl
ee
pi
ng
, w
it
h 
Ig
G
I 1
:2
56
20
13
, S
. K
ei
jm
el
 [6
1]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
ts
: a
cc
or
di
ng
 t
o 
th
e 
D
ut
ch
 g
ui
de
lin
e 
on
 Q
FS
 [6
2]
, r
ef
er
re
d 
to
 R
ad
bo
ud
 u
ni
ve
rs
it
y 
m
ed
ic
al
 c
en
te
r, 
N
ijm
eg
en
, 
th
e 
N
et
he
rl
an
ds
; a
du
lt
s 
(n
on
-p
re
gn
an
t,
 n
on
-la
ct
ati
ng
),
 ≥
18
 y
rs
, w
it
h 
la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
si
nc
e 
20
07
 a
nd
/o
r 
po
si
ti
ve
 s
er
ol
og
y 
fitti
ng
 a
 p
as
t 
in
fe
cti
on
 w
it
h 
C.
b.
, a
nd
 b
ei
ng
 s
ev
er
el
y 
fa
ti
gu
ed
 (C
IS
 fa
ti
gu
e 
≥3
5)
 fo
r 
≥6
 m
o,
 a
nd
 b
ei
ng
 d
is
ab
le
d 
be
ca
us
e 
of
 fa
ti
gu
e 
(S
IP
 t
ot
al
 s
co
re
 ≥
45
0)
, w
it
h 
a 
re
fe
re
nc
e 
to
 A
Q
F 
an
d 
ab
se
nc
e 
of
 fa
ti
gu
e 
be
fo
re
 t
he
 e
pi
so
de
 o
f A
Q
F 
or
 a
 s
ig
ni
fic
an
t 
in
cr
ea
se
 e
ve
r 
si
nc
e.
 E
xc
lu
de
d:
 C
Q
F 
[6
3]
, A
Q
F 
in
 t
he
 p
re
se
nc
e 
of
 r
is
k 
fa
ct
or
s 
fo
r 
de
ve
lo
pi
ng
 C
Q
F 
ne
ce
ss
it
ati
ng
 p
ro
ph
yl
ac
ti
c 
us
e 
of
 d
ox
yc
yc
lin
e,
 
pr
eg
na
nc
y 
or
 u
nw
ill
in
gn
es
s 
to
 u
se
 e
ff
ec
ti
ve
 c
on
tr
ac
ep
ti
ve
s 
du
ri
ng
 t
he
 s
tu
dy
, i
m
m
in
en
t 
de
at
h,
 in
ab
ili
ty
 t
o 
gi
ve
 in
fo
rm
ed
 c
on
se
nt
, 
al
le
rg
y 
or
 in
to
le
ra
nc
e 
to
 d
ox
yc
yc
lin
e,
 s
om
ati
c 
or
 p
sy
ch
ia
tr
ic
 il
ln
es
s 
ex
pl
ai
ni
ng
 c
hr
on
ic
 fa
ti
gu
e,
 c
ur
re
nt
 e
nr
ol
m
en
t 
in
 o
th
er
 
in
ve
sti
ga
ti
on
al
 d
ru
g 
tr
ia
ls
 o
r 
re
ce
iv
in
g 
in
ve
sti
ga
ti
on
al
 a
ge
nt
s,
 r
ec
ei
vi
ng
 o
r 
ha
vi
ng
 r
ec
ei
ve
d 
A
B 
>4
 w
ks
 p
ot
en
ti
al
ly
 a
cti
ve
 a
ga
in
st
 
C.
b.
, u
se
 o
f b
ar
bi
tu
ra
te
s,
 p
he
ny
to
in
, o
r 
ca
rb
am
az
ep
in
e,
 m
od
er
at
e 
or
 s
ev
er
e 
liv
er
 d
is
ea
se
, c
ur
re
nt
 e
ng
ag
em
en
t 
in
 le
ga
l p
ro
ce
du
re
 
fo
r 
fin
an
ci
al
 b
en
efi
ts
 
20
13
, S
. Y
ak
ub
o 
[6
4]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
t:
 6
 y
rs
 p
os
t 
A
I w
it
h 
ge
ne
ra
l m
al
ai
se
, s
pa
sm
 le
ft
 h
an
d,
 s
lig
ht
ly
 e
le
va
te
d 
bo
dy
 t
em
pe
ra
tu
re
, w
it
ho
ut
 
ab
no
rm
al
iti
es
 in
 p
hy
si
ca
l e
xa
m
in
ati
on
, l
ab
or
at
or
y 
ex
am
in
ati
on
 in
cl
ud
in
g 
ph
ar
yn
ge
al
 c
ul
tu
re
 a
nd
 a
dd
iti
on
al
 t
es
ts
 (c
he
st
 X
-r
ay
, 
X-
ra
y 
of
 la
ry
nx
/p
ha
ry
nx
/e
ar
s 
an
d 
pa
ra
na
sa
l s
in
us
es
, E
CG
, a
bd
om
in
al
 u
lt
ra
so
un
d,
 b
ra
in
 C
T,
 E
EG
),
 w
it
h 
ne
ga
ti
ve
 n
-P
CR
 fo
r 
C.
b.
, I
gM
I 
an
d 
Ig
M
II 
<1
:1
6,
 Ig
G
I <
1:
16
, I
gG
II 
1:
32
. S
ix
 m
o 
aft
er
 p
re
se
nt
ati
on
 Ig
G
I 1
:1
28
 
20
13
, M
. v
an
 A
ss
el
do
nk
 
[6
5]
 
A
ll 
no
ti
fie
d,
 h
os
pi
ta
lis
ed
, d
ec
ea
se
d 
an
d 
no
n-
re
po
rt
ed
 c
as
es
 o
f Q
F,
 d
et
er
m
in
ed
 fr
om
 [6
6]
 a
nd
 [6
7]
20
13
, J
. v
an
 L
oe
nh
ou
t 
[6
8]
12
 m
o 
po
st
 A
Q
F,
 p
ati
en
ts
 ≥
18
 y
rs
 d
ia
gn
os
ed
 w
it
h 
Q
F 
in
 2
01
0 
an
d 
20
11
, w
ho
 fu
lfi
lle
d 
th
e 
D
ut
ch
 n
oti
fic
ati
on
 c
ri
te
ri
a 
fo
r 
Q
F 
[6
9]
 
w
er
e 
el
ig
ib
le
 fo
r 
pa
rti
ci
pa
ti
on
20
13
, S
. Y
ak
ub
o 
[7
0]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
t:
 2
 m
o 
po
st
 A
I w
it
h 
se
ve
re
 fa
ti
gu
e,
 g
en
er
al
 m
al
ai
se
, a
rt
hr
al
gi
a,
 m
ya
lg
ia
, p
er
si
st
en
t 
sl
ig
ht
ly
 e
le
va
te
d 
bo
dy
 
te
m
pe
ra
tu
re
 (a
ro
un
d 
37
˚C
),
 w
ho
le
-b
od
y 
la
ss
it
ud
e,
 w
it
ho
ut
 a
bn
or
m
al
iti
es
 in
 p
hy
si
ca
l e
xa
m
in
ati
on
, l
ab
or
at
or
y 
ex
am
in
ati
on
 
in
cl
ud
in
g 
a 
ph
ar
yn
ge
al
 c
ul
tu
re
 a
nd
 a
dd
iti
on
al
 t
es
ts
 (c
he
st
 X
-r
ay
, E
CG
),
 b
ut
 w
it
h 
po
si
ti
ve
 n
-P
CR
 fo
r 
C.
b.
, w
it
ho
ut
 p
os
iti
ve
 a
nti
bo
di
es
20
13
, R
. B
ro
ok
e 
[7
1]
Q
F 
no
ti
fie
d 
pa
ti
en
ts
 w
it
h 
on
se
t 
sy
m
pt
om
s 
be
tw
ee
n 
1 
Ja
nu
ar
y 
20
09
 a
nd
 3
1 
D
ec
em
be
r 
20
13
. A
(H
1N
1)
pd
m
09
 n
oti
fie
d 
pa
ti
en
ts
, 
re
fle
ct
ed
 b
y 
in
flu
en
za
-li
ke
-il
ln
es
s 
re
gi
st
ra
ti
on
 fr
om
 t
he
 D
ut
ch
 S
en
ti
ne
l G
en
er
al
 P
ra
cti
ce
 N
et
w
or
k 
fo
r 
in
flu
en
za
-li
ke
-il
ln
es
s 
fr
om
 
N
IV
EL
 N
et
he
rl
an
ds
 In
sti
tu
te
 fo
r 
H
ea
lt
h 
Se
rv
ic
es
 R
es
ea
rc
h 
be
tw
ee
n 
27
 A
pr
il 
20
09
 a
nd
 2
6 
A
pr
il 
20
10
20
13
, Y
. A
ra
sh
im
a 
[7
2]
D
efi
ni
ti
on
 Q
FS
 p
ati
en
ts
: 1
8 
m
o 
po
st
 A
I w
it
h 
ge
ne
ra
l f
ati
gu
e,
 c
ou
gh
, d
ys
pn
oe
a,
 s
pu
tu
m
, b
re
at
hi
ng
 d
iffi
cu
lt
y,
 s
lig
ht
ly
 e
le
va
te
d 
bo
dy
 
te
m
pe
ra
tu
re
, h
ea
da
ch
e,
 p
oo
r 
ap
pe
ti
te
, c
op
io
us
 s
w
ea
ti
ng
, n
ig
ht
 s
w
ea
ti
ng
, n
au
se
a,
 v
om
iti
ng
, p
al
pi
ta
ti
on
s,
 a
nd
 d
iz
zi
ne
ss
, w
it
ho
ut
 
ab
no
rm
al
iti
es
 o
n 
ph
ys
ic
al
 e
xa
m
in
ati
on
, l
ab
or
at
or
y 
ex
am
in
ati
on
 (b
es
id
es
 s
lig
ht
 li
ve
r 
dy
sf
un
cti
on
),
 b
ut
 w
it
h 
po
si
ti
ve
 n
-P
CR
 fo
r 
C.
b.
, 
Ig
M
II 
1:
16
, I
gG
II 
1:
12
8
20
14
, M
. K
re
m
er
s 
[7
3]
Po
st
 la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
(A
Q
F 
ac
co
rd
in
g 
to
 t
he
 D
ut
ch
 n
oti
fic
ati
on
 c
ri
te
ri
a 
[4
8]
 d
efi
ne
d 
as
 s
ym
pt
om
ati
c 
pa
ti
en
ts
 w
it
h 
po
si
ti
ve
 
PC
R 
fo
r 
C.
b.
 D
N
A
 in
 s
er
um
 s
am
pl
es
 b
ef
or
e 
th
e 
de
ve
lo
pm
en
t 
of
 a
n 
Ig
M
II 
an
ti
bo
dy
 r
es
po
ns
e 
m
ea
su
re
d 
by
 IF
A
 o
r 
EL
IS
A
),
 b
et
w
ee
n 
A
pr
il 
20
09
 a
nd
 A
ug
us
t 
20
09
, a
nd
 a
ss
es
sm
en
t 
4 
yr
s 
po
st
 A
Q
F,
 a
ll 
w
ho
 w
er
e 
sti
ll 
al
iv
e,
 ≥
18
 y
rs
 a
nd
 o
f w
ho
m
 a
 1
2 
m
o 
FU
 s
am
pl
e 
w
as
 
pr
es
en
t
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S1
 T
ab
le
 c
on
ti
nu
ed
. O
ve
rv
ie
w
 o
f s
tu
dy
 p
op
ul
ati
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
In
cl
ud
ed
 a
rti
cl
es
St
ud
y 
po
pu
la
ti
on
s 
an
d 
us
ed
 d
efi
ni
ti
on
s
20
14
, J
. v
an
 L
oe
nh
ou
t 
[7
4]
D
efi
ni
ti
on
 Q
F 
st
ud
y 
po
pu
la
ti
on
 [7
5]
: n
oti
fie
d 
pa
ti
en
ts
 1
 y
r 
po
st
 A
Q
F 
in
 2
01
0 
an
d 
20
11
 (A
Q
F 
ac
co
rd
in
g 
to
 t
he
 D
ut
ch
 n
oti
fic
ati
on
 
cr
it
er
ia
 d
efi
ne
d 
as
 a
 la
bo
ra
to
ry
 c
on
fir
m
ati
on
 o
f Q
F 
w
it
h 
a 
se
ro
co
nv
er
si
on
 o
r 
a 
4-
fo
ld
 r
is
e 
in
 Ig
G
 a
nti
bo
dy
 ti
tr
e 
in
 a
 p
ai
re
d 
se
ru
m
 
sa
m
pl
e 
w
it
h 
≥2
 w
ks
 ti
m
e 
in
te
rv
al
 u
si
ng
 C
FT
 o
r 
IF
A
, p
re
se
nc
e 
of
 Ig
M
II 
an
ti
bo
di
es
, p
os
iti
ve
 P
CR
 o
r 
cu
lt
ur
e 
in
 b
lo
od
 o
r 
re
sp
ir
at
or
y 
m
at
er
ia
l, 
pr
es
en
ce
 o
f p
ha
se
 I 
an
ti
bo
di
es
, c
om
bi
ne
d 
w
it
h 
a 
cl
in
ic
al
 p
re
se
nt
ati
on
 w
it
h 
fe
ve
r, 
pn
eu
m
on
ia
 o
r 
he
pa
ti
ti
s,
 a
n 
on
se
t 
of
 
ill
ne
ss
 w
it
hi
n 
pr
ev
io
us
 9
0 
da
ys
 [6
9]
, a
nd
 ≥
18
 y
rs
. D
efi
ni
ti
on
 L
eg
io
nn
ai
re
s 
di
se
as
e 
st
ud
y 
po
pu
la
ti
on
: n
oti
fie
d 
pa
ti
en
ts
, 1
 y
r 
po
st
 
Le
gi
on
na
ir
es
’ d
is
ea
se
 in
 2
01
0 
(L
eg
io
nn
ai
re
s’
 d
is
ea
se
 a
cc
or
di
ng
 t
o 
th
e 
D
ut
ch
 n
oti
fic
ati
on
 c
ri
te
ri
a 
de
fin
ed
 a
s 
m
at
ch
in
g 
cl
in
ic
al
 
sy
m
pt
om
s,
 u
su
al
ly
 p
ne
um
on
ia
, c
on
fir
m
ed
 b
y 
at
 le
as
t 
1 
bu
t 
pr
ef
er
ab
ly
 2
 o
f t
he
 la
bo
ra
to
ry
 d
ia
gn
os
ti
c 
te
st
: i
so
la
ti
on
 o
f L
eg
io
ne
lla
-
sp
ec
ie
s 
fr
om
 r
es
pi
ra
to
ry
 s
ec
re
ti
on
s 
or
 b
lo
od
; L
eg
io
ne
lla
 p
ne
um
op
hi
la
-a
nti
ge
n 
in
 u
ri
ne
 b
y 
ra
di
o-
im
m
un
o-
as
sa
y,
 E
LI
SA
, o
r 
im
m
un
o-
ch
ro
m
at
og
ra
ph
ic
 a
ss
ay
; L
eg
io
ne
lla
-s
pe
ci
es
 b
y 
PC
R 
in
 c
lin
ic
al
 m
at
er
ia
l; 
si
gn
ifi
ca
nt
 ti
tr
e 
of
 Ig
M
 b
y 
EL
IS
A
; s
ig
ni
fic
an
t 
ti
tr
e 
el
ev
ati
on
 o
f 
an
ti
bo
di
es
. H
ea
lt
hy
 c
on
tr
ol
s:
 v
ia
 a
dv
er
ti
se
m
en
ts
 in
 lo
ca
l n
ew
sp
ap
er
s 
in
 t
he
 c
it
y 
of
 N
ijm
eg
en
 a
re
a.
 E
xc
lu
de
d 
co
nt
ro
ls
: u
nd
er
ly
in
g 
re
sp
ir
at
or
y 
ill
ne
ss
20
14
, A
. v
an
 D
am
 [7
6]
10
-1
9 
m
o 
po
st
 L
RT
I a
s 
di
ag
no
se
d 
by
 g
en
er
al
 p
ra
cti
ti
on
er
 b
et
w
ee
n 
1 
M
ay
 2
00
9 
an
d 
30
 S
ep
te
m
be
r 
20
09
 in
 p
ro
vi
nc
es
 o
f N
or
th
er
n 
Br
ab
an
t 
an
d 
G
el
de
rl
an
d,
 c
at
eg
or
iz
ed
 in
to
 fo
llo
w
in
g 
IC
PC
 g
ro
up
s:
 a
cu
te
 b
ro
nc
hi
ti
s,
 in
flu
en
za
, p
ne
um
on
ia
, a
nd
 o
th
er
 L
RT
I w
ho
 
w
er
e 
in
iti
al
ly
 t
es
te
d 
fo
r 
Q
F,
 ≥
18
 y
rs
 a
nd
 ≤
75
 y
rs
. D
efi
ni
ti
on
 Q
F 
po
si
ti
ve
: L
RT
I p
ati
en
ts
 w
it
h 
po
si
ti
ve
 d
ia
gn
os
ti
c 
te
st
s 
by
 e
it
he
r 
PC
R,
 
IF
A
, o
r 
CF
T
20
15
, J
. v
an
 L
oe
nh
ou
t 
[7
7]
O
ve
r 
a 
pe
ri
od
 o
f 2
4 
m
o 
(a
ss
es
se
d 
at
 3
, 6
, 9
, 1
2,
 1
8 
an
d 
24
 m
o)
 p
os
t 
la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
in
 2
01
0 
an
d 
20
11
 (A
Q
F 
ac
co
rd
in
g 
to
 
th
e 
D
ut
ch
 n
oti
fic
ati
on
 c
ri
te
ri
a 
[6
9]
),
 ≥
18
 y
rs
20
15
, J
. v
an
 L
oe
nh
ou
t 
[7
8]
D
efi
ni
ti
on
 n
oti
fie
d 
Q
F 
pa
ti
en
ts
: 4
 y
rs
 p
os
t 
la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
in
 2
00
7 
an
d 
20
08
 (A
Q
F 
ac
co
rd
in
g 
to
 t
he
 E
U
 c
as
e 
de
fin
iti
on
 [7
9]
 
w
it
h 
la
bo
ra
to
ry
 c
ri
te
ri
a 
(is
ol
ati
on
 o
f C
.b
. f
ro
m
 c
lin
ic
al
 s
pe
ci
m
en
; d
et
ec
ti
on
 o
f C
.b
. n
uc
le
id
 a
ci
d 
in
 c
lin
ic
al
 s
pe
ci
m
en
; C
.b
. s
pe
ci
fic
 
an
ti
bo
dy
 r
es
po
ns
e 
(I
gG
II 
or
 Ig
M
II)
),
 e
pi
de
m
io
lo
gi
ca
l c
ri
te
ri
a 
(e
xp
os
ur
e 
to
 c
om
m
on
 s
ou
rc
e;
 a
ni
m
al
 t
o 
hu
m
an
 t
ra
ns
m
is
si
on
),
 a
nd
 
cl
in
ic
al
 c
ri
te
ri
a 
(f
ev
er
, p
ne
um
on
ia
 a
nd
/o
r 
he
pa
ti
ti
s)
, o
ns
et
 o
f d
is
ea
se
 <
90
 d
ay
s,
 ≥
18
 y
rs
. D
efi
ni
ti
on
 n
on
-n
oti
fie
d 
Q
F 
pa
ti
en
ts
: 4
 y
rs
 
po
st
 la
bo
ra
to
ry
-p
ro
ve
n 
Q
F 
in
 2
00
8 
an
d 
20
09
 (a
cc
or
di
ng
 t
o 
th
e 
EU
 c
as
e 
de
fin
iti
on
, b
ut
 o
nl
y 
fu
lfi
lli
ng
 t
he
 la
bo
ra
to
ry
 c
ri
te
ri
a 
an
d 
no
t 
th
e 
cl
in
ic
al
 c
ri
te
ri
a 
of
 fe
ve
r, 
pn
eu
m
on
ia
 o
r 
he
pa
ti
ti
s)
, o
ns
et
 o
f d
is
ea
se
 <
90
 d
ay
s,
 ≥
18
 y
rs
20
15
, J
. v
an
 L
oe
nh
ou
t 
[8
0]
D
efi
ni
ti
on
 Q
F 
st
ud
y 
po
pu
la
ti
on
 [7
5]
: n
oti
fie
d 
pa
ti
en
ts
 a
ss
es
se
d 
3,
 6
, 9
 a
nd
 1
2 
m
o 
po
st
 la
bo
ra
to
ry
-p
ro
ve
n 
A
Q
F 
in
 2
01
0 
an
d 
20
11
 
(A
Q
F 
ac
co
rd
in
g 
to
 t
he
 D
ut
ch
 n
oti
fic
ati
on
 c
ri
te
ri
a)
, ≥
18
 y
rs
. D
efi
ni
ti
on
 L
eg
io
nn
ai
re
s 
di
se
as
e 
st
ud
y 
po
pu
la
ti
on
 [7
5]
: n
oti
fie
d 
pa
ti
en
ts
 
12
 m
o 
po
st
 L
eg
io
nn
ai
re
s’
 d
is
ea
se
 in
 2
01
0 
(L
eg
io
nn
ai
re
s’
 d
is
ea
se
 a
cc
or
di
ng
 t
o 
th
e 
D
ut
ch
 n
oti
fic
ati
on
 c
ri
te
ri
a)
A
bb
re
vi
ati
on
s:
 A
I=
 A
cu
te
 in
fe
cti
on
, A
Q
F=
 A
cu
te
 Q
-f
ev
er
, B
. h
en
se
la
e=
 B
ar
to
ne
lla
 h
en
se
la
e,
 C
.b
.=
 C
ox
ie
lla
 b
ur
ne
ti
i, 
CD
C=
 C
en
tr
es
 fo
r 
D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nti
on
, 
CF
= 
Ch
ro
ni
c 
fa
ti
gu
e,
 C
FS
(/
M
E)
= 
Ch
ro
ni
c 
fa
ti
gu
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 m
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se
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pr
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 d
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 c
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 d
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 c
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, d
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 s
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pr
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 b
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, c
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 D
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at
m
en
t,
 a
rt
hr
al
gi
a 
an
d 
sl
ig
ht
ly
 e
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os
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 p
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 c
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fie
d 
ca
se
D
A
LY
 (Y
LD
, Y
LL
).
 
D
et
er
m
in
is
ti
c 
so
ci
o-
ec
on
om
ic
 
m
od
el
N
A
To
ta
l d
is
ea
se
 b
ur
de
n 
24
62
 D
A
LY
, 
of
 w
hi
ch
 C
FS
 1
48
1 
D
A
LY
, C
Q
F 
80
6 
D
A
LY
. I
nc
om
e 
lo
ss
es
 a
cc
um
ul
at
e 
ov
er
 ti
m
e 
du
e 
to
 lo
ng
 d
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 t
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 b
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, d
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f c
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, d
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 b
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ra
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 c
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 d
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; t
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 b
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re
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D
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om
 a
cu
te
 
ill
ne
ss
, 4
02
7 
fr
om
 s
eq
ue
la
e.
 P
IF
S 
57
%
 t
ot
al
 b
ur
de
n,
 m
ai
nl
y 
45
-4
9 
ag
e 
gr
ou
p.
 In
flu
en
za
: 2
44
84
 
D
A
LY
s,
 3
03
3 
fr
om
 s
eq
ue
la
e.
 T
ot
al
 
no
 D
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m
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ra
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 m
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 ♂
, m
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, p
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.5
%
, h
os
pi
ta
lis
ed
 
61
.1
%
),
 a
nd
 Q
F 
gr
ou
p 
m
at
ch
ed
 (a
ge
, 
ge
nd
er
) h
ea
lt
hy
 
co
nt
ro
ls
 (n
or
m
al
 
lu
ng
 fu
nc
ti
on
, 
n=
12
1,
 5
5.
4%
 ♂
, 
m
ea
n 
ag
e 
51
.4
))
. 
A
ss
es
s 
an
d 
co
m
pa
re
 
he
al
th
 s
ta
tu
s 
pa
ti
en
ts
 1
 y
r 
po
st
 
Q
F/
Le
gi
on
el
la
N
CS
I, 
SF
-3
6
N
A
W
or
se
 s
co
re
 Q
F 
vs
. L
eg
io
ne
lla
 
pa
ti
en
ts
 o
n 
su
bd
om
ai
ns
 fa
ti
gu
e 
(6
0.
2%
 v
s.
 5
0.
0%
, i
.c
.w
. 2
.5
%
 
he
al
th
y 
co
nt
ro
ls
),
 G
en
er
al
 
Q
ua
lit
y 
of
 L
ife
 (5
0.
0%
 v
s.
 4
2.
6%
),
 
Ro
le
 P
hy
si
ca
l. 
A
dj
us
tm
en
t 
co
nf
ou
nd
er
s:
 o
nl
y 
Ro
le
 P
hy
si
ca
l 
re
m
ai
ne
d 
di
ff
er
en
t.
 In
 b
ot
h 
Q
F 
an
d 
Le
gi
on
el
la
: p
ro
po
rti
on
 
se
ve
re
ly
 a
ff
ec
te
d 
pa
ti
en
ts
 ↑
 
i.c
.w
. c
on
tr
ol
s
Ce
rt
ai
n 
in
fe
cti
ou
s 
ill
ne
ss
es
 a
re
 fo
llo
w
ed
 
by
 lo
ng
 t
er
m
 
im
pa
ir
ed
 h
ea
lt
h 
st
at
us
, i
nc
lu
di
ng
 P
IC
F.
 
Q
F 
an
d 
Le
gi
on
el
la
 
pa
ti
en
ts
 a
re
 a
ff
ec
te
d 
on
 ≥
1 
as
pe
ct
s 
he
al
th
 
st
at
us
, e
sp
ec
ia
lly
 
fa
ti
gu
e,
 G
en
er
al
 
Q
ua
lit
y 
of
 L
ife
, R
ol
e 
Ph
ys
ic
al
. I
m
pa
ct
 Q
F 
se
em
s 
hi
gh
er
 th
an
 
fr
om
 L
eg
io
ne
lla
. 
H
ea
lt
h 
st
aff
 n
ee
d 
to
 b
e 
aw
ar
e 
of
 t
hi
s 
im
pa
ct
 in
 o
rd
er
 t
o 
pr
ov
id
e 
ad
eq
ua
te
 
ca
re
N
A
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 T
ab
le
 c
on
ti
nu
ed
. D
om
ai
n 
ba
ck
gr
ou
nd
/d
es
cr
ip
ti
ve
Re
f
Co
un
tr
y,
 y
r 
st
ud
y,
 p
er
io
d 
an
d 
du
ra
ti
on
St
ud
y 
ty
pe
Pa
ti
en
ts
, c
on
tr
ol
s,
 
ch
ar
ac
te
ri
sti
cs
, 
co
-m
or
bi
di
ty
*
To
ol
In
te
r-
ve
n-
ti
on
O
ut
co
m
e
Co
nc
lu
si
on
s/
re
co
m
m
en
da
ti
on
s
O
th
er
 
do
-
m
ai
n
Q
A
 (C
R
 o
r 
N
O
S)
20
14
, A
. 
va
n 
D
am
 
[2
8]
N
et
he
rl
an
ds
, 
20
09
-2
01
1,
 
in
cl
us
io
n 
1s
t 
M
ay
-3
0t
h 
Se
pt
em
be
r 
20
09
CC
 
50
 Q
F 
se
ro
po
si
ti
ve
 
LR
TI
 (m
ea
n 
ag
e 
48
.1
, 
SD
14
.3
) v
s.
 3
2 
Q
F 
se
ro
ne
ga
ti
ve
 L
RT
I 
pa
ti
en
ts
 (m
ea
n 
ag
e 
57
.2
, S
D
14
.4
);
 1
8-
75
 
yr
s.
 C
om
pa
ra
bl
e 
ge
nd
er
 (6
0%
 v
s.
 
50
%
 ♂
),
 c
ur
re
nt
 
sm
ok
in
g 
(4
0%
 v
s.
 
30
%
),
 h
os
pi
ta
lis
ati
on
 
du
ri
ng
 L
RT
I (
10
%
 v
s.
 
7%
),
 c
o-
m
or
bi
di
ty
 
(4
2%
 v
s.
 5
6%
).
 Q
F 
po
si
ti
ve
: m
or
e 
oft
en
 
pn
eu
m
on
ia
 i.
c.
w
. Q
F 
ne
ga
ti
ve
. A
ss
es
s 
if 
LR
TI
 d
ue
 t
o 
Q
F 
ha
s 
hi
gh
er
 h
ea
lt
h 
st
at
us
 
im
pa
ir
m
en
t 
i.c
.w
. 
ot
he
r 
LR
TI
s 
15
 m
o 
po
st
 A
I
N
CS
I 
(c
om
pl
eti
on
 
10
-1
9 
m
o 
po
st
 
LR
TI
, m
ea
n 
15
 
m
o)
. Q
F 
po
si
ti
ve
 
te
st
ed
 w
it
h 
PC
R,
 
IF
A
 o
r 
CF
T
N
A
Q
F 
po
si
ti
ve
 L
RT
I: 
se
ve
re
ly
 
aff
ec
te
d 
G
en
er
al
 Q
ua
lit
y 
of
 L
ife
 
(4
0%
) a
nd
 fa
ti
gu
e 
(4
0%
),
 Q
F 
ne
ga
ti
ve
 L
RT
I: 
fa
ti
gu
e 
(6
4%
) a
nd
 
su
bj
ec
ti
ve
 p
ul
m
on
ar
y 
sy
m
pt
om
s 
(3
5%
).
 4
0%
 Q
F 
po
si
ti
ve
 a
nd
 5
6%
 
Q
F 
ne
ga
ti
ve
 s
ev
er
el
y 
aff
ec
te
d 
on
 >
1 
su
bd
om
ai
n.
 N
o 
di
ff
er
en
ce
 
he
al
th
 s
ta
tu
s 
sc
or
es
 Q
F 
po
si
ti
ve
 
an
d 
Q
F 
ne
ga
ti
ve
 L
RT
I p
ati
en
ts
 fo
r 
al
l s
ub
do
m
ai
ns
 e
xc
ep
t 
su
bj
ec
ti
ve
 
pu
lm
on
ar
y 
sy
m
pt
om
s
La
rg
e 
gr
ou
p 
LR
TI
 
pa
ti
en
ts
 a
ff
ec
te
d 
>1
 a
sp
ec
t 
of
 h
ea
lt
h 
st
at
us
 1
5 
m
o 
po
st
 
LR
TI
. L
itt
le
 d
iff
er
en
ce
 
in
 h
ea
lt
h 
st
at
us
 
Q
F 
po
si
ti
ve
 a
nd
 
Q
F 
ne
ga
ti
ve
 L
RT
I 
pa
ti
en
ts
. G
en
er
al
 
pr
ac
ti
ti
on
er
s 
ou
gh
t 
to
 b
e 
aw
ar
e 
of
 
lo
ng
-t
er
m
 h
ea
lt
h 
pr
ob
le
m
s 
in
 L
RT
I 
pa
ti
en
ts
 in
 g
en
er
al
N
A
« « « «
« «
« «
20
15
, J
. 
va
n 
Lo
en
-
ho
ut
 [2
9]
N
et
he
rl
an
ds
, 
st
ud
y 
pe
ri
od
: 
20
10
-2
01
3,
 F
U
 
at
 3
, 6
, 9
, 1
2,
 
18
, a
nd
 2
4 
m
o 
po
st
 A
Q
F
Co
S
33
6 
po
st
 A
Q
F 
pa
ti
en
ts
 (i
n 
20
10
-
20
11
, 5
4.
8%
 ♂
, 
m
ea
n 
ag
e 
48
.5
, 
SD
13
.9
, c
o-
m
or
bi
di
ty
 
39
.7
%
),
 c
om
pa
ri
so
n 
N
CS
I s
co
re
s 
m
at
ch
ed
 
(a
ge
, g
en
de
r)
 
he
al
th
y 
co
nt
ro
ls
. T
o 
as
se
ss
 h
ea
lt
h 
st
at
us
 
pr
og
re
ss
io
n 
of
 Q
F 
pa
ti
en
ts
 o
ve
r 
24
-m
o 
pe
ri
od
, a
nd
 id
en
ti
fy
 
in
flu
en
ci
ng
 fa
ct
or
s
N
CS
I (
3,
 1
2,
 1
8,
 
an
d 
24
 m
o)
, S
F-
36
, q
ue
sti
on
-
na
ire
s
N
A
Si
gn
ifi
ca
nt
 li
ne
ar
 im
pr
ov
em
en
t 
ov
er
 ti
m
e 
in
 9
/1
2 
he
al
th
 s
ta
tu
s 
su
bd
om
ai
ns
. S
ev
er
el
y 
aff
ec
te
d:
 
fa
ti
gu
e 
73
.0
%
 a
t 
3 
m
o,
 6
0.
0%
 
at
 1
2 
m
o,
 3
7.
0%
 a
t 
24
 m
o 
(v
s.
 
2.
5%
 h
ea
lt
hy
 r
ef
er
en
ce
 g
ro
up
),
 
G
en
er
al
 Q
ua
lit
y 
of
 L
ife
 4
2.
2%
 a
t 
3 
m
o,
 5
0.
2%
 a
t 
12
 m
o,
 3
3.
7%
 a
t 
24
 
m
o 
(v
s.
 1
9.
8%
 h
ea
lt
hy
 r
ef
er
en
ce
 
gr
ou
p)
. F
or
 3
 m
os
t 
se
ve
re
ly
 
aff
ec
te
d 
su
bd
om
ai
ns
 (f
ati
gu
e,
 
G
en
er
al
 Q
ua
lit
y 
of
 L
ife
, R
ol
e 
Ph
ys
ic
al
):
 fe
m
al
es
, y
ou
ng
 a
du
lt
s,
 
pr
e-
ex
is
ti
ng
 h
ea
lt
h 
pr
ob
le
m
s,
 a
t 
ba
se
lin
e 
w
er
e 
as
so
ci
at
ed
 w
it
h 
↓
 
lo
ng
-t
er
m
 h
ea
lt
h 
st
at
us
D
es
pi
te
 li
ne
ar
 
im
pr
ov
em
en
t 
ov
er
 
ti
m
e,
 >
1/
3 
pa
ti
en
ts
 
ha
d 
↓
 h
ea
lt
h 
st
at
us
 a
t 
24
 m
o.
 
Re
su
lt
s 
su
gg
es
t 
th
at
 
ps
yc
ho
lo
gi
ca
l d
is
tr
es
s 
is
 n
ot
 a
n 
im
po
rt
an
t 
fa
ct
or
 in
 e
xp
la
in
in
g 
↑
 fa
ti
gu
e 
le
ve
ls
A
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« «
« «
82 | CHAPTER 2
S3
 T
ab
le
 c
on
ti
nu
ed
. D
om
ai
n 
ba
ck
gr
ou
nd
/d
es
cr
ip
ti
ve
Re
f
Co
un
tr
y,
 y
r 
st
ud
y,
 p
er
io
d 
an
d 
du
ra
ti
on
St
ud
y 
ty
pe
Pa
ti
en
ts
, c
on
tr
ol
s,
 
ch
ar
ac
te
ri
sti
cs
, 
co
-m
or
bi
di
ty
*
To
ol
In
te
r-
ve
n-
ti
on
O
ut
co
m
e
Co
nc
lu
si
on
s/
re
co
m
m
en
da
ti
on
s
O
th
er
 
do
-
m
ai
n
Q
A
 (C
R
 o
r 
N
O
S)
20
15
, J
. 
va
n 
Lo
en
-
ho
ut
 [3
0]
N
et
he
rl
an
ds
, 
yr
 s
tu
dy
 2
01
1-
20
13
, s
in
gl
e 
m
ea
su
re
m
en
t 
4 
yr
s 
po
st
 A
Q
F
CC
44
8 
no
ti
fie
d 
po
st
 
A
Q
F 
(2
00
7-
20
08
, 
57
.6
%
 ♂
, m
ea
n 
ag
e 
54
.4
, S
D
12
.4
, c
o-
m
or
bi
di
ty
 5
1.
1%
) v
s.
 
19
3 
sy
m
pt
om
ati
c 
no
n-
no
ti
fie
d 
po
st
 Q
F 
(2
00
8-
20
09
, 4
5.
1%
 
♂
, m
ea
n 
ag
e 
50
.2
, 
SD
15
.3
, c
o-
m
or
bi
di
ty
 
52
.6
%
),
 v
s.
 h
ea
lt
hy
 
co
nt
ro
ls
. T
o 
co
m
pa
re
 
lo
ng
-t
er
m
 h
ea
lt
h 
st
at
us
 n
oti
fie
d 
an
d 
no
n-
no
ti
fie
d 
Q
F 
pa
ti
en
ts
N
CS
I
N
A
N
oti
fie
d:
 m
or
e 
♂
, ↑
 a
ge
 v
s.
 
no
n-
no
ti
fie
d.
 E
qu
al
 p
ro
po
rti
on
s 
fo
llo
w
ed
 a
dd
iti
on
al
 t
re
at
m
en
t 
fo
r 
lo
ng
-la
sti
ng
 h
ea
lt
h 
eff
ec
ts
 
of
 Q
F,
 b
ut
 a
dd
iti
on
 a
nti
bi
oti
c 
tr
ea
tm
en
t 
sl
ig
ht
ly
 ↑
 in
 n
oti
fie
d 
pa
ti
en
ts
. I
n 
bo
th
 g
ro
up
s:
 fa
ti
gu
e 
(n
oti
fie
d 
50
.5
%
 v
s.
 n
on
-n
oti
fie
d 
54
.6
%
) a
nd
 q
ua
lit
y 
of
 li
fe
 
(n
oti
fie
d 
42
.3
%
 v
s.
 n
on
-n
oti
fie
d 
44
.4
%
) m
os
t 
se
ve
re
ly
 a
ff
ec
te
d 
su
bd
om
ai
ns
. N
o 
di
ff
er
en
ce
 
lo
ng
-t
er
m
 h
ea
lt
h 
st
at
us
 n
oti
fie
d 
vs
. n
on
-n
oti
fie
d,
 p
ati
en
ts
 s
co
re
d 
w
or
se
 a
ll 
su
bd
om
ai
ns
 i.
c.
w
. 
he
al
th
y 
co
nt
ro
ls
Lo
ng
-t
er
m
 h
ea
lt
h 
st
at
us
 is
 n
ot
 
de
te
rm
in
ed
 b
y 
sy
m
pt
om
s 
du
ri
ng
 
ac
ut
e 
Q
F.
 L
itt
le
 
im
pr
ov
em
en
t 
he
al
th
 
st
at
us
 b
et
w
ee
n 
1 
an
d 
4 
yr
s 
po
st
 
A
Q
F.
 Im
pl
ic
ati
on
 
20
07
-2
00
9 
D
ut
ch
 
Q
F 
ou
tb
re
ak
 
un
de
re
sti
m
at
ed
 if
 
on
ly
 c
on
si
de
ri
ng
 
no
ti
fie
d 
pa
ti
en
ts
. 
Tr
ue
 b
ur
de
n 
of
 
di
se
as
e 
du
e 
to
 Q
F 
ou
tb
re
ak
 is
 la
rg
er
A
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 T
ab
le
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on
ti
nu
ed
. D
om
ai
n 
ba
ck
gr
ou
nd
/d
es
cr
ip
ti
ve
Re
f
Co
un
tr
y,
 y
r 
st
ud
y,
 p
er
io
d 
an
d 
du
ra
ti
on
St
ud
y 
ty
pe
Pa
ti
en
ts
, c
on
tr
ol
s,
 
ch
ar
ac
te
ri
sti
cs
, 
co
-m
or
bi
di
ty
*
To
ol
In
te
r-
ve
n-
ti
on
O
ut
co
m
e
Co
nc
lu
si
on
s/
re
co
m
m
en
da
ti
on
s
O
th
er
 
do
-
m
ai
n
Q
A
 (C
R
 o
r 
N
O
S)
20
15
, J
. 
va
n 
Lo
en
-
ho
ut
 [3
1]
N
et
he
rl
an
ds
, 
yr
 s
tu
dy
 N
R.
 
St
ud
y 
pe
ri
od
: 
20
10
-2
01
2,
 F
U
 
3,
 6
, 9
 a
nd
 1
2 
m
o 
po
st
 A
Q
F,
 
12
 m
o 
po
st
 A
I 
Le
gi
on
el
la
Co
S,
 w
it
h 
pa
rt
ly
 C
C
33
6 
Q
F,
 1
90
 
Le
gi
on
el
la
 p
ati
en
ts
. 
A
ss
es
s 
(p
ro
gr
es
s 
of
) 
w
or
k 
pa
rti
ci
pa
ti
on
 
of
 Q
F 
pa
ti
en
ts
 u
p 
to
 1
2 
m
o 
po
st
 A
Q
F,
 
id
en
ti
fy
 a
ss
oc
ia
te
d 
fa
ct
or
s,
 a
nd
 c
om
pa
re
 
w
or
k 
pa
rti
ci
pa
ti
on
 
be
tw
ee
n 
Q
F 
an
d 
Le
gi
on
el
la
 p
ati
en
ts
 
12
 m
o 
po
st
 A
I
Q
ue
sti
on
-
na
ir
e 
3,
 6
, 9
 a
nd
 
12
 m
o 
po
st
 A
Q
F,
 
A
D
IQ
 a
t 
12
 m
o 
bo
th
 g
ro
up
s
N
A
↓
 P
ro
po
rti
on
 Q
F 
pa
ti
en
ts
 w
it
h 
↓
 w
or
k 
pa
rti
ci
pa
ti
on
, 4
5%
 a
t 
3 
m
o 
to
 1
9%
 a
t 
12
 m
o 
(v
s.
 1
5%
 
Le
gi
on
el
la
 p
ati
en
ts
 a
t 
12
 m
o)
. 
M
ed
ia
n 
pr
op
or
ti
on
 r
ed
uc
ti
on
 
ho
ur
s 
w
or
ke
d 
st
ab
le
 o
ve
r 
ti
m
e.
 
↑
 P
ro
po
rti
on
 p
ati
en
ts
 n
ot
 
re
po
rti
ng
 s
ym
pt
om
s 
up
 t
o 
12
 
m
o.
 N
o 
sy
m
pt
om
s 
at
 1
2 
m
o:
 Q
F 
44
%
 v
s.
 5
7%
 L
eg
io
ne
lla
. M
os
t 
fr
eq
ue
nt
 s
ym
pt
om
s 
at
 1
2 
m
o 
Q
F:
 fa
ti
gu
e,
 c
on
ce
nt
ra
ti
on
/
m
em
or
y 
pr
ob
le
m
s,
 h
ea
da
ch
e 
(a
ll 
24
%
),
 a
nd
 m
us
cl
e 
pa
in
 2
3%
. 
Le
gi
on
el
la
: c
on
ce
nt
ra
ti
on
/ 
m
em
or
y 
pr
ob
le
m
s 
(2
1%
),
 
fa
ti
gu
e,
 r
es
pi
ra
to
ry
 p
ro
bl
em
s,
 
jo
in
t 
pa
in
s 
(1
3%
).
 G
ri
ev
in
g 
pr
oc
es
s:
 Q
F 
↑
 s
co
re
 d
en
ia
l a
nd
 
re
si
st
an
ce
, ↓
 a
cc
ep
ta
nc
e 
i.c
.w
. 
Le
gi
on
el
la
. Q
F;
 a
ss
oc
ia
te
d 
fa
ct
or
s 
↓
 w
or
k 
pa
rti
ci
pa
ti
on
: s
ym
pt
om
s,
 
↑
 le
ve
l s
or
ro
w
, f
or
m
er
 s
m
ok
er
 
(i.
c.
w
. n
ev
er
 s
m
ok
ed
),
 n
o 
al
co
ho
l c
on
su
m
pti
on
, f
ol
lo
w
in
g 
tr
ea
tm
en
t 
fo
r 
lo
ng
-t
er
m
 h
ea
lt
h 
eff
ec
ts
. M
ed
ia
n 
ti
m
e 
to
 fu
ll 
re
tu
rn
 t
o 
w
or
k 
in
 Q
F 
gr
ou
p 
<3
 
m
o
A
lm
os
t 
1/
5 
Q
F 
pa
ti
en
t 
an
d 
1/
6 
Le
gi
on
el
la
 p
ati
en
t 
↓
 
w
or
k 
pa
rti
ci
pa
ti
on
 a
t 
12
 m
o.
 O
cc
up
ati
on
al
 
an
d 
in
su
ra
nc
e 
ph
ys
ic
ia
ns
 n
ee
d 
to
 
be
 a
w
ar
e 
of
 lo
ng
-
te
rm
 im
pa
ct
 o
f Q
F 
an
d 
Le
gi
on
el
la
 o
n 
w
or
k 
pa
rti
ci
pa
ti
on
. 
Su
gg
es
ti
on
; 
un
de
rg
oi
ng
 Q
F 
le
ad
s 
to
 g
ri
ef
 p
ro
ce
ss
 
si
m
ila
r 
to
 p
ro
gr
es
si
ve
 
di
se
as
e,
 u
nd
er
lin
in
g 
th
e 
se
ve
ri
ty
 o
f 
se
qu
el
ae
 d
ue
 t
o 
Q
F
N
A
« « « «
« «
* 
D
efi
ni
ti
on
 o
f 
us
ed
 s
tu
dy
 p
op
ul
ati
on
 in
 a
rti
cl
es
 e
xp
la
in
ed
 in
 a
 d
iff
er
en
t 
ta
bl
e,
 in
cl
ud
in
g 
de
fi
ni
ti
on
s 
of
 Q
FS
 a
nd
/o
r 
fa
ti
gu
e 
is
 a
pp
lic
ab
le
. M
ai
n 
in
fo
rm
ati
on
 in
 t
hi
s 
ta
bl
e 
is
 o
n 
ba
ck
gr
ou
nd
/d
es
cr
ip
ti
ve
. S
om
e 
ar
ti
cl
es
 a
ls
o 
co
nt
ai
n 
re
le
va
nt
 in
fo
rm
ati
on
 o
n 
ot
he
r 
do
m
ai
ns
: D
ia
g=
 D
ia
gn
os
is
, A
= 
A
eti
ol
og
y,
 P
/T
= 
Pr
ev
en
ti
on
/t
he
ra
py
.
**
 Q
ua
lit
y 
as
se
ss
m
en
t 
ec
on
om
ic
 e
va
lu
ati
on
 s
tu
dy
 w
as
 a
ss
es
se
d 
us
in
g 
th
e 
‘E
ve
rs
 c
he
ck
lis
t’
 [3
2]
.
A
bb
re
vi
ati
on
s:
 A
D
IQ
= 
A
cc
ep
ta
nc
e 
of
 D
is
ea
se
 a
nd
 Im
pa
ir
m
en
ts
 Q
ue
sti
on
na
ir
e,
 t
o 
as
se
ss
 t
he
 d
iff
er
en
t 
st
ag
es
 o
f t
he
 g
ri
ev
in
g 
pr
oc
es
s 
du
e 
to
 t
he
 in
fe
cti
on
 t
ha
t 
pa
ti
en
ts
 u
nd
er
w
en
t,
 
A
I=
 A
cu
te
 in
fe
cti
on
, A
Q
F=
 A
cu
te
 Q
-f
ev
er
, B
Co
D
E=
 B
ur
de
n 
of
 C
om
m
un
ic
ab
le
 D
is
ea
se
s 
in
 E
ur
op
e 
pr
oj
ec
t,
 a
tt
ri
bu
te
s 
D
A
LY
s 
of
 a
n 
in
fe
cti
ou
s 
di
se
as
e 
to
 t
he
 y
ea
r 
th
e 
ac
ut
e 
in
fe
cti
on
 
oc
cu
rs
. T
hi
s 
al
lo
w
s 
fo
r t
he
 a
tt
ri
bu
ti
on
 o
f l
on
g-
te
rm
 s
eq
ue
la
e,
 w
hi
ch
 m
ay
 g
en
er
at
e 
a 
hi
gh
er
 n
um
be
r o
f D
A
LY
s,
 to
 th
e 
ca
us
ati
ve
 in
fe
cti
on
 ra
th
er
 th
an
 o
nl
y 
th
e 
in
iti
al
 a
cu
te
 il
ln
es
s,
 C
.b
.=
 
Co
xi
el
la
 b
ur
ne
ti
i, 
CB
T=
 C
og
ni
ti
ve
 b
eh
av
io
ur
al
 t
he
ra
py
, C
C=
 C
as
e-
co
nt
ro
l s
tu
dy
, C
D
C=
 C
en
tr
es
 f
or
 D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nti
on
, C
D
C-
SI
= 
G
er
m
an
 v
er
si
on
 o
f 
th
e 
CD
C-
Sy
m
pt
om
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In
ve
nt
or
y.
 T
he
 in
ve
nt
or
y 
as
ks
 in
 d
et
ai
l f
or
 1
1 
sy
m
pt
om
s 
th
at
 c
om
m
on
ly
 a
cc
om
pa
ny
 C
FS
. T
he
se
 s
ym
pt
om
s 
ha
ve
 t
o 
be
 d
es
cr
ib
ed
 w
it
h 
re
sp
ec
t 
to
 t
he
ir
 in
te
ns
it
y 
an
d 
fr
eq
ue
nc
y 
re
la
te
d 
to
 th
e 
la
st
 m
on
th
s,
 C
F=
 C
hr
on
ic
 fa
ti
gu
e,
 C
FS
= 
Ch
ro
ni
c 
fa
ti
gu
e 
sy
nd
ro
m
e,
 C
FT
= 
Co
m
pl
em
en
t fi
xa
ti
on
 te
st
, C
IS
-R
=R
ev
is
ed
 C
lin
ic
al
 In
te
rv
ie
w
 S
ch
ed
ul
e 
to
 a
ss
es
s 
th
e 
sy
m
pt
om
s 
of
 n
eu
ro
ti
c 
ps
yc
ho
pa
th
ol
og
y 
in
 t
he
 w
ee
k 
pr
io
r 
to
 in
te
rv
ie
w
. T
he
 C
IS
-R
 is
 m
ad
e 
up
 o
f 1
4 
se
cti
on
s,
 e
ac
h 
co
ve
ri
ng
 a
 p
ar
ti
cu
la
r 
ar
ea
 o
f n
eu
ro
ti
c 
sy
m
pt
om
s.
 S
um
m
ed
 s
co
re
s 
fr
om
 a
ll 
14
 s
ec
ti
on
s 
ra
ng
e 
fr
om
 0
-5
7,
 t
he
 o
ve
ra
ll 
th
re
sh
ol
d 
fo
r 
cl
in
ic
al
ly
 s
ig
ni
fic
an
t 
ps
yc
hi
at
ri
c 
m
or
bi
di
ty
 is
 1
2,
 C
N
E=
 C
ul
tu
re
 n
eg
ati
ve
 
en
do
ca
rd
iti
s,
 C
oS
= 
Co
ho
rt
 s
tu
dy
, C
Q
F=
 C
hr
on
ic
 Q
-f
ev
er
, C
R=
 C
as
e-
re
po
rt
, C
S=
 C
ro
ss
-s
ec
ti
on
al
, D
A
LY
= 
A
 c
om
po
si
te
 h
ea
lt
h 
m
ea
su
re
 t
ha
t 
re
pr
es
en
ts
 o
ne
 lo
st
 y
ea
r 
of
 
he
al
th
y 
lif
e 
be
tw
ee
n 
th
e 
cu
rr
en
t 
he
al
th
 s
ta
tu
s 
an
d 
th
at
 o
f 
an
 id
ea
l h
ea
lt
h 
si
tu
ati
on
. C
al
cu
la
te
d 
as
 t
he
 s
um
 o
f 
YL
D
 fo
r 
in
ci
de
nt
 c
as
es
 a
nd
 t
he
 Y
LL
 d
ue
 t
o 
pr
em
at
ur
e 
de
at
h,
 D
IO
S=
 D
ub
bo
 In
fe
cti
on
 O
ut
co
m
es
 S
tu
dy
, c
oh
or
t s
tu
dy
 o
f s
ub
je
ct
s 
≥1
6 
yr
s 
fo
llo
w
ed
 fr
om
 th
e 
on
se
t o
f a
 c
on
fir
m
ed
 a
nd
 d
oc
um
en
te
d 
A
I d
ue
 to
 E
BV
; C
.b
.; 
or
 R
RV
 
≤6
 w
ks
 p
os
t 
A
I u
nti
l c
om
pl
et
e 
re
co
ve
ry
, E
BV
= 
Ep
st
ei
n-
Ba
rr
 v
ir
us
, E
CG
= 
El
ec
tr
oc
ar
di
og
ra
ph
y,
 F
-S
oz
u 
K1
4=
 T
o 
as
se
ss
 s
oc
ia
l s
up
po
rt
, a
 1
4-
it
em
 q
ue
sti
on
na
ir
e 
re
su
lti
ng
 
in
 a
 t
ot
al
 s
co
re
 d
es
cr
ib
in
g 
th
e 
qu
al
it
y 
an
d 
qu
an
ti
ty
 o
f a
 p
er
so
n’
s 
so
ci
al
 s
up
po
rt
, F
U
= 
Fo
llo
w
-u
p,
 F
U
O
= 
Fe
ve
r 
of
 u
nk
no
w
n 
or
ig
in
, G
H
Q
= 
G
en
er
al
 h
ea
lt
h 
qu
es
ti
on
na
ir
e,
 
12
-it
em
 q
ue
sti
on
na
ir
e 
to
 d
et
ec
t 
cu
rr
en
t 
ca
se
s 
of
 p
sy
ch
ia
tr
ic
 c
o-
m
or
bi
di
ty
, 
I.c
.w
.=
 I
n 
co
m
pa
ri
so
n 
w
it
h,
 I
CF
= 
Id
io
pa
th
ic
 c
hr
on
ic
 f
ati
gu
e,
 I
FA
= 
Im
m
un
ofl
uo
re
sc
en
ce
 
as
sa
y,
 Ig
G
I=
 A
nti
-p
ha
se
 Ig
G
 I 
ti
tr
e,
 Ig
G
II=
 A
nti
-p
ha
se
 Ig
G
 II
 ti
tr
e,
 Ig
M
I=
 A
nti
-p
ha
se
 Ig
M
 I 
ti
tr
e,
 Ig
M
II=
 A
nti
-p
ha
se
 Ig
M
 II
 ti
tr
e,
 L
RT
I=
 L
ow
er
 r
es
pi
ra
to
ry
 t
ra
ct
 in
fe
cti
on
, 
M
FI
 2
0=
 G
er
m
an
 v
er
si
on
 o
f t
he
 M
ul
ti
di
m
en
si
on
al
 F
ati
gu
e 
In
ve
nt
or
y,
 a
 c
om
m
on
ly
 u
se
d 
20
-it
em
 q
ue
sti
on
na
ir
e 
in
di
ca
ti
ng
 d
iff
er
en
t 
di
m
en
si
on
s 
of
 fa
ti
gu
e,
 M
in
i-D
IP
S=
 
D
ia
gn
os
ti
c 
in
te
rv
ie
w
, a
 s
ho
rt
 fo
rm
 o
f t
he
 d
ia
gn
os
ti
c 
in
te
rv
ie
w
 o
f p
sy
ch
ol
og
ic
al
 d
is
or
de
rs
, M
o=
 M
on
th
(s
),
 M
O
S=
 M
ed
ic
al
 o
ut
co
m
e 
st
ud
y 
20
-it
em
 q
ue
sti
on
na
ir
e,
 u
se
d 
to
 d
efi
ne
 f
un
cti
on
al
 im
pa
ir
m
en
t 
in
 t
he
 c
on
st
ru
cti
on
 o
f 
th
e 
CF
S 
de
fin
iti
on
, N
A
= 
N
ot
 a
pp
lic
ab
le
, N
CS
I=
 N
ijm
eg
en
 c
lin
ic
al
 s
cr
ee
ni
ng
 in
st
ru
m
en
t,
 o
ri
gi
na
lly
 d
ev
el
op
ed
 
to
 p
ro
vi
de
 a
 d
et
ai
le
d 
as
se
ss
m
en
t 
of
 h
ea
lt
h 
st
at
us
 o
f C
O
PD
 p
ati
en
ts
. I
t 
co
m
bi
ne
s 
a 
nu
m
be
r 
of
 e
xi
sti
ng
 h
ea
lt
h 
st
at
us
 q
ue
sti
on
na
ir
es
, N
O
S=
 N
ew
ca
st
le
–O
tt
aw
a 
Sc
al
e:
 
S=
 s
el
ec
ti
on
 (
m
ax
im
um
 o
f 
4 
st
ar
s)
, 
C=
 c
om
pa
ra
bi
lit
y 
(m
ax
im
um
 o
f 
2 
st
ar
s)
, 
O
= 
ou
tc
om
e 
(m
ax
im
um
 o
f 
3 
st
ar
s)
;«
: 
st
ar
 e
ar
ne
d;
 ¶
: 
it
em
 n
ot
 a
pp
lic
ab
le
, 
N
/N
o=
 
N
um
be
r 
(o
f)
, (
n-
)P
CR
= 
(n
es
te
d-
) P
ol
ym
er
as
e 
ch
ai
n 
re
ac
ti
on
, N
R=
 N
ot
 r
ep
or
te
d,
 O
Q
-4
5=
 O
Q
-4
5,
 t
o 
m
ea
su
re
 p
sy
ch
ol
og
ic
al
 s
ym
pt
om
s 
an
d 
ge
ne
ra
l i
m
pa
ir
m
en
t.
 It
 is
 a
 
co
m
m
on
 s
ym
pt
om
 in
ve
nt
or
y 
us
ed
 in
 m
an
y 
ps
yc
ho
th
er
ap
y 
st
ud
ie
s 
to
 r
efl
ec
t 
to
ta
l i
m
pa
ir
m
en
t,
 s
oc
ia
l a
s 
w
el
l a
s 
in
te
rp
er
so
na
l d
is
tr
es
s 
an
d 
im
pa
ir
m
en
t 
of
 s
oc
ia
l r
ol
e 
pe
rf
or
m
an
ce
, P
H
Q
-9
= 
a 
se
lf-
ad
m
in
is
te
re
d 
su
bs
et
 o
f t
he
 P
RI
M
A
-M
D
 d
ia
gn
os
ti
c 
in
st
ru
m
en
t 
fo
r 
co
m
m
on
 m
en
ta
l d
is
or
de
rs
 to
 a
ss
es
s 
sy
m
pt
om
s 
se
ve
ri
ty
 o
f d
ep
re
ss
io
n,
 
PI
CF
= 
Po
st
-in
fe
cti
ou
s 
ch
ro
ni
c 
fa
ti
gu
e,
 P
IF
(S
)=
 P
os
t-
in
fe
cti
ve
 fa
ti
gu
e 
(s
yn
dr
om
e)
, P
.o
.=
 O
ra
l, 
PO
= 
Pe
rs
on
al
 o
pi
ni
on
, P
O
B=
 P
er
so
na
l o
bs
er
va
ti
on
, P
Q
CF
S=
 P
os
t-
Q
-f
ev
er
 
ch
ro
ni
c 
fa
ti
gu
e 
sy
nd
ro
m
e,
 P
Q
D
S=
 P
os
t-
Q
-f
ev
er
 d
eb
ili
ty
 s
yn
dr
om
e,
 P
Q
FS
= 
Po
st
-(
ac
ut
e)
Q
-f
ev
er
 (f
ati
gu
e)
 s
yn
dr
om
e,
 P
ro
s.
= 
Pr
os
pe
cti
ve
, P
S=
 P
er
fo
rm
an
ce
 s
ta
tu
s 
sc
or
e 
(r
an
ge
 0
-9
),
 w
hi
ch
 re
fle
ct
s 
th
e 
gr
ad
e 
of
 fa
ti
gu
e/
m
al
ai
se
 to
 a
ss
es
s 
th
e 
se
ve
ri
ty
 o
f C
FS
, Q
A
-C
R=
 Q
ua
lit
y 
as
se
ss
m
en
t;
 fo
r C
R 
no
 q
ua
lit
y 
ch
ec
kl
is
ts
 a
re
 a
va
ila
bl
e.
 T
he
re
fo
re
, 
th
e 
fo
llo
w
in
g 
ei
gh
t c
ri
te
ri
a 
fo
r 
qu
al
it
y 
as
se
ss
m
en
t w
er
e 
de
te
rm
in
ed
; a
dd
re
ss
in
g 
an
 a
pp
ro
pr
ia
te
 a
nd
 c
le
ar
ly
 fo
cu
se
d 
qu
es
ti
on
, r
ep
re
se
nt
ati
ve
 p
op
ul
ati
on
, d
es
cr
ip
ti
on
 
of
 t
he
 s
ur
ve
y 
m
et
ho
d 
or
 d
at
a 
co
lle
cti
on
, o
ut
co
m
e 
m
ea
su
re
s 
de
fin
ed
, o
ut
co
m
e 
m
ea
su
re
s 
de
sc
ri
be
d,
 r
es
po
ns
e 
ra
te
 r
ep
or
te
d 
an
d 
re
su
lt
s 
va
lid
 a
nd
 a
pp
lic
ab
le
 t
o 
th
e 
pa
ti
en
t 
gr
ou
p 
ta
rg
et
ed
. T
he
 a
rti
cl
es
 s
co
re
s 
on
 t
he
se
 it
em
s:
 -
/-
, -
, +
/-
, +
, o
r 
++
, b
as
ed
 o
n 
th
e 
Co
or
di
na
ti
on
 o
f 
Ca
nc
er
 C
lin
ic
al
 P
ra
cti
ce
 G
ui
de
lin
es
 in
 E
ur
op
e 
cr
it
er
ia
, 
Q
F=
 Q
-f
ev
er
, Q
F(
F)
S=
 Q
-f
ev
er
 fa
ti
gu
e 
sy
nd
ro
m
e,
 R
ef
= 
Re
fe
re
nc
e,
 R
RV
= 
Ro
ss
 R
iv
er
 v
ir
us
, S
D
= 
St
an
da
rd
 d
ev
ia
ti
on
, S
D
S=
 S
el
f-
ra
ti
ng
 d
ep
re
ss
io
n 
sc
al
e,
 c
on
si
sti
ng
 o
f 
20
 
qu
es
ti
on
s,
 s
co
re
 p
er
 q
ue
sti
on
: 1
-4
 p
oi
nt
s,
 S
D
Q
= 
So
m
ati
c 
D
is
co
m
fo
rt
 Q
ue
sti
on
na
ir
e,
 a
 c
he
ck
lis
t 
of
 2
5 
so
m
ati
c 
sy
m
pt
om
s,
 a
s 
so
m
ati
c 
sy
m
pt
om
s 
ar
e 
im
po
rt
an
t 
m
in
or
 
sy
m
pt
om
s 
in
 t
he
 c
on
st
ru
cti
on
 o
f 
CF
S 
de
fin
iti
on
, S
F-
12
= 
Th
e 
Sh
or
t 
Fo
rm
 (
12
) 
H
ea
lt
h 
Su
rv
ey
, S
F-
36
= 
Th
e 
Sh
or
t 
Fo
rm
 (
36
) 
H
ea
lt
h 
Su
rv
ey
, a
 p
ati
en
t-
re
po
rt
ed
 s
ur
ve
y 
of
 p
ati
en
t 
he
al
th
 t
o 
as
se
ss
 q
ua
lit
y 
of
 li
fe
 o
f 
pa
ti
en
ts
, f
un
cti
on
al
 im
pa
ir
m
en
t 
an
d 
re
du
ce
d 
he
al
th
 r
el
at
ed
 q
ua
lit
y 
of
 li
fe
, S
O
M
A
= 
Em
pi
ri
ca
lly
 d
er
iv
ed
 s
ub
sc
al
e 
of
 t
he
 
SP
H
ER
E,
 u
se
d 
to
 re
co
rd
 P
IF
S 
or
 il
ln
es
s 
du
ra
ti
on
. T
hi
s 
re
lia
bl
y 
pr
ed
ic
ts
 d
is
ab
ili
ty
 a
nd
 re
fle
ct
s 
pa
ti
en
ts
’ a
nd
 d
oc
to
rs
’ r
ep
or
ts
 o
f r
ea
so
ns
 fo
r p
re
se
nt
ati
on
 to
 p
ri
m
ar
y 
ca
re
. 
Sc
or
es
 ≥
3 
re
pr
es
en
ts
 a
 c
lin
ic
al
ly
-s
ig
ni
fic
an
t 
fa
ti
gu
e 
st
at
e.
 P
ro
vi
si
on
al
 P
IF
S:
 S
O
M
A
 s
co
re
s 
≥3
 a
t 
al
l ti
m
e 
po
in
ts
 u
p 
≤3
 m
on
th
s.
 C
on
fir
m
ed
 P
IF
S:
 s
ym
pt
om
s 
pe
rs
is
te
d 
>6
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m
on
th
s,
 a
nd
 a
lt
er
na
ti
ve
 e
xp
la
na
ti
on
s 
fo
r 
on
go
in
g 
ill
ne
ss
 w
as
 e
xc
lu
de
d,
 S
O
M
S=
 S
cr
ee
ni
ng
 fo
r 
So
m
at
of
or
m
 D
is
or
de
rs
, a
 5
3-
it
em
 q
ue
sti
on
na
ir
e 
as
se
ss
in
g 
sy
m
pt
om
s 
co
m
m
on
 f
or
 s
om
at
of
or
m
 a
nd
 s
om
ati
sa
ti
on
 d
is
or
de
r 
le
ad
in
g 
to
 t
he
 c
al
cu
la
ti
on
 o
f 
di
ff
er
en
t 
in
di
ce
s,
 S
PH
ER
E=
 S
om
ati
c 
an
d 
Ps
yc
ho
lo
gi
ca
l H
ea
lt
h 
Re
po
rt
, 
to
 a
ss
es
s 
a 
w
id
e 
ra
ng
e 
of
 p
hy
si
ca
l 
an
d 
ps
yc
ho
lo
gi
ca
l 
sy
m
pt
om
s,
 i
nc
lu
di
ng
 s
ev
er
it
y 
an
d 
du
ra
ti
on
 o
f 
sy
m
pt
om
s,
 T
. 
go
nd
ii=
 T
ox
op
la
sm
a 
go
nd
ii,
 U
K=
 U
ni
te
d 
Ki
ng
do
m
, 
U
RT
I=
 
U
pp
er
 r
es
pi
ra
to
ry
 t
ra
ct
 in
fe
cti
on
, V
A
S=
 V
is
ua
l a
na
lo
gu
e 
sc
or
e,
 1
0c
m
 s
ca
le
 to
 q
ua
nti
fy
 s
ym
pt
om
 s
ev
er
it
y,
 W
ks
= 
W
ee
ks
, W
I=
 W
hi
te
le
y 
In
de
x,
 to
 m
ea
su
re
 t
he
 p
ati
en
ts
’ 
te
nd
en
cy
 fo
r 
hy
po
ch
on
dr
ia
ca
l w
or
ri
es
 a
nd
 b
el
ie
fs
, Y
LD
= 
N
um
be
r 
of
 y
ea
rs
 lo
st
 d
ue
 t
o 
di
sa
bi
lit
y:
 n
um
be
r 
of
 in
ci
de
nt
 c
as
es
 x
 a
ve
ra
ge
 d
ur
ati
on
 o
f t
he
 d
is
ea
se
 x
 w
ei
gh
t 
fa
ct
or
 th
at
 re
fle
ct
s 
th
e 
se
ve
ri
ty
 o
f t
he
 d
is
ea
se
 o
n 
a 
sc
al
e 
fr
om
 0
 (p
er
fe
ct
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ea
lt
h)
 to
 1
 (d
ea
d)
, Y
LL
= 
Ye
ar
s 
of
 L
ife
 L
os
t d
ue
 to
 p
re
m
at
ur
e 
de
at
h;
 n
um
be
r o
f d
ea
th
s 
ca
us
ed
 
by
 t
he
 d
is
ea
se
 x
 s
ta
nd
ar
d 
lif
e 
ex
pe
ct
an
cy
 a
t 
th
e 
ag
e 
at
 w
hi
ch
 d
ea
th
 o
cc
ur
s,
 Y
r(
s)
= 
Ye
ar
(s
).
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an
 (o
nl
y 
in
 
su
bs
et
)
N
A
68
.2
%
 C
.b
. c
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es
 fa
ti
gu
e 
an
y 
du
ra
ti
on
, 4
2.
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ti
gu
e 
ex
cl
ud
in
g 
co
-m
or
bi
di
ty
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D
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ed
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. 5
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%
 c
on
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ol
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.2
%
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cl
ud
in
g 
co
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or
bi
di
ty
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%
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nt
ro
ls
. N
or
m
al
 E
CG
's
 7
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ca
se
s,
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9.
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 c
on
tr
ol
s,
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o 
di
ff
er
en
ce
s.
 E
ch
oc
ar
di
og
ra
ph
y:
 
co
nt
ro
ls
 ↓
 fr
ac
ti
on
al
 
sh
or
te
ni
ng
. F
ati
gu
ed
 v
s.
 n
on
-
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ti
gu
ed
 Q
F 
ca
se
s:
 c
om
pa
ra
bl
e 
ec
ho
ca
rd
io
gr
ap
hy
, E
CG
, s
hu
tt
le
 
w
al
k 
di
st
an
ce
s,
 p
ac
k 
ye
ar
s 
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ok
in
g.
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m
al
 M
U
G
A
 s
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n 
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b.
 c
as
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 (C
D
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de
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ed
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w
it
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ut
 c
o-
m
or
bi
di
ty
)
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 d
o 
no
t 
su
pp
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t 
th
e 
ex
is
te
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e 
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 s
ub
-c
lin
ic
al
 
ca
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io
m
yo
pa
th
y 
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 p
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en
ts
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it
h 
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er
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Q
F,
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re
fo
re
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es
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s 
an
d 
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ti
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e.
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ea
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 d
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B/
D
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Fr
an
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, 2
00
2.
 
D
ur
ati
on
 s
tu
dy
 
N
A
PO
N
o 
pa
ti
en
ts
/c
on
tr
ol
s.
 
Ch
ar
ac
te
ri
sti
cs
 a
nd
 
co
-m
or
bi
di
ty
: N
R
N
A
N
A
6 
m
o 
po
st
 A
Q
F 
5-
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%
 r
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l 
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th
en
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er
y 
fe
w
 >
1 
yr
. 
Su
bj
ec
ti
ve
 s
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s 
di
ffi
cu
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 t
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. C
F:
 d
iffi
cu
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 t
o 
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e,
 
w
it
h 
di
ff
er
en
t 
pr
ev
al
en
ce
. 
U
nk
no
w
n 
if 
CF
 p
sy
ch
ol
og
ic
al
 
in
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ri
gi
n/
di
re
ct
ly
 c
au
se
d 
by
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ct
er
iu
m
. M
ig
ht
 r
efl
ec
t 
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se
rv
ati
on
al
 b
ia
s,
 C
.b
. s
tr
ai
n 
or
 
cu
lt
ur
al
 d
iff
er
en
ce
s,
 o
r 
ge
ne
ti
c 
su
sc
ep
ti
bi
lit
y
A
m
pl
ic
on
 p
ro
du
cti
on
 P
CR
 in
 
pe
ri
ph
er
al
 b
lo
od
 C
F 
pa
ti
en
ts
 
ne
ed
s 
co
nfi
rm
ati
on
. N
ew
 t
oo
ls
 
m
ig
ht
 a
llo
w
 t
o 
ex
am
in
e 
ae
ti
ol
og
y 
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co
m
pl
et
el
y 
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de
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to
od
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se
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 c
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D
N
A
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A
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tr
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ia
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r 
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y 
N
R.
 S
in
gl
e 
m
ea
su
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m
en
t 
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ud
y
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23
 a
cti
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/r
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ov
er
ed
 
Q
FS
, 4
2 
co
nt
ro
ls
 R
ed
 
Cr
os
s 
bl
oo
d 
do
no
rs
, 
al
l C
au
ca
si
an
s.
 T
o 
co
m
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re
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he
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di
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m
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g 
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 c
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ok
in
e 
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d 
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m
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se
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en
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 c
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ol
s
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g 
w
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N
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M
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ne
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H
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-
D
R 
an
d 
H
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 p
ol
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or
ph
ic
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ri
an
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4 
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s 
an
al
ys
ed
N
A
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ca
nt
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ti
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N
P 
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en
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, b
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 m
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an
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di
ff
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g 
fr
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ild
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yp
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en
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c.
w
. c
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=0
.0
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. 
D
iff
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en
ce
s 
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le
lic
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eq
ue
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ie
s 
H
LA
-D
R,
 s
ig
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fic
an
t 
↑
 fr
eq
ue
nc
y 
H
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-D
R1
1 
in
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, b
ut
 n
ot
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-B
. 
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en
ot
yp
e 
fr
eq
ue
nc
ie
s 
SN
P 
in
 
ge
ne
s 
no
t 
si
gn
ifi
ca
nt
ly
 d
iff
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en
t 
fr
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 c
on
tr
ol
s.
 V
ar
ia
ti
on
 a
lle
le
 
di
st
ri
bu
ti
on
 Q
FS
 a
nd
 c
on
tr
ol
s 
IN
Fy
 
di
-n
uc
le
oti
de
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ep
ea
t.
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N
y 
ge
ne
s;
 
↑
 p
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e 
ho
m
oz
yg
ou
s 
st
at
e 
IF
N
y 
al
le
le
 2
 in
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tr
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 1
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Po
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 g
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eti
c 
ro
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xp
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io
n 
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er
t 
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c 
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.g
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on
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.b
. i
m
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se
. G
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en
 c
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it
y 
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c 
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l o
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m
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e 
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st
em
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1-
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 r
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n 
Q
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n/
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r 
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c 
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m
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po
ly
m
or
ph
ic
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 c
yt
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m
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 m
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c
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 p
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, c
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, c
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Ja
pa
n,
 y
r 
st
ud
y 
N
R.
 S
in
gl
e 
m
ea
su
re
m
en
t 
st
ud
y
CC
44
 C
FS
 (H
1:
 2
2 
CF
S,
 1
4 
♂
, 2
3-
61
 y
rs
; H
2:
 2
2 
CF
S,
 1
7 
♂
, 2
0-
46
 y
rs
),
 
38
 h
ea
lt
hy
 c
on
tr
ol
s 
(2
0 
♂
, 2
0-
59
 y
rs
).
 T
o 
in
ve
sti
ga
te
 a
ss
oc
ia
ti
on
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ra
l i
nf
ec
ti
on
s 
w
it
h 
CF
S 
an
d 
2-
5A
S 
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ti
vi
ty
 
in
 P
BM
C 
in
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pa
n 
in
 
2 
ho
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it
al
s 
(H
1,
 H
2)
 
di
ff
er
en
t 
ar
ea
s
C.
b.
, I
FA
 Ig
G
II 
po
si
ti
ve
 ti
tr
e 
≥1
:6
4
N
A
2-
5A
S 
ac
ti
vi
ty
: 1
9 
(m
ea
n 
2.
23
) 
in
 H
1,
 7
 (m
ea
n 
0.
91
) i
n 
H
2,
 4
 in
 
co
nt
ro
ls
 (m
ea
n 
0.
74
).
 D
iff
er
en
ce
s 
H
1 
an
d 
H
2,
 a
nd
 H
1 
an
d 
co
nt
ro
ls
 
(p
<0
.0
1)
. N
o 
di
ff
er
en
ce
 H
2 
an
d 
co
nt
ro
ls
. I
FN
a 
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m
ila
r 
in
 fe
w
 
CF
S 
pa
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en
ts
 a
nd
 c
on
tr
ol
s.
 N
o 
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on
sh
ip
 2
-5
A
S 
an
d 
IF
N
a 
po
si
ti
vi
ty
. E
BV
 a
nti
-E
A
-I
gG
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bo
di
es
 in
 9
%
 a
nd
 3
2%
in
 H
1 
an
d 
H
2.
 Ig
G
 C
.b
. p
os
iti
ve
 6
/2
2 
H
1,
 0
/2
2 
H
2,
 1
/9
 c
on
tr
ol
s.
 N
o 
di
ff
er
en
ce
 C
.b
. p
os
iti
ve
 H
1 
an
d 
co
nt
ro
ls
/p
ati
en
ts
 H
2 
an
d 
co
nt
ro
ls
. 
N
o 
co
rr
el
ati
on
 2
-5
A
S 
ac
ti
vi
ty
 a
nd
 
C.
b.
 ti
tr
es
 (p
>0
.0
5)
2-
5A
S 
ac
ti
vi
ty
 ↑
 P
BM
C 
CF
S 
pa
ti
en
ts
. C
FS
 m
ay
 b
e 
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so
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at
ed
 
EB
V/
C.
b.
 ↑
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-5
A
S 
su
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ts
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m
un
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ic
al
 d
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ti
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s 
w
it
h 
vi
ru
s 
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s 
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FS
. N
o 
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ti
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 ti
tr
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 C
.b
. a
nd
 2
-5
A
S 
ac
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vi
ti
es
. 2
-5
A
S 
ac
ti
vi
ty
 c
ha
ng
ed
 
fr
om
 p
os
iti
ve
 t
o 
ne
ga
ti
ve
 in
 1
 
CF
S 
pa
ti
en
t 
w
he
n 
C.
b.
 a
nti
bo
di
es
 
di
sa
pp
ea
re
d,
 s
ug
ge
st
s 
C.
b.
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so
ci
ati
on
 2
-5
A
S 
ac
ti
vi
ty
 s
om
e 
CF
S 
pa
ti
en
ts
. I
m
pl
y 
2-
5A
S 
in
 
so
m
e 
CF
S 
pa
ti
en
ts
 a
cti
va
te
d 
by
 
ot
he
r 
m
ec
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ni
sm
s,
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iti
on
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V
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 C
.b
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A
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A
us
tr
al
ia
 a
nd
 
U
K,
 2
00
1,
 s
tu
dy
 
pe
ri
od
 N
R
CC
 
(c
as
e 
fo
llo
w
-
up
 
st
ud
y)
C.
b.
 p
os
iti
ve
 U
K 
ca
se
s 
(n
=9
2)
 1
2 
yr
 p
os
t 
A
Q
F 
(B
ir
m
in
gh
am
 1
98
9,
 
n=
92
 b
lo
od
 s
am
pl
es
, 
n=
91
 P
BM
C,
 n
=3
5 
BM
A
),
 A
us
tr
al
ia
n 
ca
se
s 
(n
=2
9)
 9
 m
o-
5 
yr
s 
po
st
 A
Q
F 
(n
=2
9 
bl
oo
d 
sa
m
pl
es
 a
nd
 
PB
M
C,
 n
=2
0 
BM
A
, 
n=
14
 li
ve
r 
bi
op
sy
) 
w
it
h 
CF
S 
(C
D
C-
cr
it
er
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).
 T
o 
co
m
pa
re
 
pr
ev
al
en
ce
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fe
cti
on
 
m
ar
ke
rs
 b
et
w
ee
n 
co
ho
rt
s
I. 
C.
b.
 P
CR
 
(d
ir
ec
te
d 
ag
ai
ns
t s
ev
er
al
 
ta
rg
et
s 
in
 th
e 
ge
no
m
e)
 D
N
A
 
de
te
cti
on
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M
C 
an
d 
bo
ne
 
m
ar
ro
w
, I
I. 
CF
T,
 
IF
A
 P
ha
se
 I 
&
 II
, 
III
. i
so
la
ti
on
 C
.b
. 
ce
ll 
cu
lt
ur
es
 
of
 m
ic
e 
- P
CR
 
po
si
ti
ve
N
A
Bo
th
 g
ro
up
s 
re
m
ai
ne
d 
se
ro
po
si
ti
ve
 ir
re
sp
ec
ti
ve
 c
lin
ic
al
 
st
at
e.
 C
.b
. g
en
om
ic
 D
N
A
 d
et
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d 
by
 P
CR
 in
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5%
 o
f B
M
A
 fr
om
 
A
us
tr
al
ia
n 
vs
. 8
8%
 B
ir
m
in
gh
am
 
pa
ti
en
ts
. N
o 
C.
b.
 is
ol
at
ed
 fr
om
 
PC
R 
po
si
ti
ve
 s
am
pl
es
Re
su
lt
s 
in
di
ca
te
 m
or
e 
co
m
pl
ex
 
in
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cti
on
 b
et
w
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n 
ho
st
-
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gu
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te
d,
 p
er
si
st
en
t 
ca
rr
ia
ge
 o
f 
C.
b.
 a
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 d
is
ea
se
. A
n 
ad
di
ti
on
al
 
va
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le
 fa
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or
 o
f h
os
t 
re
gu
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ti
on
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 c
el
lu
la
r 
im
m
un
e 
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on
se
 
m
us
t 
de
te
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e 
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ve
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pe
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e 
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d 
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m
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c 
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he
si
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F 
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e,
 p
ro
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nfi
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 b
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m
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Q
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, m
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 b
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m
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 ↑
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.b
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es
 
in
 b
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w
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D
ia
g
« « « ¶
« «
2QFS, A SYSTEMATIC REVIEW  | 93
S4
 T
ab
le
 c
on
ti
nu
ed
. D
om
ai
n 
ae
ti
ol
og
y
Re
f
Co
un
tr
y,
 y
r 
st
ud
y,
 p
er
io
d 
an
d 
du
ra
ti
on
St
ud
y 
ty
pe
Pa
ti
en
ts
, c
on
tr
ol
s,
 
ch
ar
ac
te
ri
sti
cs
, c
o-
m
or
bi
di
ty
*
To
ol
In
te
r-
ve
n-
ti
on
O
ut
co
m
e
Co
nc
lu
si
on
s/
re
co
m
m
en
da
ti
on
s
O
th
er
 
do
-
m
ai
n
Q
A
 (N
O
S)
20
05
, K
. 
H
el
bi
g 
[9
]
A
us
tr
al
ia
 a
nd
 
U
K,
 y
r 
N
R,
 s
tu
dy
 
du
ra
ti
on
 N
R
CC
 
(g
en
e-
ti
c 
as
so
-
ci
ati
on
)
31
 Q
FS
 p
ati
en
ts
 
vs
. u
nc
om
pl
ic
at
ed
 
re
co
ve
ry
 u
p 
to
 1
2 
yr
s 
po
st
 A
Q
F 
(n
=2
2)
 
vs
. Q
IE
 (n
=2
2,
 m
ea
n 
ag
e 
57
, r
an
ge
 2
9-
78
, 
ti
m
e 
la
g 
in
fe
cti
on
-I
E 
8.
8 
yr
s,
 S
D
12
, r
an
ge
 
2-
40
) i
.c
.w
. s
ta
nd
ar
d 
co
nt
ro
l p
an
el
s 
ge
ne
ra
l p
op
ul
ati
on
. 
To
 c
om
pa
re
 
fr
eq
ue
nc
ie
s 
of
 a
lle
lic
 
po
ly
m
or
ph
is
m
s 
in
 
im
m
un
e 
re
sp
on
se
 
ge
ne
s 
in
 d
iff
er
en
t 
Q
F 
pa
ti
en
t 
gr
ou
ps
W
ho
le
 b
lo
od
, 
D
N
A
 e
xt
ra
cti
on
, 
H
LA
 t
yp
in
g,
 
m
ic
ro
-s
at
el
lit
e 
ty
pi
ng
, S
N
P 
an
al
ys
is
N
A
Si
gn
ifi
ca
nt
 d
iff
er
en
ce
s 
be
tw
ee
n 
3 
gr
ou
ps
. Q
FS
 p
ati
en
ts
 d
iff
er
ed
 
fr
om
 Q
IE
, t
he
 u
nc
om
pl
ic
at
ed
 
an
d 
co
nt
ro
ls
 in
 fr
eq
ue
nc
y 
of
 
H
LA
-D
RB
1*
11
 a
nd
 2
/2
 g
en
ot
yp
e 
of
 IF
N
y 
in
tr
on
 1
 m
ic
ro
sa
te
lli
te
. 
Ca
rr
ia
ge
 H
LA
 D
RB
1*
11
 a
lle
le
 
as
so
ci
at
ed
 w
it
h 
↓
 IF
N
y 
an
d 
IL
-2
 r
es
po
ns
es
 fr
om
 P
BM
C.
 Q
IE
 
sh
ow
ed
 d
iff
er
en
ce
s 
in
 IL
-1
0 
pr
om
ot
er
 m
ic
ro
sa
te
lli
te
s 
R 
an
d 
G
, 
an
d 
↑
 fr
eq
ue
nc
y 
TN
Fa
 r
ec
ep
to
r 
II 
19
6R
 p
ol
ym
or
ph
is
m
. Q
F 
pa
ti
en
ts
 
w
it
h 
un
co
m
pl
ic
at
ed
 r
ec
ov
er
y,
 
di
ff
er
ed
 fr
om
 t
ho
se
 w
it
h 
Q
FS
/Q
IE
, 
bu
t 
si
m
ila
r 
in
 a
lle
lic
 fr
eq
ue
nc
ie
s 
to
 c
on
tr
ol
 p
an
el
s
Co
nc
lu
si
on
s 
C.
b.
, p
ar
vo
vi
ru
s 
B1
9 
in
fe
cti
on
 a
nd
 C
FS
 s
tu
di
es
 s
ug
ge
st
 
th
at
 ‘i
di
op
at
hi
c’
 C
FS
 p
ati
en
ts
 
fr
om
 t
he
 w
id
er
 p
op
ul
ati
on
, a
w
ay
 
fr
om
 o
ut
br
ea
ks
/o
cc
up
ati
on
al
ly
 
ex
po
se
d 
gr
ou
ps
, a
re
 u
nl
ik
el
y 
to
 h
av
e 
la
bo
ra
to
ry
 e
vi
de
nc
e 
of
 
in
fe
cti
on
 w
it
h 
th
e 
sa
m
e 
in
fe
cti
ve
 
ag
en
t.
 A
 c
om
m
on
 im
m
un
o-
ge
ne
ti
ca
lly
 d
et
er
m
in
ed
 fa
ilu
re
 o
f 
cy
to
ki
ne
 h
om
eo
st
as
is
 t
o 
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fe
cti
ve
 
ag
en
ts
 w
it
h 
th
e 
ca
pa
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 t
o 
pe
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t 
lo
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os
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 m
or
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lik
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y
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bi
di
ty
*
To
ol
In
te
r-
ve
n-
ti
on
O
ut
co
m
e
Co
nc
lu
si
on
s/
re
co
m
m
en
da
ti
on
s
O
th
er
 
do
-
m
ai
n
Q
A
 (N
O
S)
po
si
ti
ve
 s
am
pl
es
 
(b
on
e 
m
ar
ro
w
, 
PB
M
C,
 o
r 
ao
rti
c 
va
lv
e 
sp
ec
im
en
s)
 
10
 p
ati
en
ts
 fr
om
 
su
bs
et
s 
in
oc
ul
at
ed
 
in
tr
ap
er
it
on
ea
l N
O
D
/
SC
ID
 m
ic
e.
 C
on
tr
ol
 
an
im
al
s 
re
ce
iv
ed
 
bl
oo
d 
PC
R 
ne
ga
ti
ve
, 
se
ro
ne
ga
ti
ve
 c
on
tr
ol
s.
 
To
 is
ol
at
e 
liv
in
g 
C.
b.
 t
o 
as
ce
rt
ai
n 
pa
th
ol
og
ic
al
 
eff
ec
ts
, r
et
es
t 
an
d 
de
te
rm
in
e 
na
tu
re
 
re
si
du
al
 C
.b
. c
el
l 
co
m
po
ne
nt
s
m
ac
ro
-
ph
ag
es
w
ee
k 
po
st
 in
oc
ul
ati
on
, l
at
er
 
re
co
ve
re
d 
an
d 
st
ea
dy
 w
ei
gh
t 
ga
in
 c
on
si
st
en
t 
w
it
h 
ab
se
nc
e 
in
fe
cti
on
. A
ll 
m
ou
se
 s
pl
ee
n 
sp
ec
im
en
s 
PC
R 
ne
ga
ti
ve
 (1
:1
00
 
di
lu
ti
on
s)
. D
es
pi
te
 a
bs
en
ce
 a
cti
ve
 
in
fe
cti
on
, c
ha
ng
es
: m
od
er
at
e 
sp
le
en
 e
nl
ar
ge
m
en
t 
Q
FS
gr
5 
an
d 
6 
i.c
.w
. c
on
tr
ol
s 
(p
<0
.0
5)
, n
o 
m
as
si
ve
 s
pl
en
om
eg
al
y 
by
 li
ve
 
C.
b.
 S
ec
ti
on
s 
m
ou
se
 s
pl
ee
ns
 w
it
h 
va
ri
ab
le
 a
m
ou
nt
s 
ag
gr
eg
at
es
 
st
ai
ne
d 
to
 d
et
ec
t 
sp
ec
ifi
c 
an
ti
ge
n,
 
al
so
 in
 N
O
D
/S
CI
D
 m
ou
se
 b
on
e 
m
ar
ro
w
 a
nd
 li
ve
r 
in
oc
ul
at
ed
 w
it
h 
Q
FS
 s
pe
ci
m
en
s.
 C
.b
. a
nti
ge
ns
 
no
 c
or
re
la
ti
on
 lo
w
 le
ve
ls
 C
.b
., 
su
gg
es
ts
 c
om
pl
ex
es
 t
o 
re
pr
es
en
t 
in
co
m
pl
et
el
y 
de
gr
ad
ed
 c
el
l 
m
at
er
ia
l. 
C.
b.
 a
nti
ge
ns
 lo
ca
liz
ed
 
in
 s
pl
ee
n 
ph
ag
oc
yt
es
, a
nd
 C
.b
. 
im
m
un
om
od
ul
at
or
y 
co
m
pl
ex
 in
 
ly
so
so
m
es
 m
ou
se
 s
pl
en
oc
yt
es
. 
L-
6/
IL
-1
0 
ra
ti
o 
an
d 
↑
 le
ve
l I
L-
10
 
m
ig
ht
 s
ig
na
l i
m
po
rt
an
t 
ro
le
 in
 
fa
ci
lit
ati
ng
 s
ur
vi
va
l n
on
-d
eg
ra
de
d 
ba
ct
er
ia
l m
at
er
ia
l
an
d 
Q
FS
 p
ati
en
ts
 c
on
si
de
re
d 
du
e 
to
 im
m
un
og
en
eti
c 
di
ff
er
en
ce
s 
in
 h
an
dl
in
g 
im
m
un
om
od
ul
at
or
y 
co
m
pl
ex
 a
nd
 c
yt
ok
in
e 
re
sp
on
se
s.
 H
yp
ot
he
ti
ca
l 
pa
th
og
en
eti
c 
se
qu
en
ce
 
Q
FS
; o
ve
rt
 c
lin
ic
al
 Q
F 
an
d 
im
m
un
og
en
eti
c 
po
ly
m
or
ph
is
m
 
--
> 
de
fe
cti
ve
 a
nti
ge
n 
cl
ea
ra
nc
e 
(im
m
un
e-
m
od
ul
at
or
y 
co
m
pl
ex
 
pe
rs
is
te
nc
e)
 --
> 
pe
rs
is
te
nt
 
ce
ll-
m
ed
ia
te
d 
im
m
un
it
y 
an
d 
cy
to
ki
ne
 d
ys
re
gu
la
ti
on
 --
> 
cy
to
ki
ne
-m
ed
ia
te
d 
so
m
ati
c 
ge
ne
 
m
od
ul
ati
on
 --
> 
Q
FS
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, c
on
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ol
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ch
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ac
te
ri
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cs
, c
o-
m
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bi
di
ty
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To
ol
In
te
r-
ve
n-
ti
on
O
ut
co
m
e
Co
nc
lu
si
on
s/
re
co
m
m
en
da
ti
on
s
O
th
er
 
do
-
m
ai
n
Q
A
 (N
O
S)
20
11
, S
. 
G
al
br
ai
th
 
[1
5]
A
us
tr
al
ia
, y
r 
st
ud
y 
N
R 
(s
ub
 
st
ud
y 
D
IO
S)
. 
St
ud
y 
pe
ri
od
: 
ba
se
lin
e 
m
ea
su
re
 (T
1 
0<
6 
w
ks
),
 T
2 
6<
12
 w
ks
, T
3 
3<
9 
m
o 
or
 >
9 
m
o,
 T
4 
>1
2 
m
o,
 
FU
 a
ft
er
 2
 a
nd
 
4 
w
ks
Lo
ng
i-
tu
di
na
l, 
ne
st
ed
 
CC
Ca
uc
as
ia
ns
 w
it
h 
PI
FS
 
(n
=1
8;
 E
BV
, R
RV
, C
.b
.)
 
(m
ea
n 
ag
e:
 4
0,
 S
D
18
 
ye
ar
s)
. M
at
ch
ed
 (a
ge
, 
se
x 
&
 in
fe
cti
on
 t
yp
e)
 
co
nt
ro
ls
 (n
=1
8)
 w
ho
 
re
co
ve
re
d 
pr
om
pt
ly
 
(m
ea
n 
ag
e:
 3
9,
 S
D
16
).
 
11
 ♂
 p
er
 g
ro
up
. 1
27
 
sa
m
pl
es
 a
na
ly
se
d,
 3
-4
 
ti
m
e 
po
in
ts
/s
ub
je
ct
. 
In
 lo
ng
it
ud
in
al
ly
 
co
lle
ct
ed
 s
am
pl
es
 
pe
ri
ph
er
al
 b
lo
od
 
tr
an
sc
ri
pt
om
es
 
st
ud
ie
d 
fo
r 
ge
ne
 
ex
pr
es
si
on
 p
att
er
ns
 
in
 P
IF
S 
pa
ti
en
ts
 a
nd
 
co
nt
ro
ls
. D
iff
er
en
ti
al
 
ex
pr
es
si
on
 s
ou
gh
t 
be
tw
ee
n 
ea
rl
y 
ill
ne
ss
 
an
d 
la
te
 r
ec
ov
er
y 
(w
it
hi
n-
su
bj
ec
t 
co
m
pa
ri
so
n)
, P
IF
S 
ca
se
s 
an
d 
re
co
ve
re
d 
co
nt
ro
ls
 (b
et
w
ee
n 
su
bj
ec
ts
 c
om
pa
ri
so
n)
, 
an
d 
ge
ne
s 
co
rr
el
at
ed
 
w
it
h 
en
d 
ph
en
ot
yp
es
 
de
ri
ve
d 
by
 p
ri
nc
ip
al
 
co
m
po
ne
nt
s 
an
al
ys
is
 
(b
et
w
ee
n-
co
ho
rt
s)
M
ic
ro
ar
ra
y 
an
d 
co
nfi
rm
at
or
y 
qP
CR
. S
PH
ER
E,
 
SO
M
A
N
A
23
 g
en
es
 w
it
h 
m
od
es
t 
di
ff
er
en
ti
al
 
ex
pr
es
si
on
 (0
.6
-2
.3
-f
ol
d 
ch
an
ge
) 
in
 w
it
hi
n-
su
bj
ec
t 
co
m
pa
ri
so
ns
 o
f 
ea
rl
y,
 s
ym
pt
om
ati
c 
ti
m
e 
po
in
ts
 
w
it
h 
la
te
, r
ec
ov
er
ed
 ti
m
e 
po
in
ts
. 
M
od
es
t 
di
ff
er
en
ce
s 
63
 g
en
es
, i
n 
CS
 c
om
pa
ri
so
n 
ca
se
s-
co
nt
ro
ls
 6
 
m
o 
po
st
 A
I i
n 
re
gr
es
si
on
 m
od
el
. 
22
3 
ge
ne
s 
co
rr
el
at
ed
 w
it
h 
in
di
vi
du
al
 s
ym
pt
om
 d
om
ai
ns
. 
qP
CR
 c
on
fir
m
ed
 3
3/
45
 g
en
es
, 
no
ne
 c
on
si
st
en
t 
ac
ro
ss
 c
oh
or
ts
. 
W
it
hi
n 
su
bj
ec
t 
co
m
pa
ri
so
n:
 1
2 
su
bj
ec
ts
 (5
 w
it
h 
Q
F)
 T
1 
SO
M
A
 
sc
or
es
 ≥
3,
 T
4 
SO
M
A
 s
co
re
s 
<3
. N
o 
ge
ne
s 
w
it
h 
ad
ju
st
ed
 
si
gn
ifi
ca
nc
e 
<0
.0
5.
 R
el
ati
ve
 la
ck
 
va
ri
an
ce
 g
en
e 
ex
pr
es
si
on
 le
ve
ls
 
ov
er
 ≥
12
 m
o.
 B
et
w
ee
n 
su
bj
ec
t 
co
m
pa
ri
so
ns
: 1
7 
ca
se
s 
(6
 Q
F)
, 
11
 c
on
tr
ol
s 
(2
 Q
F)
. N
o 
ge
ne
s 
w
it
h 
ad
ju
st
ed
 s
ig
ni
fic
an
ce
 <
0.
05
. 
Q
F 
su
bj
ec
ts
 p
re
do
m
in
an
tl
y 
♂
 
an
d 
ol
de
r. 
13
 g
en
es
 a
dj
us
te
d 
si
gn
ifi
ca
nc
e 
<0
.0
5,
 1
 (C
YB
A
) 
as
so
ci
at
ed
 w
it
h 
fa
ti
gu
e 
in
 2
 o
f 
3 
in
fe
cti
ve
 c
oh
or
ts
 (E
BV
, Q
F)
. 
A
na
ly
si
s 
id
en
ti
fie
d 
ill
ne
ss
 s
ev
er
it
y,
 
fa
ti
gu
e 
an
d 
ne
ur
oc
og
ni
ti
ve
 
di
st
ur
ba
nc
e,
 c
or
re
la
te
d 
fo
r 
EB
V
 
an
d 
Q
F 
co
ho
rt
s.
 C
or
re
la
ti
on
 t
es
t:
 
96
 g
en
es
 u
na
dj
us
te
d 
si
gn
ifi
ca
nt
 
at
 5
%
 fo
r 
EB
V
 a
nd
 Q
F 
fo
r 
se
ve
ri
ty
, 9
3 
fo
r 
fa
ti
gu
e 
sy
m
pt
om
 
do
m
ai
n,
 1
06
 fo
r 
ne
ur
oc
og
ni
ti
ve
 
di
st
ur
ba
nc
e.
 R
ep
ea
te
d 
co
rr
el
ati
on
 
an
al
ys
is
: n
o 
ge
ne
s 
co
rr
el
at
ed
 fo
r 
EB
V
 a
nd
 Q
F 
in
 a
ss
oc
ia
ti
on
 w
it
h 
se
ve
ri
ty
, f
ati
gu
e,
 n
eu
ro
co
gn
iti
ve
 
di
st
ur
ba
nc
e
Se
ve
ra
l i
nf
ec
ti
on
s 
tr
ig
ge
r 
PI
FS
, w
hi
ch
 s
ha
re
 k
ey
 il
ln
es
s 
ch
ar
ac
te
ri
sti
cs
 w
it
h 
ea
ch
 
ot
he
r 
an
d 
CF
S.
 P
re
vi
ou
s 
CS
 C
C 
st
ud
ie
s 
of
 C
FS
 s
ug
ge
st
ed
 u
ni
qu
e 
ge
ne
 e
xp
re
ss
io
n 
si
gn
at
ur
e 
in
 p
er
ip
he
ra
l b
lo
od
 s
am
pl
es
. 
A
lt
ho
ug
h 
ill
ne
ss
 c
ha
ra
ct
er
is
ti
cs
 
of
 P
IF
S 
pa
ti
en
ts
 h
av
e 
m
or
e 
si
m
ila
ri
ti
es
 t
ha
n 
di
ff
er
en
ce
s,
 n
o 
re
lia
bl
e 
pe
ri
ph
er
al
 b
lo
od
 g
en
e 
ex
pr
es
si
on
 c
or
re
la
te
 is
 e
vi
de
nt
. 
N
o 
ge
ne
s 
co
ns
is
te
nt
ly
 a
ss
oc
ia
te
d 
w
it
h 
ill
ne
ss
. C
FS
 in
ci
de
nc
e 
cl
os
el
y 
co
m
pa
ra
bl
e 
be
tw
ee
n 
EB
V,
 R
RV
, 
C.
b.
 L
ac
k 
of
 c
oh
er
en
t 
se
t 
of
 g
en
e 
ex
pr
es
si
on
 c
or
re
la
te
s 
ac
ro
ss
 
co
ho
rt
s 
ar
gu
es
 a
ga
in
st
 v
al
id
it
y 
of
 
pr
ev
io
us
ly
 p
ro
po
se
d 
si
gn
at
ur
es
 
fo
r 
PI
FS
 o
r 
CF
S.
 P
IF
S 
lik
el
y 
to
 
be
 t
ru
ly
 p
os
t-
in
fe
cti
ve
, u
n-
as
so
ci
at
ed
 w
it
h 
on
go
in
g 
ac
ti
ve
 
re
pl
ic
ati
on
 o
f t
ri
gg
er
in
g 
ag
en
t
N
A
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 p
er
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Pa
ti
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, c
on
tr
ol
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ch
ar
ac
te
ri
sti
cs
, c
o-
m
or
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di
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To
ol
In
te
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ve
n-
ti
on
O
ut
co
m
e
Co
nc
lu
si
on
s/
re
co
m
m
en
da
ti
on
s
O
th
er
 
do
-
m
ai
n
Q
A
 (N
O
S)
20
12
, B
. 
Pi
ra
in
o 
[1
6]
A
us
tr
al
ia
, y
r 
st
ud
y 
N
R 
(s
ub
 
st
ud
y 
D
IO
S)
. 
St
ud
y 
pe
ri
od
 
N
R.
 B
as
el
in
e,
 
FU
 2
-3
w
ks
, 
4-
6w
ks
, 3
-m
o 
in
te
rv
al
 u
nti
l 1
2 
m
o 
po
st
 A
I
Co
S
Ca
uc
as
ia
ns
 (m
ea
n 
ag
e 
34
.2
, 4
9%
 ♀
),
 <
6 
w
ks
 p
os
t 
A
I (
n=
29
6)
, 
EB
V,
 R
RV
, Q
F.
 P
ri
nc
ip
al
 
co
m
po
ne
nt
s 
an
al
ys
is
 
ac
ut
e 
ph
as
e,
 s
el
f-
re
po
rt
 s
ym
pt
om
 d
at
a 
to
 e
m
pi
ri
ca
lly
 d
er
iv
ed
 
in
di
ce
s 
fa
ti
gu
e,
 
pa
in
, n
eu
ro
co
gn
iti
ve
 
di
ffi
cu
lti
es
, m
oo
d 
di
st
ur
ba
nc
e,
 o
ve
ra
ll 
ill
ne
ss
 s
ev
er
it
y.
 A
pp
ly
 
en
do
ph
en
ot
yp
e 
co
nc
ep
t 
to
 c
lin
ic
al
 
da
ta
se
t 
de
sc
ri
bi
ng
 
sy
m
pt
om
 d
om
ai
ns
 
of
 a
cu
te
 s
ic
kn
es
s 
re
sp
on
se
 p
os
t 
vi
ra
l/
no
n-
vi
ra
l p
at
ho
ge
ns
, 
an
d 
va
lid
ati
on
 b
y 
sh
ow
in
g 
as
so
ci
ati
on
 
w
it
h 
SN
P 
in
 c
yt
ok
in
e 
ge
ne
s 
(I
L-
6,
 T
N
Fa
, 
IF
N
y,
 IL
-1
0)
SP
H
ER
E 
(a
nd
 
SO
M
A
),
 P
SC
, 
BD
Q
, p
ri
nc
ip
al
 
co
m
po
ne
nt
 
an
al
ys
is
, 
N
an
oD
ro
pR
 
N
D
-1
00
0 
(D
N
A
 
qu
an
ti
fic
ati
on
),
 
Se
qu
en
om
 
M
as
sA
RR
AY
® 
(g
en
ot
yp
in
g 
of
 
SN
P)
N
A
In
di
vi
du
al
 s
ym
pt
om
 in
di
ce
s 
co
rr
el
at
ed
 w
it
h 
ov
er
al
l s
ev
er
it
y 
an
d 
fu
nc
ti
on
al
 s
ta
tu
s.
 D
om
ai
n 
sc
or
es
 s
ta
bl
e 
ov
er
 ti
m
e 
w
it
hi
n 
su
bj
ec
ts
, b
ut
 v
ar
ie
d 
be
tw
ee
n 
su
bj
ec
ts
 w
it
h 
sa
m
e 
in
fe
cti
on
, 
an
d 
ac
ro
ss
 in
fe
cti
on
 s
ub
-c
oh
or
ts
. 
O
ve
ra
ll 
ill
ne
ss
 s
ev
er
it
y 
m
ay
 
ha
ve
 b
ee
n 
co
m
pa
ra
bl
e 
in
 s
om
e 
su
bj
ec
ts
, r
el
ati
ve
 c
on
tr
ib
uti
on
s 
fr
om
 in
di
vi
du
al
 s
ym
pt
om
 d
om
ai
ns
 
m
ak
in
g 
up
 t
he
 il
ln
es
s 
co
m
pl
ex
 
va
ri
ed
 b
et
w
ee
n 
th
es
e 
su
bj
ec
ts
. 
T 
al
le
le
 IF
N
y+
87
4T
/A
 S
N
P 
be
st
 
pr
ed
ic
to
r 
of
 ↑
 fa
ti
gu
e.
 ♀
 m
or
e 
lik
el
y 
gr
ou
pe
d 
in
 ↑
 fa
ti
gu
e 
ex
tr
em
e.
 C
 a
lle
le
 o
f I
L-
10
-5
92
C/
A
 
SN
P 
ex
er
te
d 
pr
ot
ec
ti
ve
 e
ff
ec
t 
on
 n
eu
ro
co
gn
iti
ve
 d
iffi
cu
lti
es
. A
 
al
le
le
 IL
-1
0-
59
2 
SN
P 
an
d 
G
 a
lle
le
 
IL
-6
-1
74
G
/C
 S
N
P 
as
so
ci
at
ed
 ↑
 
m
oo
d 
di
st
ur
ba
nc
e
A
cu
te
 il
ln
es
s 
re
sp
on
se
 h
as
 
di
sc
re
te
 s
ym
pt
om
s 
in
cl
ud
in
g 
fa
ti
gu
e 
w
it
h 
un
iq
ue
 g
en
eti
c 
as
so
ci
ati
on
s.
 S
tu
dy
 o
ff
er
s 
ne
w
 
pa
th
op
hy
si
ol
og
ic
al
 in
si
de
 fa
ti
gu
e 
st
at
es
. I
lln
es
s 
se
ve
ri
ty
 p
he
no
ty
pe
 
no
t 
de
pe
nd
en
t 
on
 a
ge
/s
ex
/
in
fe
cti
on
 s
ub
ty
pe
. R
ob
us
t 
co
rr
el
ati
on
 b
et
w
ee
n 
ill
ne
ss
 
se
ve
ri
ty
 a
nd
 r
ep
or
te
d 
di
sa
bi
lit
y 
in
 A
I. 
♀
 o
ve
r 
re
pr
es
en
te
d 
in
 h
ig
h 
se
ve
ri
ty
 g
ro
up
 fa
ti
gu
e,
 m
oo
d 
di
st
ur
ba
nc
e,
 n
eu
ro
co
gn
iti
ve
 
di
ffi
cu
lti
es
N
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ch
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In
te
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ve
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on
O
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lu
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re
co
m
m
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O
th
er
 
do
-
m
ai
n
Q
A
 (N
O
S)
20
12
, H
. 
H
us
sa
in
-
Yu
su
f [
17
]
U
K,
 2
00
8
CC
Co
ho
rt
 2
11
 U
K 
fa
ct
or
y 
w
or
ke
rs
 C
.b
.-
ex
po
se
d 
20
02
. F
U
 6
 y
rs
 p
os
t 
ou
tb
re
ak
, c
om
pa
ri
so
n 
Q
F 
se
ro
lo
gy
, p
re
se
nc
e 
vi
ab
le
 C
.b
., 
it
s 
D
N
A
 a
nd
 fa
ti
gu
e 
in
 p
os
t 
A
Q
F 
ca
se
s 
(n
=3
8,
 3
 u
nc
er
ta
in
 
se
ro
lo
gy
 2
00
2)
 v
s.
 
se
ro
ne
ga
ti
ve
, s
am
e 
ou
tb
re
ak
 (n
=1
4)
. 
A
ss
es
s 
if 
C.
b.
 a
nti
ge
ns
 
(im
m
un
om
od
ul
at
or
y 
co
m
pl
ex
) r
em
ai
n 
un
de
gr
ad
ed
 in
 
so
m
e 
po
st
 A
Q
F,
 w
it
h 
ab
no
rm
al
 c
yt
ok
in
e 
pr
ofi
le
 c
au
si
ng
 
on
go
in
g 
fa
ti
gu
e
Ch
al
de
r 
Fa
ti
gu
e 
Sc
al
e,
 q
PC
R 
(c
om
1 
ge
ne
) 
on
 P
BM
C 
an
d 
V
ER
O
 c
ul
tu
re
s 
(d
et
ec
t 
C.
b.
 
D
N
A
),
 IF
A
, S
CI
D
 
m
ic
e 
in
oc
ul
a-
ti
on
 (d
et
ec
t 
vi
ab
le
 C
.b
.)
N
A
18
%
 b
ec
am
e 
se
ro
ne
ga
ti
ve
, 
re
m
ai
nd
er
 1
0 
ph
as
e 
I, 
21
 p
ha
se
 
I e
n 
II 
an
ti
bo
di
es
. 2
9%
 c
on
tr
ol
s 
be
ca
m
e 
se
ro
po
si
ti
ve
. N
o 
pa
ti
en
t/
co
nt
ro
l P
BM
C 
co
nt
ai
ne
d 
vi
ab
le
 
C.
b.
/D
N
A
. N
o 
vi
ab
le
 C
.b
. i
n 
PM
BC
 
te
st
ed
 in
 c
el
l c
ul
tu
re
 a
nd
 S
CI
D
 
m
ic
e 
in
oc
ul
ati
on
. C
ha
ld
er
 F
ati
gu
e 
Sc
al
e 
sc
or
e 
aft
er
 6
 y
rs
 (n
=1
1)
: 4
 
si
gn
ifi
ca
nt
 fa
ti
gu
e,
 4
 s
om
e,
 3
 n
ot
 
fa
ti
gu
ed
. N
o 
re
la
ti
on
sh
ip
 b
et
w
ee
n 
fa
ti
gu
e 
le
ve
ls
 a
nd
 s
er
ol
og
y,
 n
or
 
w
it
h 
pr
es
en
ce
 o
f v
ia
bl
e 
C.
b.
/D
N
A
6 
yr
s 
po
st
 A
Q
F,
 s
om
e 
pa
ti
en
ts
 
be
ca
m
e 
se
ro
ne
ga
ti
ve
 b
ut
 n
on
e 
co
nt
ai
ne
d 
vi
ab
le
 C
.b
./
D
N
A
 in
 
th
ei
r 
PB
M
C.
 C
or
re
la
ti
on
 P
Q
FF
 
an
d 
pe
rs
is
te
nt
 D
N
A
 c
ou
ld
 n
ot
 b
e 
ex
am
in
ed
. A
 m
or
e 
se
ns
iti
ve
 D
N
A
 
as
sa
ys
 o
r 
m
or
e 
in
va
si
ve
 s
am
pl
in
g 
ne
ed
ed
 t
o 
te
st
 h
yp
ot
he
si
s.
 Ig
G
II 
m
os
t 
us
ef
ul
 t
o 
te
st
 p
as
t 
Q
F 
ex
po
su
re
B/
D
« « « «
« «
20
14
, M
. 
Kr
em
er
s 
[1
8]
N
et
he
rl
an
ds
, 
yr
 s
tu
dy
 2
01
3-
20
14
. S
tu
dy
 
pe
ri
od
: A
pr
il-
 
A
ug
us
t 
20
09
, 
FU
 4
 y
rs
 p
os
t 
AQ
F
Co
S
10
2 
se
ro
ne
ga
ti
ve
 P
CR
 
po
si
ti
ve
, s
ym
pt
om
ati
c,
 
A
Q
F 
pa
ti
en
ts
 (6
4.
7%
 
♂
, m
ea
n 
ag
e 
48
, 
SD
16
, r
an
ge
 1
7-
85
);
 
24
 h
os
pi
ta
lis
ed
. 9
3 
FU
 3
, 6
 o
r 
12
 m
o 
fo
r 
IF
A
 Ig
G
I a
nd
 II
. N
CS
I 4
 
yr
s 
po
st
 A
Q
F 
(n
=5
8)
. 
A
ss
es
s 
if 
↑
 C
RP
 A
Q
F 
co
in
ci
de
s 
w
it
h 
↑
 IL
-6
 
an
d 
if 
le
ve
ls
 c
or
re
la
te
 
w
it
h 
C.
b.
 D
N
A
 lo
ad
 
an
d 
di
se
as
e 
se
ve
ri
ty
, 
ex
pr
es
se
d 
by
 h
os
pi
ta
l 
ad
m
is
si
on
 a
nd
 fa
ti
gu
e 
de
ve
lo
pm
en
t
N
CS
I, 
PC
R 
(C
t 
va
lu
e)
, I
FA
, C
RP
, 
IL
-6
N
A
92
 p
ati
en
ts
 ↑
 IL
-6
, 1
01
 ↑
 
CR
P 
du
ri
ng
 A
Q
F.
 S
ig
ni
fic
an
t 
w
ea
k 
ne
ga
ti
ve
 c
or
re
la
ti
on
 
C.
b.
 D
N
A
 lo
ad
s,
 IL
-6
 a
nd
 C
RP
, 
si
gn
ifi
ca
nt
 m
od
er
at
e-
st
ro
ng
 
po
si
ti
ve
 c
or
re
la
ti
on
 IL
-6
 a
nd
 C
RP
. 
H
os
pi
ta
lis
ed
 p
ati
en
ts
: ↑
 IL
-6
 a
nd
 
CR
P 
th
an
 t
he
 n
on
-h
os
pi
ta
lis
ed
, 
C.
b.
 D
N
A
 lo
ad
 e
qu
al
. N
CS
I: 
58
 r
es
po
nd
en
ts
, 3
4 
ab
no
rm
al
 
ou
tc
om
e 
(5
8.
6%
) m
ild
 a
nd
 
se
ve
re
 fa
ti
gu
e.
 N
o 
di
ff
er
en
ce
 in
 
Ct
 v
al
ue
s,
 C
RP
 a
nd
 IL
-6
 in
 A
Q
F 
be
tw
ee
n 
pa
ti
en
ts
 w
it
h 
no
rm
al
 
ou
tc
om
e 
an
d 
ab
no
rm
al
 o
ut
co
m
e 
su
bd
om
ai
n 
fa
ti
gu
e
Co
rr
el
ati
on
 IL
-6
 a
nd
 C
RP
 in
 A
Q
F 
po
in
ts
 t
o 
im
m
un
e 
ac
ti
va
ti
on
 
pa
th
w
ay
 in
 w
hi
ch
 IL
-6
 in
du
ce
s 
CR
P.
 D
iff
er
en
ce
s 
IL
-6
 a
nd
 C
RP
 
be
tw
ee
n 
ho
sp
it
al
is
ed
 v
s.
 
th
e 
no
n-
ho
sp
it
al
is
ed
 d
es
pi
te
 
id
en
ti
ca
l D
N
A
 lo
ad
 s
ug
ge
st
 a
n 
im
po
rt
an
t 
ro
le
 fo
r 
ho
st
 fa
ct
or
s.
 
↑
 IL
-6
 a
nd
 C
RP
 s
ee
m
s 
pr
ed
ic
ti
ve
 
of
 m
or
e 
se
ve
re
 d
is
ea
se
. N
o 
su
pp
or
t 
th
at
 IL
-6
 o
r 
CR
P 
le
ve
ls
 
du
ri
ng
 A
Q
F 
ar
e 
pr
og
no
sti
c 
fo
r 
fa
ti
gu
e 
de
ve
lo
pm
en
t
N
A
« ¶ «
« «
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D
efi
ni
ti
on
 o
f 
us
ed
 s
tu
dy
 p
op
ul
ati
on
 in
 a
rti
cl
es
 e
xp
la
in
ed
 in
 a
 d
iff
er
en
t 
ta
bl
e,
 in
cl
ud
in
g 
de
fi
ni
ti
on
s 
of
 Q
FS
 a
nd
/o
r 
fa
ti
gu
e 
is
 a
pp
lic
ab
le
. M
ai
n 
in
fo
rm
ati
on
 is
 o
n 
ae
ti
ol
og
y.
 S
om
e 
ar
ti
cl
es
 a
ls
o 
co
nt
ai
n 
re
le
va
nt
 in
fo
rm
ati
on
 o
n 
ot
he
r 
do
m
ai
ns
: D
ia
g=
 D
ia
gn
os
is
, B
/D
= 
B
ac
kg
ro
un
d/
de
sc
ri
pti
ve
, P
/T
= 
Pr
ev
en
ti
on
/t
he
ra
py
.
A
bb
re
vi
ati
on
s:
 2
-5
A
S=
 2
’,5
’-
ol
ig
oa
de
ny
la
te
 s
yn
th
et
as
e,
 A
I=
 A
cu
te
 in
fe
cti
on
, A
Q
F=
 A
cu
te
 Q
-f
ev
er
, B
D
Q
= 
Br
ie
f 
D
is
ab
ili
ty
 Q
ue
sti
on
na
ir
e,
 a
ss
es
sm
en
t 
of
 t
he
 im
pa
ct
 o
f 
ill
ne
ss
 o
n 
fu
nc
ti
on
al
 c
ap
ac
it
y,
 a
nd
 d
ay
s 
ou
t o
f r
ol
e 
qu
an
ti
fie
d 
th
e 
da
ys
 o
ve
r 
th
e 
pa
st
 m
on
th
s 
th
e 
re
sp
on
de
nt
 w
as
 u
na
bl
e 
to
 c
ar
ry
 o
ut
 u
su
al
 d
ai
ly
 a
cti
vi
ti
es
 fu
lly
, B
M
A
= 
Bo
ne
 m
ar
ro
w
 a
sp
ir
at
e,
 B
M
I=
 B
od
y 
M
as
s 
In
de
x,
 C
.b
.=
 C
ox
ie
lla
 b
ur
ne
ti
i, 
CB
A
= 
Cy
to
m
et
ri
c 
be
ad
 a
rr
ay
, u
se
s 
th
e 
se
ns
iti
vi
ty
 o
f a
m
pl
ifi
ed
 fl
uo
re
sc
en
ce
 d
et
ec
ti
on
 b
y 
flo
w
 
cy
to
m
et
ry
 to
 m
ea
su
re
 s
ol
ub
le
 a
na
ly
te
s 
(e
.g
. i
nt
er
le
uk
in
s)
 in
 a
 p
ar
ti
cl
e-
ba
se
d 
im
m
un
oa
ss
ay
, C
C=
 C
as
e-
co
nt
ro
l s
tu
dy
, C
D
C=
 C
en
tr
es
 fo
r D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nti
on
, 
CF
= 
Ch
ro
ni
c 
fa
ti
gu
e,
 C
FS
(/
M
E)
= 
Ch
ro
ni
c 
fa
ti
gu
e 
sy
nd
ro
m
e 
(/
m
ye
lo
en
ce
ph
al
iti
s)
, C
FT
= 
Co
m
pl
em
en
t 
fix
ati
on
 t
es
t,
 C
ID
I=
 C
om
po
si
te
 in
te
rn
ati
on
al
 d
ia
gn
os
ti
c 
in
te
rv
ie
w
 
to
 s
cr
ee
n 
fo
r 
an
y 
hi
st
or
y 
of
 d
ep
re
ss
io
n,
 a
nx
ie
ty
 o
r 
so
m
ati
sa
ti
on
 d
is
or
de
r. 
Th
is
 c
om
pu
te
ri
se
d 
pr
og
ra
m
 f
or
m
ul
at
es
 I
CD
-1
0 
an
d 
D
SM
-I
II-
R 
di
ag
no
se
s 
an
d 
re
co
rd
s 
cu
rr
en
t 
as
 w
el
l 
as
 p
re
-e
xi
sti
ng
 p
sy
ch
ia
tr
ic
 m
or
bi
di
ty
, 
Co
S=
 C
oh
or
t 
st
ud
y,
 C
RP
= 
C-
re
ac
ti
ve
 p
ro
te
in
, 
CS
= 
Cr
os
s-
se
cti
on
al
, 
D
IO
S=
 D
ub
bo
 I
nf
ec
ti
on
 O
ut
co
m
es
 S
tu
dy
, 
co
ho
rt
 s
tu
dy
 o
f s
ub
je
ct
s 
≥1
6 
yr
s 
fo
llo
w
ed
 fr
om
 t
he
 o
ns
et
 o
f a
 c
on
fir
m
ed
 a
nd
 d
oc
um
en
te
d 
A
I d
ue
 to
 E
BV
; C
.b
.; 
or
 R
RV
 ≤
6 
w
ks
 p
os
t 
A
I u
nti
l c
om
pl
et
e 
re
co
ve
ry
, D
S1
4=
 
D
is
tr
es
se
d 
pe
rs
on
al
it
y 
sc
al
e,
 a
ss
es
sm
en
t 
of
 n
eg
ati
ve
 a
ff
ec
ti
vi
ty
 (a
n 
en
du
ri
ng
 t
en
de
nc
y 
to
 e
xp
er
ie
nc
e 
ne
ga
ti
ve
 e
m
oti
on
s)
 a
nd
 t
ra
it
 s
oc
ia
l i
nh
ib
iti
on
 (t
he
 t
en
de
nc
y 
to
 
fe
el
 in
hi
bi
te
d,
 te
ns
e,
 a
nd
 in
se
cu
re
 w
he
n 
w
it
h 
ot
he
rs
),
 D
TH
= 
D
el
ay
ed
-t
yp
e 
hy
pe
rs
en
si
ti
vi
ty
, t
o 
as
se
ss
 c
el
l-m
ed
ia
te
d 
im
m
un
e 
fu
nc
ti
on
 in
 v
iv
o,
 E
BV
= 
Ep
st
ei
n-
Ba
rr
 v
ir
us
, 
EC
G
= 
El
ec
tr
oc
ar
di
og
ra
ph
y,
 F
U
= 
Fo
llo
w
-u
p,
 G
H
Q
= 
G
en
er
al
 h
ea
lt
h 
qu
es
ti
on
na
ir
e,
 1
2-
it
em
 q
ue
sti
on
na
ir
e 
to
 d
et
ec
t 
cu
rr
en
t 
ca
se
s 
of
 p
sy
ch
ia
tr
ic
 c
o-
m
or
bi
di
ty
, I
.c
.w
.=
 In
 
co
m
pa
ri
so
n 
w
it
h,
 IF
A
= 
Im
m
un
ofl
uo
re
sc
en
ce
 a
ss
ay
, I
FN
= 
In
te
rf
er
on
, I
gG
= 
A
nti
-p
ha
se
 Ig
G
, I
gG
I=
 A
nti
-p
ha
se
 Ig
G
 I 
ti
tr
e,
 Ig
G
II=
 A
nti
-p
ha
se
 Ig
G
 II
 ti
tr
e,
 IL
= 
In
te
rl
eu
ki
n,
 
IS
= 
In
se
rti
on
 s
eq
ue
nc
e,
 K
10
= 
Ke
ss
le
r 
10
, t
o 
as
se
ss
 c
ur
re
nt
 p
sy
ch
ol
og
ic
al
 d
is
tr
es
s,
 L
M
R=
 L
ym
ph
oc
yt
e 
m
it
og
en
ic
 r
es
po
ns
es
, L
PS
= 
Li
po
po
ly
sa
cc
ha
ri
de
, M
o=
 M
on
th
(s
),
 
M
U
G
A
 s
ca
n=
 M
ul
ti
 G
at
ed
 A
cq
ui
si
ti
on
 S
ca
n 
(g
at
ed
 c
ar
di
ac
 r
ad
io
-n
uc
lid
e 
sc
an
s)
, a
 ti
m
e-
pr
ov
en
 n
uc
le
ar
 m
ed
ic
in
e 
te
st
 t
o 
ev
al
ua
te
 t
he
 f
un
cti
on
 o
f 
th
e 
ri
gh
t 
an
d 
le
ft 
ve
nt
ri
cl
es
 o
f 
th
e 
he
ar
t,
 a
llo
w
in
g 
in
fo
rm
ed
 d
ia
gn
os
ti
c 
in
te
rv
en
ti
on
 i
n 
he
ar
t 
fa
ilu
re
, 
N
A
= 
N
ot
 a
pp
lic
ab
le
, 
N
CS
I=
 N
ijm
eg
en
 c
lin
ic
al
 s
cr
ee
ni
ng
 i
ns
tr
um
en
t,
 o
ri
gi
na
lly
 
de
ve
lo
pe
d 
to
 p
ro
vi
de
 a
 d
et
ai
le
d 
as
se
ss
m
en
t 
of
 h
ea
lt
h 
st
at
us
 o
f 
CO
PD
 p
ati
en
ts
. I
t 
co
m
bi
ne
s 
a 
nu
m
be
r 
of
 e
xi
sti
ng
 h
ea
lt
h 
st
at
us
 q
ue
sti
on
na
ir
es
, N
O
S=
 N
ew
ca
st
le
–
O
tt
aw
a 
Sc
al
e:
 S
= 
se
le
cti
on
 (m
ax
im
um
 o
f 4
 s
ta
rs
),
 C
= 
co
m
pa
ra
bi
lit
y 
(m
ax
im
um
 o
f 2
 s
ta
rs
),
 O
= 
ou
tc
om
e 
(m
ax
im
um
 o
f 3
 s
ta
rs
);
 «
: s
ta
r 
ea
rn
ed
; ¶
: i
te
m
 n
ot
 a
pp
lic
ab
le
, 
N
/N
o=
 N
um
be
r 
(o
f)
, 
(n
-)
PC
R=
 (
ne
st
ed
-)
 P
ol
ym
er
as
e 
ch
ai
n 
re
ac
ti
on
, 
N
R=
 N
ot
 r
ep
or
te
d,
 P
ai
n 
te
st
 a
lg
om
et
er
= 
Fo
r 
pr
es
su
re
 p
ai
n 
th
re
sh
ol
d 
te
st
 t
o 
m
ea
su
re
 p
ai
n 
se
ns
iti
vi
ty
, P
BM
C=
 P
er
ip
he
ra
l b
lo
od
 m
on
on
uc
le
ar
 c
el
ls
, P
H
A
= 
ph
yt
oh
ae
m
ag
gl
uti
ni
n,
 P
IF
(S
)=
 P
os
t-
in
fe
cti
ve
 fa
ti
gu
e 
(s
yn
dr
om
e)
, P
O
= 
Pe
rs
on
al
 o
pi
ni
on
, P
O
M
S=
 P
ro
fil
e 
of
 M
oo
d 
St
at
es
 t
o 
as
se
ss
 c
ur
re
nt
 m
oo
d 
st
at
us
. T
hi
s 
in
st
ru
m
en
t 
in
cl
ud
es
 7
 s
ub
sc
al
es
: ‘
fa
ti
gu
e’
, ‘
de
pr
es
si
on
’, 
‘a
nx
ie
ty
’, 
‘v
ig
ou
r’,
 ‘a
ng
er
’, 
‘f
ri
en
dl
in
es
s’,
 a
nd
 ‘c
on
fu
si
on
’, 
PQ
FF
= 
Po
st
-Q
-f
ev
er
 f
ati
gu
e,
 P
Q
F(
F)
S=
 P
os
t-
(a
cu
te
)Q
-f
ev
er
 (
fa
ti
gu
e)
 s
yn
dr
om
e,
 P
ro
s.
= 
Pr
os
pe
cti
ve
, 
PS
C=
 P
hy
si
ca
l 
Sy
m
pt
om
s 
Ch
ec
kl
is
t,
 c
on
si
sti
ng
 o
f 
51
 s
ym
pt
om
 
it
em
s,
 P
SQ
= 
Pi
tt
sb
ur
gh
 S
le
ep
 Q
ue
sti
on
na
ir
e,
 t
o 
as
se
ss
 s
le
ep
 a
bn
or
m
al
iti
es
, 
Q
A
 =
 Q
ua
lit
y 
as
se
ss
m
en
t,
 Q
-C
FS
(/
M
E)
= 
Q
-f
ev
er
 in
du
ce
d 
ch
ro
ni
c 
fa
ti
gu
e 
sy
nd
ro
m
e 
(/
m
ye
lo
en
ce
ph
al
iti
s)
, Q
F=
 Q
-f
ev
er
, Q
F(
F)
S=
 Q
-f
ev
er
 f
ati
gu
e 
sy
nd
ro
m
e,
 (
Q
)I
E=
 (
Q
-f
ev
er
 in
du
ce
d)
 In
fe
cti
ve
 e
nd
oc
ar
di
ti
s,
 R
ef
= 
Re
fe
re
nc
e,
 R
RV
= 
Ro
ss
 R
iv
er
 v
ir
us
, S
CI
D
= 
Se
ve
re
 c
om
bi
ne
d 
im
m
un
od
efi
ci
en
cy
, S
D
= 
St
an
da
rd
 d
ev
ia
ti
on
, S
F-
36
= 
Th
e 
Sh
or
t F
or
m
 (3
6)
 H
ea
lt
h 
Su
rv
ey
, a
 p
ati
en
t-
re
po
rt
ed
 s
ur
ve
y 
of
 p
ati
en
t h
ea
lt
h 
to
 a
ss
es
s 
qu
al
it
y 
of
 li
fe
 o
f p
ati
en
ts
, f
un
cti
on
al
 im
pa
ir
m
en
t a
nd
 re
du
ce
d 
he
al
th
 re
la
te
d 
qu
al
it
y 
of
 li
fe
, S
N
P=
 S
in
gl
e 
nu
cl
eo
ti
de
 p
ol
ym
or
ph
is
m
, S
O
FA
= 
Sc
he
du
le
 o
f F
ati
gu
e 
an
d 
A
ne
rg
y 
to
 
id
en
ti
fy
 c
as
es
 o
f c
hr
on
ic
 fa
ti
gu
e 
sy
nd
ro
m
e.
 T
he
 s
ub
je
ct
 ra
te
s 
10
 it
em
s 
on
 a
 4
-p
oi
nt
 s
ca
le
. S
ub
je
ct
s 
w
ho
 s
co
re
 ≥
3 
it
em
s 
as
 ‘a
 g
oo
d 
pa
rt
 o
f t
he
 ti
m
e’
 o
r ‘
m
os
t o
f t
he
 ti
m
e’
 
ar
e 
cl
as
si
fie
d 
as
 c
as
es
 o
f 
‘fa
ti
gu
e/
ne
ur
as
th
en
ia
’, 
SO
M
A
= 
Em
pi
ri
ca
lly
 d
er
iv
ed
 s
ub
sc
al
e 
of
 t
he
 S
PH
ER
E,
 u
se
d 
to
 r
ec
or
d 
PI
FS
 o
r 
ill
ne
ss
 d
ur
ati
on
. T
hi
s 
re
lia
bl
y 
pr
ed
ic
ts
 
di
sa
bi
lit
y 
an
d 
re
fle
ct
s 
pa
ti
en
ts
’ a
nd
 d
oc
to
rs
’ r
ep
or
ts
 o
f r
ea
so
ns
 fo
r 
pr
es
en
ta
ti
on
 to
 p
ri
m
ar
y 
ca
re
. S
co
re
s 
≥3
 re
pr
es
en
ts
 a
 c
lin
ic
al
ly
-s
ig
ni
fic
an
t f
ati
gu
e 
st
at
e.
 P
ro
vi
si
on
al
 
PI
FS
: S
O
M
A
 s
co
re
s 
≥3
 a
t a
ll 
ti
m
e 
po
in
ts
 u
p 
≤3
 m
on
th
s.
 C
on
fir
m
ed
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ABSTRACT
Objective: Comparison of Q fever fatigue syndrome (QFS) and chronic fatigue syndrome 
(CFS) patients, with a focus on markers of inflammation and fatigue-related cognitive-
behavioural variables.
Methods: Data from two independent prospective studies on QFS (n=117) and CFS (n=173), 
respectively, were pooled and analyzed.
Results: QFS patients were less often female, had a higher BMI, and had less often received 
treatment for depression before the onset of symptoms. After controlling for symptom 
duration and correcting for differences in diagnostic criteria for QFS and CFS with respect 
to the level of impairment and the presence of additional symptoms, differences in the 
proportion of females and BMI remained significant. After correction, QFS patients were 
also significantly older. In all analyses QFS patients were as fatigued and distressed as 
CFS patients, but reported less additional symptoms. QFS patients had stronger somatic 
attributions, and higher levels of physical activity. No differences were found with regard 
to inflammatory markers and in other fatigue-related cognitive-behavioural variables. The 
relationship between cognitive-behavioural variables and fatigue, previously established in 
CFS, could not be confirmed in QFS patients with the exception of the negative relationship 
between physical activity and fatigue.
Conclusion: Differences and similarities between QFS and CFS patients were found. 
Although the relationship between perpetuating factors and fatigue previously established 
in CFS could not be confirmed in QFS patients, the considerable overlap in fatigue-related 
cognitive-behavioural variables and the relationship found between physical activity and 
fatigue may suggest that behavioural interventions could reduce fatigue severity in QFS 
patients.
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INTRODUCTION
Q fever is a zoonosis caused by the bacterium Coxiella burnetii, occurring all over the world 
[1]. From 2007 until 2011, over 4000 cases of symptomatic acute Q fever were reported 
in the Netherlands [2], and over 32,000 people were infected during this outbreak [3, 4]. 
Chronic Q fever, characterized by the persistence of C. burnetii, occurs in 1-5% of cases 
[5]. In addition, around 20% of the known symptomatic acute Q fever patients remain 
chronically fatigued, and this condition has been named Q fever fatigue syndrome (QFS) [6-
8]. QFS appeared to be one of the major causes of the Q fever-related economical sequelae 
during the Dutch outbreak, leading to loss of quality of life and health-related absenteeism 
[9]. With an increasing number of patients with QFS in the aftermath of the outbreak, 
and the societal need for uniform criteria for the syndrome, a national guideline on QFS 
was formulated and published in 2012 [10]. This consensus guideline was partly based on 
the diagnosis and treatment of chronic fatigue syndrome (CFS), as QFS and CFS at least 
partly overlap in symptoms [11]. In this guideline QFS is defined as a severe fatigue causing 
significant disabilities in daily life with a duration of at least six months, with a reference 
to an acute Q fever infection, and not being caused by somatic or psychiatric co-morbidity. 
In addition, the fatigue should be absent before the acute Q fever infection or significantly 
increased since the acute Q fever infection. No study has been published so far comparing 
the clinical characteristics of QFS and CFS patients. One study determined the prevalence of 
CFS in patients with Q fever compared to a healthy control group. In both groups only one 
patient met these criteria, although a substantial proportion of the patients with Q fever 
was chronically fatigued [12].
Little is known about the aetiology of QFS. It has been hypothesized that persistence of C. 
burnetii or its antigens could result in inflammation [13]. Ferritin, a cellular storage protein 
for iron that is important in iron absorption control, orchestrates cellular defence against 
oxidative stress and inflammation and is an acute phase reactant. It is induced by cytokines 
such as interleukin (IL)-6 and IL-18, and has been found to be significantly higher in acute 
Q fever patients than in controls [14]. Furthermore, elevated ferritin concentrations were 
observed in QFS patients, whereas in medically unexplained fatigue, such inflammatory 
markers are normally not present. To explore the presence of an inflammatory component 
in the pathogenesis of QFS, inflammatory markers of QFS patients were compared with 
those of CFS patients.
Previous research in CFS patients has shown that cognitive-behavioural variables, such as a 
reduced level of activity and fatigue-related dysfunctional beliefs, play an important role in 
the perpetuation of fatigue and disabilities. According to the model of perpetuating factors 
of CFS developed by Vercoulen et al. [15], fatigue is maintained by a low self-efficacy with 
respect to fatigue, a tendency to focus on fatigue and a lower level of activity. These fatigue-
maintaining factors are addressed in behavioural interventions, leading to significant 
reductions of fatigue and disability in CFS [16, 17]. Somatic attribution of symptoms has an 
indirect influence on fatigue and disability in CFS by further lowering the level of physical 
activity [15]. In other studies it was found that the tendency to catastrophize in response 
to fatigue and depressive mood could also play a role in the perpetuation of symptoms and 
disability in CFS patients [18, 19]. A depressive mood may also directly produce fatigue, 
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which can result in lower levels of physical activity because of inactivity. However, several 
studies showed that mood disorder is not an essential factor in the perpetuation of fatigue 
in CFS [20, 21]. It is unclear to what extent this is also true for QFS as the role of cognitive-
behavioural variables in the perpetuation of fatigue has not been investigated so far in QFS.
The main objective of this study was to explore both differences and similarities between QFS 
and CFS with a focus on inflammatory markers and cognitive-behavioural factors thought to 
perpetuate chronic fatigue. In an exploratory analysis we investigated whether there was 
a significant relationship between these cognitive-behavioural variables and fatigue in QFS 
patients.
METHOD
Study populations
The study population consisted of patients from two independently conducted prospective 
studies, one in QFS [22], and one in CFS [23]. All included patients were severely fatigued, 
defined by a score ≥35 on the subscale fatigue severity of the Checklist Individual Strength 
(CIS) [24]; all patients were ≥18 years. The fatigue lasted at least 6 months, in accordance 
with diagnostic criteria of both QFS and CFS (see below). In addition, all QFS patients met 
the criteria for QFS as formulated in the Dutch algorithm on QFS [14], with a sudden onset 
of fatigue related to a symptomatic acute Q fever infection. Fatigue was to be either absent 
before, or significantly increased after the acute Q fever infection. In all QFS patients, the 
fatigue resulted in significant functional impairment, defined as a score ≥450 on the Sickness 
Impact Profile (SIP8). Chronic Q fever and other causes of fatigue, somatic or psychiatric, 
were excluded. All QFS patients had suffered from laboratory-proven acute Q fever and/or 
a positive serology compatible with past C. burnetii infection [25]. All QFS patients (n=117), 
were assessed at the Radboud Expertise Centre for Q fever of the Radboud university 
medical center (Radboudumc) between 2011 and 2013.
The cohort of CFS patients was referred to the Expert Centre for Chronic Fatigue of the 
Radboudumc for cognitive-behavioural therapy (CBT) between 2008 and 2010. All CFS 
patients met the Centers for Disease Control and Prevention (CDC) criteria for CFS [26, 27], 
and were functionally impaired, operationalized as scoring ≥700 on the SIP8 and reporting 
≥4 additional symptoms. These criteria were met by 183 patients; however, it was unclear 
whether Q fever was considered as a possible origin of complaints. Therefore, as QFS is 
characterized by a sudden onset of fatigue, all CFS patients with a sudden or unknown onset 
of fatigue after 2007 (the start of the Q fever outbreak) were excluded (n=10). Both studies 
were approved by the medical ethical board of the Radboudumc, and all patients gave 
written informed consent.
Measures
Demographics and premorbid psychiatric treatment
Age, body mass index (BMI), gender, educational level, and marital status were recorded. 
Patients were asked if they had received treatment for an eating disorder, substance abuse, 
anxiety disorder, or depressive disorder in the past [16]. Previous treatment for these 
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psychiatric disorders was assumed to reflect prevalence of premorbid psychiatric illness.
Symptoms
Fatigue
Fatigue was assessed with the subscale fatigue severity of the CIS [24], indicating the level of 
fatigue experienced in the previous two weeks, measured with eight items on a seven-point 
Likert-scale (range 8–56). It is a reliable and validated instrument (Cronbach’s alpha .83–.92) 
[15, 28, 29]. Duration of fatigue was measured in months.
Functional impairment
The level of functional impairment was measured with the SIP8 total score [30, 31], a reliable 
instrument which shows good correlations with other health status and functional status 
measures (Cronbach’s alpha of the Dutch version is .91) [32]. A total score is derived out 
of the scores on the subscales: sleep-rest, household, mobility, social interactions, walking, 
alertness and intellectual functioning, work, and recreation.
Additional somatic symptoms
To determine the frequency of additional symptoms according to the CDC criteria for CFS, 
patients filled out a questionnaire with a 4-point scale to report prevalence of the following 
eight symptoms during the last six months: post-exertional malaise, unrefreshing sleep, 
memory or concentration impairment, muscle pain, joint pain, headaches, tender lymph 
nodes, and a sore throat.
Psychological distress and depression
The level of psychological distress was measured with the Symptom Checklist 90 (SCL90), 
consisting of 90 items scored on a five-point Likert-scale (range 90–450). Higher scores reflect 
more psychological distress. The SCL-90 is a reliable and validated instrument (Cronbach’s 
alpha of the subscales is .73–.89) [33, 34]. Depressive symptoms were measured with the 
Beck Depression Inventory-Primary Care questionnaire (BDI, Cronbach’s alpha .86) [35], 
with a score ≥4 indicative for a clinical depression.
Laboratory tests
For CFS patients the laboratory values had to be determined <1 year before assessment, 
and were derived from medical records. Laboratory values for QFS patients were derived 
from the assessment at the Radboud Expertise Centre for Q fever. Analyzed were: the 
inflammatory markers ferritin, leukocyte count, erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP), both indicators of the physical response to inflammation (acute 
phase response), and creatine kinase (CK), an enzyme used in the evaluation of patients 
presenting with muscle weakness or myalgias.
Cognitive-behavioural variables
Previous research revealed that cognition and behaviour perpetuate fatigue and disability 
in CFS [15]. A lowered self-efficacy with respect to fatigue, lowered levels of (self reported 
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and actual) physical activity, and focusing on bodily symptoms were perpetuating factors. 
Somatic attributions of symptoms indirectly influenced fatigue due to their negative effect 
on the level of physical activity. A model of perpetuating factors developed by Vercoulen 
et al [36] is depicted in figure 1. To explore if the same cognitive-behavioural variables also 
perpetuate fatigue in QFS the following variables were assessed: lowered self-efficacy with 
respect to fatigue, lowered levels of (self reported and actual) physical activity, and focusing 
on bodily symptoms.
Figure 1: Model of perpetuating factors for chronic fatigue syndrome (CFS)
Structural equation model for CFS patients [15, 36]. Reprinted from [15] with permission.
Abbreviations: CFS = Chronic fatigue syndrome.
Fatigue-related beliefs
The Self-Efficacy Scale (SES) was used to assess the patients’ sense of control over their 
symptoms (Cronbach’s alpha .68–.77) [15, 23, 37]. Seven items were scored on a 4-point 
Likert-scale, with higher scores indicating a higher sense of control over fatigue.
Physical activity
The level of physical activity was objectified using an actometer, a motion sensing device 
that registers and quantifies physical activity [38], worn during a period of 12 days around 
the ankle. A mean activity level was calculated and two activity patterns were discerned; 
a persistent low-active pattern and a fluctuating active pattern [38]. A fluctuating active 
pattern is characterized by fluctuating bursts of activity followed by a period of inactivity. 
Low active patients are characterized by consistent low levels of physical activity. The 
actometer is a reliable and valid instrument for the assessment of physical activity in CFS 
[38]. Self-reported activity was measured by the SIP8 mobility subscale.
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Focusing on bodily symptoms
Focusing on symptoms was measured with the shortened subscale ‘focusing on symptoms’ 
of the Illness Management Questionnaire (IMQ, Cronbach’s alpha .88) [39] [40], consisting 
of 9 items measured on a 6-point Likert-scale (ranging from ‘never’ to ‘always’). With the 
Jacobsen Fatigue Catastrophizing Scale (JFCS) [41], catastrophizing thoughts with respect 
to fatigue were assessed. The JFCS consists of 10 items, rated on a 5-point scale, and is a 
reliable instrument (Cronbach’s alpha .86) [40]. Higher scores reflect a stronger tendency to 
catastrophize in response to fatigue.
Attributions of symptoms
Somatic attributions regarding symptoms were measured with the Causal Attributions List 
(CAL, Cronbach’s alpha .71–.77) [42], which consists of five questions about the causes of 
fatigue measured on a 4-point Likert-scale (range 5–20). Higher scores indicate a stronger 
tendency to attribute symptoms to a certain cause.
Statistical analysis
All data were analyzed using SPSS (Version 20.0, SPSS, Inc.). The significance level was set 
at p=0.05. To correct for multiple testing, Bonferroni correction was used dividing 0.05 by 
the total number of comparisons for baseline characteristics and symptoms, inflammatory 
markers, and cognitive-behavioural factors separately.
For assessment of demographic variables, data on premorbid psychiatric treatment, and 
symptoms and disability, descriptive statistics were used including means and standard 
deviations for continuous variables, and tested with the independent t-test. Categorical 
variables were described with percentages, and tested with the χ2 test. The p-value 
after Bonferroni correction was p<0.002 for baseline characteristics and symptoms. For 
assessment of laboratory diagnostics, independent t-tests were used when comparing both 
groups. Bonferroni correction resulted in a p-value of p<0.006. Analyses were performed 
only if data of 20 or more patients were available in each group. For cognitive-behavioural 
factors, the χ2test was used for categorical variables (level of activity), and an independent 
t-test was used for continuous variables. After correction for multiple testing a value was 
found significant if p<0.007.
Different inclusion criteria were used for QFS and CFS with respect to the level of impairment 
assessed with the SIP8 total score and the number of additional symptoms that had to 
be reported. Furthermore, CFS patients with a sudden or unknown onset of fatigue after 
2007 (the start of the Q fever outbreak) were excluded. In addition, because included QFS 
patients could have experienced symptoms for a maximum of 4 to 6 years, compared to CFS 
patients who could have had symptoms long before 2007, difference in duration of illness 
between both groups exists. This leads to a priori differences between the total group of QFS 
patients and the CFS group that are not the focus of this study. Therefore, we analysed the 
differences between QFS and CFS patients in two steps. First, we compared the total group 
of QFS patients with the CFS group. Second, we compared a subgroup of QFS patients with 
CFS patients, by excluding all QFS patients with a SIP8 score ≤700 and <4 CDC symptoms and 
compared the remaining patients with the CFS patients. We used ANCOVA with duration of 
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symptoms as covariate to correct for differences in this variable.
Using the method “enter” in a multiple regression analysis in the total group of QFS patients, 
with potential perpetuating factors as predictors and fatigue severity as dependent variable, 
it was explored whether the perpetuating factors in CFS also predict fatigue severity in QFS.
RESULTS
Demographics and premorbid psychiatric treatment
The total group of QFS patients were less often female (52% vs. 75%, p<0.001), had a 
higher BMI (mean 26 vs. 24, p<0.001), and were less often treated for depression (17% 
vs. 35%, p=0.001) (Table 1). The number of patients who had received treatment for other 
psychiatric disorders than depression did not differ between CFS and QFS. Age and marital 
status also did not differ between the groups (Table 1). After excluding all QFS patients with 
<4 additional symptoms (n=14) and a SIP8 total score <700 (n=18), a total of 88/117 (75.2%) 
QFS patients met the criteria as applied for CFS. We compared this subgroup of QFS patients 
with CFS patients in an ANCOVA with symptom duration as covariate. The subgroup of QFS 
patients were still less often female (p=0.001), still had a higher BMI (p=0.001), but were 
also significantly older (p=0.001). Difference in previous treatment for depression was just 
as large as when all patients were compared (35% vs. 16%); however, the strength of the 
evidence for this difference was borderline (p=0.002), given the Bonferroni correction.
Table 1: Characteristics of Q fever fatigue syndrome (QFS) and chronic fatigue syndrome (CFS) 
patients, and the subgroup of QFS patients meeting the CFS criteria
QFS
N=117
CFS
N=173
Subgroup QFS
N=88
QFS vs. CFS
Subgroup 
QFS vs. CFS
Mean (SD) or 
proportion (%)
Mean (SD) or 
proportion (%)
Mean (SD) or 
proportion (%)
P-value P-value
Age in years [Range] 43 (13) [19-64] 39 (11) [19-63] 43 (13) [19-64] 0.003a 0.001b*
BMI (kg/m2) 26 (5)1 24 (4)2 26 (5)3 <0.001a* 0.0014,5,b*
Gender woman 61 (52%) 129 (75%) 47 (53%) <0.001c* 0.001c*
man 56 (48%) 44 (25%) 41 (47%)
Marital status married/living together 84 (72%) 108 (62%) 64 (73%) 0.121c 0.158c
living on their own 20 (18%) 48 (28%) 13 (15%)
living with parents 13 (11%) 17 (10%) 11 (13%)
Previously treated eating disorder 0 (0%) 7 (4%)6 0 (0%) 0.027c 0.054c
Previously treated alcohol disorder 2 (2%) 2 (1%)6 1 (1%) 0.701c 0.981c
Previously treated depression 20 (17%) 59 (35%)6 14 (16%) 0.001c* 0.002c
Previously treated anxiety disorder 13 (11%) 31 (18%)6 10 (11%) 0.104c 0.158c
Abbreviations: QFS = Q fever fatigue syndrome, CFS = Chronic fatigue syndrome, Subgroup QFS = 
excluding all QFS patients with <4 additional symptoms and a SIP8 total score <700, SD = Standard 
Deviation, BMI = Body mass index.
1 From a total of 115 patients. 2 From a total of 168 patients. 3 From a total of 87 patients. 4 From a 
total of 83 QFS patients. 5 From a total of 155 CFS patients. 6 From a total of 171 patients.
* Significant result after Bonferroni correction. 
a Calculated using student t-test with significance level at p<0.002.
b Calculated using ANCOVA with duration of symptoms as covariate with significance level at p<0.002.
c Calculated using Pearson Chi-square test with significance level at p<0.002.
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Symptoms
There was no difference in fatigue severity with a mean CIS fatigue of 50 (SD=5) in both 
groups (p=0.306, table 2). As expected, the total group of QFS patients showed less 
functional impairment (mean 1317±550 vs. 1547±530, p<0.001) and had fewer additional 
symptoms (mean 5.6±1.8 vs. 6.6±1.3, p<0.001). No significant differences between QFS and 
CFS patients were observed in psychological distress (SCL90 total score 155±33 vs. 163±34, 
respectively) and depressive symptoms (BDI score ≥4 in 26% vs. 31%, respectively). After 
correction for duration of symptoms and for differences in inclusion criteria the subgroup of 
QFS patients still reported fewer additional symptoms (p=0.001). 
Table 2: Comparison of symptoms of Q fever fatigue syndrome (QFS) and chronic fatigue 
syndrome (CFS) patients, and the subgroup of QFS patients meeting the CFS criteria
QFS
N=117
CFS
N=173
Subgroup QFS
N=88
QFS vs. 
CFS
Subgroup 
QFS vs. CFS
Mean (SD) or 
proportion (%)
Mean (SD) or 
proportion (%)
Mean (SD) or 
proportion (%)
P-value P-value
CIS fatigue 50 (5) 50 (5) 51 (5) 0.306a 0.247b
Length symptoms (in months) 35 (18)1 88 (81)2 35 (15)3 <0.001a* NA
CDC number of symptoms 5.6 (1.8) 4 6.6 (1.3) 6.2 (1.3) <0.001a* 0.001b*
CDC forgetfulness 92 (80%)4 163 (94%) 81 (92%) <0.001c* 0.501c
CDC concentration problems 100 (87%)4 168 (97%) 84 (95%) 0.001c* 0.488c
CDC throat pain 45 (39%)4 98 (57%) 41 (47%) 0.004c 0.124c
CDC sore neck- or axillar glands 28 (24%)4 94 (54%) 25 (28%) <0.001c* <0.001c*
CDC sore muscles 84 (73%)4 152 (88%) 74 (84%) 0.001c* 0.398c
CDC painful joints 71 (62%)4 138 (80%) 62 (70%) 0.001c* 0.093c
CDC headache 96 (83%)4 148 (86%) 79 (90%) 0.632c 0.338c
CDC waking up not well rested 107 (93%)4 172 (99%) 86 (98%) 0.002c* 0.225c
CDC increase in symptoms after 
physical activity
107 (93%)4 164 (95%) 87 (99%) 0.536c 0.106c
SCL90 total score 155 (33) 163 (34) 161 (32) 0.030a 0.667b
BDI score <4 86 (74%) 118 (69%)5 65 (74%) 0.370c 0.379c
≥4 31 (26%) 54 (31%)5 23 (26%)
SIP8 total score 1317 (550) 1547 (530) 1470 (500) <0.001a* 0.133b
Abbreviations: QFS = Q fever fatigue syndrome, CFS = Chronic fatigue syndrome, Subgroup QFS = 
excluding all QFS patients with <4 additional symptoms and a SIP8 total score <700, SD = Standard 
Deviation, CIS = Checklist Individual Strength, NA = Not applicable, CDC = Centers for Disease 
Control and Prevention questionnaire, SCL90 = Symptom Checklist 90, BDI = Beck Depression 
Inventory-Primary Care (score ≥4 indicating clinical significant level of depressive symptoms), SIP8 
= Sickness Impact Profile.
1 From a total of 111 patients. 2 From a total of 160 patients. 3 From a total of 84 patients. 4 From a 
total of 115 patients. 5 From a total of 172 patients.
* Significant result after Bonferroni correction. 
a Calculated using student t-test with significance level at p<0.002.
b Calculated using ANCOVA with duration of symptoms as covariate with significance level at 
p<0.002.
c Calculated using Pearson Chi-square test with significance level at p<0.002.
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Of the eight CDC additional symptoms, QFS patient reported significantly less often sore 
glands (p<0.001). After correction QFS and CFS patients did not differ with respect to fatigue 
severity (p=0.247), functional impairment (p=0.133), and psychological distress (p=0.667).
Inflammatory markers
The total group of QFS patients had a lower ESR (mean 5±4 vs. 8±7, p=0.001), and 
higher serum ferritin concentrations (mean 118±117 vs. 61±45, p<0.001; table 3). After 
excluding the two QFS patients and the six CFS patients with an elevated ESR (>20 mm/h 
in women and >15 mm/h in men), no significant differences in ESR between both groups 
remained (p=0.013). Nine out of 117 QFS and none of the CFS patients had an elevated 
ferritin serum concentration (>190 ng/mL in women and >280 ng/mL in men). The illness 
haemochromatosis, a condition of accumulation of iron resulting in systemic iron overload 
and end-organ damage, which could be a possible explanation for both fatigue and elevated 
ferritin concentrations, was excluded in these QFS patients. After excluding patients with an 
elevated serum concentration, the serum ferritin concentrations still differed significantly 
(mean 95±65 vs. 61±45, p=0.001). However, correcting ferritin concentrations for gender 
resulted in no significant differences between both men (mean 180±140 vs. 133±55, 
p=0.387) and women (mean 62±43 vs. 50±33, p=0.118; table 3, figure 2). No difference 
was found in CRP, leukocyte count, and CK. The pattern of results was not different when 
laboratory values of the subgroup of QFS patients were compared with those of CFS patients.
Cognitive-behavioural variables
Results of the actometer showed that QFS patients were physically more active than CFS 
patients (75±18 vs. 67±19, p=0.001), with more fluctuating active patients (93% vs. 79%, 
p=0.001, table 4). No difference was found in self-efficacy with respect to fatigue, focusing on 
symptoms, and catastrophizing thoughts in response to fatigue. Compared to CFS patients, 
QFS patients attributed their symptoms more strongly to physical causes (14±3 vs. 12±3, 
p<0.001). The strength of the somatic attribution was not related to the degree of physical 
activity (Pearson’s correlation of 0.02). The pattern of results remained the same comparing 
the subgroup of QFS patients with CFS patients. QFS patients were still physically more 
active (p=0.004), more often fluctuating active (p=0.001), and attributed their symptoms 
more strongly to physical causes (p<0.001).
In a multiple regression analysis with CIS fatigue as dependent variable and presumed 
perpetuating factors as predictors, the adjusted R2 was 0.047, which was not significant 
(F=2.148, p=0.065). A significant negative correlation was observed between actual 
(measured with the actometer) physical activity and CIS fatigue (p=0.034), and a significant 
positive correlation between self-reported limitation in physical activity (measured with 
the SIP8 subscale mobility) and CIS fatigue severity (p=0.039; table 5). In an exploratory 
analysis catastrophizing (JFCS) and ferritin levels were added to the multiple regression 
analysis as predictors, but this did not improve the model (data not shown). The same 
multiple regression analysis was performed in the CFS group, with CIS fatigue as dependent 
variable and the previously found perpetuating factors as predictors. The model significantly 
predicted fatigue (F=5.406, p<0.001). A significant direct relationship was found between
3DIFFERENCES BETWEEN QFS AND CFS PATIENTS  | 125
1
CF
S (
tot
al)
2
QF
S (
tot
al)
3
CF
S (
me
n)
4
QF
S (
me
n)
5
CF
S (
wo
me
n)
6
QF
S (
wo
me
n)
0
100
200
300
400
400
600
800
1000
Fe
rr
iti
n 
co
nc
en
tr
at
io
n 
(n
g/
m
L)
self-efficacy and CIS fatigue (p=0.005), and self-reported physical activity and CIS fatigue 
(p=0.021), and a near significant relationship between focusing on bodily symptoms and 
CIS fatigue (p=0.082). Finally, adding catastrophizing and ferritin levels as predictors did not 
improve the model, as in QFS.
Figure 2: Ferritin concentrations
Scatter dot plot showing ferritin concentration (in ng/mL) for both CFS and QFS patients.
Abbreviations: CFS = Chronic fatigue syndrome, QFS = Q fever fatigue syndrome. 
Normal ferritin values: ≤280 ng/mL in men, and ≤190 ng/mL in women. 
1 From a total of 53 patients. 2 From a total of 117 patients. 3 From a total of 7 patients. 4 From a total 
of 56 patients. 5 From a total of 46 patients. 6 From a total of 61 patients.
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Table 3: Laboratory values Q fever fatigue syndrome (QFS) and chronic fatigue syndrome (CFS) 
patients, and the subgroup of QFS patients meeting the CFS criteria
QFS
N=117
CFS
N=variable
Subgroup QFS
N=88
QFS vs. CFS
Subgroup QFS 
vs. CFS
Mean (SD) Mean (SD) Mean (SD) P-value P-value
ESR 5 (4) 8 (7)1 6 (4) 0.001a* 0.003b,2*
CRP 6 (2) 6 (3)3 6 (2) 0.963a 0.591b,4
Leukocyte count 7 (2) 8 (2)5 7 (2) 0.162a 0.236b,6
CK 106 (59) 96 (39)7 104 (62) 0.370a 0.599b,8
Ferritin 
concentration
118 (117) 61 (45)9 112 (112) <0.001a* 0.003b,10*
Ferritin 
concentration 
excluding outliers 
95 (65)11 61 (45)9 96 (64)12 0.001a* 0.001b,13*
Ferritin 
concentration in 
men only
180 (140)14 133 (55)15 173 (137)16 0.387a 0.630b,17
Ferritin 
concentration in 
women only
62 (43)18 50 (33)19 59 (33)20 0.118a 0.163b,21
Abbreviations: QFS = Q fever fatigue syndrome, CFS = Chronic fatigue syndrome, Subgroup QFS = 
excluding all QFS patients with <4 additional symptoms and a SIP8 total score <700, SD = Standard 
Deviation, ESR = Erythrocyte sedimentation rate, CRP = C reactive protein, CK = Creatine kinase. 
Ferritin elevated values: >190 ng/mL in women, and >280 ng/mL in men.
1 From a total of 66 patients. 2 From a total of 84 QFS and 64 CFS patients. 3 From a total of 50 
patients. 4 From a total of 84 QFS and 49 CFS patients. 5 From a total of 72 patients. 6 From a total 
of 84 QFS and 69 CFS patients. 7 From a total of 30 patients. 8 From a total of 84 QFS and 29 CFS 
patients. 9 From a total of 53 patients. 10 From a total of 84 QFS and 52 CFS patients. 11 From a 
total of 108 patients. 12 From a total of 84 patients. 13 From a total of 80 QFS and 52 CFS patients. 
14 From a total of 56 patients. 15 From a total of 7 patients. 16 From a total of 41 patients. 17 From a 
total of 39 QFS and 6 CFS patients. 18 From a total of 61 patients. 19 From a total of 46 patients. 20 
From a total of 47 patients. 21 From a total of 45 QFS and 46 CFS patients.
* Significant result after Bonferroni correction. 
a Calculated using student t-test with significance level at p<0.006.
b Calculated using ANCOVA with duration of symptoms as covariate with significance level at 
p<0.006.
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Table 4: Possible cognitive-behavioural perpetuating factors of fatigue in Q fever fatigue 
syndrome (QFS) and chronic fatigue syndrome (CFS) patients, and the subgroup of QFS patients 
meeting the CFS criteria
QFS
N=117
CFS
N=173
Subgroup QFS
N=88
QFS vs. CFS
Subgroup 
QFS vs. CFS
Mean (SD) or 
proportion (%)
Mean (SD) or 
proportion (%)
Mean (SD) or 
proportion (%)
P-value P-value
Sense of control over fatigue 
(SES28)
17 (3) 18 (3) 17 (3) 0.127a 0.296b,1
Actometer 
(Daily observed mean score)
75 (18) 67 (19) 74 (17) 0.001a* 0.004b,1*
Level of activity fluctuating 
active
109 (93%) 137 (79%) 83 (94%) 0.001c* 0.001c*
low-active 8 (7%) 36 (21%) 6 (7%)
Self reported physical activity 
(SIP8 – mobility)
49 (68) 70 (83) 53 (71) 0.020a 0.058b,1
Focusing on symptoms 
(IMQ focusing)
30 (10) 32 (9) 30 (10) 0.024a 0.179b,1
Catastrophizing thoughts with 
respect to fatigue (JFCS)
22 (7) 22 (6) 22 (7) 0.370a 0.885b,1
Somatic attributions regarding 
symptoms (CAL physical total 
score)
14 (3) 12 (3)2 14 (2) <0.001a* <0.001b,3*
Abbreviations: QFS = Q fever fatigue syndrome, CFS = Chronic fatigue syndrome, Subgroup QFS = 
excluding all QFS patients with <4 additional symptoms and a SIP8 total score <700, SD = Standard 
Deviation, SES28 = Self Efficacy Scale, SIP8 – mobility = Sickness Impact Profile – Self reported 
physical activity, IMQ focusing = Symptom focusing of the illness Management Questionnaire, JFCS = 
Jacobson Fatigue Catastrophizing Scale, CAL = Causal attribution list.
1 From a total of 84 QFS patients and 160 CFS patients. 2 From a total of 172 patients. 3 From a total 
of 84 QFS and 159 CFS patients.
* Significant result after Bonferroni correction. 
a Calculated using student t-test with significance level at p<0.007.
b Calculated using ANCOVA with duration of symptoms as covariate with significance level at 
p<0.007.
c Calculated using Pearson Chi-square test with significance level at p<0.007.
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Table 5: Multiple regression analysis of perpetuating factors for Q fever fatigue syndrome (QFS) 
with CIS fatigue as dependent variable
Predictorsa Unstandardized 
Coefficients
Standardized Coefficients t P-value
B β
(Constant)
Self-efficacy with respect to fatigue1
Somatic attribution of symptoms2 
Level of physical activity3
Level of self-reported physical activitiy4
Focusing on bodily symptoms5 
54.294 11.578 <.001
-.080 -.053 -.521 .603
-.016 -.008 -.088 .930
-.055 -.195 -2.146 .034
.014 .190 2.088 .039
.035 .069 .670 .504
a. Multiple regression, method enter. Dependent Variable: CIS fatigue. N = 117 QFS patients.
Abbreviations: QFS = Q fever fatigue syndrome, CIS = Checklist Individual Strength. 
1 Measured with the Self-Efficacy Scale (SES28).
2 Measured with the Causal Attribution List (CAL).
3 Measured with the DOM score of the actometer.
4 Measured with the subscale “mobility” of the Sickness Impact Profile (SIP8). 
5 Measured with the subscale “focusing on symptoms” of the Illness Management Questionnaire 
(IMQ).
DISCUSSION
To our knowledge, this is the first study directly comparing QFS and CFS patients. We found 
that QFS and CFS patients differed on several aspects. These differences could partly be 
explained by the fact that different criteria were used with respect to level of functional 
impairment and the number of additional symptoms to diagnose both syndromes, and 
difference in duration of symptoms. Differences in duration of illness between both groups 
can be explained by the fact that the Q fever outbreak in the Netherlands started in 2007, 
compared to CFS patients who could have had symptoms long before 2007. Included 
QFS patients could have experienced symptoms for a maximum of 4 to 6 years. However, 
comparing the subgroup of QFS patients with CFS patients whilst taking into account the 
different diagnostic criteria used and duration of symptoms still showed differences.
In all analyses, QFS patients had a higher BMI, a known risk factor for chronic fatigue, and 
were less often female. Consistent with previous research [43], 75% of our CFS patients were 
female, which has been shown to be a predisposing factor for CFS [44]. In contrast, only half 
of the QFS patients were female. Even though male gender predominates in notified acute 
Q fever patients [45], no significant difference in gender was found in a seroprevalence 
study [3], and no difference in gender was found between non-notified and notified acute
Q fever cases, with equally severely affected health status 4 years after infection [46]. Based 
on the absence of gender difference in seroprevalence, and the fact that the QFS cohort also 
included non-notified acute Q fever cases, female gender does not seem to be a predisposing
factor for QFS. Finally, the total group of QFS patients less often had received treatment 
for depression, assumed to reflect lower prevalence of premorbid psychiatric illness. In the 
subgroup analysis with QFS patients who met the CFS criteria, there was a tendency towards 
less often having received treatment for depression in QFS patients. This could be caused 
by the relatively small group of QFS patients meeting CFS criteria, which reduces the power
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to detect differences. Even though the strength of this evidence was borderline significant 
after Bonferroni correction, the difference in relation to previous treatment for depression 
still may be clinically important. Analysis in a larger group of QFS patient might show that 
previous depressive disorders, a predisposing factor of CFS, are less prevalent. However, 
there was no difference in current psychological distress or depressive symptoms, indicating 
that premorbid psychiatric illness in CFS might not be related to current complaints, but 
only plays a predisposing role, and that current psychological problems are secondary to the 
chronic fatigue itself and its consequences.
Compared to CFS patients, the group of QFS patients reported fewer additional symptoms, 
also when differences in diagnostic criteria and duration of symptoms were taken into 
account. This suggests the presence of a true difference in number of additional symptoms. 
However, only symptoms were registered as mentioned in the CDC consensus definition 
of CFS, whereas QFS patients frequently report other complaints such as blurred vision, 
alcohol intolerance, increased sweating, night sweats, and dyspnoea [7, 10].
A comparison of QFS and CFS patients with regard to inflammatory markers showed that 
the ESR was significantly higher in CFS patients, which can be explained by a selection bias 
with only 66 (38%) CFS patients with a known ESR level and relatively more CFS patients 
with ESR levels above the upper limit of normal compared to QFS patients (9.1% vs. 1.7%, 
respectively). The mean serum ferritin concentration in QFS patients was approximately 
twice as high as in CFS patients. However, after correction for gender, no difference in 
ferritin concentrations between both groups remained. But, as groups sizes were small 
(only seven male CFS patients) and mean values of ferritin concentration for both men and 
women were higher in QFS patients, it cannot be ruled out that a lack of power made that 
the differences failed to reach significance. It should be noted that ferritin concentrations 
were in the abnormal range in nine QFS patients and in none of the CFS patients. It is known 
that in diseases with elevated ferritin levels such as haemochromatosis, fatigue is one of the 
most common symptoms [47, 48]. More research is necessary to find out whether there is 
a significant ferritin response in QFS patients and how it is driven.
In this paper we explored whether the perpetuating factors found in CFS [15], also predicted 
fatigue severity in QFS patients. In fact they did not, even though no significant difference 
was found in fatigue severity between QFS and CFS patients. QFS patients had a significantly 
higher somatic attribution regarding symptoms, but also significantly higher levels of 
physical activity. Both were unrelated in QFS patients. This is in contrast to findings in CFS 
patients, in which stronger attributions of complaints to a somatic cause are associated with 
lower levels of physical activity [15]. Higher somatic attribution could perhaps be explained 
by the fact that QFS patients had a known exposure for their complaints, whereas often in 
CFS such a marker is not present. Because the relationship between somatic attributions 
and physical activity levels are mediated by patients’ interpretations regarding the meaning 
of symptoms, this might explain the different relationship found in QFS.
The relationship previously found between perpetuating factors and fatigue in CFS could not 
be confirmed in QFS patients. As expected, the model significantly predicted fatigue in CFS 
patients, with CIS fatigue being significantly related to both self-efficacy and self-reported 
physical activity. The relationship between CIS fatigue and focusing on bodily symptoms was 
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nearly significant, which perhaps can be explained by the relatively small sample size. In QFS 
patients, a significant negative correlation was found between objectively assessed physical 
activity and CIS fatigue. Also, self-reported limitations in physical activity were related to 
fatigue severity. Both may suggest that higher activity levels are associated with reduced 
fatigue. This has also been found in CFS and other conditions like rheumatoid arthritis [49]. 
The fact that other cognitive-behavioural variables were not related to fatigue in QFS may 
indicate that the processes involved in the perpetuation of fatigue in QFS are different from 
the processes related to fatigue in CFS. On the other hand, the small sample size might be 
an alternative explanation of bad fit of the model of perpetuating cognitions and behaviour. 
As the pathophysiological mechanism of QFS still needs to be clarified, treatment based 
on aetiological insight is hampered. However, CBT aimed at fatigue-related beliefs and 
behaviour, has already proved to be effective in other forms of chronic fatigue [50, 51]. 
CBT is a complex intervention in which several fatigue-related beliefs and therefore several 
(potential) perpetuating factors are influenced. Because factors related to cognition and 
behaviour overlap substantially between QFS and CFS patients, and gradually increasing 
physical activity is a key component of CBT, QFS patients might benefit from treatment 
directed at these factors. Furthermore, the inverse relation between physical activity 
and fatigue severity suggests that aside from CBT, graded exercise therapy might also be 
beneficial [52].
CONCLUSION
We conclude that there are differences but also similarities between QFS and CFS patients. 
With respect to fatigue severity, both groups are similar, but differences in demographics, 
number of symptoms, and fatigue-related cognitive-behavioural variables were found. 
Differences in gender and BMI – both known predisposing factors for chronic fatigue – 
suggest that there are different predisposing factors for developing QFS. More research is 
necessary to find out whether there is a significant ferritin response in QFS patients and how 
it is driven, as elevated serum ferritin concentrations were not found at all in CFS patients. 
Although the relationship between perpetuating factors and fatigue in CFS could not be 
confirmed in QFS patients, with the exception of the relation between fatigue and lowered 
levels of activity, the considerable overlap in fatigue-related cognitive-behavioural variables 
between both groups may imply that behavioural interventions could reduce fatigue severity 
in QFS patients.
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ABSTRACT
Objectives: Whether immunological mechanisms underlie Q fever fatigue syndrome (QFS) 
remains unclear. For acute Q fever, the antigen-specific interferon-y (IFNy) response may be 
a useful tool for diagnosis, and the IFNy/interleukin(IL)-2 production ratio may be a marker 
for chronic Q fever and treatment monitoring. Here we explored the specific IFNy production 
and IFNy/IL-2 ratio in QFS patients.
Methods: IFNy and IL-2 production were tested in ex-vivo stimulated whole blood of QFS 
patients (n=20), and compared to those previously determined in seropositive controls 
(n=135), and chronic Q fever patients (n=28). Also, the correlation between patient 
characteristics and IFNy, IL-2, and IFNy/IL-2 ratio was determined.
Results: QFS patients were younger (p<0.001), but gender distribution was similar to 
seropositive controls and chronic Q fever patients. Coxiella burnetii Nine Mile stimulation 
revealed a higher IFNy production in QFS (median 319.5 pg/ml) than in seropositive controls 
(120 pg/ml, p<0.01), but comparable to chronic Q fever (2846 pg/ml). The IFNy/IL-2 ratio was 
similar to that in seropositive controls, but lower than in chronic Q fever patients (p<0.01). 
Symptom duration was positively correlated with IL-2 production, and negatively correlated 
with the IFNy/IL-2 ratio.
Conclusions: These results point to an altered cell-mediated immunity in QFS, and suggest a 
different immune response than in chronic Q fever.
HIGHLIGHTS
•	 We explored the specific IFNy production, and the IFNy/IL-2 ratio in QFS patients.
•	 QFS patients have a significant higher IFNy production than seropositive controls.
•	 The IFNy/IL-2 ratio is significantly lower in QFS than in chronic Q fever patients.
•	 These results point to an altered cell-mediated immunity in QFS.
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INTRODUCTION
At present, the Netherlands is faced with the aftermath of the largest Q fever outbreak 
worldwide lasting from 2007 to 2011 [1]. During this period, over 4000 patients with 
symptomatic acute Q fever were reported, and it was estimated that over 40,000 individuals 
experienced a latent infection [2, 3]. Although most patients with symptomatic acute Q 
fever recover completely with only a serological scar left, infection with Coxiella burnetii is 
notorious for causing long-term sequelae, i.e., chronic Q fever and Q fever fatigue syndrome 
(QFS). Chronic Q fever, characterized by the persistence of viable C. burnetii, may develop in 
1-5% of both symptomatic and asymptomatic cases of acute Q fever. Chronic Q fever presents 
mainly as vascular infection [4], including mycotic aneurysms and infections of vascular 
prosthesis, and endocarditis [5]. QFS, a debilitating fatigue syndrome following acute Q 
fever, may become manifest in approximately 20% of patients [6-10]. Lasting up to 10 years 
after the acute illness [11], QFS is considered to be the major cause of the Q fever-related 
economical burden following the Dutch outbreak [12]. The pathophysiological mechanisms 
underlying QFS remain to be elucidated. Interpretations range from compensation-driven 
and psychogenic perpetuation of the original symptoms [7], to attribution of the syndrome 
to cytokine dysregulation due to chronic immune stimulation [7]. The latter might be caused 
by persisting C. burnetii, or by persisting non-infectious C. burnetii antigens [13-18]. White 
blood cells from QFS patients exposed to Q fever antigens were found to exhibit a marked 
interleukin-6 (IL-6) production [13], and the IL-6 production was similar in both chronic Q 
fever patients and seropositive controls, which was significantly higher than in seronegative 
controls [19]. In addition, the group of QFS patients contained significantly more interferon-y 
(IFNy) responders than a group of controls, whilst the proportion of IL-2 responders was 
lower among QFS patients [13]. IFNy is a cytokine that plays an important role in the host 
defence against intracellular bacteria such as C. burnetii [20-23]. To date, no diagnostic 
test is available to diagnose QFS directly and diagnosis partly relies on measurement of C. 
burnetii-specific antibodies, e.g. serology, reflecting humoral immunity. Recently our group 
developed a C. burnetii-specific whole–blood IFNy production assay, which is a promising 
diagnostic tool for C. burnetii infection [24], with similar performance and practical 
advantages over serology [25]. In addition, a high IFNy/IL-2 ratio appeared to be indicative 
of chronic Q fever, and may be a useful diagnostic marker for chronic Q fever and treatment 
monitoring [19, 26]. In addition, as suggested in animal experiments, antigen-specific IFNy 
production could also be a useful tool for diagnosis of acute Q fever [27].
In the present study, we addressed the question whether there is an aberrant antigen-specific 
IFNy production and IFNy/IL-2 ratio in QFS patients. If so, this might provide additional 
insight in the potential pathophysiological mechanisms underlying this debilitating long-
term complication and might contribute, as immunological markers, to the diagnostic 
workup of QFS.
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MATERIALS AND METHODS
Study population
The study population consisted of QFS patients (n=20), Q fever seropositive controls (n=135), 
and patients with proven chronic Q fever (n=28). All QFS patients were diagnosed with QFS 
at the Radboud Expertise Centre for Q fever, Nijmegen, the Netherlands, after a uniform 
work-up according to the Dutch guideline on QFS [28]. All QFS patients met the following 
diagnostic criteria: i. fatigue lasted ≥6 months; ii. sudden onset of severe fatigue (defined 
as a score ≥35 on the subscale fatigue severity of the Checklist Individual Strength (CIS)), or 
significant increase in fatigue related to a symptomatic acute Q fever infection; iii. chronic 
Q fever and other causes of fatigue, somatic or psychiatric, were excluded; and iv. fatigue 
resulted in significant functional impairment (defined as a total score ≥450 on the Sickness 
Impact Profile (SIP)). Blood samples were collected during regular patient care between 
May 2011 and February 2012. The seropositive controls were anonymously derived from 
the Dutch Q fever vaccination campaign, which was organized from January to April 2011 
[29]; data on their antigen-specific IFNy production has been published previously [25]. All 
controls had pre-existing risk factors for development of Q fever endocarditis or vascular 
infection, and were Q fever seropositive ≥1 year after the Q fever epidemic (IgG phase I 
or II ≥1:32, but IgG phase I ≤1:512), without clues for persistent Q fever infection. Chronic 
Q fever patients were diagnosed at participating hospitals [19], and blood samples were 
collected between December 2010 and March 2012. At the time of sampling, all patients 
were diagnosed with either Q fever endocarditis (n=9) or vascular (prosthesis) infection 
(n=18), according to the Dutch guideline on chronic Q fever [30]; patient characteristics and 
data on the cytokine production of these patients also have been published before [19, 25].
Serological measurements and detection of C. burnetii DNA
IgM and IgG antibodies against C. burnetii phase I and phase II antigens were measured by 
a commercially available immunofluorescence assay (IFA; Focus Diagnostics, Cypress, CA, 
USA). The PCR assay used to detect DNA of C. burnetii in serum was an in-house real time 
PCR directed against the insertion sequence IS1111a.
In-vitro whole blood stimulation
Whole blood stimulation, followed by measurement of IFNy and IL-2 production, was done 
as previously described [25]. In brief, venous blood was drawn into 5mL endotoxin-free 
lithium-heparin tubes (Vacutainer, BD Bioscience) and samples were processed within 12h. 
Incubation of samples was done as previously described [25]. C. burnetii Nine Mile (NM) RSA 
493 phase I, heat-inactivated, was used [25, 31], and the mitogen phytohemagglutinin (PHA) 
(Sigma–Aldrich, St Louis, MO, USA) as a positive control. As a negative control, incubation 
with only Roswell Park Memorial Institute medium (RPMI, 1640 Dutch modification, Life 
Technologies/Invitrogen, Breda, the Netherlands) was performed. After incubation, blood 
samples were centrifuged at 4656 g for 10 min and supernatants were stored at -20⁰C until 
cytokine measurement.
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Cytokine measurements
The IFNy production was measured by enzyme-linked immunosorbent assay (ELISA; Pelikine 
compact, Sanquin, Amsterdam, the Netherlands), in undiluted whole blood incubated 
for 24h either with PHA, or C. burnetii–NM in all patients, as described [24, 25]. IL-2 was 
measured using a multiplex beads assay (Merck Millipore, Billerica, MA, USA) according to 
the manufacturer’s instructions.
Ethical statement
This study was exempt from ethical approval by the local ethics committee, as there was 
no additional burden for patients. Samples were obtained during regular patient care after 
obtaining oral and written informed consent, and, in case of individuals from the Dutch Q 
fever vaccination campaign, individuals signed written informed consent to use drawn blood 
for research purposes.
Statistical analysis
Data were analyzed using Graphpad Prism (Graphpad Software Inc., version 5.03) and SPSS 
(Version 22.0, SPSS, Inc). The Kruskall–Wallis test was used as non-parametric ANOVA to 
determine differences between groups. Statistical significance was attained if p<0.05. In case 
of significance, by post-hoc analysis using Dunn’s multiple comparison test was performed 
to look at pair wise comparisons between the groups, taking into account the number 
of comparisons made. The correlation between patient characteristics and IFNy and IL-2 
production, and the IFNy/IL-2 ratio was determined with the non-parametric Spearman’s 
rank correlation coefficient.
RESULTS
Patients and controls
At the time of blood collection, QFS was already diagnosed but treatment had yet to be 
started (Table 1). The symptom duration of QFS patients, defined as the time of symptom 
onset until blood sampling, varied between 12 and 51 months (Table 1). All seropositive 
controls had IgG phase I or phase II titres ≥1:32, but IgG phase I ≤1:512, and none of them 
showed serological signs of an acute or recent Q fever infection, reflected by IgM antibodies 
in absence of IgG antibodies. The mean age of QFS patients was 50.2 yrs (SD 9.3), which 
was significantly younger (p<0.001) than 60.8 years (SD 15.1) and 66.2 years (SD 11.8) for 
the seropositive controls and chronic Q fever group, respectively. There was no correlation 
between age and IFNy production (Spearman’s rank correlation coefficient -0.71, p=0.341), 
between age and IL-2 production (Spearman’s rank correlation coefficient -0.002, p=0.978), 
and between age and IFNy/IL-2 ratio (Spearman’s rank correlation coefficient 0.060 
(p=0.466)). All groups had a predominant male distribution, with 70% being male in the 
QFS group, 78% in the seropositive control group, and 79% in the chronic Q fever group (not 
significant).
142 | CHAPTER 4
Figure 1: IFNy and IL-2 production in Q fever fatigue syndrome (QFS) patients, chronic Q fever 
patients and Q fever seropositive controls
(A) Comparable aspecific PHA-induced IFNy production between QFS patients, seropositive controls 
and chronic Q fever patients after 24h incubation of whole blood. There is no significant difference in 
specific CbNM-induced IFNy production between QFS and chronic Q fever patients. (B) CbNM-induced 
IFNy production (stimulated minus unstimulated) after 24h incubation of whole blood, showing a 
significant difference in IFNy production between seropositive controls and QFS and chronic Q fever 
patients, with an increasing trend of IFNy production towards chronic Q fever patients. (C) CbNM-
induced IL-2 production (stimulated) between seropositive controls, QFS patients and chronic Q fever 
patients after 24h incubation of whole blood. (D) IFNy/IL-2 ratio, showing a significant difference 
between chronic Q fever patients and both seropositive controls and QFS patients. A trend towards 
a higher IFNy/IL-2 ratio is observed towards chronic Q fever patients. Median ± IQR are shown. The 
Kruskall–Wallis test was used, and, in case of significance, post-hoc analysis using the Dunn’s multiple 
comparison test was performed to look at pair wise comparisons between the groups, taking into 
account the number of comparisons made.
Abbreviations: IFNy = Interferon-gamma; IL = Interleukin; QFS = Q fever fatigue syndrome; PHA = 
Phytohemagglutinin; CbNM = Coxiella burnetii Nine Mile; ns = not significant; IQR = Interquartile 
range; controls = seropositive controls.
** p-value <0.01.*** p-value <0.001.
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IFNy and IL-2 production and IFNy/IL-2 ratio
Aspecific PHA-induced IFNy production was similar in QFS patients, seropositive controls, 
and chronic Q fever patients (Table 2, Figure 1A). Specific stimulation with C. burnetii NM for 
24h in QFS patients showed a median IFNy production of 319.5 pg/ml, which was significantly 
higher (p<0.01) than in seropositive controls (median 120 pg/ml), but not significantly 
different from chronic Q fever patients (median 2846 pg/ml) (p=0.110) (Figure 1B). No 
significant difference was observed in IL-2 production between QFS patients (median 104.5 
pg/ml), seropositive controls (median 81 pg/ml), and chronic Q fever patients (median 82.5 
pg/ml) (Figure 1C). The IFNy/IL-2 ratio was calculated for each individual. The IFNy/IL-2 ratio 
in QFS patients was not significantly different from seropositive controls, but significantly 
lower than the ratio found in chronic Q fever patients (p<0.01) (Figure 1D).
Correlations between patient characteristics and cytokine measurements
Correlations between the most important characteristics of QFS patients (Table 1) and the 
measured cytokine productions were assessed (Table 3). The duration of symptoms did not 
significantly correlate with IFNy production, but did so with IL-2 production (p=0.032); it 
negatively correlated with the IFNy/IL-2 ratio (p=0.025). No correlation was found between 
the level of fatigue and IFNy or IL-2 production, as well as the IFNy/IL-2 ratio. A positive 
correlation was found between the level of perceived disabilities, reflected by the SIP 
total score, and IL-2 production (p=0.047), but no correlation was found with either IFNy 
production or the IFNy/IL-2 ratio. Finally, no correlation was found between the IgG phase I 
titres and either IFNy or IL-2 production, or the IFNy/IL-2 ratio.
DISCUSSION
In this study we assessed the antigen-specific IFNy production and IFNy/IL-2 ratio in C. 
burnetii-stimulated whole blood of QFS patients. We found that the IFNy production of 
QFS and chronic Q fever patients was not significantly different, but for both significantly 
increased compared to seropositive controls. In addition, the IFNy/IL-2 ratio in QFS patients 
was similar to that in seropositive controls, but lower than in chronic Q fever patients. Of 
note, no differences in IL-2 production between the three groups were found. These results 
suggest that C. burnetii-induced IFNy production and IFNy/IL-2 ratio may discriminate 
seropositive controls from QFS and chronic Q fever patients.
At present, the measurement of the specific humoral immune response, i.e. serology, has a 
central position in the diagnosis of Q fever, but it is increasingly accepted that cell-mediate 
immune responses are also relevant to describe the anti-C. burnetii host response. However, 
the precise relationship between T-cell function and protective immunity remains unknown. 
Memory T lymphocytes can be broadly divided in central memory T-cells, which lack 
immediate effector function and mainly secrete IL-2, and effector memory T-cells, displaying 
immediate effector function, e.g. IFNy and IL-2 secretion [32]. IFNy plays a pivotal role in 
protective immunity against many intracellular bacteria, but is also a marker of infection, 
immunity, and the extent of immune-mediated pathology [20].
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It has been proposed that full activation of the macrophage by IFNy is required to eliminate C. 
burnetii, and that the phase 1 antigen can promote downregulation of IFNy by lymphocytes, 
perhaps by modulating IL-2 production [33]. This is however difficult to reconcile with 
the finding that chronic Q fever patients exhibit a very high specific IFNy production. It 
has been postulated that distinct IFNy/IL-2 functional profiles correlate with different 
models of infection [20]. This concept is supported by previous findings, showing a high 
IL-2 production in seropositive controls, assumed to have cleared the infection successfully, 
and high IFNy and low IL-2 production in chronic Q fever patients [19]. Interestingly, our 
study revealed that QFS patients had a markedly higher C. burnetii-specific IFNy production 
than seropositive controls. In addition, the IFNy production in QFS patients and chronic Q 
fever patients did not significantly differ, although there was a trend that QFS patients had 
lower IFNy production than chronic Q fever patients, and it can be expected that with larger 
numbers of patients these differences would become significant. In that case, it is tempting 
to hypothesize that QFS represents an altered cell-mediated immunity in the spectrum of 
Q fever related syndromes, i.e. an inactive state without viable C. burnetii in contrast to 
chronic Q fever. The combined use of IFNy production and IL-2 production allows a better 
distinction between QFS patients, seropositive controls, and chronic Q fever patients [19]. 
Also, a positive correlation between IL-2 production and both symptom duration and level 
of perceived disabilities was found, suggesting that QFS patients slowly attain an inactive 
state of infection, with a subsequent negative correlation between symptom duration and 
IFNy/IL-2 ratio. Similarly, resolution of fatigue in the acute sickness response appeared to 
be associated with improvement of cell-mediated immunity [34]. The IFNy/IL-2 ratio was 
proposed as an additional diagnostic marker for chronic Q fever [19], and our results indicate 
that the IFNy/IL-2 ratio also discriminates between QFS and chronic Q fever patients, but 
not between QFS patients and seropositive controls. Our data are supported by another 
study in the literature, showing IFNy upregulation and IL-2 downregulation in QFS patients 
compared to control groups [13]. All these results point to an altered cell-mediated immune 
response in those who do not recover completely, implicating that both antigen-specific 
IFNy production and IFNy/IL-2 ratio might be used as immunological marker in the diagnostic 
workup of QFS. Although the results are strikingly similar, both our study and that of Penttila 
et al [13] deal with low numbers of patients. Thus further confirmation is needed.
Other limitations of our study are that the cytokine studies in the seropositive controls 
and chronic Q fever patients were performed earlier and derived from published studies 
of our group [19, 25]. Ideally, these studies should have been done completely in parallel 
to avoid laboratory artefacts. However, the determination of IFNy production is a standard 
procedure and therefore inter- and intra-individual variation is limited. In addition, the best 
control group for comparison with QFS patients would be patients with a previous Q fever 
infection with asymptomatic recovery, i.e., without QFS or other co-morbidity. In contrast, 
the seropositive controls were anonymously derived from a vaccination campaign; these 
subjects had an indication for vaccination but were not vaccinated because of positive 
Q fever serology. We cannot exclude that some of these patients suffered from fatigue. 
Finally, IL-6 production was not measured though it has been found that the IL-6 production 
was accentuated in QFS patients, with a significant correlation with total symptom scores 
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[13], and also higher in chronic Q fever patients and seropositive controls compared to 
seronegative controls [19].
Thus, it is too early to advice the usage of the immunological assays described here in a 
routine clinical setting. To overcome the mentioned limitations, and to investigate whether 
the IFNy production assay or IFNy/IL-2 ratio, and other cytokines such as IL-6, would be 
useful in clinical practice for diagnosing QFS, i.e. regardless of the time-point of sampling, 
a case–control study with comparison of QFS patients, CFS patients, seropositive controls 
without co-morbidity, and healthy controls will be performed in the near future.
CONCLUSION
In conclusion, the IFNy production in QFS patients is significantly higher than in seropositive 
controls, and the IFNy/IL-2 ratio is significantly lower than in chronic Q fever patients. 
Further investigation in larger cohorts of QFS patients is warranted, as these results point 
to an altered cell-mediated immunity in QFS, and hence opens up avenues for better 
understanding the pathogenesis of this enigmatic complication of Q fever and of other 
fatigue syndromes.
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ABSTRACT
Background: Q fever is a zoonosis that is present in many countries. Q fever fatigue 
syndrome (QFS) is one of the most frequent sequelae after an acute Q fever infection. 
QFS is characterized by persistent fatigue following an acute Q fever infection, leading to 
substantial morbidity and a high socio-economic burden. The occurrence of QFS is well-
documented, and has been described in many countries over the past decades. However, a 
treatment with proven efficacy is not available. Only a few uncontrolled studies have tested 
the efficacy of treatment with antibiotics on QFS. These studies suggest a positive effect of 
long-term treatment with a tetracycline on performance state; however, no randomized 
controlled trials have been performed. Cognitive behavioral therapy (CBT) has been proven 
to be an effective treatment modality for chronic fatigue in other diseases, but has not 
yet been tested in QFS. Therefore, we designed a trial to assess the efficacy of long-term 
treatment with the tetracycline doxycycline and CBT in patients with QFS.
Methods/design: A randomized placebo-controlled trial will be conducted. One-hundred-
eighty adult patients diagnosed with QFS will be recruited and randomized between one of 
three groups: CBT, long-term doxycycline or placebo. First, participants will be randomized 
between CBT and medication (ratio 1:2). A second double-blinded randomization between 
doxycycline and placebo (ratio 1:1) will be performed in the medication condition. Each 
group will be treated for six months. Outcome measures will be assessed at baseline and 
post intervention. The primary outcome measure is fatigue severity. Secondary outcome 
measures are functional impairment, level of psychological distress, and Coxiella burnetii 
PCR and serology.
Discussion: The Qure study is the first randomized placebo-controlled trial, which evaluates 
the efficacy of long-term doxycycline and of cognitive behavioral therapy in patients with 
QFS. The results of this study will provide knowledge about evidence-based treatment 
options for adult patients with QFS.
Trial registration: ClinicalTrials.gov: NCT01318356, and Netherlands Trial Register: NTR2797.
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INTRODUCTION
Q fever, a zoonosis caused by Coxiella burnetii, has been present all over the world for 
many years [1]. Between 2007 and 2010, the south-eastern part of the Netherlands has 
faced the largest outbreak of Q fever ever reported. To date, more than 4000 people have 
developed symptomatic disease [2], and at least up to 44,000 are estimated to have been 
infected [3, 4]. In recent years, several studies have described the sequelae of Q fever. Acute 
Q fever is followed by a chronic infection in 1-5% of cases [5-7]. In addition, following acute 
Q fever, patients frequently report long-lasting fatigue, which often persists for more than 
six months [8-10]. After an outbreak of Q fever in the UK, 10 years of follow-up revealed 
a high percentage of persisting fatigue, with almost 20% of patients fulfilling the Centre 
for Disease Control (CDC) criteria of chronic fatigue syndrome, compared to 4% in healthy 
controls [11]. A study among abattoir employees in Australia showed that 28% of patients 
with proven acute Q fever fulfilled the CDC criteria of chronic fatigue syndrome five years 
after the infection compared to none of the seronegative controls [10]. A recent study 
carried out in the Netherlands among 85 patients with acute Q fever found that 59% of 
patients had persistent symptoms at six months after disease onset, with fatigue being the 
most prevalent complaint in 52% of patients. Furthermore, over 25% still had complaints 
after one year [12]. Another recent survey in the Netherlands among 515 patients with Q 
fever found that 20% had severe fatigue and an impaired health status at 12–26 months 
of follow-up [13]. This fatigue following acute Q fever, sometimes accompanied by several 
other complaints, has been designated Q fever fatigue syndrome (QFS) [14-16]. According 
to the recently published Dutch algorithm on QFS [14], the diagnosis of QFS can be made 
after a uniform diagnostic work-up. There has to be a severe fatigue, which lasts for at least 
six months and has a reference to an acute Q fever infection. There must be an absence of 
fatigue before the episode of acute Q fever or a significant increase in fatigue since the acute 
Q fever infection. Furthermore, it is causing significant disabilities in daily practice. Finally, 
chronic Q fever and other causes of fatigue, somatic or psychiatric, need to be excluded.
In the Netherlands, QFS resulted in a large incurred loss due to loss of quality of life and 
health-related absenteeism in the past few years [17]. Currently, extrapolating the present 
data, at least 800 patients suffer from QFS in the Netherlands. It is expected that Q fever will 
remain an endemic disease, leading to a further increase in patients with QFS, stressing the 
need for further research into treatment regimens for QFS.
Both acute and chronic Q fever have been extensively studied in recent years; however, 
less attention has been given to QFS. Although QFS is a well-documented finding and has 
already been described in 1996 [8, 10], at present there is no consensus on the pathogenetic 
process underlying QFS [15, 18, 19]. In QFS, as in chronic fatigue syndrome, persistence 
of live microbes has been suggested [19]. Furthermore, it is still unclear whether effective 
treatment for QFS is possible. So far, few studies on the effect of treatment with antibiotics 
on fatigue after Q fever have been done. The available studies suggest a positive effect 
of long-term treatment with a tetracycline on performance status [20-22]; however, these 
studies suffer from several limitations. So far, no controlled trials have been performed and 
the above long-term treatment is currently not often used in clinical care of patients with 
QFS. Previously, it has been shown in patients with chronic fatigue syndrome (CFS) that 
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fatigue-related cognitions and behavior can maintain chronic fatigue [23-26]. CBT for chronic 
fatigue is aimed at these fatigue-related cognitions and behavior thought to perpetuate the 
symptoms. Several systematic reviews and meta-analyses demonstrated that CBT for CFS 
is able to reduce symptoms and to improve function in patients with CFS [26-28]. To date, 
the efficacy of CBT has not been studied in patients with QFS. However, our recent clinical 
experience with this treatment modality in a small cohort of QFS patients shows promising 
results.
The primary aim of our study is to determine the effect of different treatment modalities 
which have been suggested to be effective for patients with QFS. In this paper we describe 
the protocol to assess the efficacy of two treatment strategies for QFS: long-term treatment 
with either doxycycline or CBT.
METHODS/DESIGN
Study design
A randomized placebo-controlled trial (RCT), the Qure study, will be performed to determine 
whether long-term treatment with doxycycline or CBT will lead to a reduction of fatigue and 
disabilities in patients with QFS. Both treatment modalities will be compared to a placebo 
group. This study will be performed in the Radboud University Nijmegen Medical Centre 
in the Q fever outpatient clinic of the department of Internal Medicine, and in the Expert 
Centre for Chronic Fatigue (ECCF). QFS will be diagnosed at the Q fever outpatient clinic 
after a uniform diagnostic work-up according to the Dutch algorithm on QFS. Once the 
diagnosis is established, study eligibility will be assessed by the first author (SPK) according 
to specific inclusion and exclusion criteria (Tables 1 and 2). Eligible patients will be asked 
to participate in the Qure study after receiving verbal and written information about the 
study. If patients are willing to participate, written informed consent will be obtained. After 
inclusion, an individual study code is allocated to the participants. Results from the clinical 
assessment before inclusion will be used as baseline measures as well. If patients decide 
not to participate in this study, an attempt will be made to elucidate the reason for this, but 
patients are not obligated to motivate their refusal.
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Table 1: Inclusion criteria
Inclusion criteria*
(1) Males or non-pregnant, non-lactating females who are 18 years or older
(2) Laboratory-proven acute Q fever since the year 2007 and/or positive serology fitting a past 
infection with Coxiella burnetii
(3) AND being severely fatigued, defined by scoring ≥ 35 on the subscale fatigue severity of the 
CIS
(4) AND being fatigued for at least 6 months
(5) AND being disabled because of the fatigue, defined by scoring 450 or higher on the SIP
(6) Subjects must sign a written informed consent form
* All participants have to meet the criteria for QFS according to the recently published Dutch 
algorithm on QFS [14]. In addition to the mentioned inclusion criteria and according to the Dutch 
algorithm on QFS, there has to be a severe fatigue with a reference to an acute Q fever infection. 
Furthermore, there must be an absence of fatigue before the episode of acute Q fever or a 
significant increase in fatigue since the acute Q fever infection.
Abbreviations: CIS = Checklist Individual Strength questionnaire, SIP = Sickness Impact Profile 
questionnaire.
Study population
It is intended to include 180 patients diagnosed with QFS, equally randomized between 
three different treatment modalities, namely long-term doxycycline (n=60), CBT (n=60) 
or placebo (n=60). All eligible patients directly referred to Radboud University Nijmegen 
Medical Centre will be asked to participate in this study. Patients with a suspicion of QFS 
presenting to other hospitals in the area will be referred to the Q fever outpatient clinic of 
the Radboud University Nijmegen Medical Centre for screening and enrollment in the study. 
In addition, all physicians working at specific Q fever outpatient clinics in other hospitals will 
be informed about the study. Patients connected to Q-uestion, a foundation for patients 
with Q fever, will be informed about the Qure study by newsletters, and a brief description 
will be available at the website of Q-uestion. Furthermore, patients who participated in 
previous studies on Q fever in the past few years (Q-Quest II study, ZonMw dossier number:
204004003, and The PrediQt study, ZonMw dossier number: 205520003, NL36477.091.11), 
will be informed about the Qure study by letter. Finally, all general practitioners in the 
endemic Q fever region will be informed about this study by letter.
Ethical approval
According to the Dutch law, this study has been reviewed and approved by the Medical 
Ethical Review Committee of the Radboud University Nijmegen Medical Centre (registration 
number 2011/069, NL35755.091.11). This study will be conducted according to the principles 
of the Declaration of Helsinki. The inclusion of patients started in May 2011.
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Table 2: Exclusion criteria
Exclusion criteria
(1) Fulfilling criteria for chronic Q fever*
(2) Acute Q fever in the setting of a prosthetic cardiac valve or aneurysm surgery or stenting, 
necessitating prophylactic use of doxycycline
(3) Pregnancy or unwillingness to use effective contraceptives during the entire study period
(4) Imminent death
(5) Inability to give informed consent
(6) Allergy or intolerance to doxycycline
(7) Somatic or psychiatric illness that could explain the chronic fatigue
(8) Subjects who are currently enrolled in other investigational drug trials or receiving 
investigational agents
(9) Receiving or having received antibiotics for > 4 weeks, potentially active against Coxiella 
burnetii, for any other reason since Q fever diagnosis
(10) Subjects who are receiving and cannot discontinue barbiturates, phenytoin, or 
carbamazepine**
(11) Moderate or severe liver disease (AF, ALT, AST > 3 times the upper limit of normal)
(12) Current engagement in a legal procedure concerning financial benefits#
* According to the guideline chronic Q fever from the Dutch Q fever consensus group [29].
** These drugs may increase the metabolism of doxycycline; consequently, reducing the half-life 
of doxycycline.
# Temporary exclusion criterion, while current involvement interferes with the effectivity of 
cognitive behavioral therapy [30]. Once the appeal procedure ends, subjects can be included.
Abbreviations: AF = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate 
aminotransferase.
Baseline assessment
After inclusion, participants will first visit the ECCF for the baseline assessment, including 
questionnaires and measurement with an actometer (see figure 1). An actometer is a 
motion-sensing device worn at the ankle that registers and quantifies physical activity. The 
actometer has a piezoelectric sensor that is sensitive in three directions. Accelerations of 
the built-in sensor larger than a predefined threshold are considered as activity and are 
stored in an internal memory every 5 minutes. It is worn day and night during a period of 
twelve consecutive days [31]. A general physical activity score that expressed the mean 
activity level over this period in the mean number of accelerations per 5 minute interval will 
be calculated. During the period of twelve days participants rate fatigue, pain, and activity 
levels on a pre-scheduled Self-Observation List four times daily on a scale of 0 (not at all) to 
4 (very much).
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Figure	1:	Flowchart	of	trial	design.		
*	According	to	the	Dutch	guideline	Q	fever	fatigue	syndrome	[14].	Including	questionnaires:	general	questionnaire,	CIS,	SIP	
total	score.		
**	General	questionnaire,	PARS,	SES28,	IMQ,	CBRSQ,	JFCS,	CAL,	and	SCL90.		
#	Questionnaires	used	for	mediation	analysis:	PARS,	SES28,	IMQ,	CBRSQ,	and	CIS.		
¥	Exclusion	criteria:	pregnancy;	serious	adverse	events;	AST/ALT	>5	times	normal	value;	AF	>3	times	normal	value;	>10	days	
use	of	quinolon,	co-trimoxazol,	macroliden	or	tetracycline;	or	discontinuation	of	study	medication	>7	consecutive	days.		
^	CIS,	PARS,	IMQ,	JFCS,	SIP,	SES28,	CBRSQ,	and	SCL90.		
Abbreviations:	CIS	=	Checklist	Individual	Strength,	SIP	=	Sickness	Impact	Profile,	ECCF	=	Expert	Centre	for	Chronic	Fatigue,	
PARS	=	Physical	Activity	Rating,	SES28	=	Self	Efficacy	Scale,	IMQ	=	Symptom	focusing	of	the	illness	Management	
Questionnaire,	CBRSQ	=	Cognitive	and	Behavioral	Responses	to	Symptoms	Questionnaire,	JFCS	=	Jacobson	Fatigue	
Catastrophising	Scale,	CAL	=	Causal	Attribution	List,	SCL90	=	Symptom	Checklist	90,	CBT	=	cognitive	behavioral	therapy,	AST	
=	aspartate	aminotransferase,	ALT	=	alanine	aminotransferase,	AF	=	alkaline	phosphatase.	
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Figure 1: Flowchart of trial design. 
* According to the Dutch guideline Q fever fatigue syndrome [14]. Including questionnaires: general 
questionnaire, CIS, SIP total score. 
** General questionnaire, PARS, SES28, IMQ, CBRSQ, JFCS, CAL, and SCL90. 
# Questionnaires used for mediation analysis: PARS, SES28, IMQ, CBRSQ, and CIS. 
¥ Exclusion criteria: pregnancy; serious adverse events; AST/ALT >5 times normal value; AF >3 times 
normal value; >10 days use of quinolon, co-trimoxazol, macroliden or tetracycline; or discontinuation 
of study medication >7 consecutive days. 
^ CIS, PARS, IMQ, JFCS, SIP, SES28, CBRSQ, and SCL90. 
Abbreviations: CIS = Checklist Individual Strength, SIP = Sickness Impact Profile, ECCF = Expert Centre 
for Chronic Fatigue, PARS = Physical Activity Rating, SES28 = Self Efficacy Scale, IMQ = Symptom 
focusing of the illness Management Questionnaire, CBRSQ = Cognitive and Behavioral Responses to 
Symptoms Questionnaire, JFCS = Jacobson Fatigue Catastrophising Scale, CAL = Causal Attribution List, 
SCL90 = Symptom Checklist 90, CBT = cognitive behavioral therapy, AST = aspartate aminotransferase, 
ALT = alanine aminotransferase, AF = alkaline phosphatase. 
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Randomization procedure and blinding
The randomization order is created by an independent biostatistician using block-
randomization. An administrative assistant with no affiliation to the project group made 
envelopes for individual study codes ranging from 1–180, according to the Figure 1: 
randomization list. At the end of the first visit to the ECCF, participants receive their 
envelope (which contains a corresponding number coherent to the individual study 
code) from the psychological assistant, to see to which treatment they are randomized. 
First, participants will be randomized between CBT and medication (ratio 1:2). Secondly, 
double-blinded randomization between doxycycline treatment or placebo (ratio 1:1) will 
be performed within the medication condition by the study pharmacist (department of 
Clinical Pharmacy, Radboud University Nijmegen Medical Centre). The double-blinded 
randomization assignment will be known to the study pharmacist only, and is available 
in a sealed envelope stored at the pharmacist’s office for emergency use. If the code is 
broken, it will render the participant not eligible. The first randomization list and second 
double-blinded randomization list will be made available respectively by the independent 
biostatistician and the study pharmacist to the principal investigator when the entire study 
is completed. Obviously, allocation to the CBT intervention cannot be blinded.
Interventions
Study medication
Preparation and labeling of doxycycline and placebo will be performed by the Clinical Trials 
Unit department of the Clinical Pharmacy of the Radboud University Nijmegen Medical 
Centre, and will be done according to the relevant Good Manufacturing Practice (GMP) 
guidelines. Study medication will be prepared as capsules with identical appearance. 
Participants allocated to study medication will be treated at the Q fever outpatient clinic. 
Participants will receive either doxycycline (200 mg once daily) or placebo (once daily), 
both orally administered, for a period of 24 weeks. Study medication will be provided by 
the first author (SPK). For safety considerations all participants in the medication condition 
will visit the Q fever outpatient clinic 4, 8, and 16 weeks after start of the treatment (see 
figure 1). Furthermore, liver enzymes will be checked, and drug utilization will be recorded. 
Therefore, patients are required to bring the study medication to all visits. In addition, blood 
samples drawn 8 weeks after start of treatment will be stored by the study pharmacist, 
who performed the double-blinded randomization. Eventually, doxycycline levels will only 
be determined in participants receiving doxycycline, and results will be kept secret until 
the entire study is completed. After completion, it is known whether doxycycline levels 
were sufficient to sort out effect [32]. Participants will be excluded in case of: serious side 
effects; aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels more than 
5 times the upper limit of normal; alkaline phosphatase (AF) levels more than 3 times the 
upper limit of normal; more than 10 days use of antibiotics potentially active against C. 
burnetii (co-trimoxazol, quinolon, macrolides or tetracyclines); or discontinuation of study 
medication for more than 7 consecutive days.
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Cognitive behavioral therapy
CBT for QFS is aimed at changing the beliefs and behaviors assumed to maintain fatigue. On 
average, CBT consists of 12–14 sessions over a period of 24 weeks, and is individually delivered 
by trained cognitive-behavioral therapists from the ECCF, according to a written treatment 
manual. The treatment is based on CBT for CFS [33]. First, the model of fatigue perpetuating 
beliefs and behaviors is explained to patients. At the start of the therapy patients formulate 
their goals in behavioral terms. These goals usually include the resumption of work, hobbies, 
and other activities that imply that the patient is no longer severely fatigued and disabled, 
which is the goal of CBT for QFS. Patients regulate their bedtimes and stop sleeping during 
the day in order to stop possible disruption of the circadian rhythm. During the sessions, 
the therapist elicits and challenges patients’ non-accepting and catastrophising beliefs 
with respect to fatigue. Additionally, patients are taught how to distract their attention 
from their fatigue. Two groups of patients are discerned: relatively active patients, who are 
characterized by bursts of activity followed by periods of relative inactivity, and low active 
patients, who have extremely low activity levels on most days [31]. Relatively active patients 
first learn how to divide their activities more evenly across the day. Low active patients 
start with a graded activity program immediately after the initial cognitive interventions. 
This activity program consists of daily walking or cycling, which is gradually increased. The 
increase in activity is not determined by the level of symptoms, but is time contingent. When 
patients succeed in increasing their physical activity, they also start to increase their social 
and mental activities. In the last phase of therapy, patients work systematically towards 
reaching their goals, which are formulated at the start of the therapy. Following this, they 
are encouraged to perceive feelings of fatigue as a normal part of an active and healthy life.
Post intervention
Twenty-four weeks after start of treatment, all participants visit the ECCF for the end-of-
therapy study visit, including assessment of the outcome measures (see figure 1). Twenty-six 
weeks after start of treatment, participants visit the Q fever outpatient clinic for the end-of- 
study visit. During this end-of-study visit, C. burnetii serology and PCR will be determined.
Outcome measures
The primary outcome measure is the fatigue severity measured by the subscale fatigue 
severity (8 items, 7-point Likert Scale) of the Checklist Individual Strength (CIS questionnaire) 
[34] with a severity range from 8–56. High scores indicate a high level of fatigue. Patients 
with a cut-off score of ≥35 are classified as severely fatigued. This questionnaire has excellent 
psychometric properties, including good reliability and discriminative validity [35, 36].
Secondary outcome measures are:
(1) Level of functional impairment measured with the Sickness Impact Profile (SIP) [37, 
38]. The SIP is an instrument that is used to gauge sickness-related dysfunction. The 
weighted total score on eight sub-scales of the SIP8 (SIP8 total score) will be used to 
assess functional disability in all domains of functioning. This instrument is reliable with 
sufficient content validity, and it shows good correlations with other health status and 
functional status measures [39].
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(2) Level of psychological distress measured with the total score of the Symptom Checklist 
90 (SCL90). The SCL90 consist of 90 items scored on a five-point scale. Scores range from 
90–450. A low total score reflects psychological well-being. The SCL-90 is a reliable and 
valid instrument [40].
(3) C. burnetii serology (immunofluorescence assay; Focus Diagnostics, Inc., Cypress, CA, 
USA) and serum PCR.
Other study parameters will be: demographic data; data on symptoms, diagnosis and 
treatment of acute Q fever; previous history; serology results performed before inclusion 
in the study; use of medication, smoking, and the use of alcohol or drugs; and data on self 
reported symptoms, disabilities, and behavioral factors.
Mediation analysis
Testing mediation is a strategy to identify variables that intervene in the relationship 
between treatment and outcome. Mediation analysis can help to better understand how 
treatment works [41]. To assess a change in variables that might affect fatigue severity, 
possible mediators and fatigue severity will be assessed at baseline, eight weeks after 
start of treatment, and at end of therapy in all treatment modalities (see figure 1). The 
proposed mediators are fatigue related cognitions and behaviors. Four instruments will be 
used to assess the mediators: 1) Subscales ‘resting/avoidance’, ‘all-or-nothing’ behavior, 
and ‘catastrophising’ of the Cognitive Behavioral Responses to Symptoms Questionnaire 
(CBRSQ) [42], 2) Subscale focusing on symptoms of the Illness Management Questionnaire 
(IMQ) [43, 44], 3) Total score on the Physical Activity Rating Scale (PARS, measuring the level 
of confidence and expectation on fatigue performing 16 different activities, rated on a five-
point scale), and 4) Total score on the Self Efficacy Scale (SES28) [45].
Withdrawal of individual participants
Participants are informed that they can stop participating in the study at any time, without 
consequences. Although participants will be asked for the reason for discontinuation, 
giving a reason for withdrawal is not obligatory. The investigator can decide to withdraw 
a participant from the study in case of medical urgency. In addition, study medication will 
be stopped in case of pregnancy, and the participant will be withdrawn. According to the 
Intention To Treat (ITT) principle the analysis will be based on the initial treatment intent. 
Therefore, in case of discontinuation, all efforts will be made to complete and report the 
observations as thoroughly as possible. A complete final evaluation in accordance to the 
study protocol end-of-therapy study visit will be performed if the withdrawn participant 
agrees. Because of absence of an evidence-based treatment for QFS, other treatment 
options for QFS in regular health care for withdrawn participants in the CBT group are not 
available. Long-term doxycycline treatment is not offered, because of possible (serious) 
side-effects and a lack of evidence so far.
Adverse events
Adverse events are defined as any undesirable experience occurring to a subject during 
the study, whether or not considered related to the experimental treatment. All adverse 
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events in the medication condition will be recorded during the pre-scheduled controls 
at the outpatient clinic, and, if applicable, during the trial if spontaneously reported by 
the participant. The most frequent side-effects of doxycycline include gastrointestinal 
complaints, like nausea and diarrhea, and photo-sensibilisation. Other side-effects are 
rare. The drug should not be given to children and to pregnant women. This RCT involves 
a non-critical indication for the use of doxycycline, and the drug under investigation is well 
characterised and commonly used in daily practice. Even though the delivery of CBT to adults 
is considered safe [46, 47], all adverse events reported spontaneously by the participant or 
observed by the therapist will be recorded by the psychological assistant at pre-scheduled 
time-points during the therapy (8 weeks after the start of therapy, and 24 weeks after start 
of therapy). All adverse events will be followed until they have abated, or until a stable 
situation has been reached. If applicable, serious adverse events in both groups will be 
reported according to the principles of Good Clinical Practice (GCP).
Statistical analysis
The primary analysis will be the comparison between the experimental groups (CBT or 
doxycycline) and the placebo group. ITT will be the basis for all analysis. The primary analysis 
will be done on the data of completers. Completers are all participants who completed 
the post intervention measurements. When statistical significant differences are found, a 
sensitivity analysis will be performed on the basis of different assumptions about the values 
of missing data. To determine if there is a significant difference between the intervention 
arm and placebo condition, ANCOVA will be used with the outcome measure on the second 
assessment as dependent measure, the baseline score as covariate, and condition as fixed 
factor. A priori contrasts will be defined for the factor condition comparing CBT versus 
placebo, and comparing doxycycline versus placebo. For the secondary outcome measures, 
namely psychological distress and functional limitations, the same analysis will be repeated, 
but with the secondary outcome measures at the second assessment as dependent variable, 
and the scores at baseline as covariate. In this kind of trials ANCOVA yields greater power 
than other statistical methods [48]. Statistical significance will be assumed at p<0.05 in all 
analysis. Data will be presented as quantitative results.
Power calculation
The power calculation is based on the estimated maximal number of eligible patients who 
will be available for the study. In the Netherlands there has been only one major outbreak of 
Q fever. Since then, the number of new cases is limited. Furthermore, following the outbreak 
several studies investigating the symptoms following Q fever are ongoing which limits the 
number of eligible patients that will be available to enter the present study. The maximal 
number of available patients is estimated to be 180, 60 patients for each arm of the study. 
We assumed a drop-out rate of 20 percent, leaving a sample size for the power calculation 
of 50 participants per arm. Compared to a t-test, using ANCOVA increases statistical power. 
The sample size of 50 can be divided by a design factor of 0.884 (1–0.342), with 0.34 being 
the correlation between the CIS fatigue severity at baseline and second assessment [49]. 
The required effect size was estimated using G-Power 3.1.5. based on a sample size of 
164 | CHAPTER 5
56, a power of 0.80 and an alpha of 0.05. The analysis showed that we need to assume 
a moderate controlled effect size of 0.53 to obtain a power of 0.8 for demonstrating a 
significant difference between the results in the treatment groups and in the placebo group.
DISCUSSION
The Qure study will be the first randomized placebo-controlled clinical trial to assess the 
efficacy of long-term treatment with doxycycline and CBT in adult patients with QFS. A limited 
amount of previous uncontrolled studies suggest a positive effect of long-term treatment 
with a tetracycline on performance state. The result of one study shows improvement in 
symptoms, including fatigue, in all patients after 3 months of treatment. However, not all 
patients met the current criteria for QFS, whereas 7 patients were PCR positive, meeting 
the current criteria for chronic Q fever [20]. Furthermore, patients were included with 
complaints lasting for only 3 months, whereas chances for spontaneous recovery are high in 
the first 6 months after the initial infection. The other study, primarily focussing on the role of 
C. burnetii in CFS, reports improvement in performance status, a decreased mean headache 
score, and a decrease in mean weekly temperature after treatment [21]. However, of the 
54 patients included, 34 patients were PCR positive at baseline, suggesting chronic Q fever. 
Furthermore, patients were included with complaints lasting for only 1 month. Therefore, 
these results cannot be extrapolated, and this long-term treatment is currently not often 
used in clinical care of patients with QFS. Furthermore, the efficacy of CBT in patients with 
QFS has not been evaluated in a randomized design. Currently, the decision whether or not 
to treat is made arbitrarily, as evidence-based strategies are lacking. The Dutch outbreak 
offers us a great and maybe the only opportunity to conduct research on the best treatment 
of QFS. 
In conclusion, the Qure study will provide greater insight into effectiveness of treatment 
options for adult patients with QFS. If an effective treatment modality for QFS will be 
found, significant benefit can be achieved in quality of life, efficiency in treatment and 
cost-effectiveness. Furthermore, this study will possibly contribute to the establishment of 
evidence-based guidelines for the treatment of QFS.
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ABSTRACT
Background: Approximately 20% of patients with acute Q fever will develop chronic fatigue, 
referred to as Q fever fatigue syndrome (QFS). The objective of this randomized controlled 
clinical trial was to assess the efficacy of either long-term treatment with doxycycline or 
cognitive-behavioral therapy (CBT) in reducing fatigue severity in patients with QFS.
Methods: Adult patients were included who met the QFS criteria according to the Dutch 
guideline: a new onset of severe fatigue lasting ≥6 months with significant disabilities, 
related to an acute Q fever infection, without other somatic or psychiatric comorbidity 
explaining the fatigue. Using block randomization, patients were randomized between oral 
study medication and CBT (2:1) for 24 weeks. Second, a double-blind randomization between 
doxycycline (200 mg/day, once daily) and placebo was performed in the medication group. 
Primary outcome was fatigue severity at end of treatment (EOT; week 26), assessed with the 
Checklist Individual Strength subscale Fatigue Severity.
Results: Of 155 patients randomized, 154 were included in the intention-to-treat analysis 
(doxycycline, 52; placebo, 52; CBT, 50). At EOT, fatigue severity was similar between 
doxycycline (40.8 [95% confidence interval {CI}, 37.3–44.3]) and placebo (37.8 [95% CI, 
34.3–41.2]; difference, doxycycline vs placebo, −3.0 [97.5% CI, −8.7 to 2.6]; P = .45). Fatigue 
severity was significantly lower after CBT (31.6 [95% CI, 28.0–35.1]) than after placebo 
(difference, CBT vs placebo, 6.2 [97.5% CI, .5–11.9]; P = .03).
Conclusions: CBT is effective in reducing fatigue severity in QFS patients. Long-term 
treatment with doxycycline does not reduce fatigue severity in QFS patients compared to 
placebo.
Clinical Trials Registration: NCT01318356, and Netherlands Trial Register: NTR2797.
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INTRODUCTION
Q fever, caused by the gram-negative intracellular coccobacillus Coxiella burnetii, is notorious 
for long-term sequelae. Besides chronic Q fever (ie, persistent C. burnetii infection), which 
occurs in 1%–5% of cases [1], a debilitating fatigue syndrome has been described [2–11]. This 
Q fever fatigue syndrome (QFS) persists for years in approximately 20% of cases following 
acute Q fever [2–6, 9–11]. Many QFS patients fulfill the case definition of chronic fatigue 
syndrome (CFS) [2, 8, 10, 12]. QFS has major health impacts with severe fatigue, substantial 
disabilities, and reduced quality of life [8, 11, 13–15]. Following the largest Q fever outbreak 
ever reported [1], which occurred in the Netherlands with >4000 notified patients, the need 
for an evidence-based treatment regimen increased. The large number of QFS patients had 
major economical consequences [16]. The pathophysiology of QFS remains to be elucidated, 
hampering treatment based on etiology.
Long-term treatment with tetracyclines has been reported to improve performance status 
and reduce fatigue in QFS [4, 17], but subsequent reports have been conflicting [5, 18]. 
No randomized controlled trials (RCTs) have been performed, and available studies all have 
major limitations, precluding extrapolation of these results. Cognitive-behavioral therapy 
(CBT), aimed at fatigue-related cognitions and behavior thought to perpetuate symptoms, 
can reduce symptoms and improve functioning in CFS [19]. A considerable overlap in 
fatigue-perpetuating factors between QFS and CFS implies that CBT might also reduce 
fatigue severity in QFS [12].
We performed an RCT (the Qure study) to assess the efficacy of long-term treatment with 
either doxycycline or CBT in patients with QFS.
METHODS
Study Design, Setting, and Participants
The trial was approved by the Medical Ethical Review Committee region Arnhem-Nijmegen 
(2011/069, NL35755.091.11) and conducted in compliance with the most recent provisions 
of the Declaration of Helsinki, the International Conference on Harmonisation guidelines on 
Good Clinical Practice, and appropriate regulatory requirements. The trial was performed 
at 2 sites of the Radboud university medical center (Radboudumc): the Radboud Expertise 
Center for Q fever and the Expert Center for Chronic Fatigue (ECCF). The study protocol has 
been published [20]. This trial was overseen by an independent monitor.
All men and nonpregnant, nonlactating women, aged ≥18 years suspected of Q fever-
related fatigue were screened for QFS, using standard clinical and laboratory protocols. 
Eligibility was assessed according to previously described inclusion and exclusion criteria 
(Supplementary Table 1) [20]. QFS was defined as severe fatigue (score ≥35 on the Checklist 
Individual Strength [CIS] subscale Fatigue Severity) for ≥6 months, causing significant 
disabilities (score ≥450 on the Sickness Impact Profile [SIP8]) in daily functioning, not being 
caused by chronic Q fever or other somatic or psychiatric morbidity, directly related to an 
acute Q fever infection, and the fatigue should have been either absent before or have 
significantly increased since the acute Q fever infection. Chronic Q fever was excluded based 
on negative serum polymerase chain reaction (PCR), Q fever serology (immunoglobulin G 
phase I titers <1:1024), and absence of signs of endocarditis or vascular infection.All enrolled 
patients provided written informed consent.
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Randomization and Blinding
Patients were randomly assigned to receive either study medication or CBT (2:1 ratio). 
Second, a double-blind randomization was performed within the medication group, 
allocating patients to doxycycline or placebo (1:1 ratio). The randomization sequence 
was computer-generated using block randomization, performed by an independent 
biostatistician. Allocation concealment was achieved by sealed opaque envelopes with 
individual codes according to the randomization list, made by an administrative assistant with 
no affiliation to the project group. The double-blind randomization within the medication 
condition was performed by the pharmacist. The first randomization list and the double-
blind randomization list were made available by the independent biostatistician and the 
study pharmacist, respectively, to the principal investigator after completion of the study. 
All trial-related personnel, except the study pharmacist, and participants were masked with 
regard to the medication group. Allocation to CBT was not blinded.
Interventions
Patients in the medication group were treated with doxycycline 200 mg or placebo, both 
orally administered once daily, for 24 weeks. Study medication was prepared and labeled 
by the Clinical Trials Unit department of the Clinical Pharmacy of Radboudumc, according 
to Good Manufacturing Practice guidelines. Doxycycline was reencapsulated and placebo 
was prepared as capsules with identical appearance. Study visits were at 4, 8, and 16 weeks 
after start of treatment, including medical history, physical examination, and laboratory 
investigation. Patients were excluded if they met the exclusion criteria during treatment 
with medication (Supplementary Table 2) [20]. Compliance was verified by pill counting. 
Patients allocated to CBT received approximately 24 weeks of individual CBT, based on the 
manual of CBT for CFS [20, 21], by trained and supervised cognitive-behavioral therapists 
[20]. Treatment frequency was determined on individual basis, with intended sessions once 
every 2 weeks. Details of the assessments per visit have been published [20].
Outcomes
Outcomes were assessed by self-completed questionnaires and laboratory investigation at 
baseline, 26 weeks (end of treatment period [EOT]), and 28 weeks (end of study [EOS]). The 
primary outcome measure was fatigue severity at EOT, measured by the CIS subscale Fatigue 
Severity [22], with a cutoff score of ≥35 as classification for severe fatigue. Clinical meaningful 
improvement, taking into account whether the magnitude of change on the CIS subscale 
Fatigue Severity is clinically relevant, was defined as a reliable change index (RCI) × 1.96 
plus a CIS Fatigue Severity score of <35 [23]. The RCI was calculated based on the standard 
deviation of the baseline CIS fatigue score with 0.88 as reliability factor [22]. Secondary 
outcomes were level of functional impairment at EOT, measured with weighted total score 
on 8 subscales of the SIP8 with a cutoff score of ≥450 indicating significant disabilities [24], 
the level of psychological distress at EOT, measured with the total score of the Symptom 
Checklist 90 (SCL-90) with a low total score reflecting psychological well-being [25], and C. 
burnetii serology (immunofluorescence assay; Focus Diagnostics, Cypress, California) and 
serum PCR (in-house, real-time PCR directed against insertion sequence IS1111a) at EOS.
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Adverse Events
Safety was assessed by monitoring adverse events (AEs) and concomitant drug use. AEs 
in the medication condition were recorded during the prescheduled study visits, and, if 
applicable, during the trial when reported by the patient. For patients allocated to CBT, AEs 
were monitored at 8 weeks after start of therapy and at EOT.
Statistical Analysis
Following the Dutch Q fever outbreak, the number of new cases decreased drastically and 
several studies concurrently investigated health-related aspects following acute Q fever, 
limiting the number of eligible patients. Because there were only a limited number of 
patients available for participation, a traditional power analysis was not possible. Instead, 
we performed an analysis to estimate the effect size that has to be assumed for a power 
of 80%. The maximum number of available patients was estimated as 180 (60 patients 
per arm). Assuming a 20% dropout rate, this left a sample size of 50 patients per arm. 
This sample size was divided by a design factor of 0.884 (1–0.342), with 0.34 being the 
correlation between fatigue severity at baseline and EOT [26], leaving a sample size of 56. 
Using G*Power software (version 3.1.5) based on a sample size of 56, a power of 0.80, and 
an α of .05, a moderate effect size of 0.53 needed to be assumed to obtain a power of 0.8 
for demonstrating a significant difference.
Primary analyses were performed on the data of all participants who completed the 
postintervention measurements, irrespective of whether or not they completed the 
treatment: intention-to-treat was the basis for all analyses. In the primary analysis, each of 
the experimental groups (doxycycline and CBT) was compared to the placebo group at EOT 
using analysis of covariance with the EOT CIS fatigue score as dependent measure, baseline 
CIS fatigue score as covariate, and the condition as fixed factor. For the secondary outcome 
measures, the same analysis was repeated but with the EOT secondary outcome measures 
as dependent variable and scores at baseline as covariate. No interim analyses were 
undertaken. Two-sided 5% significance levels were used. Because primary and secondary 
analyses entailed 2 separate hypotheses, Bonferroni correction was used, which means 
that reported P values are twice the P values found in the analyses. Also, when reporting 
estimated effects, 97.5% confidence intervals (CIs) were used. Statistical analyses were 
performed blinded for group allocation, using SPSS version 22 and SAS version 9.2 software.
RESULTS
Figure 1 shows the trial profile. In total, 438 patients with suspected QFS were screened for 
eligibility. The most prevalent reason for ineligibility was another cause for the fatigue. Of 
the 221 patients meeting the QFS criteria, 21 were not eligible for study participation and 
44 refused participation (22%). Between May 2011 and January 2015, 156 patients signed 
informed consent and were randomized; of these, 155 started treatment, either doxycycline 
(n = 52), placebo (n = 52), or CBT (n = 51). One patient refused double-blind randomization 
after allocation to the medication group, and received no treatment. There were no significant 
baseline differences between the treatment groups (Table 1; Supplementary Table 3). The 
intention-to-treat analysis included 154 patients. There was a median of 1.0 pill left at EOT in 
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Figure	1.	Trial	profile.	Primary	analyses	were	based	on	intention-to-treat	and	included	the	data	of	all	patients	who	
completed	the	end	of	treatment	(EOT)	and	end	of	study	(EOS)	assessments.	*As	described	in	the	study	protocol	[20],	
including	a	cutoff	score	of	≥35	on	the	Checklist	Individual	Strength	subscale	Fatigue	Severity,	and	a	cutoff	score	of	≥450	on	
the	Sickness	Impact	Profile	8	total	score	to	classify	severe	fatigue	and	substantial	fatigue-related	disabilities.	†Leading	to	
discontinuation	of	study	medication	for	>7	consecutive	days.	‡Use	of	ciprofloxacin	of	14	days	because	of	prostatitis.	
Abbreviations:	CBT,	cognitive-behavioral	therapy;	EOS,	end	of	study;	EOT,	end	of	treatment;	QFS,	Q	fever	fatigue	syndrome;	
SIP8,	Sickness	Impact	Profile.	
 
	
	 	
Figure 1. Trial profile. Primary analyses were based on intention-to-treat and included the data of all 
patients who completed the end of treatment (EOT) and end of study (EOS) assessments. 
*As described in the study pr tocol [20], including a cutoff score of ≥35 on the Checklist Individual 
Strength subs ale Fatigue Severity, and a cutoff score of ≥450 on the Sickness Impact Profile 8 total 
score to classify severe fatigue and substantial fatigue-related disabilities. †Leading to discontinuation 
of study medication for >7 consecutive days. ‡Use of ciprofloxacin of 14 days because of prostatitis.
Abbreviations: CBT, cognitive-behavioral therapy; EOS, end of study; EOT, end of treatment; QFS, Q 
fever fatigue syndrome; SIP8, Sickness Impact Profile.
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both the doxycycline and placebo groups. In the CBT group, patients received a median of 9 
sessions (interquartile range, 7.50–11.25). Treatment was completed by 142 patients (92%): 
doxycycline, 49 (94%); placebo, 50 (96%); and CBT, 43 (84%). During CBT, 1 patient withdrew 
informed consent, and the other 7 patients discontinued treatment because they could not 
adhere to the therapy for various reasons.
Table 1. Baseline Characteristics of All Included Patients with Q Fever Fatigue Syndromea
Characteristic Doxycycline
(n=52)
Placebo
(n=52)
CBT
(n=51)
Female sex, No. (%) 29 (56) 20 (38) 25 (49)
Age, y, mean ± SD
Duration of symptoms, mo
43.6 ± 10.2 44.6 ± 12.3 43.3 ± 13.7
     Median 36.00 37.50 40.00
     Interquartile range 24.25 – 57.00 25.50 – 50.75 22.00 – 59.00
CIS subscale Fatigue Severity, mean ± SD 51.4 ± 4.7 50.2 ± 4.8 49.7 ± 4.7
SIP8 total score, mean ± SD 1304.9 ± 537.7 1295.1 ± 593.7 1369.4 ± 646.7
SCL-90 total score, mean ± SD 152.2 ± 31.4 159.1 ± 41.0 156.4 ± 35.0
IFA, No. (%)
     IgM phase I 24 (46) 28 (54) 25 (49)
     IgM phase II 30 (58) 32 (62) 32 (63)
     IgG phase I 45 (87) 42 (81) 40 (78)
     IgG phase II 52 (100) 50 (96) 49 (96)
Negative Coxiella burnetii PCR, No. (%) 52 (100) 52 (100) 51 (100)
aBetween-group differences in primary and secondary outcome characteristics at baseline were 
analyzed with analysis of variance for continuous variables.
Abbreviations: CBT, cognitive-behavioral therapy; CIS, Checklist Individual Strength; IFA, 
immunofluorescence assay; IgG, immunoglobulin G; IgM, immunoglobulin M; PCR, polymerase 
chain reaction; SCL-90, Symptom Checklist 90; SD, standard deviation; SIP8, Sickness Impact 
Profile.
Primary Endpoint
The primary endpoint in the intention-to-treat analysis, fatigue severity at EOT adjusted 
for baseline fatigue severity, did not significantly differ between doxycycline (40.8 [95% CI, 
37.3– 44.3]) and placebo (37.8 [95% CI, 34.3–41.2]; difference, doxycycline vs placebo, −3.0 
[97.5% CI, −8.7 to 2.6]; P = .45), and was significantly lower after CBT (31.6 [95% CI, 28.0–
35.1]) than after placebo (difference, CBT vs placebo, 6.2 [97.5% CI, .5–11.9]; P = .03) (Table 
2; Figure 2). Clinically meaningful improvement, that is, a reduction of 9 points on the CIS 
subscale Fatigue Severity plus a score of <35, was reached by 44% of patients: doxycycline, 
31%; placebo, 46%; CBT, 56% (P = .04; Supplementary Table 4).
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Figure 2. Mean fatigue severity and standard deviation per treatment group at baseline and at end of 
treatment (EOT), 26 weeks, measured with the Checklist Individual Strength subscale Fatigue Severity 
with a severity range from 8 to 56. Higher scores indicate a higher level of fatigue. Patients with a 
cutoff score of ≥35 are classified as severely fatigued. 
Figure	2.	Mean	fatigue	severity	and	standard	deviation	per	treatment	group	at	baseline	and	at	end	of	treatment	(EOT),	26	
weeks,	measured	with	the	Checklist	Individual	Strength	subscale	Fatigue	Severity	with	a	severity	range	from	8	to	56.	Higher	
scores	indicate	a	higher	level	of	fatigue.	Patients	with	a	cutoff	score	of	≥35	are	classified	as	severely	fatigued.	Abbreviations:	
CBT,	cognitive-behavioral	therapy;	CIS,	Checklist	Individual	Strength;	EOT,	end	of	treatment.	
 
	 	
Abbreviations: CBT, cognitive-behavioral therapy; CIS, Checklist Individual Strength; EOT, end of 
treatment. 
Secondary Endpoints
At EOT, the mean SIP8 total score did not differ significantly between either doxycycline and 
placebo (difference, doxycycline vs placebo, −137.7 [97.5% CI, −409.9 to 134.6]; P = .51) 
or CBT and placebo (difference, CBT vs placebo, 177.0 [97.5% CI, −98.3 to 452.3]; P = .30). 
Doxycycline yielded no difference in SCL-90 total score compared with placebo (difference, 
doxycycline vs placebo, −6.5 [97.5% CI, −18.7 to 5.7]; P = .45), whereas the SCL-90 total 
score significantly improved after CBT compared with placebo (difference, CBT vs placebo, 
15.6 [97.5% CI, 3.3–27.8]; P = .010). At EOS, the majority of patients had stable or declining 
antibody titers compared to baseline, and the number of patients with declining titers was 
similar in all groups (Supplementary Tables 3 and 5). Coxiella burnetii PCR remained negative 
in all patients.
Adverse Events
Overall, 138 (90%) patients reported at least 1 AE, and 2 (1%) AEs of gastrointestinal origin 
led to study discontinuation, both in the doxycycline group. In the doxycycline group, both 
the total number of AEs and the median number of AEs per patients were highest, and 
fewer patients reported no AEs (Supplementary Table 6). No serious adverse events (SAEs) 
occurred during treatment with doxycycline. Two SAEs were reported in the placebo group. 
One patient who had not yet started treatment was admitted to hospital with urosepsis. 
The other patient was admitted for clinical evaluation of preexisting cardiological symptoms, 
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which yielded no diagnosis. In the CBT group, 42 (84%) patients reported at least 1 AE. No 
SAE occurred during CBT treatment. 
DISCUSSION
In this RCT in QFS patients, long-term treatment with doxycycline was associated with a 
reduction in fatigue severity compared to baseline, but no more than with placebo, whereas 
CBT proved to be effective in reducing fatigue severity and the level of psychological 
distress compared to placebo. None of the treatment regimens showed a significant effect 
on functional impairment. Significantly more QFS patients showed a clinically meaningful 
improvement in fatigue following CBT.
This study is the first RCT evaluating both long-term treatment with doxycycline and CBT in 
QFS patients. The finding that long-term treatment with doxycycline was no more effective 
than placebo was contrary to previously published results [4, 17]. Both Arashima et al [4] and 
Iwakami et al [17] reported clinical improvement in QFS patients who received tetracycline 
treatment for 3 months. In the former uncontrolled open-label study [4], 20 patients were 
treated with minocycline 200 mg/ day (n = 18), levofloxacin 200 mg/day, or erythromycin 
400 mg/ day. In the latter pilot study [17], 58 patients (54 with assumed QFS) received 
minocycline 100 mg/day (n = 29), doxycycline 100 mg/day (n = 26), or levofloxacin 200 mg/
day (n = 3). However, both studies lacked a clear description of the criteria for QFS, and 
included patients who were C. burnetii PCR positive at baseline, indicating chronic Q fever; 
such patients might benefit from antibiotic treatment because of persistent infection. In 
our study, patients with a possible persistent (chronic) Q fever infection—based on clinical 
signs, serology, and PCR results—were not included. Furthermore, both previous studies 
included patients with a symptom duration of 1–4 months, whereas it is known that the 
percentage of patients experiencing severe fatigue decreases in the first months following 
acute Q fever while only a subset of patients will experience persistent fatigue [9, 11]. In 
contrast to these positive studies, in a case series of QFS patients [5] and in a case report 
[18], long-term treatment with a tetracycline showed inconsistent results. This study with 
a longer duration of antibiotic administration does not support long-term treatment with 
doxycycline for QFS, and such treatment should not be advised. These results will hopefully 
prevent discussions on the value of long-term antibiotic treatment for QFS and prevent 
patients from unnecessary prolonged antimicrobial therapy. This has already been seen in 
the treatment of prolonged symptoms attributed to Lyme disease, which eventually also 
proved ineffective [27]. In addition, most AEs occurred in the doxycycline group, including 
the highest median number of AEs per patient. In contrast to doxycycline, 2 SAEs were 
noticed in the placebo group; none of these were drug related. In this study, the observed 
placebo effect is remarkably high. This can be explained by the regular follow-up visits 
during the treatment course, which included standard advice on how to manage chronic 
fatigue (eg, regulation of bedtimes, quitting sleeping during the day, and maintaining mental 
and physical activities as much as possible). For several years no standard care was available 
for QFS patients, and this study, the initiation of which was partly patient-driven, provided 
support for patients.
CBT had significantly better results than placebo in all but 1 of the secondary outcomes. 
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In addition, the positive effect of CBT on fatigue severity was also clinically relevant. CBT 
is effective in reducing symptoms and improving functioning in CFS patients [19] and in 
chronic fatigue in chronic illnesses [28–30]. CBT is a complex intervention, encompassing a 
stepwise increase in physical activity and challenging dysfunctional fatigue-related beliefs. 
A change in beliefs about fatigue and the ability to become active seems to mediate the 
positive effects in CBT for CFS [31]. Previously, an overlap in fatigue-related and cognitive-
behavioral variables between QFS and CFS was found, but the relationship between 
perpetuating factors and fatigue as is found in CFS could not be confirmed in QFS [12]. 
Although CBT proved effective in reducing fatigue and psychological distress in QFS patients 
as well, it remains unclear whether the process of change during CBT in QFS is similar to that 
in CFS [31]. Different processes involved in the perpetuation of disabilities might explain 
the absence of effect of CBT on functional impairment, for which CBT for CFS has proven 
efficacy [32–34]. However, this might also be due to the inclusion of patients with moderate 
levels of overall impairment (SIP8 total score ≥450) [32–34] and, thus, less opportunity for 
improvement. The mean number of AEs per patient was lowest in the CBT group, and no 
SAE occurred in this group. Therefore, patients need not be concerned about safety if CBT is 
performed by qualified and trained therapists [35].
The effectiveness of CBT does not imply that the cause of QFS is psychological. Several 
hypotheses regarding the etiology of QFS exist, varying from a biopsychological etiology 
with C. burnetii acting as trigger for fatigue development [6] and the determination of 
symptoms by host and genetic factors [36], to cytokine dysregulation, supported by low 
levels of C. burnetii DNA found in bone marrow aspirates, thin-needle liver biopsies, and 
blood mononuclear cells [37–39]. In addition, it should be noted that prevalence of chronic 
fatigue differs between studies in different countries [40]. Although this could be due to a 
real difference in prevalence, this could also be explained by different research methods. 
Nevertheless, further research into the etiology is necessary.
The present findings are strengthened by the high therapy compliance in all groups and low 
number of dropouts and missing data. This study also has limitations. It was not designed 
to compare doxycycline and CBT directly, due to the limited number of available patients. 
However, as the EOT scores in the doxycycline group were similar to placebo, with even 
higher mean scores, the results imply a favorable effect of CBT. As masking for CBT was 
not possible, this trial was partly blinded. CBT was directly compared to placebo plus usual 
care, which might explain some of the differences observed as patients in the CBT group 
clearly know they are being treated. Due to the maximum number of available patients, 
it was not possible to include a control group without any form of treatment. Finally, it is 
unclear whether the detected effects will be sustained over time. To evaluate the long-term 
beneficial effects of CBT, as has been shown for CBT for CFS [41], patients are currently 
surveyed by poststudy questionnaires 12–15 months posttreatment. Furthermore, a 
mediation analysis is planned to identify cognitive and behavioral variables that mediate 
the positive effect of CBT on fatigue in QFS.
In conclusion, CBT is effective in reducing fatigue severity and the level of psychological 
distress in QFS patients. Longterm treatment with doxycycline does not significantly reduce 
fatigue severity in QFS patients and should not be advised.
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Supplementary Table 1. Inclusion and Exclusion Criteria
Inclusion criteria*
1. Males or non-pregnant, non-lactating females who are ≥18 years
2. Laboratory-proven acute Q fever since the year 2007 and/or positive serology fitting a 
past infection with C. burnetii
3. AND being severely fatigued, defined by scoring ≥35 on the CIS subscale fatigue severity
4. AND being fatigued for ≥6 months
5. AND being disabled because of the fatigue, defined by scoring ≥450 on the SIP8
6. Subjects must sign a written informed consent form
Exclusion criteria
1. Fulfilling criteria for chronic Q fever†
2. Acute Q fever in the setting of a prosthetic cardiac valve or aneurysm surgery or stenting, 
necessitating prophylactic use of doxycycline
3. Pregnancy or unwillingness to use effective contraceptives during the entire study period
4. Imminent death
5. Inability to give informed consent
6. Allergy or intolerance to doxycycline
7. Somatic or psychiatric illness that could explain the chronic fatigue
8. Subjects who are currently enrolled in other investigational drug trials or receiving 
investigational agents
9. Receiving or having received antibiotics for >4 weeks, potentially active against C. burnetii, 
for any other reason since Q fever diagnosis
10. Subjects who are receiving and cannot discontinue barbiturates, phenytoin, or 
carbamazepine‡
11. Moderate or severe liver disease (ALP, ALT, AST >3 times the upper limit of normal)
12. Current engagement in a legal procedure concerning financial benefits§
*In addition to the inclusion criteria, the fatigue needed to be directly related to an acute Q fever 
infection, and should be either absent before or significantly increased since the acute Q fever 
infection.
†Chronic Q fever was excluded with a negative serum PCR, or an IgG phase I <1:1024, in 
combination with the absence of clinical signs of endocarditis or vascular infection (including both 
vascular prosthesis and mycotic aneurysms).
‡These drugs may increase the metabolism of doxycycline; consequently, reducing the half-life of 
doxycycline.
§Temporary exclusion criterion, as current involvement interferes with the effectiveness of 
cognitive-behavioral therapy [1]. Once the appeal procedure ends, patients can be included.
Abbreviations: CIS, Checklist Individual Strength; SIP8, Sickness Impact Profile; ALP, alkaline 
phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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Supplementary Table 2. Key Exclusion Criteria During Treatment with Medication
Exclusion criteria
1. Pregnancy
2. Serious side effects
3. >10 days use of other antibiotics potentially active against C. burnetii*
4. Discontinuation of study medication for >7 consecutive days
5. Moderate or severe liver disease, defined as ALT or AST >5 times, and ALP >3 times the upper 
limit of normal
*Quinolon, co-trimoxazol, macrolide or tetracycline.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline 
phosphatase.
Supplementary Table 3. IFA at Baseline of Patients Included in the Intention-To-Treat Analysis*
Characteristic Total
(n=154)
Doxycycline
(n=52)
Placebo
(n=52)
CBT
(n=50)
IFA, No. (%)
     IgM phase I 77 (50) 24 (46) 28 (54) 25 (50)
          1:16 23 (15) 8 (15) 8 (15) 7 (14)
          1:32 23 (15) 7 (13) 8 (15) 8 (16)
          1:64 18 (12) 7 (13) 3 (6) 8 (16)
          1:128 8 (5) 1 (2) 5 (10) 2 (4)
          1:256 4 (3) 1 (2) 3 (6) 0 (0)
          1:512 1 (1) 0 (0) 1 (2) 0 (0)
     IgM phase II 93 (60) 30 (58) 32 (62) 31 (62)
          1:16 21 (14) 11 (21) 7 (13) 3 (6)
          1:32 24 (16) 10 (19) 8 (15) 6 (12)
          1:64 18 (12) 6 (12) 3 (6) 9 (18)
          1:128 12 (8) 1 (2) 6 (12) 5 (10)
          1:256 12 (8) 1 (2) 6 (12) 5 (10)
          1:512 4 (3) 0 (0) 2 (4) 2 (4)
          1:1024 2 (1) 1 (2) 0 (0) 1 (2)
     IgG phase I 126 (82) 45 (87) 42 (81) 39 (78)
          1:16 18 (12) 10 (19) 2 (4) 6 (12)
          1:32 25 (16) 11 (21) 9 (17) 5 (10)
          1:64 30 (19) 9 (17) 10 (19) 11 (22)
          1:128 28 (18) 6 (12) 13 (25) 9 (18)
          1:256 18 (12) 7 (13) 6 (12) 5 (10)
          1:512 7 (5) 2 (4) 2 (4) 3 (6)
     IgG phase II 150 (97) 52 (100) 50 (96) 48 (96)
          1:16 9 (6) 2 (4) 3 (6) 4 (8)
          1:32 10 (6) 4 (8) 2 (4) 4 (8)
          1:64 23 (15) 9 (17) 10 (19) 4 (8)
          1:128 30 (19) 16 (31) 5 (10) 9 (18)
          1:256 34 (22) 10 (19) 12 (23) 12 (24)
          1:512 34 (22) 8 (15) 13 (25) 13 (26)
          1:1024 7 (5) 2 (4) 3 (6) 2 (4)
          1:2048    3 (2) 1 (2) 2 (4) 0 (0)
*Focus Diagnostics, Inc., Cypress, CA, USA, detecting IgM and IgG antibodies against phase I- and 
phase II-antigens, with a titer of >1:16 being considered positive.
Abbreviations: CBT, cognitive-behavioral therapy; IFA, immunofluorescence assay.
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Supplementary Table 4. Clinical Meaningful Improvement at End Of Treatment of Patients 
Included in the Intention-To-Treat Analysis
Doxycycline
(n=52)
Placebo
(n=52)
CBT
(n=50)
P value*
Clinical meaningful improvement
CIS subscale Fatigue Severity <35 16 (31%) 24 (46%) 29 (58%) 0.02
CIS subscale Fatigue Severity <35 
and a minimal drop of nine points†
16 (31%) 24 (46%) 28 (56%) 0.03
*P values were based on the Chi-square test for comparison of the three groups.
†Taking into account whether the magnitude of change is clinically relevant, defined as: reliable 
change index (RCI) * 1.96 surplus a CIS fatigue severity score of <35 [2]. The mean SD baseline CIS 
fatigue was 4.87, and with 0.88 as reliability factor [3], the RCI was 4.28. This score is multiplied 
with 1.96 (= 8.40), and means a minimal drop of nine points on the CIS subscale Fatigue Severity.
Abbreviations: CBT, cognitive-behavioral therapy; CIS, Checklist Individual Strength questionnaire; 
RCI, reliable change index.
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Supplementary Table 5. IFA at End Of Study of Patients Included in the Intention-To-Treat 
Analysis*
Characteristic Total
(n=154)
Doxycycline
(n=52)
Placebo
(n=52)
CBT
(n=50)
IFA, No. (%)
     IgM phase I 72 (47) 24 (46) 28 (54) 20 (40)
          1:16 36 (23) 15 (29) 12 (23) 9 (18)
          1:32 15 (10) 5 (10) 5 (10) 5 (10)
          1:64 15 (10) 3 (6) 7 (13) 5 (10)
          1:128 4 (3) 0 (0) 3 (6) 1 (2)
          1:256 1 (1) 1 (2) 0 (0) 0 (0)
          1:512 1 (1) 0 (0) 1 (2) 0 (0)
     IgM phase II 88 (57) 27 (52) 32 (62) 29 (58)
          1:16 28 (18) 11 (21) 10 (19) 7 (14)
          1:32 20 (13) 6 (12) 8 (15) 6 (12)
          1:64 17 (11) 8 (15) 5 (10) 4 (8)
          1:128 12 (8) 1 (2) 6 (12) 5 (10)
          1:256 7 (5) 0 (0) 1 (2) 6 (12)
          1:512 2 (1) 0 (0) 2 (4) 0 (0)
          1:1024 1 (1) 0 (0) 0 (0) 1 (2)
          1:2048 1 (1) 1 (2) 0 (0) 0 (0)
     IgG phase I 119 (77) 43 (83) 39 (75) 37 (74)
          1:16 34 (22) 17 (33) 8 (15) 9 (18)
          1:32 26 (17) 7 (13) 8 (15) 11 (22)
          1:64 26 (17) 9 (17) 12 (23) 5 (10)
          1:128 23 (15) 6 (12) 7 (13) 10 (20)
          1:256 8 (5) 2 (4) 4 (8) 2 (4)
          1:512 2 (1) 2 (4) 0 (0) 0 (0)
     IgG phase II 147 (95) 51 (98) 50 (96) 46 (92)
          1:16 6 (4) 1 (2) 3 (6) 2 (4)
          1:32 11 (7) 6 (12) 2 (4) 3 (6)
          1:64 25 (16) 12 (23) 7 (13) 6 (12)
          1:128 43 (28) 15 (29) 11 (21) 17 (34)
          1:256 33 (21) 10 (19) 13 (25) 10 (20)
          1:512 22 (14) 5 (10) 11 (21) 6 (12)
          1:1024 6 (4) 2 (4) 3 (6) 1 (2)
          1:2048    1 (1) 0 (0) 0 (0) 1 (2)
*Focus Diagnostics, Inc., Cypress, CA, USA, detecting IgM and IgG antibodies against phase I- and 
phase II-antigens, with a titer of >1:16 being considered positive.
Abbreviations: CBT, cognitive-behavioral therapy; IFA, immunofluorescence assay. 
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Supplementary Table 6. Adverse Events of Patients Included in the Intention-To-Treat Analysis*
Type of event Total
(n=154)
Doxycycline
(n=52)
Placebo
(n=52)
CBT
(n=50)
Any AE, No. (%) 138 (90) 51 (98) 45 (87) 42 (84)
Discontinued treatment due to 
AE, No. (%)
2 (1) 2 (4) 0 (0) 0 (0)
Any SAE, No. (%) 2 (1) 0 (0) 2 (4) 0 (0)
No. AE – patients, No. (%)
     0 16 (10) 1 (2) 7 (13) 8 (16)
     1 27 (18) 8 (15) 6 (12) 13 (26)
     2 33 (21) 9 (17) 12 (23) 12 (24)
     3 24 (16) 7 (13) 10 (19) 7 (14)
     4 19 (12) 9 (17) 7 (13) 3 (6)
     5 18 (12) 8 (15) 8 (15) 2 (4)
     6 9 (6) 4 (8) 1 (2) 4 (8)
     7 5 (3) 4 (8) 1 (2) 0 (0)
     8 2 (1) 1 (2) 0 (0) 1 (2)
     9 1 (1) 1 (2) 0 (0) 0 (0)
Median no. AE† 3.0 4.0 3.0 2.0
Total no. AE 445 192 141 112
Type of AE – patients, No. (%)
     Infection 77 (50) 22 (42) 26 (50) 29 (58)
     Gastrointestinal 63 (41) 31 (60) 27 (52) 5 (10)
     Musculoskeletal 53 (34) 22 (42) 17 (33) 14 (28)
     Skin 35 (23) 20 (38) 10 (19) 5 (10)
     Neurological 29 (19) 13 (25) 10 (19) 6 (12)
     Bone and teeth 6 (4) 3 (6) 2 (4) 1 (2)
     Allergic reaction 0 (0) 0 (0) 0 (0) 0 (0)
     Other§ 55 (36) 24 (46) 13 (25) 18 (36)
     Laboratorial 21 (20)** 14 (27) 7 (13) NA
Total no. AE per type, No. (%)
     Infection 133 (30) 33 (17) 46 (33) 54 (48)
     Gastrointestinal 89 (20) 51 (27) 33 (23) 5 (4)
     Musculoskeletal 68 (15) 28 (15) 22 (16) 18 (16)
     Skin 46 (10) 29 (15) 12 (9) 5 (4)
     Neurological 32 (7) 13 (7) 11 (8) 8 (7)
     Bone and teeth 7 (2) 4 (2) 2 (1) 1 (1)
     Allergic reaction 0 (0) 0 (0) 0 (0) 0 (0)
     Other§ 70 (16) 34 (18) 15 (11) 21 (19)
     Laboratorial 24 (7)** 16 (8) 8 (6) NA
*Laboratorial AE were excluded, as laboratory investigations for safety were only performed in the 
doxycycline and placebo group.
†The median number of AE per patient per group was significantly different based on a Kruskall-
Wallis nonparametric test (p=0.001).
§Includes respiratory, gynecological, urological, and endocrinological complaints, cardiological 
symptoms, ocular symptoms, onycholysis, operations, wounds, weight loss/gain, insomnia, and an 
increase in depressive thoughts, forgetfulness, fatigue, or sweating.
**Only based on patients from the doxycycline and placebo group.
Abbreviations: CBT, cognitive-behavioral therapy; AE, adverse event; SAE, serious adverse event; 
NA, not applicable.
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ABSTRACT
Differentiating acute Q fever from infections caused by other pathogens is essential. We 
conducted a retrospec tive case–control study to evaluate differences in clinical signs, 
symptoms, and outcomes for 82 patients with acute Q fever and 52 control patients who 
had pneumonia, fever and lower respiratory tract symptoms, or fever and hepati tis, but 
had negative serologic results for Q fever. Patients with acute Q fever were younger and 
had higher C-reactive protein levels but lower leukocyte counts. However, a large overlap 
was found. In patients with an indication for prophy laxis, chronic Q fever did not develop 
after patients received prophylaxis but did develop in 50% of patients who did not receive 
prophylaxis. Differentiating acute Q fever from other respiratory infections, fever, or hepatitis 
is not possible with out serologic testing or PCR. If risk factors for chronic Q fever are present, 
prophylactic treatment is advised.
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INTRODUCTION
Q fever is a zoonosis caused by the bacterium Coxiella burnetii. During 2007–2010, the 
southern part of the Netherlands had the largest outbreak of Q fever ever re ported [1, 
2]. Infection with C. burnetii is symptomatic in ≈40% of all patients [3]. Clinical signs range 
from a mild influenza-like illness to pneumonia or a hepatitis-like syn drome and can differ 
by region [4, 5]. After initial infection, chronic Q fever will develop in 1%–5% of patients [1, 
3]. Furthermore, long-lasting fatigue will develop in ≈20% of all patients with symptomatic 
acute Q fever [6-8] without development of chronic Q fever [9].
Treatment for acute infection decreases the duration of fever, increases recovery from 
pneumonia [10], and might lead to a lower percentage of patients in whom chronic Q fever 
will develop [10-13]. In addition, several reports in dicate that, in acute Q fever patients at 
risk for development of chronic Q fever, prophylactic treatment might prevent persistent 
infection [12, 14]. Therefore, recognizing Q fever in an early stage is a useful strategy.
The only available data on symptoms of acute Q fe ver in the Netherlands 
were obtained from a retrospective study that collected data several months 
after onset of dis ease by sending questionnaires to patients with acute Q fe-
ver [15]. However, this method for obtaining data is limited by a high risk for recall 
bias. To help physicians differenti ate acute Q fever from other diseases, a clear 
description of signs and symptoms compatible with C. burnetii infection is desirable. 
The purpose of this case–control study was to evaluate differences in clinical signs and 
symptoms between patients with acute Q fever referred to a hospital and a control group of 
patients with signs and symptoms that led to addition of Q fever in the differential diagnosis. 
Furthermore, outcome of patients hospitalized with acute Q fever were evaluated, and the 
effect of prophylactic treatment for those patients with an indication to prevent development 
of chronic Q fe ver was analyzed.
MATERIALS AND METHODS
Patients
The study group consisted of adult patients who came to the Radboud university medical 
center or Canisius Wilhelmi na Hospital in Nijmegen, the Netherlands, during January 2007–
March 2011 with pneumonia, fever and lower respi ratory tract symptoms, or fever and 
hepatitis, and who were given a diagnosis of acute Q fever. Symptoms had to be present for 
<3 weeks before presentation. Exclusion criteria were chronic Q fever and a known previous 
acute Q fever episode. The same clinical criteria were used for the con trol group, but Q 
fever serologic results and, if available, PCR results had to remain negative. A standardized 
case report form was completed for every patient. According to national law, this study was 
exempt from approval by an ethics committee because of the retrospective characteris tics 
of the study and the anonymous storage of data.
PCR and serologic analysis
During January 2007–March 2011, several laboratory techniques were used to diagnose 
acute Q fever. Because both hospitals collaborate extensively, the same microbio logical 
laboratory techniques were used in both hospitals. The PCR used to detect DNA of C. burnetii 
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in serum was an in-house, real-time PCR directed against insertion se quence IS1111a.
Serologic analysis was performed for blood samples by using the Coxiella burnetii (Q Fever) 
IgM ELISA (Pan Bio Pty Ltd., Windsor, Queensland, Australia), which de tects IgM against phase 
II antigens and has a cutoff index of 1.1; a complement fixation assay (CFA) (Virion-Serion, 
Würzburg, Germany), which detects C. burnetii phase II antigens and shows a positive result 
if the titer is >1:10; and a Q fever immunofluorescent assay (IFA) for IgG and IgM (Focus 
Diagnostics Inc., Cypress, CA, USA), which detects IgM and IgG against phase I and phase II 
antigens and shows a positive result if the titer is >1:16.
Definition of acute Q fever
On the basis of the algorithm published by the Dutch work ing group on diagnostics of acute 
Q fever [16], the follow ing definition of acute Q fever was used for all included patients: 
pneumonia, lower respiratory tract symptoms and fever, or hepatitis-like symptoms and 
fever, all <3 weeks before presentation; and 1) a positive serum PCR result <21 days of onset 
of disease; or 2) a negative serum PCR result, but a positive ELISA result for IgM against 
phase II antigens of C. burnetii and a positive CFA result for im munoglobulins against C. 
burnetii; or 3) a negative serum PCR result but a positive ELISA result and a positive IFA result 
for IgM and IgG against phase I and phase II antigens of C. burnetii; or 4) two serum samples 
tested by CFA or IFA during an interval of >2 weeks that showed serocon version or a 4-fold 
increase in titer.
A blood sample for Q fever serologic analysis obtained >2 weeks after the first day of illness 
was required because it was not possible to rule out acute Q fever if serologic samples 
are taken only at an earlier point, even if PCR re sults were negative during that period 
[16]. Patients were selected only if an appropriate diagnostic procedure for Q fever was 
performed.
Treatment
Adequate treatment for acute Q fever was defined as anti microbial drug therapy with 
doxycycline (200 mg/d), moxi floxacin (400 mg 1×/d), or ciprofloxacin (500 mg 2×/d) for >14 
days [17, 18]. Indications for prophylactic treatment to prevent development of chronic 
Q fever were patients who met the criteria for endocarditis prophylaxis according to the 
international guidelines of the American Heart Associa tion [19]; patients with a structural 
aortic valve defect or mitral valve defect [12]; patients with a known aneurysm of the aorta 
or other large vessels; and patients with a vascular prosthesis. Adequate prophylactic 
treatment was defined as doxycycline (200 mg/d) and hydroxychloroquine (200 mg 3×/d) 
for >6 months.
Statistical methods
All data were analyzed by using SPSS version 20.0 (IBM, Armonk, NY, USA). For analysis 
of qualitative data, the Pearson’s χ2 test was used. To evaluate the effect of pro phylactic 
treatment, the Barnard exact test was used be cause this test is more powerful than the 
Fisher exact test for instances of smaller sample sizes [20]. For quantitative data, the Student 
t-test was used. A p-value <0.05 was con sidered significant.
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RESULTS
General characteristics
A total of 82 patients with acute Q fever who fulfilled in clusion criteria for the study group 
and 52 patients who fulfilled criteria for the control group were included in the study (Table 
1). Patients with acute Q fever were younger (mean ± SD age 52 ± 16 years vs. 59 ± 16 years; 
p=0.03); had less often a history of lung disease (p=0.001); and were immunocompromised 
less often (p=0.002). Patients with acute Q fever had more history of smoking (p=0.01) and 
a higher frequency of a sore throat (p=0.008) (Table 2). Production of sputum was reported 
less frequently by patients with acute Q fever (p=0.049).
Table 1: Characteristics for patients with acute Q fever and control group with negative 
serologic results for Q fever, the Netherlands*
Characteristic Study group Control group p-value
No. patients 82 52 NS†
Male sex, no. (%) 53 (65) 38 (73) NS‡
Mean ± SD age, y (range) 52±16 (23-91) 59±16 (19-85) 0.027†
Mean no. days between first day of 
sickness and presentation
5.5 5.4 NS†
History of lung disease 8/78 (10) 18/51 (35) 0.001‡
Immunocompromised§ 5/81 (6) 13/51 (25) 0.002‡
Valvular dysfunction 8/81 (10) 3/52 (6) NS‡
Valve prosthesis 3/82 (4) 0/52 (0) NS‡
Aneurysm 2/82 (2) 3/52 (6) NS‡
Vascular prosthesis 3/82 (4) 3/52 (6) NS‡
Liver disease 1/82 (1) 1/52 (2) NS‡
Malignancy 2/82 (2) 9/52 (17) 0.002‡
Diabetes 9/82 (11) 7/52 (13) NS‡
Contact with cattle 29/47 (62) 8/20 (40) NS‡
History of smoking 58/74 (78) 25/44 (57) 0.013‡
Alcohol use 17/44 (39) 12/27 (44) NS‡
Illicit drugs 4/35 (11) 0/18 (0) NS‡
Proton pump inhibitors¶ 13/82 (16) 22/52 (42) 0.001‡
Corticosteroids¶ 5/82 (6) 10/51 (20) 0.017‡
* Values are no. positive/no. tested (%) unless otherwise indicated. NS, not significant. 
† By Student t-test. 
‡ By χ2 test. 
§ Also includes patients using corticosteroids. 
¶ Only medications that differed significantly between groups is shown.
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Physical examination
Of patients with acute Q fever, 18% had shortness of breath (Table 3) compared with 44% 
in the control group (p=0.03). A total of 4% of patients with acute Q fever had rhonchi 
at pulmonary examination compared with 22% in the control group (p=0.005). Oxygen 
saturation was sig nificantly higher in patients with acute Q fever (p=0.02).
Laboratory values
Patients with acute Q fever had a higher levels of C-reac tive protein (mean 167 mg/L vs. 117 
mg/L; p=0.02) (Ta ble 4) and lower leukocyte counts (mean 9.0 × 109 cells/L vs. 11.5 × 109 
cells/L; p=0.006). Leukocyte counts re mained significantly lower in the first 3 days after pre-
sentation (p=0.006–0.043). At admission to the hospi tal, no differences were found between 
the groups for levels of alkaline phosphatase and у-glutamyl transpep tidase. However, from 
day 1 onward, levels of alkaline phosphatase and у-glutamyl transpeptidase were signifi-
cantly higher in patients with acute Q fever (p=0.01–0.047 and p=0.007–0.05, respectively).
PCR and serologic analysis
Serum PCR for DNA of C. burnetii was performed for 41 patients in the study group (Table 
5). Blood samples were obtained at day 8 ± 7 (mean ± SD) of illness. The sensitiv ity of this 
PCR was 56%. For 4 patients, a second blood sample was obtained at day 12 ± 5 of illness. 
The sensitiv ity of this PCR was 25%.
Table 2: Signs and symptoms for patients with acute Q fever and control group with negative 
serologic results for Q fever, the Netherlands*
Characteristic Study group, n=82, no. 
positive/no. tested (%)
Control group, n=52, no. 
positive/no. tested (%)
p-value†
Fever 64/75 (85) 37/49 (76) NS
Chills 31/42 (74) 16/28 (57) NS
Myalgia 22/24 (92) 11/14 (79) NS
Night sweats 12/19 (63) 9/17 (53) NS
Weight loss 11/26 (42) 7/14 (50) NS
Chest pain 11/55 (20) 13/38 (34) NS
Dyspnea 37/65 (57) 31/43 (72) NS
Rhinorrhea 1/12 (8) 7/14 (50) NS
Sore throat 12/22 (55) 1/12 (8) 0.008
Cough 49/76 (64) 38/48 (79) NS
Sputum production 18/73 (25) 20/48 (42) 0.049
Nausea 14/48 (29) 12/37 (32) NS
Vomiting 17/47 (36) 10/39 (26) NS
Abdominal pain 9/51 (18) 6/33 (18) NS
Diarrhea 9/50 (18) 4/36 (11) NS
Headache 38/54 (70) 21/27 (78) NS
Weakness 9/21 (43) 1/9 (11) NS
Painful joints 7/20 (35) 2/16 (13) NS
Arthritis 0/17 (0) 1/16 (6) NS
* NS, not significant. 
† By χ2 test.
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ELISA was performed on samples from 33 patients with acute Q fever and 18 patients in the 
control group. Blood samples were obtained from the study group at day 10 ± 8 of illness 
and from the control group at day 7 ± 6 of illness. Sensitivity of this ELISA was 61%.
CFA, which was performed for 81 patients in the study group at day 9 ± 19 of illness and for 
52 patients in the control group at day 8 ± 6 of illness, showed a sensitivity of 22% (Table 5). 
A total of 57 patients were hospitalized, of whom 36 were given a diagnosis of acute Q fever 
during their hospitalization.
Imaging studies
A total of 78% of chest radiographs for patients with acute Q fever showed signs of 
pneumonia. A total of 54% of chest radiographs for patients in the control group showed 
signs of pneumonia (p=0.003) (Table 5).
Treatment
Treatment was started before a diagnosis was made. Signifi cantly more patients with acute 
Q fever started treatment with doxycycline than patients in the control group (35% vs. 
Table 3: Physical examination results for patients with acute Q fever and control group with 
negative serologic results for Q fever, the Netherlands*
Characteristic Study group, n=82 Control group, n=52 p-value
Dyspnea 13/73 (18) 18/41 (44) 0.03†
Abnormal heart sounds 1/80 (1) 0/51 (0) NS†
Cardiac murmur 11/80 (14) 4/50 (8) NS†
Decreased breath sounds 6/78 (8) 7/46 (15) NS†
Bronchial breath sounds 9/64 (14) 5/37 (14) NS†
Crackles 36/76 (47) 19/43 (44) NS†
Rhonchi 3/68 (4) 9/41 (22) 0.005†
Palpable liver 1/69 (1) 1/39 (3) NS†
Palpable spleen 0/68 (0) 0/36 (0) NS†
Exanthema 2/9 (22) 0/6 (0) NS†
Lymphadenopathy 2/27 (7) 2/21 (10) NS†
Temperature, ˚C (no. patients) 38.4 (67) 38.3 (48) NS‡
Heart rate, beats/min (no. patients) 93 (73) 91 (50) NS‡
Systolic blood pressure, mmHg (no. 
patients)
134 (73) 138 (49) NS‡
Respiratory rate, breaths/min (no. 
patients)
25 (24) 25 (21) NS‡
Saturation, % oxygenation (no. 
patients)§
97 (57) 95 (34) 0.022‡
* Values are no. positive/no. tested (%) unless otherwise indicated. NS, not significant. 
† By χ2 test.
‡ By Student t-test.
§ Saturation without oxygen.
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Table 4: Laboratory values for patients with acute Q fever and control group with negative 
serologic results for Q fever, the Netherlands*
Laboratory value Study group, n=82 Control group, n=52 p-value‡
Day† Mean No. tested Mean No. tested
Hemoglobin, mmol/L; reference 
range: men 8.1-10.7 mmol/L, 
women 7.3-9.7 mmol/L
0 8.3 77 8.0 51 NS
1 7.4 28 7.3 34 NS
2-3 7.7 27 7.0 29 0.036
4-6 7.6 27 7.0 29 NS
Leukocytes, x 109 cells/L; reference 
range 3.5–11.0 x 109 cells/L
0 9.0 80 11.5 50 0.006
1 8.5 40 10.8 28 0.043
2-3 8.0 34 11.1 33 0.021
4-6 10.9 28 9.2 31 NS
Platelets, x 109/L; reference range 
20–350 x 109/L
0 239 78 208 50 NS
1 242 23 178 29 0.038
2-3 229 19 172 26 0.042
4-6 298 24 208 27 0.011
Total bilirubin, μmol/L; reference 
value <17 μmol/L
0 14 26 16 20 NS
1 12 14 14 8 NS
2-3 9 12 28 6 0.017
4-6 8 12 9 6 NS
AP, U/L; reference value <120 U/L 0 104 75 85 50 NS
1 127 19 75 12 0.047
2-3 126 26 66 12 0.010
4-6 145 23 95 15 0.036
ALT, U/L; reference value <45 U/L 0 45 76 37 49 NS
1 64 22 58 16 NS
2-3 66 30 40 13 0.050
4-6 81 22 84 18 NS
γ-GT, U/L; reference value: men <50 
U/L, women <35
0 74 68 65 49 NS
1 117 21 53 12 0.030
2-3 106 27 42 9 0.007
4-6 112 22 66 14 0.050
CRP, mg/L; reference value <10 
mg/L
0 167 79 117 50 0.015
1 184 44 150 37 NS
2-3 132 46 147 32 NS
4-6 76 41 98 27 NS
Urea, mmol/L; reference value 
2.5–7 mmol/L
0 6.4 79 8.6 51 0.039
1 6.4 33 7.9 35 NS
2-3 5.4 38 8.7 35 0.014
4-6 5.8 34 9.3 30 0.018
Creatinine, μmol/L; reference value: 
men <110 μmol/L, women <90 
μmol/L
0 86 80 105 52 0.042
1 84 38 103 38 NS
2-3 79 37 103 37 NS
4-6 81 36 136 31 NS
* NS, not significant; AP, alkaline phosphatase; ALT, alanine aminotransferase; γ-GT, γ-glutamyl 
transpeptidase; CRP, C-reactive protein.  
† Day 0 is the day of coming to the hospital. 
‡ By Student t-test.
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Table 5: PCR and serologic results for patients in study group with acute Q fever and control 
group with negative serologic results for Q fever, the Netherlands*
Characteristic Study 
group, 
n=82
Control 
group, 
n=52
Day of illness 
for study group, 
mean ± SD
Day of illness for 
control group,  
mean ± SD
Sensitivity, 
%
PCR
     First sample 23/41 0/15 8 ± 7 8 ± 7 56
     Second sample 1/4 0/1 12 ± 5 30 ± 0 25
ELISA
     First sample 20/33 0/18 10 ± 8 7 ± 6 61
     Second sample 15/18 0/2 20 ± 11 25 ± 8 83
CFA
     First sample 18/81 0/52 9 ± 19 8 ± 6 22
     Second sample 27/34 0/28 18 ± 9 20 ± 12 79
     Third sample 5/5 0/3 21 ± 6 26 ± 5 100
Culture
     Blood† 0/42 (0) 0/40 (0) NA NA NA
     Urine† 0/30 (0) 0/37 (0) NA NA NA
     Sputum‡ 1/15 (7) 3/22 (14) NA NA NA
Chest radiograph§ 62/79 (78) 28/52 (54) NA NA ¶
* Values are no. positive/no. tested (%) unless otherwise indicated. CFA, complement fixation 
assay; NA, not applicable. 
† Includes only results for first cultures obtained after coming to the hospital. 
‡ Includes only results for first cultures obtained after coming to the hospital. In the study group, 
1 patient was positive for parainfluenza virus. In the control group, 1 patient was positive for 
Moraxella catarrhalis, 1 patient was positive for Legionella pneumophila, and 1 patient was 
positive for Streptococcus pneumonia and Staphylococcus aureus. 
§ Includes only first chest radiographs after coming to the hospital. Values are no. abnormal/no. 
tested (%). 
¶ p=0.003, by χ2 test.
15%; p=0.001) (Table 6). For 8 patients in the study group, the duration of antimicrobial 
drug treatment was un known. Of the remaining 74 patients with acute Q fever, 34 (46%) 
patients were given adequate treatment. The mean ± SD follow-up time for patients given 
adequate treatment was 11.7 ± 5 months compared with 13.3 ± 9 months for patients given 
inadequate treatment.
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Table 6: Initial treatment for patients with acute Q fever and control group with negative 
serologic results for Q fever, the Netherlands*
Initial treatment Study group, n=82, no. 
positive/no. tested (%)
Control group, n=52, no. 
positive/no. tested (%)
p-value†
Doxycycline 29/82 (35) 8/52 (15) 0.001
Moxifloxacin 5/82 (6) 2/52 (4) NS
Ciprofloxacin 7/82 (9) 6/52 (12) NS
Penicillin 7/82 (9) 1/52 (2) 0.049
Amoxicillin 13/82 (16) 5/52 (10) NS
Amoxicillin/clavulanic acid 3/82 (4) 4/52 (8) NS
Piperacillin/tazobactam 1/82 (1) 5/52 (10) NS
Cephalosporin 14/82 (17) 17/52 (33) NS
Co-trimoxazole 0/82 (0) 1/52 (2) NS
Flucloxacillin 2/82 (2) 0/52 (0) NS
Clarithromycin 0/82 (0) 1/52 (2) NS
No treatment 1/82 (1) 1/52 (2) NS
Unknown 0/82 (0) 1/52 (2) NS
Patients with adequate 
treatment‡
34/74 (46) NA NA
* NS, not significant; NA, not applicable.
† By χ2 test.
‡ Defined as use of doxycycline (200 mg/d), moxifloxacin (400 mg 1x/d), or ciprofloxacin (500 mg 
2x/d) for ≥2 wk.
Outcomes
Hospitalization (70% vs. 94%; p=0.001), admission to an intensive care unit (4% vs. 18%; 
p=0.002), and need for respiratory support (2% vs. 16%; p=0.001) were less com mon for the 
study group than for the control group (Table 7). Also, duration of hospital stay was shorter 
for patients with acute Q fever (9 ± 7 days vs. 17 ± 15 days; p=0.001). Accurate follow-up 
data were available for 59 of 82 pa tients with acute Q fever who had a mean ± SD follow-up 
of 12.8 ± 8.2 months. Chronic Q fever developed in 6 (10%) patients in the Q fever group.
Sixteen patients with acute Q fever met the criteria for prophylactic treatment to prevent 
development of chronic Q fever (Table 8). Indications were valvular dysfunction (n=8); 
cardiac valve prosthesis (n=3); aneurysm (n=1); vas cular prosthesis (n=3, of whom 1 patient 
also had a cardiac valve prosthesis); and a new cardiac murmur (n=2). Eight (50%) of these 
patients received prophylactic treatment. Proper follow-up data for development of chronic 
Q fever were available for 14 patients with an indication for prophy laxis. Chronic Q fever 
did not develop in any of the 8 pa tients who received prophylaxis. The other 6 patients 
with an indication for prophylaxis for whom follow-up serum sam ples were available did 
not receive prophylaxis because the indication for prophylaxis was not recognized by the 
treating physician. Chronic Q fever developed in 3 (50%) of these 6 patients (p=0.02). In the 
group without an indication for prophylaxis, chronic Q fever developed in 3 (6%) patients. 
Six (11%) of 56 patients in the study group for whom these data were available reported 
long-lasting fatigue.
The mortality rate during a 12-month follow-up period was 6% for the study group 
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compared with 19% for the control group (p=0.02). None of the patients in the study group 
died during the episode of acute Q fever. Four pa tients in the study group died because 
of reasons unrelated to Q fever. One patient died of consequences of an infected vascular 
prosthesis caused by chronic Q fever, although adequate treatment was started after the 
diagnosis. In con trast, 2 patients in the control group died during initial hos pitalization, 1 
of a Mycoplasma sp. infection and 1 of pneu monia without a known causative agent. Eight 
patients in the control group died during follow-up. One of them died of a non-Hodgkin 
lymphoma and 1 of consequences of an Aspergillus sp. infection. For the other 6 patients 
who died, no detailed information was available.
A total of 49 control patients were given a diagnosis of pneumonia; for 38 of these 
patients, no causative agent was found. For the remaining 11 patients, causative agents 
were Pneumocystis jiroveci, Moraxella catarrhalis, Legionnel la pneumophila, Chlamydia 
sp., Haemophilus influenzae (2 patients), Mycoplasma sp. (3 patients), influenza vi rus and 
Mycoplasma sp., and Staphylococcus aureus and Streptococcus pneumonia. The remaining 
3 patients were given diagnoses of acute myeloid leukemia, non-Hodgkin lymphoma, and 
restrictive pericarditis.
Table 7: Outcome, follow-up, and prophylaxis for patients with acute Q fever and control group 
with negative serologic results for Q fever, the Netherlands*
Characteristic Study group Control group p-value
Outcome
     Hospitalized 57/82 (70) 49/52 (94) 0.001†
     Need for ICU 2/57 (4) 9/49 (18) 0.002†
     Need for respiratory support 1/57 (2) 8/49 (16) 0.001†
     Mean ± SD duration of hospitalization, d 9 ± 7 17 ± 15 0.001‡
     Mean ± SD duration of time in ICU, d 5 ± 1 14 ± 10 0.266‡
Follow-up
     Development of chronic Q fever 6/59 (10) NA NA
     Development of long-lasting fatigue§ 6/56 (11) NA NA
     Death 5/82 (6) 10/52 (19) 0.019†
     Q fever-related death 1/82 (1)¶ NA NA
Indication for prophylaxis 16/82 (20) NA NA
Development of chronic Q fever
     Prophylactic treatment 0/8 (0) NA NA
     No prophylactic treatment 3/6 (50) NA 0.018#
* Values are no. positive/no. tested (%) unless otherwise indicated. ICU, intensive care unit; NA, 
not applicable. 
† By χ2 test.
‡ By Student t-test.
§ Defined as persisting fatigue for >6 months after acute Q fever in the absence of chronic Q fever. 
¶ This patient died of consequences of an infected vascular prosthesis caused by chronic Q fever. 
# By unilateral Barnard exact test.
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Table 8: Characteristics of 16 patients with acute Q fever with an indication for prophylaxis, the 
Netherlands*
Patient 
no.
Age, 
y/sex
Hospitalized Indication at presentation 
for prophylactic treatment
Prophylactic 
treatment 
and duration, mo
Chronic 
Q fever
Died
1 42/M Yes Valvular dysfunction (AS) D + H, 12 No No
2 49/M Yes Cardiac bioprosthesis and 
vascular prosthesis
D + H, 12 No No
3 51/M Yes Cardiac bioprosthesis and 
TOF
D 12 + H 4 (added 
after 8)
No No
4 54/M Yes Aneurysm common iliac 
artery
D + H, 9 No No
5 43/M Yes Valvular dysfunction (TI) 
and TGV 
D + H, 7 No No
6 78/F Yes Cardiac bioprosthesis D + H, 1, switched 
to Mox, 3
No Yes†
7 26/M No Vascular prosthesis D + H, 2.5 No No
8 81/F Yes Valvular dysfunction (MI) D + H, 12 No Yes‡
9 65/M Yes Valvular dysfunction (MI) No No No
10 80/M Yes Valvular dysfunction (MI) No No No
11 78/F No Valvular dysfunction (MI) No No No
12 64/F Yes Vascular prosthesis No Yes Yes§
13 75/F Yes New cardiac murmur No Yes No
14 75/M No New cardiac murmur No Yes No
15 57/F No Valvular dysfunction (AS) No Unknown¶ No
16 58/M Yes Valvular dysfunction (MI) No Unknown¶ No
* AS, aortic valve sclerosis; D, doxycycline 100 mg 2x/d; H, hydroxychloroquine 200 mg 3x/d; TOF, tetralogy 
of Fallot; TI, tricuspid insufficiency; TGV, transposition of the great vessels; Mox, moxifloxacine 400 mg 
1x/d; MI, mitral insufficiency; CFA, complement fixation assay; IFA, immunofluorescence assay. 
† This patient was rehospitalized shortly after the acute Q fever episode and died because of a reason 
unrelated to Q fever. The last available serologic follow-up showed no signs of chronic Q fever (negative 
PCR result; CFA titer 1:10, IFA IgG phase I negative result; IgG phase II titer 1:256; IgM phase I negative 
result; and IgM phase II titer 1:64). 
‡ This patient eventually died because of a reason unrelated to Q fever. The last available serologic follow-
up 1 year after the acute Q fever episode showed no signs of chronic Q fever (negative PCR result; CFA 
titer 1:10; IFA IgG phase I titer 1:64; IgG phase II titer 1:512; IgM phase I titer 1:16, and IgM phase II titer 
1:16). 
§ This patient was hospitalized and admitted to the intensive care unit for 5 d. She was treated with 
several antimicrobial drugs (penicillin, ciprofloxacin, cefuroxim, metronidazol, ceftazidim, and teicoplanin) 
before given a diagnosis of an infected vascular prosthesis caused by chronic Q fever. Although doxycycline 
and hydroxychloroquine were given after the diagnosis was made, this patient eventually died from 
consequences of an infected vascular prosthesis caused by chronic Q fever. 
¶ No follow-up with reference to Q fever was performed for this patient.
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DISCUSSION
This retrospective case–control study evaluated differences in clinical signs and symptoms 
between patients with acute Q fever referred to a hospital and a control group. Because 
patients in the control group had Q fever included in the differential diagnosis, a selection 
bias is possible. How ever, differences were found between the 2 groups. In ad dition, because 
of the Q fever outbreak during that time, C. burnetii was considered a possible etiologic 
agent in many patients who came to a hospital. The higher number of pa tients in the study 
group can be explained by strict imple mentation of inclusion criteria for the control group.
Consistent with findings of earlier studies [1, 21], we found that patients with acute Q 
fever more often had a his tory of smoking. However, a history of lung disease was found 
less often. A lower mean age in the study group than in the control group might explain 
this finding. Previous studies suggest typical signs and symptoms of acute Q fever: fever, 
headache, and cough [1, 3, 22]. However, no difference was observed in the occurrence 
of fever. It has been postu lated that headache is rather specific for acute Q fever [5, 23]. 
However, in our study, headache was less common in pa tients with acute Q fever than in 
the control group. Although cough was a relatively common sign in both groups, sputum 
production was reported less often in patients with acute Q fever. In addition, a sore throat 
was reported more often in the study group, which has not been previously reported.
A limitation of these results is the retrospective nature of the study because physicians 
probably did not include all signs and symptoms in patient charts. In general, patients 
with lung disease often use corticosteroids, which might ex plain why fewer patients in the 
study group were classified as immunocompromised. In contrast to medical and physi cal 
examination results, more patients with acute Q fever showed signs of an infiltrate on chest 
radiographs when they came to the hospital. Although acute Q fever usually is a relatively 
mild influenza-like disease, it has been reported that chest radiographs often shows signs 
of an infiltrate [24]. Compared with our control group, fewer patients in the study group 
needed hospitalization, and duration of hospitalization was shorter. These findings might be 
explained by the lower mean age of patients with acute Q fever, assuming that they were in 
a more healthy condition. Furthermore, C. burnetii is known for its self-limiting character, in 
contrast to those of other pathogens found in the control group.
In the Netherlands, a Q fever hospitalization rate of 50% in 2007 was registered, which 
stabilized at ≈20% in later years [25]. This rate is higher than that previously reported (2%–
5%)[5]. However, large variations in hos pitalization rates for acute Q fever patients have 
been re ported [26]. In this study, 70% of patients with acute Q fever were hospitalized. Most 
patients with acute Q fever are asymptomatic or have only a mild influenza-like illness. Thus, 
a selection bias caused by the study design is likely. We found that 78% of patients in the 
study group had an ab normal result on a chest radiograph, which might indicate that only 
patients with severe symptoms were hospitalized.
Although C-reactive protein levels and leukocyte counts differed between the study group 
and the control group, this finding did not contribute to differentiation between C. bur netii 
and other pathogens at hospitalization because differ ences were small and showed much 
overlap. In addition, although leukocyte counts were usually within the reference range, 
patients with acute Q fever more often had a lower leukocyte count, which is consistent with 
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results of other studies [3, 4]. In contrast to these studies, which found throm bocytopenia 
in patients with acute Q fever, we found slightly higher levels of platelets, all within the 
reference range, in the study group than in the control group. Increased levels of liver 
enzymes have been reported in patients with acute Q fever [3, 5, 22]. However, we found no 
differences in these levels between both groups at hospitalization. Furthermore, creatinine 
levels were not increased, in contrast to results re ported in a previous study [3].
Although antimicrobial drug treatment was inade quate in an unexplainably high percentage 
of patients with acute Q fever, more patients in the study group than in the control group 
were initially treated with doxycycline, the treatment of choice for patients with acute Q 
fever. The choice of antimicrobial drug treatment in patients with community-acquired 
pneumonia (CAP) of unknown origin in the Netherlands depends on the Confusion, Urea 
nitro gen level in blood, Respiratory rate, Blood pressure, age >65 years (CURB-65) score 
[27]. In addition, although CURB-65 scores could not be calculated for all patients, fewer 
patients in the study group were hospitalized, needed admission to an intensive care unit, 
and needed respiratory support, which suggests lower CURB-65 scores in the study group 
than in the control group.
Although changes were made in the national guidelines for treating CAP issued by the Dutch 
Working Party on An tibiotic Policy in 2011 [28], until 2011, doxycycline was the first choice 
for patients with a low CURB-65 score [29]. In addition, more patients in the study group 
were given a diagnosis of having an infiltrate, which suggested that ini tial treatment in the 
study group was also aimed at atypical microorganisms. Presumably, patients in the control 
group were treated with broader spectrum antimicrobial drugs be cause of higher CURB-65 
scores. Also, more patients in the control group were immunocompromised, which also 
could have influenced the choice of treatment.
Long-term prophylactic treatment with doxycycline and hydroxychloroquine has been 
suggested for patients with risk factors for development of chronic Q fever [12, 14]. 
Although controversy still exists (e.g., with regard to treatment duration and patient 
selection), prophylactic treatment of high-risk pa tients after an episode of acute Q fever 
can be beneficial and is widely advised [30-32]. In our study, not all patients who had an 
indication according to our definition received pro phylaxis. Chronic Q fever developed in 
3 of 6 patients who did not receive prophylaxis, in contrast to none of the patients who 
received prophylaxis, which is a difference that clearly supports findings of other studies in 
which prophylactic treat ment was suggested to prevent development of chronic Q fever in 
patients with risk factors for this disease [12, 14]. On the basis of these results, prophylactic 
treatment is advised if risk factors for developing chronic Q fever exist, but potential side 
effects must be taken into consideration [33].
For 48 of 67 patients without indication for prophylactic treatment, follow-up data were 
available on development of chronic Q fever. Chronic Q fever developed in 3 (6%) of these 
patients, which is slightly higher than expected [1, 34]. This finding might be explained 
by the fact that we included only patients who were referred to a hospital, and therefore 
selected patients most affected by C. burnetii infection. It is possible that more severely 
acute Q fever predisposes for development of chronic Q fever [13].
After having acute Q fever, patients often report long-lasting fatigue, which frequently 
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persists for >6 months. This symptom after acute Q fever has been designated Q fever 
fatigue syndrome. Our data suggest a prevalence of 11%, which is lower than expected; 
other studies reported a prevalence of ≈20% worldwide and a higher prevalence in the 
Netherlands [6, 35, 36]. The prevalence found in this study is presumably an underestimation 
because proper analysis was not performed for most patients.
Although we found some differences in clinical mani festations for patients with acute Q 
fever coming to a hospi tal compared with controls, considerable overlap between both 
groups hamper the use of these variables for clini cal differentiation. Differentiating C. 
burnetii from other pathogens is not possible without Q fever serologic analy sis and PCR 
in patients coming to a hospital. In disease-endemic areas or in instances in which patients 
have risk factors for Q fever, suspicion should remain high, and the threshold for performing 
Q fever serologic analysis and PCR should remain low. Because only 46% of patients received 
adequate treatment acute Q fever in our study, treatment for acute Q fever should be 
improved. Further more, our findings underline the recommendation that pro phylactic 
treatment should be given to patients with risk factors for developing chronic Q fever. 
However, more studies are needed to develop uniform guidelines with re gard to optimal 
prophylactic treatment.
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ABSTRACT
Background: Chronic Q fever usually presents as endocarditis or endovascular infection. 
We investigated whether 18F-FDG PET/CT and echocardiography were able to detect the 
localization of infection. Also, the utility of the modified Duke criteria was assessed.
Methods: Fifty-two patients, who had an IgG titre of ≥1024 against C. burnetii phase I ≥3 
months after primary infection or a positive PCR ≥1 month after primary infection, were 
retrospectively included. Data on serology, the results of all imaging studies, possible risk 
factors for developing proven chronic Q fever and clinical outcome were recorded.
Results: According to the Dutch consensus on Q fever diagnostics, 18 patients had proven 
chronic Q fever, 14 probable chronic Q fever, and 20 possible chronic Q fever. Of the patients 
with proven chronic Q fever, 22% were diagnosed with endocarditis, 17% with an infected 
vascular prosthesis, and 39% with a mycotic aneurysm. 56% of patients with proven chronic 
Q fever did not recall an episode of acute Q fever. Ten out of 13 18F-FDG PET/CT-scans in 
patients with proven chronic Q fever localized the infection. TTE and TEE were helpful in 
only 6% and 50% of patients, respectively.
Conclusions: If chronic Q fever is diagnosed, 18F-FDG PET/CT is a helpful imaging technique 
for localization of vascular infections due to chronic Q fever. Patients with proven chronic 
Q fever were diagnosed significantly more often with mycotic aneurysms than in previous 
case series. Definite endocarditis due to chronic Q fever was less frequently diagnosed in the 
current study. Chronic Q fever often occurs in patients without a known episode of acute Q 
fever, so clinical suspicion should remain high, especially in endemic regions. 
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BACKGROUND
Q fever is a zoonosis caused by Coxiella burnetii [1, 2]. The acute form of Q fever is 
asymptomatic in 60% of patients. Patients with symptomatic disease usually present with 
mild flu-like symptoms, pneumonia or hepatitis [1, 3]. Following primary infection, 1-5% of 
patients develop chronic Q fever [1, 4-6]. In the literature, the most described localization 
of chronic Q fever is endocarditis, accounting for 60-80% of cases [1, 2, 7, 8]. Less frequently 
reported manifestations of chronic Q fever include infections of aneurysms or vascular 
prostheses (9% of cases), chronic infections during pregnancy (5%) and other persistent 
infections (8%), such as osteomyelitis and chronic hepatitis [8, 9]. However, following the 
recent Q fever epidemic in the Netherlands [10-12], substantially more patients have been 
diagnosed with an infected aneurysm or vascular prosthesis [4, 13].
The diagnosis of chronic Q fever is challenging. Persistent infection usually develops 
insidiously and most patients present with non-specific symptoms such as low-grade fever, 
night sweats, weight loss, hepatosplenomegaly, and a persistently raised erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) [1, 3, 8, 14, 15]. Both serology and 
PCR aid the laboratory diagnosis of chronic Q fever [16, 17]. High levels of antibodies to 
phase I more than 3 months after primary infection are found in chronic Q fever, whereas 
antibodies to phase II predominate after convalescence from acute Q fever without signs 
of chronic infection [5, 16, 18]. Localization of infectious foci is important, because, in 
addition to prolonged antimicrobial therapy, adjuvant therapeutic measures such as surgical 
drainage or graft replacement are often necessary [9, 19]. This demonstrates the need for 
reliable imaging methods. Infected aneurysms or vascular prostheses can be identified by 
using computed tomography (CT) or 18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET/CT) [20-23]. In case of Q fever endocarditis, however, the diagnosis is usually more 
complex and vegetations are rarely seen by echocardiography [18, 24, 25]. This commonly 
delays the diagnosis with several months [26].
From 2007 until 2010, the southern part of the Netherlands faced the largest outbreak of 
Q fever ever reported [4, 10]. Physicians were confronted with an increasing number of 
patients with suspected chronic infection. The Dutch Q fever consensus group provided 
a new guideline on the diagnosis of chronic Q fever discriminating 3 categories: possible, 
probable and proven chronic Q fever [15]. We investigated whether FDG-PET/CT and 
echocardiography were able to detect the localization of infection in all patients with 
chronic Q fever treated at 2 hospitals specialized in Q fever in the Netherlands. In addition, 
the utility of the modified Duke criteria was assessed.
METHODS
Study design and patients
All patients referred to Radboud University Nijmegen Medical Centre and Canisius 
Wilhelmina Hospital in Nijmegen, the Netherlands between August 2008 and March 2011 
were retrospectively included if they fulfilled the following criteria: detection of C. burnetii 
DNA in serum or tissue by PCR ≥1 month after primary infection or an anti-phase I IgG titre 
of ≥1024 against C. burnetii phase I ≥3 months following acute Q fever. Patients without 
symptomatic acute infection were included if anti-phase I IgG remained >1024 over the 
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course of >3 months, or if there was positive serum PCR over the course of >1 month. The 
exclusion criterion was age <18 years. For each patient a standardized case report form was 
completed. According to the Dutch law, this study was exempt from approval by an ethics 
committee, because of the retrospective character of this study and the anonymous storage 
of data.
Diagnostic work-up
Serology and molecular detection
In 1994, the French National Centre for Rickettsial Diseases proposed a cut-off value 
for anti-phase I IgG of 1:800 for the diagnosis of chronic Q fever, using an in-house 
immunofluorescence assay (IFA) [16]. This cut-off value was adopted by the modified Duke 
criteria [27] and is considered as diagnostic for chronic Q fever in most literature. However, 
it is recently recognized that the results of Q fever IFA vary according to the centre in which 
they are carried out and the methods used (commercially available immunofluorescence 
kits) [28, 29]. This also applies to the Dutch situation, where much higher anti-phase I 
IgG titres were measured, especially during the first months after acute infection [4]. The 
Dutch Q fever consensus group proposed a cut-off value for anti-phase I IgG of 1:1024 
(immunofluorescence assay; Focus Diagnostics, Inc., Cypress, CA, USA), measured at least 3 
months after acute infection, for the diagnosis of chronic Q fever in the Netherlands. In our 
study, sera were also tested for C. burnetii antibodies using a complement fixation test (CFT) 
(Institute Virion/Serion, GmbH, Würzburg, Germany), testing only anti-phase II antibodies.
Dutch consensus on chronic Q fever
The guideline on the classification of chronic Q fever [15], that has been developed by the 
Dutch Q fever consensus group, was used for diagnosis and classification of chronic Q fever 
in this study. This guideline uses a combined approach based on risk factors, symptoms, 
microbiological findings and imaging studies to discriminate 3 groups of chronic Q fever:
Proven chronic Q fever Chronic Q fever is considered proven in case of (1) a positive C. 
burnetii PCR on blood or tissue without evidence for acute Q fever OR (2) IFA anti-phase I IgG 
≥1024 is present >3 months after acute infection AND definite endocarditis according to the 
modified Duke criteria OR (3) IFA ≥1024 for anti-phase I IgG AND proven vascular infection 
by abdominal ultrasound (AUS), CT, or FDG-PET/CT.
Probable chronic Q fever Chronic Q fever is classified as probable when IFA anti-phase I IgG 
≥1024 is present >3 months after acute infection in combination with (1) valvular defects 
not meeting the modified Duke criteria OR (2) a known aneurysm and/or vascular or cardiac 
valve prosthesis without signs of infection by means of echocardiography, FDG-PET/CT, CT or 
AUS OR (3) suspected osteomyelitis or hepatitis as manifestation of chronic Q fever OR (4) 
pregnancy OR (5) symptoms of chronic infection OR (6) granulomatous tissue inflammation, 
histologically proven OR (7) being immunocompromised.
Possible chronic Q fever Possible chronic Q fever is diagnosed when IFA anti-phase I IgG 
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≥1024 is present >3 months after acute infection without manifestations meeting the 
criteria for proven or probable chronic Q fever.
Modified Duke criteria
The modified Duke criteria for infective endocarditis (IE) [27] were applied to all patients who 
underwent echocardiography. As a result, patients were stratified into 3 different groups: 
definite, possible and rejected IE. Besides the well-adopted modified Duke criteria by Li and 
colleagues [27], we also assessed 2 adjusted versions of these criteria that have been used 
previously in studies on Q fever endocarditis. In the first adjustment, the molecular (serum 
PCR) diagnosis of C. burnetii was considered as an additional major criterion [17, 30]. In 
the second adjustment, the echocardiographic minor criteria that were eliminated by the 
modified Duke criteria in 2000 were reintroduced [27, 31]. Echocardiographic minor criteria 
include nodular valvular thickening, nonoscillating targets, and new valvular fenestrations 
[31].
Imaging studies
Data on the following imaging studies were recorded: AUS, CT, FDG-PET/CT, transthoracic 
echocardiography (TTE) and transesophageal echocardiography (TEE). FDG-PET/CT-scans 
were performed according to international guidelines [32], using integrated PET/CT-
scanners (Biograph™; Siemens, Knoxville, TN, USA or Gemini™, Philips, Eindhoven, the 
Netherlands). All FDG-PET/CT-scans were performed in regular patient care and therefore 
reviewed by specialized nuclear radiologists from the department of Nuclear Medicine, 
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, as well as the 
department of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands. 
Higher metabolic activity than physiological uptake in surrounding tissue in tissues with 
normally low physiological uptake was considered to be indicative of infection. In addition, 
irregular/localized FDG-uptake in tissues with normally homogenous uptake was considered 
indicative of infection. Each original report was used to score for relevant abnormal findings. 
If these findings enabled localization of infection, they were considered helpful. Abnormal 
results that gave rise to further analysis, i.e. suspected malignancy, but were not caused by 
chronic Q fever, were labelled as unexpected findings.
Clinical data and outcome
Acute Q fever infection was regarded symptomatic if patients were diagnosed with Q fever 
pneumonia or if they could recall an episode of fever and pneumonia and/or headache, 
that was not caused by other known pathogens and that preceded the first positive Q fever 
serology or positive serum PCR. Patients were regarded to have pre-existing valvular disease 
if they were previously known with a valvulopathy ≥grade II (stenosis or insufficiency, 
including congenital heart disease), or if they had a medical history of valve replacement. 
Valvular dysfunction was defined as the aggravation of pre-existing valvulopathies to ≥grade 
2, the occurrence of new valvulopathies of ≥grade 2 or signs of artificial valve dysfunction, 
or evidence of increasing heart failure or the need for acute cardiac valve replacement. 
Data on other possible risk factors for chronic Q fever were collected (age, smoking, known 
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aneurysm, presence of a vascular prosthesis, immunosuppression or –deficiency, other 
co-morbidity, and symptomatic acute Q fever). The diagnostic work-up was considered 
complete if both echocardiography and screening for abdominal infection were completed. 
Patients were considered to be cured if their anti-phase I IgG antibody titre at least showed 
a fourfold decrease or had declined to <1024 during subsequent serological testing, serum 
PCR had become and/or remained negative, and diagnostic imaging during follow-up 
showed no signs of active infection.
Statistical methods
All data were analyzed using SPSS (version 16.0, SPSS, Inc.). Two-tailed Pearson’s chi-square 
tests or Fischer’s exact tests were used to compare qualitative data, whereas mean values 
were analyzed by Student’s t-tests. Differences were considered to be statistically significant 
at a p-value less than 0.05.
RESULTS
All 52 patients fulfilling the inclusion criteria were included in the study (Tables 1, 2, 3).
Table 1: Population characteristics of 52 patients with possible, probable and proven chronic Q fever*
Proven chronic Q fever Probable chronic Q 
fever
Possible chronic Q fever
Number of patients Number of patients Number of patients
(% or range) (% or range) (% or range)
General
     Number of patients 18 14 20
     Male sex 17 (94) 8 (57) 11 (55)
     Age at diagnosis 61 ± 16 yrs (26-88) 63 ± 12 yrs (43-84) 54 ± 15 yrs (26 – 81)
     Mean BMI 25 ± 3 kg/m2 (18-30) 25 ± 4 kg/m2 (18-30) 25 ± 7 kg/m2 (19-41)
     History of smoking 14 (78) 9 (64) 10 (50)
     Symptomatic acute 
     infection
8 (44) 12 (86) 13 (65)
     Symptomatic chronic    
     infection
14 (78) 2 (14) 0
     Mean interval acute Q 
     fever to analysis
12 ± 9 months (1-27) 16 ± 11 months (1-41) 7 ± 5 months (1-15)
     Antibiotic therapy for 
     chronic Q fever
18 (100) 7 (50) 3 (15)
Localization of infection 13 (72) 2 (14) 0
     Definite endocarditis 4 (22)†‡ 2 (14)§ 0
     Vascular prosthesis 3 (17)‡ 0 0
     Mycotic aneurysm 7 (39) 0 0
     Focus unknown 5 (28) 12 (86) 20 (100)
* Adapted from Wegdam-Blans et al. [15].
† Definite endocarditis according to the modified Duke criteria.
‡ One patient had a definite endocarditis according to the modified Duke criteria and an infected 
vascular prosthesis.
§ Possible endocarditis according to the modified Duke criteria.
Abbreviation: BMI = body mass index.
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Table 2: Risk factors for developing chronic Q fever in 52 patients with possible, probable and 
proven chronic Q fever*
Proven chronic Q 
fever
Probable chronic Q 
fever
Possible chronic Q 
fever
Number of 
patients (%) 
Number of patients 
(%)
Number of patients 
(%)
Number of patients 18 14 20
Pre-existing valvular disease†‡ 5 (28) 4 (29) 0
     Mitral regurgitation 0 2 (14) 0
     Tricuspid regurgitation 0 1 (7) 0
     Bicuspid aortic valve 0 1 (7) 0
     Congenital (not bicuspid aortic valve) 1 (6) 1 (7) 0
     Rheumatic fever 1 (6) 0 0
     Cardiac valve prosthesis† 4 (22) 0 0
       Biological aortic prosthesis 3 (17) 0 0
       Biological mitral prosthesis 1 (6) 0 0
       Mechanical aortic prosthesis 1 (6) 0 0
Known aneurysm 8 (44) 1 (7) 0
     Abdominal aortic aneurysm 7 (39) 0 0
     Dilated aortic root 1 (6) 0 0
     Cerebral aneurysm 0 1 (7) 0
Vascular prosthesis 11 (61) 4 (29) 0
     Abdominal aortic graft 7 (39) 1 (7) 0
     Thoracic aortic graft 2 (11) 0 0
     PTA, iliacal or renal arteries 1 (6) 2 (14) 0
     Goretex vascular shunt 1 (6) 0 0
     Coiling of cerebral aneurysm 0 1 (7) 0
Immunocompromised 1 (6) 6 (43) 0
     Immunosuppressive therapy 1 (6) 4 (29) 0
     Myelodysplastic syndrome 0 2 (14) 0
Co-morbidity† 18 (100) 14 (100) 8 (40)
     Chronic renal insufficiency 6 (33) 4 (29) 1 (5)
     Diabetes 3 (17) 2 (14) 4 (20)
     Active malignancy 1 (6) 4 (29) 1 (5)
     Systemic sclerosis 1 (6) 2 (14) 0
     COPD 2 (11) 3 (21) 5 (25)
     Other§ 5 (28) 3 (21) 3 (15)
* Adapted from Wegdam-Blans et al. [15].
† Multiple predisposing conditions are possible for a patient.
‡ Including cardiac valve prosthesis; valvulopathies were considered clinically significant if ≥grade II.
§ Including severe peripheral arterial disease, coronary artery bypass graft, congestive heart failure 
and liver cirrhosis.
Abbreviations: PTA = Percutaneous transluminal angioplasty, COPD = Chronic obstructive pulmonary 
disease.
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Table 3: Diagnostics, treatment and outcomes in 52 patients with possible, probable and proven 
chronic Q fever*
Proven chronic Q fever Probable chronic Q 
fever
Possible chronic Q 
fever
Number of patients Number of patients Number of patients
(% or range) (% or range) (% or range)
Number of patients 18 14 20
Serum PCR 12 (67) 0 0
Tissue PCR 6 (33) 0 0
Anti-phase I IgG at diagnosis 4096 (256-65536) 2048 (1024-32768) 2048 (1024-16384)
CFT at diagnosis 1280 (0-20480) 320 (80-5120) 320 (40-2560)
Time to anti-phase I IgG <1024 (months) 23.3 ± 7.9 [n=4] 12.6 ± 3.9 [n=5] 7.5 ± 5.1 [n=8]
Time to negative serum PCR 3.6 ± 3.0 [n=7] NA NA
Complete diagnostic work-up 16 (89) 9 (64) 8 (40)
Abdominal ultrasound 8 (44) 6 (43) 8 (40)
     Fluid collection 3 0 0
     Increased diameter of aneurysm 1 0 0
     Helpfulness 4/8 (50) 0 0
Screening abdominal CT 2 (11%) 1 (7) -
     Aneurysm 2 0 -
     Suggestive of infected aneurysm or 
     prosthesis
1 0 -
     Helpfulness 2/2 (100) 0 -
CT on account of PET/CT 3 (17) 0 0
     Aneurysm 2 - -
     Suggestive of infected aneurysm or    
     prosthesis
3 - -
     Helpfulness 3/3 (100) - -
FDG-PET/CT 13 (72) 8 (57) 9 (45)
     Focal uptake aneurysm 7 0 0
     Focal uptake vascular prosthesis 3 0 0
     Soft tissue inflammation 4 0 0
     Para-aortal lymfadenopathy 1 0 0
     Mediastinal lymfadenopathy 1 3 0
     Unexpected findings 4 4 2
     Helpfulness 10/13 (77) 0 0
TTE 16 (89) 13 (93) 12 (60)
     Echocardiographic major criteria 0 0 0
     Echocardiographic minor criteria 12 8 4
     Helpfulness 1/16 (6) 1/13 (8)† 0
TEE 6 (33) 3 (21) 4 (20)
     Echocardiographic major criteria 2 0 0
     Echocardiographic minor criteria 6 1 3
     Helpfulness 3/6 (50) 1/3 (33)† 0
Antibiotic therapy 18 (100) 7 (50) 3 (15)
Mortality during treatment 3 0 0
Ongoing treatment 13 7 2
Treatment completed successfully 2 0 1
     Mean duration of treatment (months) 21.5 ± 6.4 [n=2] - 2 [n=1]
Surgery 6 (33) 0 0
     Aortic graft surgery‡ 4 (22) - -
     Cardiac valve surgery 2 (11) - -
Mortality 3 (17) 0 0
* Adapted from Wegdam-Blans et al. [15].
† TTE and TEE were considered helpful in 2 patients where pre-existing valvulopathies aggravated.
‡ One patient had surgery twice.
Abbreviations: PCR = Polymerase chain reaction, CFT = Complement fixation test, NA = Not applicable, CT 
= Computed tomography, FDG-PET/CT = 18F-fluorodeoxyglucose positron emission tomography combined 
with CT, TTE = Transthoracic echocardiography, TEE = Transesophageal echocardiography.
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Table 3: Diagnostics, treatment and outcomes in 52 patients with possible, probable and proven 
chronic Q fever*
Proven chronic Q fever Probable chronic Q 
fever
Possible chronic Q 
fever
Number of patients Number of patients Number of patients
(% or range) (% or range) (% or range)
Number of patients 18 14 20
Serum PCR 12 (67) 0 0
Tissue PCR 6 (33) 0 0
Anti-phase I IgG at diagnosis 4096 (256-65536) 2048 (1024-32768) 2048 (1024-16384)
CFT at diagnosis 1280 (0-20480) 320 (80-5120) 320 (40-2560)
Time to anti-phase I IgG <1024 (months) 23.3 ± 7.9 [n=4] 12.6 ± 3.9 [n=5] 7.5 ± 5.1 [n=8]
Time to negative serum PCR 3.6 ± 3.0 [n=7] NA NA
Complete diagnostic work-up 16 (89) 9 (64) 8 (40)
Abdominal ultrasound 8 (44) 6 (43) 8 (40)
     Fluid collection 3 0 0
     Increased diameter of aneurysm 1 0 0
     Helpfulness 4/8 (50) 0 0
Screening abdominal CT 2 (11%) 1 (7) -
     Aneurysm 2 0 -
     Suggestive of infected aneurysm or 
     prosthesis
1 0 -
     Helpfulness 2/2 (100) 0 -
CT on account of PET/CT 3 (17) 0 0
     Aneurysm 2 - -
     Suggestive of infected aneurysm or    
     prosthesis
3 - -
     Helpfulness 3/3 (100) - -
FDG-PET/CT 13 (72) 8 (57) 9 (45)
     Focal uptake aneurysm 7 0 0
     Focal uptake vascular prosthesis 3 0 0
     Soft tissue inflammation 4 0 0
     Para-aortal lymfadenopathy 1 0 0
     Mediastinal lymfadenopathy 1 3 0
     Unexpected findings 4 4 2
     Helpfulness 10/13 (77) 0 0
TTE 16 (89) 13 (93) 12 (60)
     Echocardiographic major criteria 0 0 0
     Echocardiographic minor criteria 12 8 4
     Helpfulness 1/16 (6) 1/13 (8)† 0
TEE 6 (33) 3 (21) 4 (20)
     Echocardiographic major criteria 2 0 0
     Echocardiographic minor criteria 6 1 3
     Helpfulness 3/6 (50) 1/3 (33)† 0
Antibiotic therapy 18 (100) 7 (50) 3 (15)
Mortality during treatment 3 0 0
Ongoing treatment 13 7 2
Treatment completed successfully 2 0 1
     Mean duration of treatment (months) 21.5 ± 6.4 [n=2] - 2 [n=1]
Surgery 6 (33) 0 0
     Aortic graft surgery‡ 4 (22) - -
     Cardiac valve surgery 2 (11) - -
Mortality 3 (17) 0 0
* Adapted from Wegdam-Blans et al. [15].
† TTE and TEE were considered helpful in 2 patients where pre-existing valvulopathies aggravated.
‡ One patient had surgery twice.
Abbreviations: PCR = Polymerase chain reaction, CFT = Complement fixation test, NA = Not applicable, CT 
= Computed tomography, FDG-PET/CT = 18F-fluorodeoxyglucose positron emission tomography combined 
with CT, TTE = Transthoracic echocardiography, TEE = Transesophageal echocardiography.
Proven chronic Q fever 
Proven chronic Q fever was diagnosed in 18 patients (Table 1). One patient developed 
systemic sclerosis during treatment. Only 8 patients (44%) recalled an episode of acute Q 
fever. Fourteen patients (78%) had symptomatic chronic infection: fever (9/14), abdominal 
pain (4/14), fatigue (3/14), weight loss (3/14), valvular dysfunction (3/14), night sweats 
(2/14) or lumbar pain (2/14). In two out of five patients with a pre-existing valvulopathy, 
valvular dysfunction occurred (left ventricular function deterioration due to Q fever 
endocarditis, and a new dysfunction of an artificial cardiac valve, as a consequence of Q 
fever endocarditis). One patient with valvular dysfunction was not familiar with a previous 
valvulopathy. The mean interval between symptomatic acute Q fever and the diagnosis 
of chronic Q fever was 12 ± 9 months (range: 1-27). Definite endocarditis was diagnosed 
in 4 patients (22%), an infected vascular prosthesis in 3 patients (17%), and an infected 
aneurysm in 7 patients (39%). One of these patients had both a definite endocarditis and an 
infected vascular prosthesis. In 5 patients (28%), no definite focus was identified. According 
to the modified Duke criteria, 4 of these patients had possible endocarditis and the fifth 
patient declined further diagnostic tests due to his age and underlying medical condition.
The median anti-phase I IgG titre at diagnosis was 4096 (range: 256-65536), and the median 
height of CFT was 1280 (range: 0-20480) (Figures 1 and 2). One patient had an anti-phase 
I IgG titre of only 256 and a negative CFT at diagnosis, but was considered to have proven 
chronic Q fever because serum PCR tested positive >1 month following primary infection. In 
4 patients, the anti-phase I IgG titre decreased to <1024 after a mean duration of treatment 
of 23.3 ± 7.9 months. By PCR, C. burnetii DNA was successfully isolated from tissue samples 
(cardiac valve, vascular prosthesis) in 5 out of 6 patients who underwent surgery (1 patient 
underwent surgery twice). There was 1 positive PCR on fluid spontaneously draining from 
a fistula between an abscess around a vascular prosthesis and the skin. Four out of the 6 
patients with positive fluid/tissue PCR were analyzed by FDG-PET/CT, all of which showed 
FDG-positive lesions. The other 2 were already found to have definite IE according to the 
modified Duke criteria and no FDG-PET/CT was performed. In these 2 patients, PCR was 
positive on infected cardiac valves that were replaced by surgery. In 7 of 12 patients with a 
positive serum PCR, PCR became negative after an average of 3.6 ± 3.0 months. Two patients 
died when PCR had not become negative yet, 1 patient was lost to follow-up, and 2 patients 
still had a positive serum PCR after 4 and 6 weeks of treatment, respectively.
A complete diagnostic work-up for chronic Q fever was performed in 16 patients (89%) (Table 
3). In 2 patients, this work-up was incomplete: 1 patient refused further analysis, and in 1 
patient only echocardiography was done. In 13 patients (72%), FDG-PET/CT was performed, 
which was helpful in identifying the site of infection in 10 of 13 investigations (77%). All 7 
patients with an aneurysm as identified site of Q fever infection showed focal FDG-uptake 
of the aneurysm. Furthermore, all 3 patients with a vascular prosthesis as identified site 
of Q fever infection showed focal uptake around the vascular prosthesis (Figure 3). In 4 
out of the 13 above mentioned FDG-PET/CT-scans, FDG-positive lesions were confirmed by 
positive C. burnetii PCR on tissue. In all of these 4 patients, FDG-PET/CT was conducted 
prior to PCR. In the remaining patients, surgery was not indicated and the lesions were very 
difficult to reach so tissue PCR could not be performed. Unexpected findings were observed 
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in 4 patients (31%). As a result, 2 patients required a biopsy because of focal FDG-uptake in 
the lungs, leading to the diagnosis of lung carcinoma in 1 patient and fibrosis in the other. 
In 1 patient, massive mediastinal lymphadenopathy was seen, eventually leading to the 
diagnosis of systemic sclerosis. CT was performed in 5 patients. Two of these investigations 
were done initially (‘screening abdominal CT’), and the remaining 3 were conducted on 
account of a preceding abnormal FDG-PET/CT-scan (one chest CT and two CT-scans of both 
chest and abdomen). Both screening CT-scans enabled localization of infection and were 
considered helpful. The 3 CT-scans that were performed on the basis of pathology on FDG-
PET/CT all confirmed the abnormal FDG-PET/CT findings. TTE was performed in 16 patients 
(89%); none of these examinations showed a major criterion, whereas echocardiographic 
minor criteria were seen in 12 patients (75%). Nevertheless, TTE was regarded helpful in 
1 patient where nodular valvular thickening of an aortic bioprosthesis was seen. TEE was 
performed in 6 patients (33%), 4 following a prior TTE. In 2 patients, an echocardiographic 
major criterion was observed, whereas echocardiographic minor criteria were recorded 
in all of the performed TEEs. In 3 patients (50%), TEE was considered helpful: 2 because 
of echocardiographic major criteria and 1 as a result of aggravated pre-existing valvular 
disease. In 4 out of 5 patients with no definite localization and possible IE there were minor 
echocardiographic criteria. In all 5 patients TTE was performed. Two out of 5 TTE’s showed 
minor criteria. In 4 patients TEE was performed, 3 of which showed minor criteria.
Long-term antibiotic treatment (doxycycline 200 mg/day and hydroxychloroquine 600 
mg/day) was given to all patients. Thirteen patients (72%) are still under treatment, 3 of 
whom are being treated for more than 18 months. Three patients (17%) died during the 
course of therapy as a consequence of chronic Q fever infection. Death from chronic Q 
fever was defined as death as a result of active chronic infection. One patient died at 11 
months following cardiac valve replacement due to progressive heart failure, probably as a 
result of artificial valve dysfunction due to chronic Q fever. PCR on valve tissue was positive. 
The second patient died in the perioperative period (in the first month) due to bleeding 
following acute aneurysm repair for a symptomatic aneurysm. PCR on aneurysm tissue was 
positive for Q fever. The third patient died in the perioperative period (in the first month) 
due to SIRS following acute cardiac valve replacement for severe Q fever endocarditis, with 
tissue PCR being positive. In 2 patients (11%), treatment was completed successfully after a 
treatment duration of 18 and 26 months with a follow-up after completion of treatment of 
16 and 4 months, respectively. Six patients (33%) underwent surgery: abdominal aortic graft 
surgery with open repair was performed in 1 patient, endovascular aneurysm repair (EVAR) 
in 2 patients, first EVAR later followed by abscess drainage, excision of infected tissue and 
lavage with omentum plasty in 1 patient, and cardiac valve replacement in 2 patients.
Probable chronic Q fever
Probable chronic Q fever was diagnosed in 14 patients (Table 1). In this group, 6 patients 
(43%) were immunocompromised (Table 2). Twelve patients (86%) experienced symptomatic 
acute infection in the past. Two patients (14%) experienced symptoms of chronic infection: 
fever and night sweats (n=1), and weight loss and fatigue (n=1). The mean interval between 
acute Q fever and analysis for chronic infection was 16 ± 11 months (range: 1-41 months). 
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Figure 1: Titres of anti-phase I IgG at the time of chronic Q fever diagnosis
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Figure 2: Titres of complement fixation test at the time of chronic Q fever diagnosis
Abbreviation: CFT = Complement fixation test.
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 Figure 3. 18F-FDG-PET/CT image demonstrating a mycotic aneurysm
18F-FDG-PET/CT images (left column coronal sections, right column transverse sections, upper row 
PET images, lower row PET/CT fusion images) of a patient with proven chronic Q fever demonstrating 
a mycotic aneurysm and associated abscess adjacent to the left common iliac artery (arrows). 
Abbreviations: 18FDG-PET/CT = 18F-fluorodeoxyglucose positron emission tomography combined with 
CT. 
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While in 12 patients (86%) no focus was localized, endocarditis (possible endocarditis 
according to the modified Duke criteria) was regarded as the most probable site of infection 
in 2 cases.
The median anti-phase I IgG titre at first analysis was 2048 (range: 1024-32768) and the 
median CFT-value was 320 (range: 80-5120). In 5 patients the anti-phase I IgG titre decreased 
to <1024. Of these 5 patients, 2 received treatment for chronic Q fever and their anti-phase 
I IgG titre decreased to <1024 in 12 and 18 months, respectively. In the 3 patients without 
treatment, anti-phase I IgG titre decreased to <1024 after 4, 10, and 12 months, respectively.
A complete diagnostic work-up was performed in 9 patients (64%) (Table 3). Two patients 
were asymptomatic and considered low-risk, 1 patient refused further analysis because of 
co-morbidity, and in 2 patients FDG-PET/ CT was postponed (because of recent surgery and 
a concomitant severe pneumonia, respectively). FDG-PET/CT was performed in 8 patients 
(57%). None of these investigations localized infection (otherwise the patient would 
have proven chronic Q fever). Four of the performed FDG-PET/CT-scans (50%) revealed 
unexpected findings. These include mediastinal lymphadenopathy (eventually leading to 
the diagnosis of systemic sclerosis) in 1 patient, and focal FDG-uptake in the dental region in 
another patient. In 1 patient with multiple enlarged mediastinal lymph nodes, subsequent 
broncheoalveolar lavage (BAL) did not lead to a definitive diagnosis. In 1 patient, multiple 
unexpected findings were observed (focal uptake in the left thyroid gland followed by 
hemithyroidectomy leading to a diagnosis of adenoma and multiple foci in the prostate and 
iliac bone, leading to the diagnosis of prostate carcinoma). TTE was performed in 13 patients 
(93%) and was considered helpful once (8%), because progression of pre-existing valvular 
disease was observed. In 8 patients (62%), echocardiographic minor criteria were recorded. 
TEE was performed in 3 patients (21%), which was helpful in 1 patient. Echocardiographic 
minor criteria were seen in 1 patient (33%).
Seven patients (50%) received long-term treatment with antibiotics (doxycycline 200 mg/
day and hydroxychloroquine 600 mg/day); none of these patients completed treatment yet. 
Of the remaining 7 patients, a decision on treatment was pending in 2 patients, 3 were not 
treated because of severe co-morbidity, and 3 were asymptomatic and considered low-risk. 
All patients that were not on antibiotic treatment were followed closely.
Possible chronic Q fever
Twenty patients were diagnosed with possible chronic Q fever (Table 1). Thirteen (65%) 
patients could recall a symptomatic episode of acute Q fever and none of the patients 
experienced symptoms of chronic infection. The mean interval between acute infection and 
analysis for chronic Q fever was 7 ± 5 months (range: 1-15 months). In 77% of the patients 
with possible chronic Q fever and a previously known episode of acute Q fever, routine 
serological follow-up at 3, 6, 9 and 12 months was performed.
The median anti-phase I IgG titre at first analysis was 2048 (range: 1024-16384), and the 
median CFT-value was 320 (range: 40-2560). In 8 patients, the anti-phase I IgG titre decreased 
to <1024, with an average of 7.5 ± 5.1 months. Of these patients, 1 patient was treated and 
the anti-phase I IgG titre decreased to <1024 within 7 months.
A complete diagnostic work-up was performed in 8 out of 20 patients (40%) (Table 3). 
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Six patients were asymptomatic and considered low-risk, 1 patient suffered from severe 
co-morbidity, 3 patients were lost to follow-up, and 2 patients were not yet completely 
analyzed. FDG-PET/CT was performed in 9 patients (45%). None of these investigations 
were helpful. Two FDG-PET/CT-scans (22%) resulted in an unexpected finding: 1 patient 
with FDG-uptake in the colon, followed by colonoscopy diagnosing a non-neoplastic polyp, 
and 1 patient with FDG-uptake in the left clavicle, followed by CT that was normal. TTE was 
performed in 12 patients (60%) and was considered helpful in none of the investigations. In 
4 patients (33%), echocardiographic minor criteria were recorded. TEE was performed in 4 
patients (20%), being helpful in none of the patients. Echocardiographic minor criteria were 
seen in 3 patients (75%).
Long-term antibiotic treatment was prescribed to three patients (15%) because of debilitating 
symptoms (severe fatigue and muscle ache). One of these patients initially started treatment 
because of suspected chronic Q fever, but stopped after 2 months because anti-phase I IgG 
titres were rapidly decreasing. The 2 other patients had not completed treatment yet. Of 
the remaining 17 patients, 11 were considered low-risk, in 5 a decision on treatment was 
pending, and 1 patient had severe co-morbidity.
Comparison between patients with proven chronic Q fever and patients with probable and 
possible chronic Q fever 
In order to evaluate potential differences between patients with proven chronic Q fever 
and those with possible or probable chronic Q fever, data were compared by univariate 
analysis (Table 4). Age at diagnosis, history of smoking, and mean interval from acute 
infection to analysis for chronic Q fever did not differ significantly between the groups. Male 
sex (p=0.04) and symptomatic chronic infection (p<0.01) were significantly more present in 
patients with proven chronic Q fever. Concerning risk factors, which were found previously 
in other studies, the presence of pre-existing valvular disease, indication for endocarditis 
prophylaxis, and immunodeficiency did not differ significantly between the groups in our 
study. In contrast, cardiac valve prostheses (p=0.01), known aneurysms (p<0.01), and 
vascular prostheses (p<0.01) were significantly associated with proven chronic Q fever.
Anti-phase I IgG (p=0.01) and CFT-values (p<0.01) were significantly higher in patients with 
proven chronic Q fever when compared to the groups of probable and possible Q fever 
combined (Figures 1 and 2). Also, the mean time to anti-phase I IgG <1024 was significantly 
longer in this group (p<0.01). In contrast to AUS and FDG-PET/CT, the helpfulness of CT, TTE 
and TEE showed no significant differences between the groups. Both antibiotic treatment 
(p<0.01) and surgery (p<0.01) were used more often in patients with proven chronic Q 
fever. Most importantly, a clear association was seen between proven chronic Q fever and 
mortality rates (p=0.03).
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Table 4: Significant differences between patients with proven chronic Q fever and patients with 
probable and possible chronic Q fever (univariate analysis)*
Proven chronic Q 
fever
Probable and possible 
chronic Q fever
Significance 
Number of patients Number of patients (p-value)
(% or range) (% or range)
Patient characteristics
     Number of patients 18 34
     Male sex 17 (94) 19 (56) 0.04
     Symptomatic chronic infection 14 (78) 2 (6) <0.0001
     Cardiac valve prosthesis 4 (22) 0 0.01
     Known aneurysm 8 (44) 1 (3) 0.0004
     Abdominal aortic aneurysm, infrarenal 7 (39) 0 0.0003
     Vascular prosthesis 11 (61) 4 (12) 0.004
     Co-morbidities 18 (100) 22 (65) 0.021
Diagnostic work-up 16 (89) 17 (50) 0.04
     Positive serum PCR 12 (67) 0 <0.0001
     Positive tissue PCR 6 (33) 0 0.011
     Anti-phase I IgG at diagnosis 4096 (256-65536) 2048 (1024-32768) 0.013
     CFT at diagnosis 1280 (0-20480) 320 (40-5120) 0.001
     Months to anti-phase I IgG <1024 23.3 ± 7.9 [n=4] 9.5 ± 5.2 [n=13] 0.001
     Helpfulness of abdominal ultrasound 4/8 (50) 0/14 (0) 0.01
     Helpfulness of FDG-PET/CT 10/13 (77) 0 <0.0001
Antibiotic therapy 18 (100) 10 (29) <0.0001
     Mortality during treatment 3/18 (17) 0 0.037
     Ongoing treatment 13/18 (72) 9/10 (90) 0.008
Surgery 6 (33) 0 0.001
     Aortic graft surgery† 4 (22) 0 0.011
     Cardiac valve surgery 2 (11) 0 NS
Mortality 3 (17) 0 0.033
* Adapted from Wegdam-Blans et al. [15].
† One patient had surgery twice.
Abbreviations: PCR = polymerase chain reaction; CFT = complement fixation test; FDG-PET/CT = 
18F-fluorodeoxyglucose positron emission tomography; NS = not significant.
Analysis after adjustments to the modified Duke criteria
The modified Duke criteria and the 2 aforementioned adjustments to these criteria were 
applied to all patients (Table 5). Applying the modified Duke criteria, 4 cases of definite IE 
were diagnosed, and 20 cases of possible IE. Of 20 patients with possible IE (all groups), 11 
out of 19 patients who underwent TTE had minor criteria by TTE, and 4 out of 7 patients who 
underwent TEE had minor criteria. When echocardiographic minor criteria were included 
(first adjustment), 8 cases were considered definite IE and 28 cases possible IE. Including 
a positive serum PCR for C. burnetii as a major criterion (second adjustment), 12 patients 
scored definite IE and 14 possible IE. The modified Duke criteria were compared with the 
modified Duke criteria including our first and second adjustments, respectively, by a 2-tailed 
Wilcoxon test, which showed significant differences (p=0.046 and p<0.01, respectively).
230 | CHAPTER 8
Table 5: Comparison of (adjustments to) modified Duke criteria: complete case series
Modified 
Duke 
criteria 
[27]
Modified Duke 
criteria, including 
echocardiographic 
minor criteria [31]
Significance† 
(comparison with 
modified Duke 
criteria) (p-value)‡
Modified Duke 
criteria, including 
PCR as a major 
criterion [30]
Significance† 
(comparison 
with modified 
Duke criteria) 
(p-value)§
Definite IE (%) 4 (9) 8 (19) 0.046 12 (28) 0.005
Possible IE (%) 20 (47) 28 (65) 0.046 14 (33) 0.034
Rejected IE (%) 19 (44) 7 (16) 0.001 17 (40) 0.157
Total 43* 43* - 43* -
† Wilcoxon test, 2-tailed.
‡ Modified Duke criteria compared to ‘modified Duke criteria, including echocardiographic minor criteria’.
§ Modified Duke criteria compared to ‘modified Duke criteria, including PCR as a major criterion’.
* Nine patients were not examined by echocardiography; the modified Duke criteria could therefore not 
be calculated.
Abbreviations: PCR = polymerase chain reaction; IE = infective endocarditis.
DISCUSSION
In this study, the diagnostic work-up of 52 patients with chronic Q fever according to the 
Dutch consensus on Q fever diagnostics was evaluated. We demonstrated that FDG-PET/
CT might be a valuable tool for localization of vascular infection with C. burnetii. It was 
shown that infected aneurysms or vascular prostheses are the most common manifestation 
of proven chronic Q fever in our population.
The mean age of patients was similar to previously reported case series of chronic Q fever 
[6, 8, 17]. The overall male predominance has been shown before as well, but the portion 
of male patients with proven chronic Q fever (94%) was distinct. This possibly results from a 
higher incidence of aneurysms and cardiovascular disease in male subjects, which are clear 
risk factors for developing chronic Q fever [3, 8, 33]. A history of smoking was established 
as a risk factor for chronic Q fever, especially in those patients with proven chronic Q fever. 
Smoking was not included in the possible risk factors for developing chronic Q fever in the 
recently published Dutch study by Kampschreur et al. [33]. Furthermore, patients with 
proven chronic Q fever more often had a cardiac valve prosthesis, a known aneurysm, or a 
vascular prosthesis as was also found by Kampschreur et al. [33]. Although reported in some 
previous studies, pre-existing valvular disease other than valve prosthesis did not appear 
to be an important risk factor in this study [6, 14, 33]. A similar observation was done by 
another Dutch group [34, 35], that found a low risk of progression to Q fever endocarditis in 
the presence of degenerative valvular disease.
Only 44% of patients with proven chronic Q fever could recall an episode of acute Q fever, 
compared to 74% of those with possible/probable Q fever. Symptomatic acute infection 
most often results in antibiotic treatment, which might reduce the chance of developing 
proven chronic Q fever. In addition, in patients with acute Q fever, serological follow-up 
is performed while this was of course not the case in patients without symptomatic (and 
thus usually unknown) infection. It is possible that elevating titres of IgG anti-phase I found 
during follow-up led to earlier diagnosis and treatment, possibly preventing progression 
from possible and probable chronic Q fever to proven chronic Q fever.
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A large retrospective study from France identified endocarditis as the predominant 
manifestation of chronic Q fever (73% of cases) [8]. In contrast, only 22% of our patients with 
proven chronic Q fever have been diagnosed with Q fever endocarditis. Infected aneurysms 
and infected vascular prostheses were found in 39% and 17% of patients, respectively. It has 
been suggested that mycotic aneurysms may be caused by non-diagnosed endocarditis in 
patients with chronic Q fever. However, applying the modified Duke criteria to all patients 
with proven chronic Q fever, only 1 patient had an infected vascular prosthesis and definite 
IE at the same time. One patient with an infected vascular prosthesis and 1 patient with an 
infected aneurysm had rejected IE according to the modified Duke criteria. The last patient 
with an infected vascular prosthesis and all other patients with an infected aneurysm had 
possible IE according to the modified Duke criteria. The cause of this striking difference 
in predominant manifestation of chronic Q fever remains largely unclear, and probably 
results from a combination of factors. First, most patients in other series were evaluated 
because of endocarditis, whereas in our case series, also other complaints (fever, night 
sweats, presence of aneurysm) and routine serological follow-up after acute Q fever led 
to evaluation for Q fever because of the current epidemic. In addition, not all patients 
underwent echocardiography, possibly leading to an underestimation of endocarditis in our 
group. Furthermore, it is possible that in those patients without a full diagnostic work-up 
only one site of infection was notified, whereas it is possible that patients had 2 sites of 
infection. Second, pre-existing valvular disease was seen less often in this case series than 
in those patients reported in literature. This could be influenced by the fact that screening 
echocardiography is not performed in patients with acute Q fever in the Netherlands. 
Although our study did not found pre-existing valvular disease to be a significant risk factor 
for proven chronic Q fever, this contrasts with previous studies [6, 14], but is in accordance 
with the other Dutch study on risk factors for developing proven chronic Q fever [33]. Third, 
the Dutch C. burnetii strain is possibly more likely to cause endovascular infection other than 
endocarditis. Even though it is possible that more vascular infections were found because 
FDG-PET/CT was performed more often, it is unlikely that vascular infections would go 
unnoticed in other chronic Q fever series, in which hardly any vascular infection was seen. 
If these patients would have had unidentified vascular infection in addition to endocarditis, 
more complications would be expected because of the high mortality rate of vascular chronic 
Q fever, even in case of optimal (surgical) treatment. Finally, it is not clear if other research 
groups applied the modified Duke criteria in the same strict manner as we did for this study.
In 1994, Durack et al. [31] introduced a new set of diagnostic criteria for IE that subsequently 
came to be known as the Duke criteria. Li and colleagues [27] proposed modifications to the 
Duke criteria in 2000, adding a positive serology for C. burnetii as a major criterion, which had 
already been proposed earlier by Fournier et al. [18]. In addition, the modifications included 
the elimination of echocardiographic minor criteria, because a widespread use of TEE was 
assumed. It is well-recognized that the sensitivity of these criteria is diminished in Q fever 
endocarditis, since it is known for its subtle valve abnormalities and absence of vegetations 
[4, 18, 24]. Nonetheless, we strictly applied the modified Duke criteria to this case series, 
resulting in only 4 patients (9%) with definite IE and 20 patients (47%) with possible IE. Even 
if we merely reflect on patients with proven chronic Q fever, the percentage of definite IE 
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was only 22%. There were another 5 patients (28%) with an unidentified focus, 4 of whom 
had possible IE according to the modified Duke criteria. TEE was performed in a minority 
of patients (25%), while the elimination of echocardiographic minor criteria was based on 
the widespread use of TEE [27]. We cannot rule out the possibility that in some patients 
vegetations were missed because TTE was conducted exclusively.
In the past, several adjustments have been proposed to further improve the sensitivity of 
the modified Duke criteria. One of these adjustments was the use of PCR techniques as a 
major criterion [30], which is not implemented in international guidelines. However, in a 
recent study on Q fever endocarditis [6], a positive serum PCR served as major criterion. It is 
not clear whether PCR was an additional major criterion or served as substitute for serology. 
The theoretical addition of a positive serum PCR as major criterion to the modified Duke 
criteria appeared most useful. From our experience, we suggest that a positive serum PCR 
for C. burnetii in patients with chronic Q fever without an identified site of infection should 
be treated as Q fever endocarditis. Furthermore, the presence of echocardiographic minor 
criteria should raise the clinician’s suspicion of endocarditis, and TEE should be performed 
in all patients with chronic Q fever with an unknown focus. It is essential to bear in mind 
that the Duke criteria are useful for the classification of IE, but that they were designed for 
research purposes and thus should not replace clinical judgment in clinical practice.
CT was performed initially in only 2 patients with proven chronic Q fever, making it impossible 
to estimate the helpfulness of this technique. In contrast, FDG-PET/CT, localized infection in 
77% of patients with proven chronic Q fever, which suggests that FDG-PET/CT is a valuable 
tool for the localization of vascular Q fever infection. FDG-PET/CT is also very well suited 
for diagnosing osteomyelitis, which is another possible focus of chronic Q fever. A well-
recognized disadvantage of FDG-PET/CT is its specificity, as it does not differentiate between 
inflammation, infection, and malignancy. As such, unexpected findings were observed in 9 
patients (30%), including the detection of previously unknown malignancies in 2 patients 
and newly diagnosed systemic sclerosis in another 2 patients. Five patients underwent 
invasive diagnostic procedures as a result of suspected malignancies, but pathological 
examination remained negative. The number of unexpected findings is higher than found 
in previous studies on the use of FDG-PET in other infections and fever of unknown origin 
(FUO) [36, 37], which might be explained by the higher age of the patients and the male 
predominance in combination with a higher than average percentage of smokers, increasing 
the risk of associated malignancy when compared to patients with FUO. A limitation of our 
study is of course its retrospective character. Unfortunately, not all patients underwent a 
complete diagnostic work-up. Therefore, it is important to bear in mind that some patients 
might have had two sites of infection, which might have been missed. This emphasizes the 
need for a full diagnostic work-up in patients with chronic Q fever. Also, the time point of 
diagnostic imaging in the course of infection differed between the patients, which might 
have influenced the helpfulness.
CONCLUSIONS
In conclusion, if chronic Q fever is diagnosed, FDG-PET/CT is a helpful imaging technique 
for localization of vascular infection. Patients with proven chronic Q fever were diagnosed 
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significantly more often with mycotic aneurysms than in previous case series. Theoretical 
adjustment of the modified Duke criteria by adding serum PCR as a major criterion results 
in more diagnoses of Q fever endocarditis. We recommend treating patients with chronic 
Q fever with a positive serum PCR for C. burnetii without an identified site of infection as 
Q fever endocarditis. To increase sensitivity after previous exclusion of echocardiographic 
minor criteria from the modified Duke criteria, TEE is recommended in patients with chronic 
Q fever. A minority of all patients with proven chronic Q fever recalls a previous episode of 
acute Q fever, so clinical suspicion should remain high, especially in endemic regions.
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ABSTRACT
Cutaneous hyperpigmentation is a well-known side effect of tetracyclines, but doxycycline-
induced cutaneous hyperpigmentation has only been described in one patient with a 
therapeutic dosage of doxycycline, and in one patient using suprapharmacological doses. 
We describe four patients with cutaneous hyperpigmentation in previously unaffected skin, 
and speculate that this was due to treatment with doxycycline in therapeutic doses. After 
cessation of therapy, the hyperpigmentation diminished in all four patients, illustrating the 
need for recognition and timely cessation of therapy.
What was known on this topic?
Cutaneous hyperpigmentation induced by doxycycline 
is a very uncommon side effect.
What does this add? 
Cutaneous hyperpigmentation is a potential side 
effect of doxycycline. Awareness and recognition of 
this reversible or partially reversible side effect of 
this widespread prescribed antibiotic is necessary in 
order to discontinue therapy in time.
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INTRODUCTION
Well-known side effects of doxycycline are photosensitivity, teeth discolouration, nausea, 
vomiting, and diarrhoea. Cutaneous hyperpigmentation is a common side effect of 
minocycline and, to a lesser extent, of other tetracyclines, with only one report of a patient 
with progressive, symmetric blue-grey periocular discolouration due to three years of 
treatment with therapeutic doses of doxycycline [1]. Furthermore, hyperpigmentation has 
been described in one patient with self-induced intoxication by doxycycline (1 gm/day) for 
12 years [2]. Both brown discolouration of the fingernails and discolouration of acne scars 
have been described after a short course of doxycycline [3, 4]. We report four patients who 
received long-term treatment with doxycycline and hydroxychloroquine because of either 
chronic Q fever or Whipple’s disease. They showed extensive cutaneous hyperpigmentation 
in previously unaffected skin, probably induced by doxycycline.
CASE DESCRIPTIONS
Case 1
A 75-year-old man with an abdominal aneurysm, immunosuppressive therapy because 
of rheumatoid arthritis and a known valvulopathy was diagnosed with chronic Q fever. 
Doxycycline 200 mg/day was initiated, in addition to hydroxychloroquine 400 mg/day, 
which he had already been taking for more than five years because of rheumatoid arthritis. 
After four months, doxycycline 300 mg/day was introduced because of persistently low 
doxycycline levels. Eight months after the start of therapy, progressive bluish-purple to 
black cutaneous hyperpigmentation of his lower arms, back of his hands, and interdigital 
areas (Figure 1A) developed since increasing the doxycycline dose (serum concentrations 
of 5.8 mg/ml). The doxycycline was stopped and hydroxychloroquine was continued. The 
hyperpigmentation slowly diminished, but 12 months later dark bluish-grey macules were 
still visible on the back of his hands and his lower arms (Figure 1B).
Case 2
A 72-year-old man, diagnosed with relapse of Whipple’s disease, was treated with ceftriaxone 
for four weeks, followed by doxycycline 200 mg/day and hydroxychloroquine 600 mg/day. 
Eight months later, increasing black discolouration on the back of both hands was seen 
(doxycycline serum concentrations of 5.7 mg/ml) (Figure 2A). Therapy was stopped, and 
co-trimoxazole was reintroduced. Ten months later his cutaneous hyperpigmentation was 
slowly fading (Figure 2B).
Case 3
A 71-year-old man with an endovascular aneurysm repair (EVAR) and a femoral-popliteal 
bypass was referred because of aortitis due to chronic Q fever, and started on doxycycline 
200 mg/day and hydroxychloroquine 600 mg/day. After 48 months of therapy, he reported 
increasing pretibial bluish-brown-black discolouration on both legs, and the dorsal side of 
his feet (Figure 3). In retrospect, the discolouration started 11 months before, but he had 
never reported it. Doxycycline and hydroxychloroquine were substituted by moxifloxacin 
and rifampicin. Six months later, the discolouration diminished.
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Case 4
A 72-year-old man with an infected EVAR with retroperitoneal abscesses due to chronic 
Q fever was referred for surgery. He had already received six months of doxycycline 300 
mg/day and hydroxychloroquine 600 mg/day (doxycycline serum concentration: 6.2 mg/
ml), which was continued post-surgery. For six months, he received doxycycline 200 mg/
day because of side effects. However, because of a low doxycycline serum concentration 
(2.8 mg/ml), doxycycline 300 mg/day was reintroduced, leading to a near-therapeutic 
concentration (4.7 mg/ml). Eight months post-surgery, he presented with increasing black 
discolouration around the surgical scars on both legs. Doxycycline and hydroxychloroquine 
were substituted by moxifloxacin. Two months later, the black discolouration diminished.
DISCUSSION
We describe four patients with hyperpigmentation of previously healthy skin after prolonged 
use of doxycycline. This has been described before in only one patient with therapeutic doses 
of doxycycline [1], and in a patient with self-induced doxycycline intoxication (1 g/day during 
12 years leading to doxycycline serum concentrations of 34 mg/ml, normal therapeutic 
range: 1-5 mg/ml, for chronic Q fever: 5-10 mg/ml)[2, 5]. In our cases, patients received 
relatively high doses with serum concentrations in the therapeutic range, and developed 
marked cutaneous hyperpigmentation. However, compared with other indications for which 
doxycycline is given, chronic Q fever and Whipple’s disease require prolonged treatment 
with a higher therapeutic range. Because tetracyclines produce autofluorescence, with 
positive in-vivo conjunctival autofluorescence of palpebral conjunctival minocycline 
deposits [6], the hyperpigmentation of the first two cases was investigated with Wood’s light 
(extinction 365 nm). However, no fluorescent signal was obtained (Figures 1C and 2C). This 
may have been due to the long time that elapsed between the cessation of doxycycline and 
this investigation (12 and 10 months, respectively). As the dorsal side of the hands of the 
first patient still showed clear pigmentations (Figure 1B), the pigment might not represent 
the doxycycline itself. Previously, biopsies of doxycycline-induced hyperpigmentation 
revealed increased melanisation in the basal layers of the epidermal keratinocytes [4, 
5], suggesting activation of melanocytes either by the tetracycline derivative itself or by 
another co-stimulus. Also, indications were found for the presence of melanin or melanin-
like pigment in the histiocytes of the upper dermis. In contrast, in histiocytes of the lower 
dermis and subcutaneous fat, pigment was stored with increased amounts of iron and 
calcium, and no melanosomes were detected, suggesting a different nature of the pigment. 
Furthermore, data suggested that doxycycline, possibly chelated with iron and/or calcium, 
was directly deposited in the lesional skin [5]. The role of hydroxychloroquine and its 
interaction with doxycycline in these cases cannot be completely ruled out, as cutaneous 
hyperpigmentation induced by hydroxychloroquine has been described in 13% of treated 
patients, mainly as a bluish-grey pigmentation [7], mostly localised at the hard palate, gums, 
face, and pretibial area [8]. To our knowledge, no literature exists describing an increased 
risk of hyperpigmentation using doxycycline and hydroxychloroquine concomitantly. 
As both medications can cause cutaneous hyperpigmentation a synergistic effect on the 
development of hyperpigmentation might exist. However, based on the localisation of 
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hyperpig mentation, without mucosal involvement [9-11], doxycycline is still thought to be 
the main aetiological agent in our cases. Furthermore, in the first patient, hyperpigmentation 
developed after introduction of doxycycline 300 mg/day, and significantly diminished 
after stopping doxycycline, while hydroxychloroquine was continued. And, as seen in our 
fourth patient, discolouration restricted to scars has been reported with doxycycline [4]. 
Most described cases of cutaneous hyperpigmentation during tetracycline treatment are 
induced by minocycline [12], which is frequently prescribed for long periods. However, 
indications for prolonged therapy with doxycycline also exist, with an increasing number of 
chronic Q fever patients [13]. It should be advised to discontinue therapy. As in our patients, 
partial to complete resolution of cutaneous hyperpig mentation has been described eight 
months after cessation of prolonged doxycycline therapy [1]. Furthermore, in the case with 
doxycycline intoxication, the pretibial hyperpig mentation had faded significantly one year 
after doxycycline cessation [2]. Finally, almost complete disappearance of methacycline-
induced hyperpigmentation was reported five years after onset, except for two patients 
who were substituted with doxycycline [14]. Complete disappearance of hyperpigmentation 
after cessation of therapy is possible; however, recovery may take up to several years [14].
In conclusion, cutaneous hyperpigmentation is a potential side effect of doxycycline therapy 
within the therapeutic dose range, and the chance to evoke this adverse effect might be 
increased with the concomitant use of hydroxychloroquine. Given the widespread use 
of doxycycline, in both short and prolonged regimens, it is important to recognise this 
reversible or partially reversible side effect in order to discontinue therapy. Especially its use 
in chronic Q fever, when prolonged relatively high doses are given nowadays in combination 
with hydroxychloroquine, prescribers and patients should be aware of this side effect.
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Figure 1
A 75-year-old man with chronic Q fever, with a progressive bluish-purple to black cutaneous 
hyperpig mentation of his lower arms, back of his hands, and interdigital area, during therapy with 
doxycycline (A). Twelve months after stopping doxycycline, the cutaneous hyperpigmentation had 
diminished. However, dark bluish-grey macules were still visible (B). No fluorescent signal of the 
hyperpigmentation was obtained using Wood’s light, 12 months after cessation of therapy (C).
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Figure 2
A 72-year old man, with Whipple’s disease, presented with black discolouration on the back of his 
hands during therapy with doxycycline and hydroxychloroquine (A). Ten months after discontinuation 
of therapy, the cutaneous hyperpig mentation was significantly reduced, but confluating grey-brown-
bluish macules were still visible (B). Wood’s light investigation showed no fluorescent signal, ten 
months after cessation of therapy (C).
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Figure 3 
A 71-year-old man with chronic Q fever developed an increasing bluish-brown-black pretibial 
discolouration on both legs, and the dorsal side of his feet, during therapy with doxycycline and 
hydroxychloroquine. Six months after stopping therapy, the cutaneous discolouration had clearly 
diminished. 
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ABSTRACT
Background: Chronic Q fever is a rare infection, which mainly manifests as endocarditis, 
infection of vascular prostheses or aortic aneurysms. We present the case of a 74-year-old 
immunocompromised man with a haematologically disseminated Coxiella burnetii infection, 
which has never been reported before. 
Case report: He was diagnosed with a chronic Q fever infection of an aneurysm with an 
endovascular prosthesis in 2015, but he died despite optimal treatment. Autopsy revealed 
a disseminated C. burnetii infection, confirmed by a positive PCR on samples from several 
organs. Retrospectively, he already had complaints and signs of inflammation since 2012, 
for which he had already been admitted in February 2014. At that time, Q fever diagnostics 
using PCR, complement fixation assay, and enzyme-linked immunosorbent assay on serum 
were all negative. In retrospect however, retesting available samples from February 2014 
using immunofluorescence assay (IFA) already revealed serology compatible with chronic 
Q fever. 
Conclusion: Clinicians should be aware of this silent killer, especially in case of risk factors, 
and perform an appropriate diagnostic work-up for Q fever including IFA serology and PCR.
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INTRODUCTION
Following primary infection with Coxiella burnetii, an intracellular Gram-negative 
coccobacillus, 1-5% of patients develop chronic Q fever, which is characterized by the 
persistence of C. burnetii. Chronic Q fever mainly manifests as endocarditis, infection of 
vascular prostheses or aortic aneurysms, or both [1]. Increasingly, other manifestations 
are reported, such as osteomyelitis, pericarditis, hepatitis, pseudotumor(s) of the lung, 
chronic pulmonary fibrosis, cerebral venous thrombosis, and musculoskeletal infections [2, 
3]. However, there are no reports describing a disseminated chronic Q fever infection with 
both locoregional and haematogenous seeding of C. burnetii. We report a fatal case of a 
disseminated chronic Q fever infection, confirmed by positive PCR for C. burnetii on lung 
tissue, an endovascular aneurysm repair (EVAR) specimen, a psoas abscess specimen, and 
ascites from the abdominal right lower quadrant.
CASE REPORT
A 74-year-old man was admitted to our department in January 2015 with general 
malaise, weight loss, dyspnoea, abdominal pain and back pain. His history revealed 
active rheumatoid factor positive rheumatoid arthritis (RA) since 1972, treated with 
prednisone since January 2000 and abatacept since August 2014, deep venous thrombosis, 
emphysema, and hypertension. In 2008, an infrarenal abdominal aortic aneurysm (AAA) 
was diagnosed and treated with an endovascular aneurysm repair (EVAR) in February 2012 
after symptomatic presentation. In October 2012, transthoracic echocardiography (TTE) 
revealed aneurysms of the aortic sinus (44 mm) and ascending aorta (42 mm), without 
valve abnormalities. In February 2014, increasing back pain and left-sided abdominal 
pain, without fever, night sweats or weight loss, resulted in admission to the department 
of Surgery. CT angiography (CTA) showed right renal artery occlusion, and an expanded 
AAA connecting with a fluid collection around the left iliopsoas muscle. The infectious 
diseases specialist advised to perform Q fever diagnostics. The PCR (in-house real-time PCR 
targeting IS1111a), enzyme-linked immunosorbent assay (ELISA, PanBio Pty Ltd., Windsor, 
QLD, Australia), and complement fixation assay (CFA; Virion-Serion, Würzburg, Germany) 
on serum were negative. Repetitive TTE in 2014 depicted a stable cardiac condition. On 
physical examination at presentation in January 2015, he was afebrile with a blood pressure 
of 184/97 mmHg, with 96% saturation. Cardiac examination was normal, endocarditis 
stigmata were absent, as was lymphadenopathy. Pulmonary examination revealed left-sided 
rales and right-sided crackles. He reported tenderness on palpation of the thoracic spine. 
Besides a C-reactive protein (CRP) of 67 mg/l (normal range, <5 mg/l) and hemoglobin level 
of 7.3 mmol/l (normal range, 8.4–10.8 mmol/l), laboratory results were normal. Chest X-ray 
revealed a recent thoracic spinal fracture, and abdominal ultrasound showed hepatomegaly 
and a psoas hematoma. CTA showed no leakage of the aortic graft. 18F-fluorodeoxyglucose 
positron emission tomography/low-dose CT (18FDG-PET/CT) 3 days later showed a normal 
FDG distribution in the patients’ head, neck, and brain parenchyma, but a high pulmonary 
FDG-uptake suggestive for pneumonia, and signs of an infected AAA expanding to the 
left psoas muscle. CT-guided puncture of the psoas abscess revealed pus, which was PCR 
positive for C. burnetii. Immunofluorescence assay (IFA; Focus Diagnostics Inc., Cypress, 
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CA, USA) showed high anti-C. burnetii antibody titres: IgG phase I 1:4096, phase II 1:2048, 
IgM phase I and II negative. Serum PCR remained negative. Chronic Q fever was diagnosed 
and treatment with doxycycline 200 mg/day and hydroxychloroquine 600 mg/day was 
initiated. Prednisone (5 mg/day) was continued, but abatacept was stopped and the 
abscess was drained percutaneously. Shortly after being discharged, he was readmitted 
because of collapse, confusion, and increasing back pain. CT showed a new thoracic aortic 
aneurysm (52 mm) and an expanded multiloculated psoas abscess, which again was drained 
percutaneously. In the absence of a clinical response, moxifloxacin 400 mg/day was added, 
but had to be stopped due to a markedly prolonged QTc-interval. Despite several drains in 
the multiloculated abscess, CRP increased to 261 mg/l and he developed a fever. His hospital 
stay was complicated by two episodes of presumed hospital-acquired pneumonia (for which 
he received piperacillin/tazobactam), acute decompensated heart failure, respiratory failure 
presumably due to an aspiration pneumonia, and sepsis, for which he was temporarily 
transferred to the intensive care unit twice. Furthermore, he developed a gastroparesis, 
acute progressive renal insufficiency and a delirium. A new 18FDG-PET/CT (Figs. 1, 2) showed 
increased FDG-uptake extending into the vertebrae and high FDG-uptake in his spleen 
Figure 1 
18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) (a), low-dose CT (b), and integrat-
ed 18FDG-PET/CT (c) images, demonstrating increased FDG-uptake in the abscess formation in the left 
iliopsoas muscle, extending into the intervertebral space cranially of L4 and into the adipose tissue 
reaching the left abdominal wall. The 18FDG-PET could not be assessed for disseminated lesions in 
the brain due to a motion artifact of the head during the procedure.
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suggestive for satellite infection. Despite treatment with adequate doxycycline levels, the 
patient died 4 months after presentation. Autopsy was performed, macroscopically showing 
inflamed tissue around the EVAR (Fig. 3) with fistulas to the iliopsoas muscle in continuation 
with the spine with softened vertebrae. Microscopy yielded a chronic granulomatous 
necrotizing inflammation of the aortic vascular wall around the EVAR, fully necrotic iliopsoas 
muscle and surrounding area, and a hypertrophic cardiomyopathy. Necrotizing granulomas 
were found in both lungs, being PCR positive for C. burnetii, as were EVAR specimens, pus 
from the psoas abscess and ascites from the abdominal right lower quadrant around the 
appendix. Cultures for C. burnetii remained negative. Post-mortem examination of the brain 
was not performed. Retrospectively, IFA was performed on stored serum from February 
2014, already showing an IgG phase I 1:4096, IgG phase II 1:2048, with negative IgM phase 
I and phase II, suggestive for chronic Q fever. Retesting the stored serum with CFA and ELISA 
confirmed the previously found negative results.
Figure 2
Transversal integrated 18F-fluorodeoxyglucose positron emission tomography/low-dose CT (18FDG-
PET/CT) images, from cranial to caudal, demonstrating: (a) increased FDG-uptake in the left iliopsoas 
muscle dorsally extending through the musculature of the back, and increased FDG-uptake in the wall 
of the aortic aneurysm adjacent to the endovascular aneurysm repair (EVAR). (b) a per continuitatem 
infection arising from the abdominal aortic aneurysm (AAA), thrombosis of aortic aneurysm and low 
activity in the cavity of the EVAR resulting from blood flow. The infection extends to the abscess and 
left iliopsoas muscle. (c) percutanous drain in situ in the abscess, increased FDG-uptake in the cranial 
portion of the vertebra, and increased FDG-uptake in adipose tissue of the left abdominal wall in 
continuitatem with the abscess (not visible at the level of this transversal slice). (d) increased FDG-
uptake in the aortic wall adjacent to the caudal part of the EVAR, and increased FDG-uptake extending 
into adipose tissue of the left abdominal wall.
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Figure 3
Cranial view, during autopsy, of the abdominal aorta with the endovascular aneurysm repair (EVAR) 
stent-graft. The lumen of the celiac trunk and superior mesenteric artery are visible. Around the EVAR 
the aneurysmatic plaque inside the dilated vascular wall is still in situ, the material was PCR positive for 
C. burnetii. A fistula from the abdominal aortic aneurysm (AAA) to the psoas abscess was present (not 
visible on picture). Inside the EVAR an intra-prosthetic deposition of amorphous material is visible.
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DISCUSSION
We describe an immunocompromised patient with a widely disseminated chronic Q fever 
infection with infectious foci in the EVAR and surrounding AAA, both lungs, iliopsoas muscle, 
spine, spleen, and in ascites from the abdominal right lower quadrant. To our knowledge, 
such an extensive C. burnetii infection has not been described before. Rare complications, 
e.g., osteomyelitis [2], periaortic adenopathy, aortaduodenal fistula, psoas abscesses [4, 5], 
and fistula to the groin [6], have been described as part of locoregional spreading of C. 
burnetii. Such locoregional expansion is probably the result of a contiguous infected vascular 
aneurysm. In our patient, however, besides locoregional spreading, haematogenous seeding 
of C. burnetii is likely because of signs of metastatic infection in the spleen and the presence 
of C. burnetii DNA and granulomatous inflammation in lung tissue. Haematogenous spread 
can also result in hepatic abscesses, described in one patient with both splenic and hepatic 
abscesses [3]. However, this occurred during an acute C. burnetii infection, instead of chronic 
Q fever as in our case, with complete resolution of symptoms and abscesses after 21 days 
of doxycycline.
Probably the immunocompromised state of the patient (due to the use of abatacept and 
prednisone) contributed to the widespread infection. A disseminated Q fever infection with 
acute endocarditis in experimentally infected immunocompromised mice 10 days after 
intraperitoneal inoculation of C. burnetii has been described, showing microabscesses, 
granulomas, and microthrombi in spleen, liver, myocardium and bone marrow [7]. Such 
a disseminated infection was also found in immunocompetent mice [8]. However, these 
self-limiting systemic infections were found after intraperitoneally induced acute infection, 
with characteristic histopathological changes only in the acute setting, whereas persistent 
infection was found only in the kidneys of a single immunocompromised animal [7]. 
Abatacept treatment, so far, has not been complicated by many opportunistic or serious 
infections, in contrast to anti-TNF treatment [9]. However, based on a small number of 
RA patients, the use of TNF blockers was not associated with increased risk of chronic Q 
fever, in contrast to corticosteroid use [10], which our patient also used. In addition, it was 
suggested that RA and its treatment, either with or without anti-TNF, may be considered 
as a risk factor for chronic Q fever development, and it was advised to monitor RA patients 
carefully in case of C. burnetii infection [10]. The role of abatacept in the dissemination 
of C. burnetii in our patient remains unresolved. Abatacept, inhibiting T cell activation by 
preventing co-stimulatory interaction between CD80/CD86 and CD28, did not prevent 
formation of C. burnetii-positive granulomata, corresponding with previous findings in C. 
burnetii-infected CD28-deficient mice, in which granuloma formation was also not affected 
[11]. Interestingly, in these CD28-deficient mice, the C. burnetii burden in infected tissue 
was decreased, suggesting that costimulation of CD28 increases C. burnetii replication, 
implicating a favourable effect of abatacept. Although abatacept was stopped, prednisone 
was continued during the course of disease because of the long-term use with subsequent 
hypothalamic–pituitary–adrenal axis suppression. In addition, the patient needed steroid 
stress dosing due to several complications. However, despite the continuation of prednisone 
in this specific case, physicians should always consider stopping immunosuppressive therapy 
while treating chronic Q fever. Another explanation for the widespread infection might 
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be C. burnetii resistance to doxycycline, as doxycycline resistant isolates do exist [12, 13]. 
However, this does not appear to be a common occurrence [14], and it is more likely that the 
patient died due to an already widely disseminated Q fever infection at the time doxycycline 
and hydroxychloroquine were initiated, while the immunosuppressive therapy favoured the 
expansion of the infection.
Diagnosing chronic Q fever is challenging, and often delayed because of the lack of recognition 
by physicians, mainly due to non-specific symptoms and unfamiliarity with chronic Q fever. 
However, early diagnosis has major implications, as chronic Q fever causes high morbidity 
and mortality [1]. Eventually, the indication to test for Q fever was recognized in this case, 
but retrospectively the patient already reported general malaise for years, chronic chest 
pain and left flank pain ever since the EVAR procedure. Furthermore, he already had an 
elevated CRP whilst consulting the cardiologist, pulmonologist and rheumatologist in the 
years before presentation, who related this to his active RA and intercurrent problems. Our 
patient lived in an area in the Netherlands with the highest incidence of Q fever during 
the large Q fever outbreak from 2007 until 2010 [15, 16], and inhalation of contaminated 
aerosols was probably the route of initial infection [17]. In Q fever endemic areas or in 
the years after outbreaks, physicians should stay alert on signs and symptoms suggestive 
for chronic Q fever, especially in case of risk factors, also in the absence of a known acute 
Q fever episode. Well-known risk factors for developing chronic Q fever include vascular 
grafts and aneurysms, cardiac valve prosthesis or valvulopathy, and immunosuppresion 
[18]. Despite the fact that EVAR specimens appeared to be PCR positive for C. burnetii, the 
EVAR could not be revised in this case. The main reason for the decision to abstain from 
surgical intervention was the already expanded infection, and the patients’ deteriorating 
physical condition. However, in case of a chronic Q fever infection of a vascular prosthesis, 
surgical interventions can lead to a better outcome and should always be considered [2, 19]. 
Our case further emphasizes the need for using IFA to screen for chronic Q fever, as CFA and 
ELISA have limited sensitivity. Also, this case illustrates that PCR alone is insufficient to rule 
out chronic Q fever due to the low sensitivity in blood specimens [1].
CONCLUSION
In conclusion, we report a fatal case of an immunocompromised patient with a confirmed 
disseminated chronic Q fever infection, underlining the severity of this disease and the 
diversity of signs and symptoms that may occur, and highlighting the need for increased 
awareness and recognition by physicians especially in case of risk factors. Furthermore, we 
advocate performing an adequate diagnostic work-up using at least IFA serology and PCR for 
screening for chronic Q fever.
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GENERAL DISCUSSION
In this thesis, the findings of several retrospective and prospective studies in patients with Q 
fever fatigue syndrome (QFS) were described. Also, challenges in diagnosis and treatment of 
acute and chronic Q fever were addressed. This thesis underscores that Q fever is a complex 
disease with diverse manifestations and still many queries.
Awareness and recognition of fatigue following acute Q fever
Although fatigue following acute Q fever has been recognised for years worldwide [1-6], 
the systematic review presented in chapter 2 illustrates that information on aetiology, 
prevention, treatment, and prognosis of QFS is scarce in the international literature. Several 
names have been used to indicate the presence of persistent fatigue following acute Q fever, 
but it was concluded that QFS is the preferred international term to aid comparison between 
studies.
Definition and diagnosis of QFS
Although QFS is the preferred international term, in chapter 2 it was concluded that the 
main limitations in the international literature with regard to QFS are the lack of a uniform 
definition and the absence of a standardized diagnostic tool. In order to facilitate comparison 
of findings, and as platform for future studies, a uniform definition and diagnostic work-
up and uniform measurement tools for QFS are necessary. This will also provide an aid for 
physicians and recognition for patients. A detailed description of QFS has been published in 
the Dutch guideline on QFS [7] and in an Australian thesis [8]. The latter is, however, based 
on a retrospective comparative-cohort study and is not available online, which limits its 
usefulness for international comparisons. Although the Dutch guideline on QFS was originally 
written in Dutch, the definition has been translated and includes a detailed description 
of QFS, and might be used as international uniform definition to achieve uniformity in 
diagnosis, treatment, and comparison of research results [7, 9, 10]. In brief, QFS is defined as 
severe fatigue causing significant disabilities in daily life, present for at least 6 months, with 
a temporal relationship with acute Q fever, and not caused by co-morbidity. Fatigue should 
be absent before the onset of acute Q fever or should have significantly increased since the 
infection. In addition, it is essential to use validated screening instruments for measuring 
fatigue severity and disabilities, e.g., the Checklist Individual Strength [11, 12] and Sickness 
Impact Profile [13-15], respectively. Guidelines with regard to the examination of chronic 
fatigue should be followed to rule out other diseases that can cause chronic fatigue. In 
addition, QFS should not be confused with chronic Q fever [16]. QFS is accompanied by high 
morbidity, but in contrast to chronic Q fever, does not account for Q fever-related mortality. 
The definition of QFS clearly excludes chronic Q fever based on a negative serum PCR, Q 
fever serology (IgG phase I titer <1:1024), and the absence of signs of endocarditis and 
vascular infection. Therefore, there is neither controversy nor confusion between QFS and 
chronic Q fever [17].
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Which symptoms should be part of the case definition of QFS?
Many nonspecific symptoms accompanying fatigue in QFS have been described, but these 
have not been systematically registered in patients. QFS patients frequently report symptoms 
like myalgia, arthralgia, neurocognitive problems, sleeping problems, headache, blurred 
vision, mood disorders, and increased (night) perspiration. Although these symptoms 
should all be taken seriously, they should not yet be included in the QFS case definition. 
Until prospective follow-up studies become available of well-defined QFS populations, one 
should refrain from attributing additional symptoms to QFS. There should be reluctance 
to diagnose QFS solely based on a list of symptoms for which the causal relationship with 
previous Coxiella burnetii infection is unknown.
Differences between QFS and chronic fatigue syndrome
Until more research on QFS has been performed, it is prudent to identify QFS and CFS as 
separate entities, as there are several differences. In CFS the precipitating factor is usually 
unknown, while in QFS a C. burnetii infection can be identified as such. Furthermore, in QFS 
there is a sudden onset of fatigue, while in CFS this is not always the case. In addition, in a 
study of two independently conducted prospective studies, presented in chapter 3, the direct 
comparison of QFS and CFS patients revealed several differences in demographics (including 
gender), number of symptoms, and fatigue-related cognitive-behavioural variables. The 
relationship between perpetuating factors and fatigue in CFS - as found in a previous study 
[18] - could not be confirmed in QFS patients. This suggests that the mechanisms involved in 
the perpetuation of fatigue in QFS are different from those related to fatigue in CFS, despite 
the considerable overlap in fatigue-related cognitive behavioural variables. Finally, there is 
still a lack of knowledge with regard to the pathogenetic process underlying QFS, but might 
be precipitated by C. burnetii as trigger [19-21], and therefore this might not be identical 
to CFS. It could be debated whether QFS represents a subset of CFS patients, i.e., those 
with post-infectious fatigue syndrome. Whether this is the case or not, until now it is wise 
to differentiate QFS from CFS. The differences found between QFS and CFS as well as the 
importance of the attribution for patients still justify the use of the term QFS.
Aetiology and the use of immunological assays in QFS
Several hypotheses regarding the underlying pathophysiological mechanism of QFS 
have been proposed, but no conclusive answers have been identified yet. At present, it 
is tempting to hypothesize that QFS represents a state of altered cell-mediated immunity 
against C. burnetii in the spectrum of Q fever-related syndromes. To date, no diagnostic test 
is available to diagnose QFS. Ever since the discovery of C. burnetii, the specific humoral 
immune response played a central role in the diagnosis of Q fever. Increasingly, the cell-
mediated immune responses appear also relevant in the anti-C. burnetii host response. 
Interferon-y (IFNy) and other cytokines such as interleukin-2 (IL-2) already proved to play 
a pivotal role in the host defence against intracellular bacteria such as C. burnetii [22-25]. 
The antigen-specific IFNy production was developed for the diagnosis of acute Q fever 
[26], and the IFNy production assay already proved to be a useful diagnostic tool for C. 
burnetii infection [27, 28]. Q fever seropositive controls showed a high IL-2 production, 
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whilst a high IFNy/IL-2 ratio appeared indicative for chronic Q fever. Subsequently, the IFNy/
IL-2 ratio was proposed as additional diagnostic marker for chronic Q fever and treatment 
monitoring [29, 30]. In QFS, however, the added value of immunological assays was unclear. 
IFNy upregulation and IL-2 downregulation in QFS patients compared to control groups was 
found, but this study only included a small number of QFS patients [21]. In chapter 4 it was 
shown that the IFNy production in QFS patients is significantly higher than in seropositive 
controls, and that the IFNy/IL-2 ratio is significantly lower than in chronic Q fever patients. 
As such, both the antigen-specific IFNy production and IFNy/IL-2 ratio may become a tool in 
the diagnostic workup of QFS, as the combined use of IFNy and IL-2 production might allow a 
better distinction between QFS patients, seropositive controls, and chronic Q fever patients. 
However, widespread use of immunological assays in QFS patients cannot be recommended 
in clinical practice before these results are confirmed and compared with other control 
groups in larger cohorts of patients. In addition, it should be evaluated whether these 
results only holds true on group level, or whether individual patients can be classified into 
QFS, seropositive control, or chronic Q fever, solely on the basis of immunological assays.
Treatment of QFS
From the randomised, partly double-blind, placebo-controlled trial described in chapters 5 
and 6, it can be concluded that cognitive behavioural therapy (CBT) is effective in reducing 
fatigue severity and the level of psychological distress in QFS patients. The sensitivity 
analysis revealed a consistently positive effect, and the positive effect of CBT on fatigue 
severity was also clinically relevant. In addition, the mean number of adverse events per 
patient was lowest in this group and no serious adverse events occurred. Therefore, CBT 
for QFS is a safe therapy if performed by qualified and trained therapists, as has been 
reported before for CBT in CFS [31]. CBT already proved effective in reducing symptoms 
and improving functioning in CFS patients [32, 33], and in chronic fatigue in several chronic 
diseases [34-36], and this study proved its efficacy in QFS patients. CBT should therefore 
be recommended to QFS patients following diagnosis. However, no data are available with 
regard to the effect of the patients’ attitude on treatment engagement and outcome. In 
CFS, the attitude of the patient towards the treatment model appeared to be an important 
contributor to treatment engagement, and therefore possibly outcome, in a cognitive 
behavioural intervention [37]. It is likely that QFS patients with a negative attitude towards 
CBT and its underlying treatment model will probably not accept referral for CBT or will 
drop-out in an early stage. Motivating interventions by the referring physician could be 
valuable to optimise treatment expectancies and subsequently treatment engagement and 
outcome even before starting CBT. This already starts with the communication towards 
patients before referral, as for many physicians it is tempting to regard QFS as either a 
somatic disorder or a psychological disorder, in a Cartesian fashion. However, QFS should 
be seen as a syndrome in which somatic, psychological, social, and behavioural factors all 
play an important role. Explaining this to patients is difficult, but increases patients’ insight 
in their complaints and subsequently increases treatment motivation. Solely regarding 
QFS as somatic disorder will increase the somatic attribution of patients, which influences 
the motivation and treatment engagement negatively. Although CBT proved an effective 
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treatment for fatigue in QFS patients, the underlying mechanisms by which CBT has a 
positive effect on fatigue are unknown. Identifying cognitive and behavioural variables 
that intervene in the relation between treatment and outcome is of major importance to 
individualize and optimize therapy, which can lead to an even better outcome. A mediation 
analysis is therefore planned. Furthermore, to evaluate the long-term beneficial effects of 
CBT, patients are currently surveyed by questionnaires 12–15 months post-treatment.
It can be concluded that long-term treatment with doxycycline does not significantly 
reduce fatigue severity in QFS patients. This is the first randomised controlled trial ever 
performed in QFS patients, and results with regard to the effect of long-term doxycycline 
clearly contradict those previously described [4, 38]. As described, all previously published 
studies had major limitations, precluding the extrapolation of the described results [3, 4, 
38, 39]. All the limitations in these studies were addressed in this randomised controlled 
trial, and the period of antibiotic administration was even longer. Strengthened by the low 
number of dropouts and missing data, our results do not support a positive effect of long-
term treatment with doxycycline for QFS. In addition, the mean number of adverse events 
per patient was highest among patients who received doxycycline. Hence, prescription of 
prolonged antimicrobial therapy in case of QFS is useless, and such treatment should not be 
prescribed. This advice also holds true for the alternative therapies described in literature, 
which were both case reports [39, 40].
One of the limitations of this study is that it was not designed to compare doxycycline and 
CBT directly, due to the limited number of eligible patients available and the impossibility 
to blind for the treatment modality. However, the scores in the doxycycline group at end 
of treatment were similar to placebo with even worse mean scores. The results therefore 
imply a favourable effect of CBT, but it should be noted that this was not formally 
investigated. Furthermore, it can be debated whether the level of evidence originating 
from this randomized controlled trial should be supported by confirmation studies as basis 
for guideline recommendations. Evidence-based practice usually relies on a broad, diverse 
base of evidence, which is obviously not available for the treatment of QFS. In a scientific 
view, these results should be verified in other randomized controlled trials. However, based 
on a practical view, it is very unlikely that a study of this size can be repeated to confirm 
our findings because the recruitment of sufficient QFS patients will be extremely difficult. 
Although it is likely that new Q fever outbreaks will occur, an exceptionally large Q fever 
outbreak as occurred in the Netherlands is rare, and may not happen again in the near 
future. Until an outbreak occurs that facilitates the confirmation of these results, this study 
provides the strongest level of evidence so far.
Diagnosing acute Q fever
Both acute and chronic Q fever are often underdiagnosed due to poor recognition among 
clinicians [41, 42]. Previous studies suggest typical signs and symptoms of acute Q fever: 
fever, headache, and cough [43-45], and headache has been postulated to be rather specific 
for acute Q fever [46, 47]. However, results from the retrospective case-control study 
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presented in chapter 7, contradict a typical presentation of acute Q fever. Although some 
differences in clinical manifestations between acute Q fever patients coming to a hospital 
and controls were found, the considerable overlap between both groups hamper the use of 
these variables for clinical differentiation. Although others previously observed remarkable 
differences in clinical presentation between hospitalized C. burnetii pneumonia patients and 
patients hospitalized for pneumonia with a different aetiology [48], it can be concluded that 
differentiating C. burnetii from other pathogens is not possible without Q fever serological 
analysis and PCR in patients coming to a hospital. The cornerstone in diagnosing acute 
Q fever is therefore the awareness among physicians to consider C. burnetii as possible 
aetiological agent and requesting appropriate diagnostic tests.
Prophylactic treatment of high-risk patients
Long-term prophylactic treatment with doxycycline and hydroxychloroquine has been 
suggested for acute Q fever in patients with risk factors for development of chronic Q fever 
[49, 50]. As demonstrated in the retrospective study described in chapter 7, of the patients 
with an indication for prophylaxis, none of the patients who received prophylaxis developed 
chronic Q fever, in contrast to 50% of patients who did not receive prophylaxis despite the 
indication. These findings clearly support the recommendation that prophylactic treatment 
is beneficial and should be given to patients with risk factors for developing chronic Q fever 
[49-53], but potential side effects must be taken into consideration [54].
Diagnosis and clinical manifestations of chronic Q fever
The diagnosis of chronic Q fever is also challenging, and relies on a combination of 
symptoms, risk factors, microbiological findings, and imaging techniques [55]. The diagnosis 
is often delayed, and hampered by the fact that many known chronic Q fever patients do 
not recall an acute Q fever episode [56], which is supported by findings presented in chapter 
8. However, early diagnosis has major implications [56], and as illustrated in chapter 10, a 
diagnostic delay can lead to a fatal outcome. Clinicians should be aware of this silent killer, 
especially in disease-endemic areas or when patients have risk factors for the development of 
chronic Q fever. The case presented in chapter 10 also illustrates the need for an appropriate 
diagnostic work-up for Q fever including at least IFA serology and PCR. Other diagnostic 
tests, for example complement fixation assay and enzyme-linked immunosorbent assay, or 
performing PCR alone proved insufficient to rule out chronic Q fever. Besides microbiological 
findings, imaging methods play an important role in the diagnosis of chronic Q fever. 
Localisation of infectious foci is important, because surgical interventions can lead to a better 
outcome and should always be considered in chronic Q fever patients [57, 58]. The results 
described in chapter 8 further demonstrated that 18F-fluorodeoxyglucose positron emission 
tomography/CT (18F-FDG PET/CT) is a valuable tool for localisation of vascular infection with 
C. burnetii. It is therefore recommended to perform 18F-FDG PET/CT in all patients with a 
suspicion of chronic Q fever, especially because it has already been shown that infected 
aneurysms or vascular prostheses are present more commonly in the Netherlands compared 
to other countries [43, 59-61], which is also illustrated in chapter 8. Furthermore, the data 
emphasise the need for performing transesophageal echocardiography (TEE) instead of 
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transthoracic echocardiography (TTE) in patients with a suspicion of Q fever endocarditis. 
Q fever endocarditis is known for its subtle valve abnormalities that are easily missed using 
only TTE in the absence of vegetations [43, 62, 63]. Chronic Q fever mainly manifests as 
endocarditis or vascular infection, but the clinical features are, like in acute Q fever, diverse. 
There are many reports describing rare complications as a result of locoregional expansion 
of C. burnetii [58, 64-66]. In chapter 10, however, it was demonstrated for the first time 
that besides locoregional spreading, haematogenous seeding beyond the vascular tree of C. 
burnetii is possible in chronic Q fever. This finding is important as it increases our knowledge 
on the pathophysiology and treatment of chronic Q fever.
Treatment of chronic Q fever
Following a diagnosis of chronic Q fever, treatment is the next challenge. If left untreated, 
a high mortality rate is observed, but also in case of adequate treatment, chronic Q fever 
remains an unpredictable disease with a high mortality rate, as illustrated in chapter 10. 
No single drug has been shown to be bactericidal against C. burnetii as monotherapy [44]. 
Consequently, treatment preferably consists of an antibiotic combination regime, i.e. 
doxycycline and hydroxychloroquine, for a prolonged period, which proved to be effective in 
patients with Q fever endocarditis [67-70]. Although the regimen for vascular chronic Q fever 
has not been investigated as thoroughly as in Q fever endocarditis, the antibiotic regimes for 
Q fever endocarditis have been applied to this disease entity as well. Pursuing the optimal 
treatment in patients normally favours the outcome, but many chronic Q fever patients 
who use doxycycline and hydroxychloroquine experience side effects, including severe 
photosensitivity, nausea, vomiting, diarrhoea, and cutaneous hyperpigmentation [69]. 
The latter is demonstrated in the case series presented in chapter 9, describing cutaneous 
hyperpigmentation that occurred during doxycycline therapy within the therapeutic dose 
range due to the prolonged treatment regimen for chronic Q fever. Side effects can have a 
major effect on the quality of life [71], and are an important reason for discontinuation of 
therapy. Therefore, both prescribers and patients should be aware of potential side effects. 
In case of unacceptable side effects or in case of treatment failure using doxycycline and 
hydroxychloroquine, physicians should consider to switch to other antibiotic regimens.
FUTURE PERSPECTIVES
The Q fever outbreak in the Netherlands provided the opportunity to gain knowledge 
about different aspects of this relatively rare but serious infectious disease. As the 
number of notified acute Q fever cases in the Netherlands significantly decreased since 
2010, the research focus changed from the acute illness to its long-term consequences, 
i.e. QFS and chronic Q fever. Several questions regarding the long-term consequences are 
still unanswered and the results presented in this thesis also open up avenues for future 
research by producing new questions. It is now known that the long-term consequences of 
Q fever have major impact on public health. For example, the majority of patients return 
to work within the first 12 months after acute Q-fever, but up to 20% reported reduced 
work participation [72]. In addition, it is observed that many patients still report decreased 
psychosocial functioning years after the primary Q fever infection. However, information 
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with regard to the long-term (>5 years) impact on work and psychosocial functioning in 
both QFS and chronic Q fever patients is lacking. By comparing the functioning of patients 
to references groups, it will be possible to determine which part of the impact or reduced 
psychosocial functioning can be attributed to QFS and chronic Q fever.
Still little is known about the pathogenesis of QFS, and one of the main questions is why 
patients remain fatigued. Research into the pathophysiological mechanism of QFS is 
therefore necessary. For example, it can be hypothesized that C. burnetii elicits epigenetic 
changes in monocytes, macrophages and perhaps microglial cells, ultimately resulting in a 
changed cytokine profile that might result in state of prolonged fatigue (QFS). Ideally, this 
should be investigated in a cohort of acute Q fever patients with a follow-up period long 
enough to investigate the role of epigenetic changes in the development of QFS.
Furthermore, it is important to try to find an objective method to diagnose QFS to optimise 
individual patient care. Although it is too early to use immunological assays in a routine clinical 
setting, these assays seem promising for diagnosing QFS and warrants further investigation, 
in which at least the positive and negative predictive values should be known. Revealing 
the pathophysiological mechanism of QFS might also result in additional treatment options 
for QFS patients, and might also contribute to prevention of this debilitating syndrome. 
By defining early predictors for the development of QFS, new therapeutic modalities may 
be developed. This might lead to earlier treatment regimens or, even more preferably, 
interventions to reduce or prevent the development of QFS.
Although CBT is an effective treatment modality to reduce fatigue severity, many patients 
experience CBT as time-consuming, intense, and strenuous. In addition, the treatment 
capacity is limited. Providing web-based CBT and tailoring the amount of contact with the 
therapist to the individual needs of the patient may overcome these issues [73-76]. Another 
possibility might be graded exercise therapy, which has also proved effective for CFS [77, 
78], but has not yet been investigated for QFS. Finally, the long-term beneficial effects of CBT 
for QFS are currently under investigation.
Despite the advances in knowledge on chronic Q fever in recent years, diagnosis and 
treatment of chronic Q fever remains challenging. Early case-finding, by targeted screening 
and increased awareness among physicians, will improve prognosis. Furthermore, it is 
necessary to gain more insight into the immunological mechanisms leading to chronic Q 
fever. It is still not entirely understood why C. burnetii is cleared ineffectively after the initial 
infection in those individuals who develop chronic Q fever. It is also unknown why persistent 
C. burnetii infection predominantly manifests as endocarditis or vascular infection, instead 
of primarily targeting other organs. Little is known about the auto-immune phenomena that 
are increasingly recognised in chronic Q fever patients, and still many questions exist with 
regard to the best treatment strategies. It is therefore essential to gain knowledge on the 
IFNy pathway in the primary and late defence mechanism, identifying a C. burnetii-specific 
immune response (immunological footprint), and to identify genetic factors that increase 
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the likelihood of developing chronic Q fever. Although prophylactic antibiotic treatment 
should be given to high-risk patients after an episode of acute Q fever, controversy still exist 
with regard to treatment duration, dosage, and patient selection. Therefore, more studies 
are needed to develop uniform guidelines with regard to optimal prophylactic treatment. 
Furthermore, the first choice antibiotic regime in case of chronic Q fever, i.e. doxycycline 
and hydroxychloroquine, accounts for many side effects and the efficacy is not entirely clear. 
The latter also holds true for alternative antibiotic treatment regimens used for chronic Q 
fever in daily practice. A randomised controlled trial with regard to treatment of chronic Q 
fever in the future is desirable in case a second epidemic with similar expanse would take 
place. Because acute Q-fever is no longer a common disease in the Netherlands (only 12 
reported new acute Q fever cases in 2016 [79]), international collaboration is mandatory to 
obtain sufficient patients for these studies.
So far, most Q fever-related research has been descriptive and retrospective in nature. The 
Dutch epidemic provided opportunities to do prospective studies, but since the epidemic is 
over the possibility for new prospective studies is limited. As C. burnetii has caused numerous 
outbreaks all over the world since its discovery in 1935, it is likely that new outbreaks will 
occur in the future. When such outbreaks occur, funding should be made available without 
delay, to perform prospective studies on the questions that remain unanswered regarding Q 
fever and its long-term consequences.
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Query (Q) fever, the original name related to the consequences of a Coxiella burnetii infection 
because of the unfamiliarity with the causative pathogen, still seems an appropriate name, 
reflecting all queries with regard to the different clinical manifestations of this disease. The 
Q fever outbreak in the Netherlands has been the largest Q fever outbreak reported to date, 
and offered the opportunity to gain new insight with respect to Q fever. In this thesis, some 
challenging questions with regard to Q fever were investigated with an emphasis on Q fever 
fatigue syndrome (QFS). The primary aims of this thesis were increasing the recognition 
of QFS, revealing new insights in the pathophysiology of QFS, and evaluating the efficacy 
of treatment with long-term doxycycline and cognitive behavioural therapy (CBT) in QFS 
patients. A secondary aim was to investigate diagnostic and treatment challenges in both 
acute and chronic Q fever. Following a general introduction and outline of the thesis in 
chapter 1, this thesis is divided in two main themes: recognition and treatment of QFS (part 
I) and challenges in diagnosis and treatment of acute and chronic Q fever (part II).
PART I: Recognition and treatment of QFS
In chapter 2, a systematic review is provided to describe the literature, and identify 
knowledge gaps regarding the definition, diagnosis, background, description, aetiology, 
prevention, therapy, and prognosis, of fatigue following acute Q fever. Although most 
patients recover from fatigue within 6-12 months after acute Q fever, approximately 20% 
remain chronically fatigued. It is concluded that the occurrence and long-term persistence 
of fatigue following acute Q fever, generally referred to as QFS, has major health-related 
consequences. However, still several questions with regard to QFS exist, as information 
on aetiology, prevention, treatment, and prognosis of QFS is underrepresented in the 
international literature. In order to facilitate comparison of findings and as a platform for 
future studies, an international uniform definition is desirable. It is therefore proposed to 
use the definition and diagnostic work-up for QFS according to the Dutch QFS guideline.
In chapter 3, differences and similarities between QFS and chronic fatigue syndrome (CFS) 
patients were investigated, with a focus on inflammatory markers and fatigue-related 
cognitive-behavioural factors. In an exploratory analysis, the relationship between these 
cognitive-behavioural variables and fatigue in QFS patients was investigated. Data from 
two independent prospective studies on QFS (n=117) and CFS (n=173), respectively, were 
pooled and analysed. QFS patients were less often female, had a higher body-mass index 
(BMI), and had less often received treatment for depression before the onset of symptoms. 
After controlling for symptom duration and correcting for differences in diagnostic criteria 
for QFS and CFS, differences in the proportion of females and BMI remained significant, 
and QFS patients appeared to be older. QFS patients were as fatigued and distressed as 
CFS patients, but reported less additional symptoms. QFS patients had stronger somatic 
attributions, and higher levels of physical activity. No differences were found with regard to 
inflammatory markers or other fatigue-related cognitive-behavioural variables. Differences 
in known predisposing factors for chronic fatigue suggest other predisposing factors 
for developing QFS. Although the relationship between cognitive-behavioural variables 
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and fatigue previously established in CFS could not be confirmed in QFS patients, the 
considerable overlap in fatigue-related cognitive-behavioural variables and the relationship 
found between physical activity and fatigue suggest that behavioural interventions could 
reduce fatigue severity in QFS patients.
In chapter 4, the specific interferon-y (IFNy) production and IFNy/Interleukin(IL)-2 ratio in 
20 QFS patients was explored and compared to those previously determined in seropositive 
controls (n=135), and chronic Q fever patients (n=28). Also, the correlation between patient 
characteristics and IFNy and IL-2 production, and IFNy/IL-2 ratio was determined. QFS 
patients were younger, but gender distribution was similar to seropositive controls and 
chronic Q fever patients. The IFNy production in QFS patients was significantly higher than in 
seropositive controls, and the IFNy/IL-2 ratio was significantly lower than in chronic Q fever 
patients. Symptom duration was positively correlated with IL-2 production, and negatively 
correlated with the IFNy/IL-2 ratio. It is concluded that these results point to an altered cell-
mediated immunity in QFS, and suggest an immune response different from that in chronic 
Q fever.
In chapter 5, the study protocol of a prospective randomised, partly double-blind, placebo-
controlled trial (the Qure study) is provided, which evaluates the efficacy of long-term 
doxycycline and CBT in QFS patients compared to placebo. In chapter 6, the results of this 
trial are described. Of the 155 patients randomised to CBT (n=51), doxycycline (n=52), 
or placebo (n=52), 154 patients were included in the intention-to-treat analysis. Fatigue 
severity following treatment, corrected for baseline fatigue severity, did not significantly 
differ between doxycycline and placebo, and was significantly lower after CBT than after 
placebo. The level of functional impairment did not differ significantly between both 
doxycycline and placebo and CBT and placebo. Doxycycline yielded no difference in the 
level of psychological distress compared to placebo, whereas the level of psychological 
distress significantly improved after CBT compared to placebo. Most patients had stable or 
declining antibody titres compared to baseline, and the number of patients with declining 
antibody titres was similar in all groups. It is concluded that CBT is effective in reducing 
fatigue severity and the level of psychological distress in QFS patients. Long-term treatment 
with doxycycline does not significantly reduce fatigue severity in QFS patients, and should 
not be advised.
PART II: Challenges in diagnosis and treatment of acute and chronic Q fever
In chapter 7, it was investigated whether acute Q fever could be differentiated from 
infections caused by other pathogens in patients presenting to hospitals, and whether 
prophylactic antibiotic treatment was effective to prevent the development of chronic Q 
fever in acute Q fever patients with risk factors. A retrospective case–control study was 
performed, evaluating differences in clinical signs, symptoms, and outcomes for 82 acute 
Q fever patients and 52 control patients who had pneumonia, fever and lower respiratory 
tract symptoms, or fever and hepatitis, but had negative serologic results for Q fever. Acute 
Q fever patients were younger and had higher C-reactive protein levels but lower leukocyte 
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counts. However, a large overlap was found. It is concluded that differentiating acute Q fever 
from other respiratory infections, fever, or hepatitis is not possible without serologic testing 
or PCR. Furthermore, the data showed that in patients with an indication for antibiotic 
prophylaxis, chronic Q fever did not develop in patients who received such prophylaxis, 
but did develop in 50% of patients who did not receive prophylaxis. This underlines the 
recommendation that prophylactic treatment should be given to patients with risk factors 
for developing chronic Q fever.
In chapter 8, it was retrospectively evaluated whether 18F-fluorodeoxyglucose positron 
emission tomography/CT (18F-FDG PET/CT) and echocardiography were able to detect the 
localisation of infection in 52 chronic Q fever patients (18 proven, 14 probable, and 20 
possible chronic Q fever patients according to the Dutch Q fever consensus group). Data on 
serology, the results of all imaging studies, possible risk factors for developing proven chronic 
Q fever and clinical outcome were recorded. Of those with proven chronic Q fever, 22% had 
endocarditis, 17% had an infected vascular prosthesis, and 39% had a mycotic aneurysm. 
Ten out of 13 18F-FDG PET/CT-scans in patients with proven chronic Q fever demonstrated 
the localisation of the infection. Transthoracic echocardiography and transesophageal 
echocardiography were helpful in only 6% and 50% of patients, respectively. Furthermore, 
56% of these patients did not recall an acute Q fever episode. Our data show that if chronic Q 
fever is diagnosed, 18F-FDG PET/CT is a helpful imaging technique for localisation of vascular 
infections due to chronic Q fever. Patients with proven chronic Q fever were diagnosed 
significantly more often with mycotic aneurysms than in previous case series. Furthermore, 
chronic Q fever often occurs in patients without a known episode of acute Q fever, so clinical 
suspicion should remain high, especially in endemic regions.
In chapter 9, a case series of four patients with treatment-induced cutaneous 
hyperpigmentation in previously unaffected skin is described. This relatively rare 
phenomenon diminished in all four patients after cessation of therapy, illustrating the need 
for recognition and timely cessation of therapy. It was not possible to determine the nature 
of the pigment deposited in the skin. It is concluded that cutaneous hyperpigmentation is 
a potential side effect of doxycycline therapy within the therapeutic dose range, and that 
the chance to evoke this adverse effect might be increased with the concomitant use of 
hydroxychloroquine. This is especially of importance in chronic Q fever, for which prolonged 
relatively high doses are given in combination with hydroxychloroquine.
In chapter 10, a fatal case of an immunocompromised patient with a confirmed unusual 
haematogeneously disseminated chronic Q fever infection is reported. This underlines the 
severity of this disease and the diversity of signs and symptoms that may occur, and highlights 
the need for increased awareness and recognition by physicians especially in case of risk 
factors. Also, a brief review of the literature with regard to the diverse clinical presentation 
of chronic Q fever is provided. It is concluded that an adequate diagnostic work-up using at 
least IFA serology and PCR for screening for chronic Q fever should be performed.
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Chapter 11 contains a general discussion of the results presented in this thesis and their 
possible future implications.
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Query (Q) fever, de naam die oorspronkelijk werd verbonden aan een Coxiella burnetii 
infectie vanwege onbekendheid met het veroorzakende pathogeen, lijkt nog steeds een 
toepasselijke naam. Tot op heden is de Nederlandse Q-koortsuitbraak de grootste die 
ooit beschreven werd. Deze uitbraak heeft de mogelijkheid geboden nieuwe inzichten te 
verkrijgen in diverse vraagstukken op het gebied van Q-koorts. In dit proefschrift wordt een 
aantal uitdagende vragen op het gebied van Q-koorts onderzocht, waarbij de nadruk ligt op 
het Q-koortsvermoeidheidssyndroom (QVS). De primaire doelstellingen van dit proefschrift 
waren het vergroten van de (h)erkenning van QVS, het verkrijgen van nieuwe inzichten in 
de pathofysiologie van QVS en het evalueren van het effect van behandeling met langdurig 
doxycycline en cognitieve gedragstherapie (CGT) in QVS-patiënten. Het tweede doel was het 
onderzoeken van diagnostiek en behandeling van acute en chronische Q-koorts. Hoofdstuk 
1 bevat een algemene inleiding over Q-koorts en de diverse klinische manifestaties van 
deze ziekte. Tevens wordt hierin een overzicht gegeven van de inhoud en de doelen van dit 
proefschrift. Hierna wordt het proefschrift onderverdeeld in twee hoofdthema’s: herkenning 
en behandeling van QVS (deel I) en uitdagingen in de diagnostiek en behandeling van acute 
en chronische Q-koorts (deel II).
DEEL I: Herkenning en behandeling van QVS
In hoofdstuk 2 wordt aan de hand van een ‘systematic review’ een overzicht gegeven van 
de literatuur over vermoeidheid na een acute Q-koortsinfectie. Deze studie identificeert 
lacunes in de huidige kennis over vermoeidheid na een acute Q-koortsinfectie met 
betrekking tot de definitie, diagnose, achtergrond, beschrijving, etiologie, preventie, 
therapie en prognose. Ondanks dat de meeste patiënten binnen 6-12 maanden na een acute 
Q-koortsinfectie herstellen, blijft ongeveer 20% last houden van chronische vermoeidheid. 
Vermoeidheid na acute Q-koorts wordt over het algemeen aangeduid als QVS. Er wordt 
geconcludeerd dat het bestaan en langdurig aanwezig blijven van vermoeidheid na een 
acute Q-koortsinfectie een grote impact heeft. Er bestaan echter nog steeds diverse vragen 
over QVS, aangezien informatie over de etiologie, preventie, behandeling en prognose van 
QVS ondervertegenwoordigd is in de internationale literatuur. Een internationale definitie 
is wenselijk in toekomstige studies om bevindingen te kunnen vergelijken. Daarom wordt 
het voorstel gedaan om de definitie en het diagnostische algoritme van de Nederlandse 
‘Multidisciplinaire LCI-richtlijn Q-koortsvermoeidheidssyndroom (QVS)’ internationaal te 
gebruiken.
Hoofdstuk 3 beschrijft een onderzoek naar verschillen en overeenkomsten tussen QVS-
patiënten en patiënten met chronisch vermoeidheidssyndroom (CVS), waarbij de nadruk 
ligt op ontstekingswaarden en vermoeidheidsgerelateerde cognitieve gedragsfactoren. 
Tevens werd in een exploratieve analyse de relatie tussen deze cognitieve gedragsfactoren 
en vermoeidheid in QVS-patiënten onderzocht. Hiervoor werden de gegevens van twee 
onafhankelijke prospectieve studies op het gebied van QVS (n=117 patiënten) en CVS (n=173 
patiënten) samengevoegd en geanalyseerd. QVS-patiënten bleken minder vaak vrouw te 
zijn, hadden een hogere body-mass index (BMI) en hadden voordat hun klachten begonnen 
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minder vaak een behandeling ondergaan voor een depressie. Na het corrigeren voor 
klachtenduur en diagnostische criteria voor QVS en CVS bleek dat het verschil in geslacht 
en BMI nog steeds significant was. Ook bleek dat QVS-patiënten ouder waren. De ernst 
van zowel vermoeidheid als psychische klachten bleek bij QVS-patiënten niet te verschillen 
van CVS-patiënten, maar QVS-patiënten rapporteerden minder additionele symptomen. 
Verder hadden QVS-patiënten een sterkere somatische attributie en een hogere fysieke 
activiteit. Er werden geen verschillen gevonden op het gebied van ontstekingswaarden en 
in andere vermoeidheidsgerelateerde cognitieve gedragsfactoren. De gevonden verschillen 
in bekende predisponerende factoren voor chronische vermoeidheid suggereren dat 
andere predisponerende factoren een rol spelen bij het ontstaan van QVS. De relatie 
tussen cognitieve gedragsfactoren en vermoeidheid zoals eerder vastgesteld in CVS kon 
niet worden bevestigd bij QVS-patiënten. Desondanks is er wel een aanzienlijke overlap in 
vermoeidheidsgerelateerde cognitieve gedragsfactoren. Samen met de gevonden relatie 
tussen fysieke activiteit en vermoeidheid suggereert dit dat gedragsinterventies zouden 
kunnen leiden tot een afname van de ernst van vermoeidheid in QVS-patiënten.
In hoofdstuk 4 worden de resultaten beschreven van de specifieke interferon-y (IFNy) 
productie en de IFNy/Interleukine(IL)-2 ratio in 20 QVS-patiënten. Deze resultaten werden 
vergeleken met eerdere resultaten bij seropositieve controles (n=135) en chronische 
Q-koortspatiënten (n=28). Daarnaast werd gekeken naar de correlatie tussen karakteristieken 
van QVS-patiënten en de IFNy- en IL-2-productie en de IFNy/IL-2-ratio. QVS-patiënten waren 
jonger, maar de geslachtsverdeling was identiek aan die van seropositieve controles en 
chronische Q-koortspatiënten. QVS-patiënten hadden een significant hogere IFNy-productie 
dan seropositieve controles. Bij QVS-patiënten bleek de IFNy/IL-2-ratio significant lager te 
zijn dan die in chronische Q-koortspatiënten. Daarnaast bleek de klachtenduur positief te 
zijn gecorreleerd met de IL-2-productie en negatief te zijn gecorreleerd met de IFNy/IL-2-
ratio. Er wordt geconcludeerd dat deze resultaten wijzen op een veranderde celgemedieerde 
immuniteit in QVS-patiënten. Daarnaast lijkt er sprake van een andere immuunrespons dan 
in chronische Q-koorts.
In hoofdstuk 5 wordt het studieprotocol gepresenteerd van een prospectieve, 
gerandomiseerde, deels geblindeerde, placebo gecontroleerde studie (de Qure-studie). Het 
doel van deze studie was het evalueren van de effectiviteit van langdurig doxycycline en 
CGT in QVS-patiënten in vergelijking met placebo. In hoofdstuk 6 worden de resultaten van 
deze studie weergegeven. Van de 155 patiënten die zijn gerandomiseerd tussen CGT (n=51), 
doxycycline (n=52) en placebo (n=52), zijn 154 patiënten geincludeerd in de intention-to-
treat analyse. Er bleek geen significant verschil in ernst van de vermoeidheid na behandeling 
met doxycycline in vergelijking met placebo. De ernst van de vermoeidheid was significant 
lager na CGT in vergelijking met placebo. Deze resultaten zijn gecorrigeerd voor de ernst van 
de vermoeidheid bij aanvang van de studie. De ernst van de dagelijkse beperkingen bleek na 
behandeling met zowel doxycycline als CGT niet significant te verschillen in vergelijking met 
placebo. Behandeling met doxycycline verschilde in effect op de ernst van psychische klachten 
niet van placebo, terwijl na behandeling met CGT daarentegen de ernst van de psychische 
284 | CHAPTER 13
klachten significant afnam in vergelijking met placebo. In vergelijking met de meting bij 
aanvang van de studie hadden de meeste patiënten stabiele of gedaalde antistoftiters 
na behandeling. Het aantal patiënten waarbij de antistoftiter was gedaald gedurende de 
behandeling was niet verschillend tussen alle groepen. Er wordt geconcludeerd dat CGT 
effectief is in het reduceren van de ernst van de vermoeidheid en de ernst van psychische 
klachten in QVS-patiënten. Langdurige behandeling met doxycycline zorgt echter niet voor 
een significante daling van de ernst van vermoeidheid en wordt niet geadviseerd.
DEEL II: Uitdagingen in de diagnostiek en behandeling van acute en chronische Q-koorts
In hoofdstuk 7 worden de resultaten weergegeven van een retrospectief patiënt controle-
onderzoek waarin onderzocht werd of acute Q-koorts kan worden onderscheiden van 
infecties veroorzaakt door andere pathogenen bij patiënten die zich presenteerden in het 
ziekenhuis. Ook werd onderzocht of profylactische behandeling met antibiotica bij acute 
Q-koortspatiënten met risicofactoren effectief is om het ontstaan van chronische Q-koorts 
te voorkomen. Gegevens over klinische symptomen, klachten en het beloop werden 
verzameld van 82 patiënten met acute Q-koorts. Deze gegevens werden vergeleken met 
die van 52 controle-patiënten die zich presenteerden met een pneumonie, of met koorts en 
lage luchtwegklachten, of met koorts en hepatitis, maar waarbij acute Q-koorts uiteindelijk 
kon worden uitgesloten. Patiënten met acute Q-koorts waren jonger, hadden een hoger 
C-reactief proteïne, maar een lager leukocytenaantal. Desondanks werd een grote overlap 
gevonden tussen patiënten met acute Q-koorts en controles. Geconcludeerd wordt dat het 
onderscheiden van acute Q-koorts ten opzichte van andere respiratoire infecties, koorts, 
of hepatitis, niet mogelijk is zonder serologische analyse of PCR. Verder bleek dat bij acute 
Q-koortspatiënten met een indicatie voor profylactische behandeling met antibiotica er geen 
chronische Q-koorts ontwikkelde indien deze patiënten daadwerkelijk profylaxe ontvingen, 
terwijl 50% van de patiënten die geen profylaxe ontvingen wel chronische Q-koorts 
ontwikkelde. Dit bevestigt de aanbeveling om acute Q-koortspatiënten met risicofactoren 
voor het ontwikkelen van chronische Q-koorts profylactisch te behandelen met antibiotica. 
Hoofdstuk 8 beschrijft een retrospectieve studie naar de waarde van 18F-fluorodeoxyglucose 
positron emissie tomografie/CT (18F-FDG PET/CT) en echocardiografie in het detecteren 
van de lokalisatie van de infectie in 52 chronische Q-koortspatiënten (onderverdeeld in 
18 bewezen, 14 waarschijnlijke en 20 mogelijke chronische Q-koortspatiënten volgens de 
Nederlandse consensusgroep diagnostiek Q-koorts). De serologische resultaten, resultaten 
van beeldvormende onderzoeken, mogelijke risicofactoren voor het ontwikkelen van een 
bewezen chronische Q-koortsinfectie en gegevens over het verdere klinische beloop werden 
verzameld. Van de patiënten met een bewezen chronische Q-koortsinfectie bleek 22% een 
endocarditis te hebben, 17% had een geïnfecteerde vaatprothese en 39% een mycotisch 
aneurysma. Tien van de 13 18F-FDG PET/CT-scans die werden verricht bij patiënten met 
een bewezen chronische Q-koortsinfectie toonden de lokalisatie van de infectie aan. 
Transthoracale echocardiografie en transoesofageale echocardiografie waren respectievelijk 
maar in 6% en 50% van deze patiënten behulpzaam in het lokaliseren van de infectie. Verder 
bleek dat 56% van de patiënten met een bewezen chronische Q-koortsinfectie zich geen 
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acute Q-koortsepisode kon herinneren. Geconcludeerd wordt dat als chronische Q-koorts 
is gediagnosticeerd, 18F-FDG PET/CT een waardevolle beeldvormende techniek is voor het 
lokaliseren van vaatinfecties veroorzaakt door chronische Q-koorts. In deze studie werden 
patiënten met een bewezen chronische Q-koortsinfectie significant vaker gediagnosticeerd 
met een mycotisch aneurysma dan in eerdere case series. Verder komt chronische 
Q-koorts vaak voor zonder dat patiënten weten dat ze een (acute) Q-koortsinfectie hebben 
doorgemaakt. Daarom moet de klinische verdenking op chronische Q-koorts hoog blijven, 
voornamelijk in gebieden waar Q-koorts endemisch is.
In hoofdstuk 9 wordt een reeks casussen beschreven van vier patiënten met cutane 
hyperpigmentatie die door behandeling met doxycycline werd geïnduceerd. Voorafgaand 
aan deze behandeling was er op de plaatsen met hyperpigmentatie sprake van een 
normale, gezonde huid. De uitgebreidheid van dit relatief zeldzame fenomeen nam af na het 
stoppen van de therapie in alle beschreven patiënten. Dit illustreert het belang van tijdige 
herkenning en het tijdig stoppen van de behandeling. Het was niet mogelijk om de aard van 
het pigment in de huid te bepalen. Er wordt geconcludeerd dat cutane hyperpigmentatie 
een potentiële bijwerking is van behandeling met doxycycline binnen de therapeutische 
marge en dat de kans op deze bijwerking mogelijk wordt vergroot door het gelijktijdig 
gebruik van hydroxychloroquine. Dit is vooral van belang in de behandeling van chronische 
Q-koorts, waarvoor gedurende een lange periode een relatief hoge dosering doxycycline 
wordt voorgeschreven in combinatie met hydroxychloroquine.
In hoofdstuk 10 wordt een casus met fatale afloop beschreven van een 
immuungecompromitteerde patiënt met een zeldzame hematologisch gedissemineerde 
chronische Q-koortsinfectie. Deze casus onderstreept de ernst van deze ziekte en de 
diversiteit aan symptomen die kunnen optreden bij chronische Q-koorts. Daarnaast 
illustreert deze casus het belang van verhoogde waakzaamheid bij artsen voor en herkenning 
van chronische Q-koorts, vooral indien risicofactoren aanwezig zijn. Verder wordt een kort 
overzicht gegeven van de beschikbare literatuur over de diverse klinische presentatievormen 
van chronische Q-koorts. Er wordt geconcludeerd dat adequate diagnostiek naar chronische 
Q-koorts moet worden verricht, waarbij tenminste gebruik gemaakt moet worden van IFA 
serologie en PCR.
Hoofdstuk 11 bevat een algemene discussie aangaande de belangrijkste bevindingen uit 
dit proefschrift. Tevens wordt het mogelijke vervolg van de onderzoeken in dit proefschrift 
toegelicht.
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DANKWOORD
“Quand il n’y a pas de solution, il n’y a pas de problème”, was het gezegde dat ik in mijn 
achterhoofd had toen ik mijn promotie-onderzoek startte. Met oplossingsgericht denken 
kan men veel bereiken, maar zonder samenwerking en, zowel directe als indirecte, hulp van 
anderen, zou dit proefschrift niet tot stand zijn gekomen. Dit dankwoord is aan hen gericht.
Wellicht niet standaard en eigenwijs (of op mijn eigen manier, zoals ik ook mijn 
promotietraject heb doorlopen), wil ik mijn dankwoord in eerste instantie richten aan 
alle deelnemende Q-koortspatiënten die mijn proefschrift mogelijk hebben gemaakt. Zij 
hebben een centrale positie in de zorg en in mijn onderzoeken en daarmee ook in mijn 
dankwoord. Het positieve beeld omtrent het onderzoek is grotendeels te danken aan een 
actieve patiëntenvereniging (Q-uestion, Stichting voor mensen met Q-koorts). Dank voor 
het meedenken, en het beschikbaar stellen van jullie kwaliteiten en mogelijkheden om het 
onderzoek op de kaart te zetten en uit te voeren. In het bijzonder noem ik hier Michel 
van den Berg, voormalig voorzitter en één van de drijvende krachten achter deze stichting. 
Dank voor je onuitputtelijke inzet voor alle Q-koortspatienten en daarmee ook voor mijn 
onderzoek. Ook Q-support heeft door subsidiëring en blijvende aandacht voor o.a. de Qure-
studie een groot aandeel in het afronden van dit proefschrift gehad.
Mijn promotores en co-promotor verdienen elk eigenlijk een apart boekwerk als dankwoord. 
Helaas kreeg ik een restrictie opgelegd om het aantal pagina’s beperkt te houden (dezelfde 
restrictie kreeg ik overigens voor mijn poliklinische correspondentie over patiënten…).
Prof. dr. van der Meer, beste Jos, veel promovendi dromen er van onder jou te mogen 
promoveren, een eer die voor mij is weggelegd. Je onuitputtelijke kennis over o.a. chronische 
vermoeidheid, infectieziekten en de onderliggende relatie tilden de onderzoeken naar een 
hoger niveau. Op elk vraagstuk heb je een gefundeerd antwoord. Ook ben jij diegene die 
mij heeft aangenomen voor de opleiding tot internist. Ik ben er trots op dat je één van mijn 
promotoren wilt zijn.
Prof. dr. Bleijenberg, beste Gijs, van begin tot eind ben ik onder de indruk geweest van je gave 
een wetenschappelijke blik te combineren met patiëntgerichtheid. Je bent een expert op het 
gebied van chronische vermoeidheid en met hart en ziel betrokken bij zowel patiëntenzorg 
als promovendi. Overleg was altijd mogelijk, manuscripten kwamen snel retour voorzien van 
zorgvuldig commentaar vanuit diverse invalshoeken. De communicatietraining die ik van jou 
kreeg opende nieuwe deuren voor patiëntenzorg en het verrichten van wetenschappelijk 
onderzoek. Nog steeds pluk ik hier dagelijks de vruchten van. Dank voor je vertrouwen en 
de investering die je in mij hebt gestopt.
Prof. dr. Knoop, beste Hans, sommige mensen kunnen oplossingsgericht denken, waar 
anderen, zoals jij, dat nog veel beter kunnen. Je gaf me inkijk en trok me mee in de manier van 
denken vanuit de psychologie, een waardevol bezit voor mijn toekomstige carrière. Ik ben 
je zeer erkentelijk voor al het overleg op elk mogelijk tijdstip op de dag, je betrokkenheid en 
geduld, je bemoedigende woorden bij tegenslagen, en het altijd ‘samen’ oplossingsgericht 
denken en openstaan voor de andere kant van het verhaal.
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Dr. Bleeker-Rovers, beste Chantal, in jou vond ik mijn evenbeeld qua precisie en aanpak. Jij 
was het die mij de mogelijkheid bood te promoveren en tot op heden ken ik niemand die 
de begeleiding kreeg zoals ik die van jou heb gekregen. Jouw adviezen, feedback, sturing, 
steun, enthousiasme, tips en vertrouwen hebben mij ontwikkelt tot de arts (en ook deels 
de persoon) die ik nu ben. Naast letterlijk alle werkgerelateerde aspecten kon ik altijd bij 
je terecht met niet-vakinhoudelijke aspecten van het leven die mij overkwamen, op elk 
moment van de dag en zelfs tijdens je eigen vakanties. Jij als dokter, als onderzoeker en je 
passie en beleving voor het vak zijn voor mij een groot voorbeeld.
Drs. Delsing, beste Corine, met je overstap naar het Medisch Spectrum Twente ben ik tijdens 
mijn traject tot mijn grote teleurstelling één van mijn dagelijkse begeleidsters een beetje 
‘kwijt geraakt’. Jouw substantiële bijdrage bij de start en opzet van mijn promotietraject 
hebben mede tot dit resultaat geleidt. Ik hoop oprecht dat onze paden zich in de toekomst 
opnieuw zullen kruisen.
Dr. Tromp, beste Mirjam, er zijn weinig mensen aan wie ik mijn werkzaamheden durf uit te 
besteden (een nadelige eigenschap van mezelf), maar in jou heb ik volledig vertrouwen. Ik 
wil je bedanken voor je hulp in de zorg voor patiënten met langdurige klachten na Q-koorts, 
je luisterend oor op belangrijke momenten en je positivisme. Het is mede aan jou te danken 
dat we de inclusie in de Qure-studie toch naar tevredenheid konden afronden.
Prof. dr. Van der Ven en dr. De Mast, beste André en Quirijn, dankzij jullie heb ik mogen ruiken 
aan de beginselen van het verrichten van wetenschappelijk onderzoek. Mijn enthousiasme, 
precisie en volharding in onderzoek doen, zijn mede door jullie enthousiaste begeleiding 
gegroeid. Hiervoor, en voor alle geboden mogelijkheden, ben ik jullie zeer dankbaar. De van 
jullie geleerde opmerking “zolang er geen oplossing is, is er ook geen probleem”, zal ik altijd 
bij me dragen. Quirijn, ook dank voor de supervisie bij afwezigheid van Chantal.
Dr. Simon, beste Anna, de afgelopen jaren heb ik wekelijks je kamer mogen ‘misbruiken’ 
voor overleg met Chantal. Dank hiervoor, als ook voor je gezelligheid, je kookkunst (lees: 
koekjes en chocolade) waarvoor ik graag nog een keer langs kwam op je kamer en het 
laagdrempelige overleg dat met jou gevoerd kon worden als ik weer eens een patiënt tegen 
kwam met hypogammaglobulinemie of andere immuundeficiëntie.
Leden van de manuscriptcommissie, prof. dr. Speckens, prof. dr. Van Dissel en prof. dr. 
Wertheim: hartelijk dank voor het lezen en beoordelen van mijn manuscript.
Lianne, ik weet niet waar ik moet beginnen. Wat ik wel weet is dat een deel van dit proefschrift 
indirect en direct de verdienste is van jouw tomeloze inzet en enthousiasme. Al sinds het begin 
was er een vlekkeloze samenwerking welke zich voor mij heeft ontwikkeld in een blindelings 
vertrouwen op de werkvloer. Ik ben je veel dank verschuldigd. Carel, Liesbeth, Judith en 
Tiny, ook jullie verdienen hulde voor jullie werkzaamheden als psychologisch medewerkers 
in het kader van mijn proefschrift. Thea, dank voor de secretariele ondersteuning. 
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Ook bedank ik de therapeuten (Anthonie, Dennis, Hans, José, José, Kati, Petra, Susanne en 
Thea) die studiepatiënten in de Qure-studie hebben behandeld en het secretariaat (Thea en 
Ellis) om alles logistiek mogelijk te maken. De ondersteuning van de medewerkers van poli 
blauw en het secretariaat van de Interne Geneeskunde mag niet vergeten worden. Collega-
onderzoekers van het Nijmeegs Kenniscentrum Chronische Vermoeidheid (Anthonie, 
Hanneke, Harriet, Iris, Jan, Juliane, Lotte, Margreet, Marieke en Megan), meer nog dan 
van het maandagochtendoverleg genoot ik van de avonden eten en borrelen op diverse 
Nijmeegse plekken. Stephanie, dank voor je hulp bij statistische analyses en het kritisch 
meekijken naar artikelen.
Van alle Q-koortspromovendi in Nederland wil ik diegenen bedanken waarmee ik nauw 
heb samengewerkt. Anne, Gabriella, Joris, Julia, Lieke en Teske, heerlijk om ervaringen uit 
te wisselen tijdens de periodieke etentjes met deze selecte groep Q-koortsonderzoekers. 
Gabriëlla, we verschillen in veel dingen voor wat betreft onderzoek doen en als persoon. 
Toch hebben we veel bereikt samen, waar ik met een goed en positief gevoel op terug kijk. 
Joris, altijd een klankbord tijdens een kop koffie (voor jou uiteraard thee) en zeer behulpzaam 
in meedenken. Lieke, dankzij jouw medewerking op meerdere vlakken kon ik grote groepen 
Q-koortspatiënten bereiken. Je hebt een belangrijke indirecte rol bij meerdere hoofdstukken 
van dit proefschrift. Linda, als iemand enthousiasme kan overbrengen ben jij het. Dank voor 
het meedenken en –werken. Daphne, dank voor de fijne samenwerking.
Een speciaal dankwoord wil ik richten aan mijn collega’s van de Q-room. In het bijzonder 
Teske en Anne, sinds het begin samen werkend aan hetzelfde onderwerp en altijd 
roomies geweest. Ondanks onze verschillen hebben jullie er mede voor gezorgd dat mijn 
enthousiasme op het werk altijd groot was. Teske, ik heb je oprecht gemist op de kamer en op 
de ECCMID toen je klaar was. Anne, ook met jouw vertrek na afronding viel er een leegte. Ik 
heb bewondering voor je positivisme en doorzettingsvermogen en ben blij dat ik samen met 
Teske in Lausanne bij je langs ben gegaan. Siroon, hard werken kon ik altijd van je afkijken. 
Net zoals dat we vaak goede gesprekken hebben gehad. Uiteraard mag ik het beroemde 
“Siroontje” in de middag niet vergeten, een bak koffie om naar uit te kijken. Megan, met 
jouw komst had ik een partner in crime die begreep hoe patiëntgebonden onderzoek in 
zijn werk ging, wat samen met je gezonde dosis vergelijkbaar cynisme zorgde voor nieuwe 
motivatie. Charlotte, de laatste versterking van de Q-room, dank voor je gezelligheid. Als 
laatste wil ik hier Martin noemen, de enige andere vaste mannelijke collega op de Q-room 
en de enige die net als ik standaard (erg) vroeg op het werk was. Dank voor het “overleg” op 
vrijdagmiddag, alle ongein en hulp daar waar nodig. Jullie waren er allemaal op momenten 
dat het nodig was. Ik ga jullie missen.
Ruud, jouw aanstelling als “opvolger” heeft gezorgd voor een positieve boost bij iedereen, 
zeker bij mij. Het was leuk je vanaf het begin te mogen begeleiden. Op alles wat voorbij komt 
reageer je met een dosis positieve energie, die in elk geval op mij oversloeg. Tanja, inmiddels 
ben je al lange tijd een goede vriendin, maar in het begin hebben we veel over onderzoek 
gepraat en heb je me geholpen door te zetten. Jaap, je was er om de patiëntenzorg op te 
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vangen in mijn afwezigheid. En naast de leuke (wekelijkse) etentjes met Karin, Rutger en 
Tanja, bood je me (letterlijk, 2x) onderdak in moeilijke tijden. Dit zal ik nooit vergeten. Niet te 
vergeten zijn Dennis, Elmer en Johanna, die allen middels hun wetenschappelijke stage een 
belangrijke bijdrage aan dit proefschrift hebben geleverd. Hier wil ik ook alle mede-auteurs 
bedanken die ik nog niet apart bij naam heb genoemd, in het bijzonder Marrigje en Tom. 
Ook wil ik iedereen bedanken die zich heeft ingezet als monitor van de Qure-studie, wat een 
tijdrovende klus was. Rogier en Wim, dank voor jullie hulp met de statistische uitdagingen. 
Mijn huidige situatie had er heel anders uit gezien zonder de subsidie vanuit ZonMw. Ik wil 
dan ook de personen die ik nog niet genoemd heb bedanken voor zijn of haar hulp op welke 
manier dan ook bij de aanvraag van deze subsidie (prof. dr. Netea, prof. dr. Kullberg, prof. 
dr. van der Velden, dr. Wijkmans, dr. Paget, dr. Hautvast).
Ook mijn collega’s uit het CWZ wil ik bedanken voor het opvangen van diensten, het 
overnemen van de afdeling en presentaties en het begrip voor mijn afwezigheid op bepaalde 
momenten om te kunnen werken aan het afronden van mijn promotie. Jullie zijn toppers.
Beste Dorien, je hebt een groot deel van mijn promotietraject aan mijn zijde gestaan. Ik wil 
je ontzettend bedanken voor je altijd aanwezige begrip, je motiverende houding en het feit 
dat je altijd voor me klaar stond. Ik wens je al het beste voor de toekomst.
Beste Peter en Annie, Rick en Juul, en natuurlijk ook kleine Nori, jullie hebben mij allen 
altijd een warm hart toegedragen, waarvoor veel dank. Het voelde bij jullie altijd als 
“thuiskomen”. De goede gesprekken en jullie bijna onuitputtelijke oprechte interesse in mijn 
onderzoek hebben mij geholpen de laatste loodjes af te ronden. Ik zal jullie nooit vergeten.
Lieve Renée, de dingen zijn niet gelopen zoals we beiden eigenlijk voor ogen hadden, 
maar dat maakt mijn gevoel over wat je voor mij hebt betekend tijdens en naast mijn 
promotietraject niet anders. Je bent een ontzettende steun geweest in moeilijke periodes 
en stond altijd voor me klaar, zowel qua werk als privé. Ik ben je enorm dankbaar voor alles 
wat je voor me hebt gedaan. Ik hoop oprecht dat de toekomst je veel positiviteit en geluk 
brengt.
Lieve vrienden (Gerwin (en Stefanie), Abel, Gerjan, Jasper en Claartje), zonder onze 
onvoorwaardelijke vriendschap zou ik niet zijn wie ik nu ben en zou ik niet staan waar ik nu 
sta. Jullie zijn vrienden voor het leven. Gerwin, ik ben vereerd dat jij mijn paranimf wilt zijn.
Lieve Karin, René, Bram en Tim, jullie zijn voor mij een rots in de branding. Woorden schieten 
te kort om jullie rol in mijn leven en tijdens mijn promotietraject te beschrijven. Jullie zijn 
geweldige mensen waarmee ik nog lang hoop te genieten van het leven.
Lieve pap (Ton) en mam (Ingrid), het gevoel van trots en vertrouwen hebben jullie altijd 
uitgesproken, wat mij enorm heeft gesteund. Dank dat jullie altijd voor mij klaar staan 
ongeacht wat er gebeurd. Dat geldt ook voor mijn zus (Susanne) en zwager (Henri), twee 
292 | CHAPTER 14
geweldige ouders. Ik ben blij dat we heel erg naar elkaar zijn toe gegroeid en dat jij, Suus, 
mijn andere paranimf wil zijn. Lief neefje (Caylen), je bent nog te klein om te bevatten wat 
je met mijn gevoel hebt gedaan sinds jij tijdens mijn promotietraject op de wereld kwam. 
Ik heb bewondering voor de kracht in je kleine lichaam. Lieve Devlin, mijn andere neefje, 
zo klein en nu al zo een positief karakter. Jij bent mijn kleine voorbeeld. Ik ben trots op mijn 
kleine neefjes en nog trotser om jullie voogd te zijn. Lieve familie, het is niet in woorden te 
omschrijven hoeveel ik om jullie geef en hoe dankbaar ik jullie ben.
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Stephan Patrick Keijmel werd geboren op 9 september 1986 in Deventer en groeide op in de 
Hanzestad Zutphen. Hij voltooide in 2004 het VWO aan het Isendoorn College te Warnsveld, 
waar hij een gecombineerd profiel deed van Natuur & Techniek en Natuur & Gezondheid. 
In datzelfde jaar startte hij de opleiding Geneeskunde aan de Radboud Universiteit Nijmegen, 
waarvoor hij een jaar later zijn propedeuse behaalde. In december 2010 rondde hij de 
opleiding Geneeskunde af. Sinds het tweede jaar van zijn opleiding tot op heden woont hij 
in Nijmegen. Zijn interesse voor infectieziekten is sinds zijn studie geneeskunde alleen maar 
toegenomen. Na deelname als proefpersoon aan de AMA-1 studie, een vaccinatie-studie 
tegen malaria, hielp hij met het rekruteren van proefpersonen in opvolgende malariastudies 
(EHMI-8 studie, PfLSA-3-rec studie). Ook nam hij van 2007 tot 2008 als student deel aan 
de dataverwerking van een grootschalig onderzoek naar de lange termijn uitkomst van 
prematuren (ELBW studie). Voor de verplichte onderzoeksstage in de opleiding Geneeskunde 
verbleef hij van januari 2008 t/m juni 2008 in Sumba, Indonesië, waar hij onderzoek deed 
naar malaria (hepcidine concentratie in asymptomatisch dragerschap van P. falciparum en P. 
vivax malaria). Daarna werkte hij tot en met januari 2011 naast zijn opleiding bij de Thuiszorg 
in Nijmegen. Hij deed zijn seniorcoschap op de afdeling Infectieziekten in het Radboudumc 
en werd daar gevraagd als kandidaat voor dit promotietraject.
In februari 2011 begon hij aan zijn promotietraject met het hoofdonderwerp 
“Q-koortsvermoeidheidssyndroom (QVS)”, onder begeleiding van prof. dr. van der Meer, 
prof. dr. Bleijenberg, prof. dr. Knoop en dr. Bleeker-Rovers. Diverse onderzoeken werden 
gedaan, met als grootste de Qure-studie. Hij zag meer dan 500 nieuwe patiënten met 
klachten na Q-koorts op de polikliniek van het Radboud Q-koorts Expertisecentrum. Stephan 
nam intensief deel aan de ontwikkeling van de landelijke LCI-richtlijn QVS, die in februari 
2012 werd gepubliceerd, en aan de Vlaams-Nederlandse Onderzoekersgroep-Chronische 
Vermoeidheid (VNO-CHROVER). Hij spande zich succesvol in om de wachtlijstproblematiek 
voor cognitieve gedragstherapie voor QVS-patiënten te beperken middels een gehonoreerde 
aanvraag voor financiële ondersteuning vanuit het ministerie van Volksgezondheid, Welzijn 
en Sport. Vanaf juni 2013 tot en met december 2015 was hij naast zijn onderzoekswerk in het 
Nijmeegs Kenniscentrum Chronische Vermoeidheid (NKCV), betrokken bij de screening van 
patiënten voor de behandeling van chronische vermoeidheid. Hij gaf onderwijs aan studenten 
Geneeskunde en begeleidde vier studenten in hun verplichte wetenschappelijke stage voor 
de opleiding Geneeskunde. Ook was hij intensief betrokken bij de aanvraag van inmiddels 
gehonoreerde subsidies (“De rol van het immuunsysteem hij QVS”, “De impact van Q-koorts 
op arbeid en psychosociaal functioneren van patiënten met chronische Q-koorts of QVS” en 
“De Nederlandse Q-koortsepidemie in kaart gebracht: een meta-analyse van de impact op 
korte en lange termijn”, allen gesubsidieerd vanuit Q-support) en verzorgde hij een deel van 
de begeleiding van de nieuw aangestelde promovendus op het eerstgenoemde project in 
2015. Daarnaast heeft hij zich vanaf 2011 belangeloos ingezet voor vele informatieavonden 
van Q-uestion, Stichting voor mensen met Q-koorts, en stichting Q-support.
Hij is inmiddels per 1 april 2016 gestart met de opleiding tot internist, waarvoor hij reeds werd 
aangenomen tijdens zijn promotietraject, met als uiteindelijke differentiatie infectieziekten.
